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Preface to ”New Technologies for the Treatment of
Coronary and Structural Heart Diseases”
There has been significant progress in the field of interventional cardiology, from the
development of newer devices to newer applications of technology, resulting in improved
cardiovascular outcomes. The goal of this Special Issue is to update practicing clinicians and provide
a comprehensive collection of original articles, reviews, and editorials.
To this end, we invited state-of-the-art reviews, including reviews of new technology and
therapeutics, as well as original research in this area to be considered for inclusion in this issue.
Examples include the history and evolution of interventional techniques, reviews of specific devices
and technologies for coronary artery disease (i.e., stent technology, atherectomy devices, coronary
physiology, intracoronary imaging, and robotics), structural heart diseases (i.e., ASD: atrial septal
defect; LAAC: left atrial appendage closure; MC: MitraClip; PFO: patent foramen ovale; TAVI:
transcatheter aortic valve implantation), advances in the management of challenging coronary
anatomy, new biomarkers of cardiovascular disease (noncoding RNAs, etc.), and interventional
techniques in the management of heart failure, peripheral arterial diseases, and pulmonary embolism.
This Special Issue presents the most recent advances in the field of coronary and structural heart
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Abstract: Recently, two randomized trials, the PARTNER 3 and the Evolut Low Risk Trial,
independently demonstrated that transcatheter aortic valve replacement (TAVR) is non-inferior
to surgical aortic valve replacement (SAVR) for the treatment of severe aortic stenosis in patients
at low surgical risk, paving the way to a progressive extension of clinical indications to TAVR. We
designed a meta-analysis to compare TAVR versus SAVR in patients with severe aortic stenosis at
low surgical risk. The study protocol was registered in PROSPERO (CRD42019131125). Randomized
studies comparing one-year outcomes of TAVR or SAVR were searched for within Medline, Scholar
and Scopus electronic databases. A total of three randomized studies were selected, including nearly
3000 patients. After one year, the risk of cardiovascular death was significantly lower with TAVR
compared to SAVR (Risk Ratio (RR) = 0.56; 95% CI 0.33–0.95; p = 0.03). Conversely, no differences were
observed between the groups for one-year all-cause mortality (RR = 0.67; 95% CI 0.42–1.07; p = 0.10).
Among the secondary endpoints, patients undergoing TAVR have lower risk of new-onset of atrial
fibrillation compared to SAVR (RR = 0.26; 95% CI 0.17–0.39; p < 0.00001), major bleeding (RR = 0.30;
95% CI 0.14–0.65; p < 0.002) and acute kidney injury stage II or III (RR = 0.28; 95% CI 0.14–0.58;
p = 0.0005). Conversely, TAVR was associated to a higher risk of aortic regurgitation (RR = 3.96; 95%
CI 1.31–11.99; p = 0.01) and permanent pacemaker implantation (RR = 3.47; 95% CI 1.33–9.07; p = 0.01)
compared to SAVR. No differences were observed between the groups in the risks of stroke (RR= 0.71;
95% CI 0.41–1.25; p = 0.24), transient ischemic attack (TIA; RR = 0.98; 95% CI 0.53–1.83; p = 0.96), and
MI (RR = 0.75; 95% CI 0.43–1.29; p = 0.29). In conclusion, the present meta-analysis, including three
randomized studies and nearly 3000 patients with severe aortic stenosis at low surgical risk, shows
that TAVR is associated with lower CV death compared to SAVR at one-year follow-up. Nevertheless,
paravalvular aortic regurgitation and pacemaker implantation still represent two weak spots that
should be solved.
Keywords: TAVR; TAVI; low risk; STS; aortic stenosis; SAVR
1. Introduction
Transcatheter aortic valve replacement (TAVR) has been established as a standard of care for
patients with severe aortic stenosis (AS) deemed at prohibitive or high surgical risk [1]. Of note, over
the last years, its use has progressively increased, along with continuous improvements of devices
and implantation techniques, to encompass patients at lower surgical risk [2,3]. Indeed, both the
J. Clin. Med. 2020, 9, 439; doi:10.3390/jcm9020439 www.mdpi.com/journal/jcm1
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balloon-expandable as well as self-expandable devices were non-inferior to the surgical aortic valve
replacement (SAVR) for short- and long-term outcomes in intermediate-risk patients [4] and are
becoming a feasible alternative in appropriately selected low-risk patients. However, since SAVR has
shown a low rate of mortality and stroke in these relatively young and healthy patients [5], some have
hypothesized that the benefit of using TAVR may be futile over SAVR. Moreover, peri-procedural TAVR
outcomes such as vascular access complications, conduction disturbances, bleeding and post-procedural
paravalvular leak (PVL) after TAVR need further investigations in this large portion of patients [6].
Very recently, two randomized trials, the Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart
Valve in Low Risk Patients With Aortic Stenosis (PARTNER 3) trial [7], using the balloon-expandable
valve, and the Evolut Low Risk Trial [8], using a self-expandable nitinol-frame valve, independently
demonstrate that TAVR is non-inferior to SAVR in patients at low surgical risk. However, the
non-inferiority design of these trials may be underpowered to detect statistical differences in hard
clinical endpoints, as most were powered only for composite endpoints. Given this context, we
have undertaken a systematic review and meta-analysis of the available evidence on TAVR to better
characterize the safety and efficacy of the currently FDA-approved transfemoral TAVR in comparison
with SAVR in patients with symptomatic aortic valve stenosis and at low operatory risk.
2. Methods
2.1. Search Strategy and Study Selection
Published randomized trials comparing transcatheter to surgical aortic valve replacement were
searched for within Medline, Scholar and Scopus electronic databases up to March 19th, 2019.
The following syntax was used for the search: “transcatheter aortic valve replacement” OR “TAVR”
OR “TAVI” AND “surgical aortic valve replacement” OR “SAVR” OR “SAVI” AND “low risk”. Time
of publication and language were not limiting criteria for our analysis. All reports including the
search terms were independently screened by two investigators for relevance and eligibility (A.P.,
S.S.). Additionally, references from relevant articles were also scanned for eligible studies. The authors
discussed their evaluation and any disagreement was resolved through discussion and re-reading.
All selected trials were thoroughly checked and classified by the author’s institution in order to avoid
any effect from duplicity of data. The study protocol was registered in PROSPERO (CRD42019131125).
Studies were considered eligible if the following statements applied: (a) randomized clinical trials;
(b) they involved a study population with aortic stenosis; (c) they compared TAVR versus SAVR; (d) they
included mostly transfemoral TAVR (>95%); (e) they included patients at low risk (Society of Thoracic
Surgeons (STS) score: ≤4); (f) follow-up length of 1 year; (g) they reported the following outcome data
(all-cause mortality, cardiovascular death, myocardial infarction, stroke, transient ischemic attack, aortic
regurgitation, new-onset atrial fibrillation, permanent pacemaker implantation, major and minor bleedings).
Exclusion criteria were (just one was sufficient for study exclusion): duplicate publication, observational data.
2.2. Data Abstraction, Validity Assessment and Analysis
Baseline characteristics, as well as numbers of events, were extracted from the single studies,
through careful scanning of the full article by two independent reviewers (A.P., S.S.). Divergences were
resolved by consensus. In particular, the following data were abstracted: year of publication, location,
number of study patients, study design, clinical outcome data (all-cause mortality, cardiovascular
death, myocardial infarction, stroke, transient ischemic attack, aortic regurgitation, new-onset atrial
fibrillation, permanent pacemaker implantation, major and minor bleedings) and baseline patients’
characteristics. Selection and data abstraction were performed according to the PRISMA statement [9].
The primary endpoint of this analysis was cardiovascular death. Further outcomes were: all-cause
mortality, myocardial infarction (MI), stroke, transient ischemic attack (TIA), aortic regurgitation,
new-onset atrial fibrillation, permanent pacemaker implantation, life-threatening or disabling bleeding
and acute kidney disease (AKI) stage II or III. The quality of randomized trials included in the
2
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meta-analysis was appraised by using Cochrane methods (selection bias, performance bias, detection
bias, attrition bias, reporting bias and other bias) as previously described [10].
2.3. Statistical Analysis
The summary measure used was the Risk Ratio (RR) with 95% confidence. The random-effects
model was used, as previously described, to combine the collected values [11,12]. This model calculates
a weighted average of the relative risks by incorporating within-study and between-study variations.
Heterogeneity was assessed by means of the Cochrane Q test using a chi-squared function, with p < 0.10
considered significant for heterogeneity, as previously described [13]. Additionally, I2 values were
calculated for the estimation of variation in weighted mean differences among studies attributable to
heterogeneity. Power calculation of the meta-analysis was performed as described by Valentine et al. [14].
Small study effects were evaluated through graphical inspection of funnel plots, as already previously
described [15]. Forest plots were used to graphically display the results of the meta-analysis, as already
previously described [16]. Briefly, the measure of effect (RR) for every single study included (represented
by a square) is plotted, together with confidence intervals, represented by horizontal lines. The area of
each square is proportional to the study’s weight in the meta-analysis. The overall measure of effect is
reported on the bottom line of the plot as a diamond, whose lateral ends indicate the confidence interval
for the summary effect. Analyses were performed by means of RevMan 5.3.
3. Results
3.1. Search Results
Our search retrieved a total of 2660 entries, which were reduced to 2145 studies after an initial
pre-screening. A total of 110 studies were then excluded for one of the following reasons: (a) they were
not related to our research question; (b) they were not original articles. In the assessment of eligibility, a
further seven studies were excluded. Finally, a total of three studies were included [7,8,17]. The study
selection procedure was reported in detail in Figure 1.
Figure 1. Study selection flow chart.
3
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3.2. Study Characteristics
The main characteristics of the selected studies were reported in Table 1. Quality assessment
revealed a high study quality (Supplementary Figure S1). The specific study designs made both
patients’ and investigators’ blinding impossible. Endpoint assessment and data analysis was blinded
in all included studies. A total of 2629 patients were included of which 1363 patients were randomized
to TAVR and 1266 to SAVR.
Baseline clinical and procedural characteristics across the trials are reported in Table 2. Across the
studies, patients were predominantly male, one-fourth of patients had diabetes mellitus and less than
1% had creatinine level >2 mg/dL at presentation. The mean STS score was less than 3% across all
the trials. In the TAVR arm, the most frequently implanted valve was a self-expandable valve which
included Corevalve, Evolute R and Evolute PRO (Medtronic), whereas the remaining patients (n = 496)
were treated with a balloon-expandable valve, Sapien 3 (Edwards).
3.3. Study Outcomes
After one year, the risk of cardiovascular death was significantly lower with TAVR compared to
SAVR (Risk Ratio (RR) = 0.56; 95% CI 0.33–0.95; p = 0.03; I2 = 0%; Figure 2A). Similarly, a trend risk
reduction for one-year all-cause mortality was also observed in favor of TAVR (RR = 0.67; 95% CI
0.42–1.07; p = 0.10; I2 = 0%; Figure 2B). The effect was consistent also in fixed effect and no evidence of
publication bias was found for this endpoint. Among the secondary endpoint, patients undergoing
TAVR have a lower risk of new-onset of atrial fibrillation compared to SAVR (RR = 0.26; 95% CI
0.17–0.39; p < 0.00001; I2 = 75%; Figure 2C), major bleeding (RR = 0.30; 95% CI 0.14–0.65; p < 0.002;
I2 = 84%; Figure 2D) and AKI stage II or III (RR = 0.28; 95% CI 0.14–0.58; p = 0.0005; I2 = 0%; Figure 2E).
Conversely, TAVR was associated to a higher risk of aortic regurgitation (RR = 3.96; 95% CI
1.31–11.99; p = 0.01; I2 = 41%; Figure 3A) and permanent pacemaker implantation (RR = 3.47; 95% CI
1.33–9.07; p = 0.01; I2 = 89%; Figure 3B) compared to SAVR. No differences were observed between
the groups in the risks of stroke (RR = 0.71; 95% CI 0.41–1.25; p = 0.24; I2 = 29%; Figure 3C), TIA (RR
= 0.98; 95% CI 0.53–1.83; p = 096; I2 = 0%; Figure 3D) and MI (RR = 0.75; 95% CI 0.43–1.29; p = 0.29;
Figure 3E). The effect was consistent also in fixed effect and no evidence of publication bias was found
for this endpoint for all the secondary outcomes.
4
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Figure 2. Meta-analysis of cardiovascular death, all-cause mortality, new-onset atrial fibrillation,
life-threating bleeding, acute kidney injury II or III stage. (A) Forest plot and summary effect of the
difference in the incidence of cardiovascular death, showing a significantly lower incidence in the TAVR
arm (p = 0.03). (B) Forest plot and summary effect of the difference in the incidence of all-cause mortality
showing no difference between transcatheter aortic valve replacement (TAVR) and surgical aortic valve
replacement (SAVR; p = 0.10). (C) Forest plot and summary effect of the difference in the incidence
of new-onset atrial fibrillation, showing a significantly lower incidence in the TAVR arm (p < 0.001).
(D) Forest plot and summary effect of the difference in the incidence of life-threating bleeding, showing
a significantly lower incidence in the TAVR arm (p < 0.002). (E) Forest plot and summary effect of the
difference in the incidence of acute kidney injury II or III stage, showing a significantly lower incidence
in the TAVR arm (p < 0.0005).
6
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Figure 3. Meta-analysis of aortic regurgitation, permanent PM implantation, stroke, transient ischemic
attack (TIA) and myocardial infarction. (A) Forest plot and summary effect of the difference in the
incidence of aortic regurgitation, showing a significantly lower incidence in the SAVR arm (p = 0.01).
(B) Forest plot and summary effect of the difference in the incidence of permanent PM implantation,
showing a significantly lower incidence in the SAVR arm (p = 0.01). (C) Forest plot and summary
effect of the difference in the incidence of stroke, showing no difference between TAVR and SAVR
(p = 0.24). (D) Forest plot and summary effect of the difference in the incidence of TIA, showing no
difference between TAVR and SAVR (p = 0.96). (E) Forest plot and summary effect of the difference in
the incidence of myocardial infarction, showing no difference between TAVR and SAVR (p = 0.29).
7
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4. Discussion
We performed a meta-analysis with only randomized studies comparing a one-year outcome after
treatment of severe aortic stenosis with TAVR or SAVR in patients at low surgical risk.
Recently, several meta-analyses showed promising results of TAVR [18–20]. However, there are
some differences with our meta-analysis. Kheiri et al. performed a meta-analysis of patients at low
risk, but including transapical TAVR [21] and a post-hoc analysis of the SURTAVI trial [22]. Similarly,
Kolte and colleagues also included in their work the post-hoc analysis of the SURTAVI trial finding a
significant difference in the rate of all-cause death [20]. Conversely, we found only a nonsignificant
difference in such hard clinical end-points. A recently updated meta-analysis [18] of RCTs including
all surgical risk categories had reported a reduction in all-cause mortality up to two years of TAVR
irrespective of baseline surgical risk. However, in the subgroup at low surgical risk, they had reported
only all-cause mortality outcomes with a dishomogenous follow-up. Hence, different TAVR access
approaches were performed in most of the studies. In our meta-analysis, we included only studies
with >95% of transfemoral access-site since current data and expertise strongly favor the femoral artery
as the preferred and most widespread access route for TAVR.
In the present meta-analysis, including three randomized studies and nearly 3000 patients, we
found a superiority of TAVR against SAVR for cardiovascular death (primary endpoint) at the one-year
follow-up (Figure 2A). Interestingly, results on this hard clinical endpoint were strongly homogeneous
across individual studies and could be explained by several factors. Patients undergoing TAVR had less:
acute kidney injury (Figure 2E); new-onset atrial fibrillation (Figure 2C); major bleedings (Figure 2D).
These factors could have a strong impact on mortality, also in the long-term.
The second key finding of our meta-analysis is a significant reduction in the risk of AKI in patients
undergoing TAVI compared with SAVR. Several studies have shown that AKI is a serious complication
after both TAVR and SAVR. Adams and colleagues reported a lower incidence with TAVR compared to
SAVR (6.0% vs. 15.1%; p < 0.001) [23]. Similarly, Bagur et al. showed that 9% suffered from AKI after
TAVR, whereas SAVR was associated with an incidence of AKI in 26% [24]. These results could be of
impact, in fact, AKI was associated with an increased risk of 30-day and long-term (up to seven years)
mortality (42.3% versus 22.7% for seven-year mortality; HR 1.71 (95% CI 1.30–2.25)) [25].
The third key finding of our meta-analysis is a significant reduction in the risk of new-onset atrial
fibrillation (NOAF) in patients undergoing TAVI compared with SAVR. New-onset atrial fibrillation
(NOAF) has emerged in the last few years as a potential prognostic factor in patients undergoing
TAVR [12]. NOAF after TAVR could be detrimental due to atrio-ventricular dyssynchrony resulting
in reduced cardiac output and increased filling pressures. In addition, NOAF could be responsible
for fatal cerebrovascular events. Recently, Gargiulo et al. performed a meta-analysis of eight studies
encompassing 4959 patients to investigate the role of NOAF as a potential prognostic factor in patients
undergoing TAVR. Interestingly, they found a borderline increase of 30-day and a significant increase
in one-year all-cause death in the NOAF group compared with those in sinus rhythm [26].
The fourth key finding of our meta-analysis is a significant reduction in the risk of NOAF in
patients undergoing TAVI compared with SAVR. The impact of bleeding on hard clinical endpoints in
patients undergoing TAVR was already discussed by Piccolo et al. [27]. Among patients with severe
aortic stenosis undergoing TAVR, both access-site and non-access-site bleeding were independently
associated with an increased risk for mortality.
Finally, all these three factors (bleedings, AKI, NOAF) for the reasons mentioned above, could
explain, at least in part, the superiority of TAVR against SAVR for cardiovascular death, also in a
population at low surgical risk at one-year follow-up.
Cerebral embolization is a common complication leading to stroke after TAVR and SAVR [28].
In this meta-analysis, we found no difference in stroke and TIA rates between the groups. These results
are in line with the results of single studies [7,8,17].
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However, some concerns should be raised, and some limitations should be mentioned about TAVR:
(1) paravalvular aortic regurgitation; (2) major incidence of pacemaker implantation; (3) durability at
longer follow-up.
Paravalvular aortic regurgitation and the need for permanent pacemaker implantation have
historically been the limit of TAVR compared with SAVR. Nevertheless, advances in TAVR technology,
along with operator experience, precise valve sizing and implantation technique, may further reduce
the associated pacemaker implantations and paravalvular aortic regurgitation risks. However, in
a recent real-world study of TAVR among lower surgical risk patients, promising rates of 30-day
moderate-to-severe paravalvular leak (0.5%) and permanent pacemaker implantation (6.5%) were
reported [29].
Finally, the question of durability has been an Achilles heel of TAVR. Some recent data seem to
suggest similar longevity between transcatheter and surgical tissue valves out to five to seven years. A
post-hoc analysis wherein investigators looked for valve dysfunction and failure in the NOTION trial
showed that bioprosthetic valve dysfunction was numerically lower in TAVR group over five years
(55.4% versus 65.2%, p = 0.10) [30] compared to SAVR. However, to date, it is not clear if that is good
enough to get TAVR into younger patients.
5. Limitations
As for any meta-analysis, some limitations should be acknowledged that are related to: (1) different
definitions in the studies for different endpoints; (2) differences in the baseline characteristics between
the studies; (3) not all the outcomes are reported in the studies; (4) short-term follow-up.
6. Conclusions
The present meta-analysis, including three randomized studies and nearly 3000 patients with
severe aortic stenosis at low surgical risk, shows that TAVR is associated with lower CV death
compared to SAVR at 1-year follow-up. Nevertheless, paravalvular aortic regurgitation and pacemaker
implantation still represent two weak spots that should be solved.
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Figure S1: Quality assessment.
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Mirosław Gozdek 1,2, Kamil Zieliński 2,3, Michał Pasierski 2,4, Matteo Matteucci 5,6,
Dario Fina 5,7, Federica Jiritano 5,8, Paolo Meani 5,9, Giuseppe Maria Raffa 10,
Pietro Giorgio Malvindi 11, Michele Pilato 10, Domenico Paparella 12,13, Artur Słomka 2,14,
Jacek Kubica 1, Dariusz Jagielak 15, Roberto Lorusso 5, Piotr Suwalski 4 and
Mariusz Kowalewski 2,4,5,* on behalf of Thoracic Research Centre
1 Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Collegium Medicum,
85067 Bydgoszcz, Poland; gozdekm@wp.pl (M.G.); kubicajw@gmail.com (J.K.)
2 Thoracic Research Centre, Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Innovative
Medical Forum, 85067 Bydgoszcz, Poland; kamilziel@gmail.com (K.Z.); michalpasierski@gmail.com (M.P.);
artur.slomka@cm.umk.pl (A.S.)
3 Department of Cardiology, Warsaw Medical University, 02091 Warsaw, Poland
4 Clinical Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior and
Administration, Centre of Postgraduate Medical Education, 02607 Warsa, Poland; suwalski.piotr@gmail.com
5 Department of Cardio-Thoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre,
6229 HX Maastricht, The Netherlands; teo.matte@libero.it (M.M.); dario.fina88@gmail.com (D.F.);
fede.j@hotmail.it (F.J.); paolo.meani@ospedaleniguarda.it (P.M.); roberto.lorussobs@gmail.com (R.L.)
6 Department of Cardiac Surgery, Circolo Hospital, University of Insubria, 21100 Varese, Italy
7 Department of Cardiology, IRCCS Policlinico San Donato, University of Milan, 20097 Milan, Italy
8 Department of Cardiac Surgery, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy
9 Department of Intensive Care Unit, Maastricht University Medical Centre (MUMC+), 6229 HX Maastricht,
The Netherlands
10 Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation,
IRCCS-ISMETT (Instituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione), 90127 Palermo,
Italy; giuseppe.raffa78@gmail.com (G.M.R.); mpilato@ISMETT.edu (M.P.)
11 Wessex Cardiothoracic Centre, University Hospital Southampton, Southampton SO16 6YD, UK;
pg.malvindi@hotmail.com
12 GVM Care & Research, Department of Cardiovascular Surgery, Santa Maria Hospital, 70124 Bari, Italy;
domenico.paparella@uniba.it
13 Department of Emergency and Organ Transplant, University of Bari Aldo Moro, 70121 Bari, Italy
14 Chair and Department of Pathophysiology, Nicolaus Copernicus University, Collegium Medicum,
85067 Bydgoszcz, Poland
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Abstract: Frequent occurrence of paravalvular leak (PVL) after transcatheter aortic valve replacement
(TAVR) was the main concern with earlier-generation devices. Current meta-analysis compared
outcomes of TAVR with next-generation devices: ACURATE neo and SAPIEN 3. In random-effects
meta-analysis, the pooled incidence rates of procedural, clinical and functional outcomes according
to VARC-2 definitions were assessed. One randomized controlled trial and five observational studies
including 2818 patients (ACURATE neo n = 1256 vs. SAPIEN 3 n = 1562) met inclusion criteria.
ACURATE neo was associated with a 3.7-fold increase of moderate-to-severe PVL (RR (risk ratio):
3.70 (2.04–6.70); P < 0.0001), which was indirectly related to higher observed 30-day mortality with
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ACURATE valve (RR: 1.77 (1.03–3.04); P = 0.04). Major vascular complications, acute kidney injury,
periprocedural myocardial infarction, stroke and serious bleeding events were similar between devices.
ACURATE neo demonstrated lower transvalvular pressure gradients both at discharge (P < 0.00001)
and at 30 days (P< 0.00001), along with lower risk of patient–prosthesis mismatch (RR: 0.29 (0.10–0.87);
P = 0.03) and pacemaker implantation (RR: 0.64 (0.50–0.81); P = 0.0002), but no differences were
observed regarding composite endpoints early safety and device success. In conclusion, ACURATE
neo, as compared with SAPIEN 3, was associated with higher rates of moderate-to-severe PVL,
which were indirectly linked with increased observed 30-day all-cause mortality.
Keywords: meta-analysis; ACURATE neo; SAPIEN 3; transcatheter aortic valve replacement
1. Introduction
Since first its mention by Cribier in 2002 [1], transcatheter aortic valve replacement (TAVR) has been
complementary method to surgical aortic valve replacement (SAVR) in inoperable or high-risk patients
with severe symptomatic aortic stenosis. Similar [2] or even lower [3] one-year mortality rate of TAVR,
as compared to SAVR, was shown in selected groups of patients. Hence, TAVR is now considered to be an
alternative treatment option and is recommended not only in inoperable, high or increased risk surgical
patients [2–5] but also in intermediate and lower risk individuals [6–10]. Commercially available
earlier-generation transcatheter valves, despite providing good clinical outcomes, were not free from
shortcomings; indeed, high rates of conduction abnormalities, permanent pacemaker implantation
(PPI) or vascular complications remained important issues to be addressed. More importantly, though,
higher incidence of paravalvular leak (PVL), in turn associated with increased late mortality and higher
rate of other adverse clinical incidents, as compared to SAVR [11–13], often outweigh the benefits of
transcatheter approach.
To minimize these shortcomings, technological innovations were developed in next-generation
valves including the following: balloon-expandable SAPIEN 3 (Edwards Lifesciences, Irvine, CA,
USA) and self-expandable ACURATE neo (Boston Scientific Corporation, Marlborough, MA, USA).
Since direct comparisons of these two devices are few and one recent randomized controlled trial
(RCT) [14] did not demonstrate non-inferiority of the ACURATE neo device as compared to SAPIEN 3
as opposed to previous observational studies [15–21] that, however, pointed to comparable or superior
results with ACURATE, the debate is ongoing.
The objective of the present investigation was to evaluate and compare short-term results of
TAVR with ACURATE neo and SAPIEN 3 in patients presenting with symptomatic severe native aortic
valve stenosis.
2. Experimental Section
2.1. Data Sources and Search Strategy
The systematic review and meta-analysis were performed in accordance to MOOSE statement
and PRISMA guidelines [22,23]. The MOOSE checklist is available as Table A1. We searched PubMed,
ClinicalKey, the Web of Science and Google Scholar all until October 2019. Search terms were as follows:
“ACURATE neo” (or “ACCURATE neo”), “Symetic ACURATE”, “Boston ACURATE” and/or “SAPIEN
3”, “SAPIEN III” and “transcatheter valve” or “aortic”. The literature was limited to peer-reviewed
articles published in English. References of original articles were reviewed manually and cross-checked.
2.2. Selection Criteria and Quality Assessment
Studies were included if having met all of the following criteria: (1) human study; (2) study or
study arms comparing directly strategy of transcatheter aortic valve replacement with ACURATE neo
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and SAPIEN 3; (3) RCT or propensity score matched observational study. Studies were excluded if they
fell into the following categories: (1) in-vitro study; (2) single arm; (3) adjustment not PS or methods
not reported; (4) outcomes of interest not reported; and (5) sub-studies or overlapping populations.
No restrictions regarding number of patients included or characteristic of the population were imposed.
Two reviewers (M.G. and K.Z.) selected the studies for the inclusion, extracted studies and patients’
characteristics of interest and relevant outcomes. Two authors (M.G. and K.Z.) independently assessed
the trials’ eligibility and risk of bias. Any divergences were resolved by consensus.
Quality of RCTs was appraised by using the components recommended by the Cochrane
Collaboration [24]; observational studies were, instead, appraised with ROBINS-I (Risk of Bias in
Nonrandomised Studies-of Interventions), a tool used for assessment of the bias (the selection of the
study groups; the comparability of the groups; and the ascertainment of either the exposure or outcome
of interest) in cohort studies included in a systematic review and/or meta-analysis [25].
2.3. Endpoints Selection
Endpoints were established according to the Valve Academic Research Consortium-2 (VARC-2)
definitions [26]. Procedural outcomes of interest were predilatation and postdilatation, procedural
times and contrast volume. Clinical endpoints assessed included the following: PPI, major vascular
complications (MVC), serious bleeding (life-threatening and/or major), acute kidney injury (AKI), stroke,
myocardial infarction and 30-day mortality. Functional outcomes were as follows: mean transvalvular
gradients, prosthesis-patient mismatch (PPM), and mild and moderate-to-severe paravalvular leak (PVL).
Composite endpoints were as per VARC-2: device success (defined as absence of procedural death, correct
position of 1 valve in the proper location, mean gradient < 20 mm Hg or peak velocity < 3 m/s, absence of
moderate-to-severe PVL and absence of PPM) and early safety (composite of all-cause death, any stroke,
life-threatening or disabling bleeding, major vascular complications, coronary artery obstruction requiring
intervention, acute kidney injury (stage 2 or higher), rehospitalization for valve-related symptoms
or congestive heart failure, valve-related dysfunction requiring repeat procedure, and valve-related
dysfunction determined by echocardiography (mean aortic valve gradient≥ 20 mm Hg and either effective
orifice area ≤ 0.9–1.1 cm2 (depending on body surface area) or Doppler velocity index < 0.35; or moderate
or severe prosthetic PVL).
2.4. Statistical Analysis
Data were analyzed according to intention-to-treat principle, wherever applicable. Risks ratios
(RR) and 95% confidence intervals (95% CI) served as primary index statistics for dichotomous
outcomes. For continuous outcomes, mean difference (MD) and corresponding 95% CI were calculated
by using a random effects model. To overcome the low statistical power of Cochran Q test, the statistical
inconsistency test I2 = [(Qdf)/Q]×100%, where Q is the chi-square statistic and df is its degrees of
freedom, was used to assess heterogeneity [27]. It examines the percentage of inter-study variation,
with values ranging from 0% to 100%. An I2 value of 25% indicates low heterogeneity, 50% are suggestive
of moderate heterogeneity and 70% of high heterogeneity. Because of high degree of heterogeneity
anticipated among predominantly nonrandomized trials, an inverse variance (DerSimonian–Laird)
random-effects model was applied as a more conservative approach for observational data accounting
for between- and within-study variability. Whenever a single study reported median values and
interquartile ranges instead of mean and standard deviation (SD), the latter were approximated as
described by Wan and colleagues [28]. In case there were “0 events” reported in both arms, calculations
were repeated, as a sensitivity analysis, using risk difference (RD) and respective 95% CI. Additionally,
we performed a set of meta-regression analyses to address potential relationships between 30-day
all-cause mortality and other endpoints and baseline characteristics assessed. For the analyses of
clinical endpoints, RCTs and PS-matched studies were analyzed separately. Review Manager 5.3
(The Nordic Cochrane Centre, Copenhagen, Denmark) was used for statistical computations. P-values
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≤ 0.05 were considered statistically significant and reported as two-sided, without adjustment for
multiple comparisons.
3. Results
3.1. Study Selection and Bias
Study selection process and reasons for exclusion of some studies are described in Figure 1.
Figure 1. Study selection and inclusion process.
Systematic search of the online databases allowed collection of 58 potentially eligible records
that were retrieved for scrutiny. Of those, 52 were further excluded because they were not pertinent
to the design of the meta-analysis or did not meet the explicit inclusion criteria. One RCT [14]
and five observational studies [15–19] enrolling the total of 2818 patients were eventually included
in the analysis. Potential sources of the studies’ bias were analyzed with the use of components
recommended by the Cochrane Collaboration and ROBINS-I tool, and the results are enclosed as
Table A2. Overall, the studies reported moderate risk of bias. Most commonly, biases arose from
participants selection for the study by designated heart teams and subjective distribution of the
participants within the study arms. All but one study [14] lacked a core lab assessment of PVL and
central adjudication of clinical events.
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Patients were divided into two groups: those treated with ACURATE neo transcatheter valve
(n = 1256) and SAPIEN 3 transcatheter valve (n = 1562). Summary of the valve characteristics is
available as Table 1.
Table 1. Valve characteristics and features.
ACURATE neo (Boston Scientific Corporation) SAPIEN 3 (Edwards Lifesciences)
Supra-annular Intra-annular
Porcine pericardial leaflet tissue Bovine pericardial leaflet tissue
Self-expanding, deployment in a top-down
mechanism of nitinol frame. Balloon-expandable cobalt-chromium frame
Transfemoral sheath size (valve size)
18-French for all devices: Small (23 mm), Medium (25
mm), Large (27 mm).
Ready for ultra-low profile: 14 F (20, 23, 26 mm); 16 F
(29 mm), 18 F (20, 23, 26 mm), 21 F (29 mm)
Special features
-Upper and lower crown;
-Three stabilization arches;
-Outer and inner pericardial skirt.
-Outer sealing and inner skirt at the inflow
Studies’ characteristics, as well as definitions or diagnostic criteria for assessed clinical endpoints,
are reported in Table 2. Table A3 lists selection criteria for the procedure and valve, as well as
inclusion and exclusion criteria within particular studies. Patients’ baseline characteristics and detailed
procedural characteristics are available as Tables A4 and A5. All studies reported data on 30-day clinical
outcomes; three reported Kaplan–Meier estimates of survival at longer-term follow-ups [15,16,18].
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3.2. Patients Characteristic
Groups treated with ACURATE neo and SAPIEN 3 did not differ regarding patients’ age (P = 0.363),
body mass index (P = 0.708), NYHA III/IV status (P = 0.115) or left ventricle ejection fraction (P = 0.178).
No difference was found in the baseline logistic EuroSCORE as well (P = 0.749). SAPIEN 3 group
included significantly fewer female individuals, 59.7% vs. 64.1%, respectively (P = 0.037). Aortic
valve baseline echo-parameters, i.e., mean trans-aortic gradient were comparable: 43.4 ± 15.8 vs.
43.6 ± 15.5 mmHg (P = 0.861) in ACURATE neo and SAPIEN 3, respectively (Figure 2), although the
aortic annulus plane area were on average 4 mm2 smaller in the ACURATE neo recipients 439.7 ± 62.4
vs. 446.7 ± 76.3; P = 0.037 as compared to SAPIEN 3. Transfemoral access was mostly widely employed
during TAVR procedure; in five studies, it was used exclusively [14,16–19]. Barth et al. [15] included
both transfemoral and transapical access in 75.7% vs. 24.3% and 74.5% vs. 25.5% for ACURATE neo
and SAPIEN 3, respectively. For the transapical approach, ACUARATE TA device was used.
Figure 2. Analysis of mean transaortic gradients before and after transcatheter aortic valve replacement (TAVR).
3.3. Procedural Outcomes
Five studies [14,15,17–19] and 2722 patients contributed to the analysis of procedural outcomes
between two devices. Both predilatation and postdilatation were more common with ACURATE neo
valve; predilatation was necessary in 1124/1271 (88.4%) of cases as compared to 801/1514 (52.9%); RR
2.05, 95% CI, (1.44, 2.94) P < 0.0001; I2 = 97%); postdilatation: RR 3.10, 95% CI, (2.01, 4.77) P < 0.00001; I2
= 88%) with respective rates of 45.3% vs. 17.2% for ACURATE neo and SAPIEN 3, respectively. Figure 1
and A2. The procedures performed with ACURATE neo required significantly greater amount of
contrast: 130.3 ± 56.1 mL vs. 109.7 ± 50.3 mL (MD 18.22 95% CI, (10.04, 26.40) mL; P < 0.0001). Figure 3).
Four studies [14,15,17,19] including 1116 ACURATE neo and 1411 SAPIEN 3 cases provided data on
procedure duration, which on average 3 minutes longer in the former: 60.1 ± 28.6 min. vs. 56.5.9 ±
26.0 min. (MD 3.06, 95% CI, (−0.66, 6.76) min) without reaching statistical significance (Figure 4). Use
of >1 valve was necessary in 35 cases (26 ACURATE neo vs. nine SAPIEN 3; RR 3.24, 95% CI, (1.47,
7.13) P = 0.004; I2 = 0%). Incidence of cardiac tamponade was reported in three studies [14,15,18] with
respective event rates of 1.0% vs. 0.7% for ACURATE neo and SAPIEN 3 valves: RR 1.17, 95% CI, (0.52,
2.63) P = 0.70; I2 = 0%. Early procedural complications included the following: coronary obstruction in
three ACURATE neo patients and total of eight annular ruptures, 20 conversions to surgery and 20
valve malpositionings without differences between two devices.
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3.4. Clinical Outcomes
Six studies [14–19] enrolling 2818 patients contributed data for the analysis of early safety as defined by
VARC-2; with the corresponding rates of 13.9% (174/1256) and 12.6% (197/1562) for ACURATE neo and
SAPIEN 3 valves, respectively, there were no statistical differences between two devices (RR 1.15, 95% CI,
(0.94, 1.40) P = 0.16; I2 = 0%) and pooled estimates of RCT and PS-matched studies in subgroup analysis
(Pinteraction = 0.47) (Figure 3a). In the pooled analysis of device success (five studies included (2634 patients.)),
there were no differences between two types of valve in the pooled analysis: RR 1.01, 95% CI, (0.92, 1.10)
P = 0.89; I2 = 89%). Analyzed separately, there were strong between-subgroup differences between RCT
and pooled estimate from PS-matched studies: RR 1.44, 95% CI, (1.24, 1.66); P < 0.00001; I2 =NA and RR




Figure 3. Individual and summary risk ratios with corresponding 95% confidence intervals for the
comparison of ACURATE neo vs. SAPIEN 3 in the analysis of clinical outcomes: (a) early safety,
(b)·device success and (c) permanent pacemaker implantation.
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There were no differences between ACURATE neo and SAPIEN 3 valves in terms of risk of major
vascular complications (RR 1.21, 95% CI, (0.89, 1,65); P = 0.23; I2 = 6%; Figure 5), acute kidney injury
(RR 1.28, 95% CI, (0.71, 2,31); P = 0.42; I2 = 15%; Figure 6), periprocedural myocardial infarction
(RR 1.76, 95% CI, (0.36, 8.47); P = 0.428 I2 = 0%; Figures 7 and 8), stroke (RR 0.95, 95% CI, (0.57, 1.57);
P = 0.84 I2 = 0%; Figures 9 and 10), and serious bleeding events (RR 1.23, 95% CI, (0.95, 1.61); P = 0.12;
I2 = 0%; Figure 11).
Based on the data from six studies (2818 pts.), PPI was required nearly 30% less often after
ACURATE neo implantation as compared to SAPIEN 3 (RR 0.72, 95% CI, (0.58, 0.89); P = 0.003;
I2 = 75.9%) with corresponding frequency of 10.1% vs. 14.2%, respectively (Figure 3c). Importantly,
the estimates derived from SCOPE I differed from the pooled estimates (Pinteraction = 0.04) with higher
rates of PPI observed in SAPIEN 3 arm in PS-matched studies (9.3% vs. 15.8%) Table 6 lists the VARC-2
derived quality criteria for PPI appraisal
3.5. Functional Outcomes
With five studies [14–16,18,19] and 1885 patients included, mild PVL occurred less frequently in
SAPIEN 3 recipients, 28.0% (263 of 940), compared to ACURATE neo group, 45.5% (430 of 945); (RR 1.60,
95% CI, (1.40, 1.84) P < 0.00001; I2 = 14%) (Figure 4a). Moderate-to-severe PVL was uncommon in
the entire series (6.5%); however, there was a significant 3.7-fold increase in moderate-to-severe PVL
risk with ACURATE neo implantation: (RR 3.70, 95% CI, (2.04, 6.70) P < 0.0001; I2 = 53%) (Figure 4b)





Figure 4. Individual and summary risk ratios with corresponding 95% confidence intervals for the
comparison of ACURATE neo vs. SAPIEN 3 in the analysis of functional outcomes: (a) mild and (b)
moderate-to-severe paravalvular leak.
Data regarding postprocedural transaortic gradient came from all six studies with 2818 patients.
Mauri et al. [18] reported on 1-year transaortic gradients as well. (Figure 2). Mean postprocedural
transaortic gradients were higher in SAPIEN 3 patients both at discharge and at 30 days post-op:
12.4 ± 4.7 vs. 8.7 ± 4.5 mmHg (P < 0.00001) and 11.5 ± 4.9 vs. 7.5 ± 3.4 mmHg (P < 0.00001) respectively.
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3.6. All-Cause Mortality
Six studies reported on 30-day all-cause mortality. Overall, 61 (2.2%) patients died within the first
30 days, with respective rates of 2.9% and 1.6% in ACURATE neo and SAPIEN 3 groups; ACURATE
neo was associated with 77% higher 30-day mortality risk (RR 1.77, 95% CI, (1.03, 3.04); P = 0.04; I2 = 0%
(Figure 5a and Appendix Figure 12). A random-effects meta-regression was fitted, counter-opposing
all-cause mortality risk ratio against the risk difference of moderate-to-severe PVL; there was a trend for
higher 30-day mortality rates with higher incidence of moderate-to-severe PVL (beta = 0.023; P = 0.093)
(Figure 5b); similarly, a meta-regression was fitted with all-cause mortality risk ratio against the mean
annulus area in the ACURATE neo arm showing a trend for lower between devices mortality ratio in
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(c) 
Figure 5. Individual and summary risk ratios with corresponding 95% confidence intervals for the
comparison of ACURATE neo vs. SAPIEN 3 in the analysis of (a) 30-day all-cause mortality; (b,c) meta
regression analyses.
4. Discussion
To the best of our knowledge, this is the first systematic review and meta-analysis of observational
trials comparing major procedural, short-term clinical and functional outcomes between the ACURATE
neo and SEPIEN 3, the next-generation transcatheter valves designed to minimize shortcomings of the
earlier-generation devices. Our analysis, by pooling data from one RCT and five PS-matched studies,
demonstrated excellent data regarding short-term performance of both devices. Compared populations
of patients were well balanced with respect to baseline characteristics and severity of underlying
valvular disease. Main findings of the current study are that the ACURATE neo implantation as
compared to SAPIEN 3 was associated with lower transvalvular gradients and lower risk of permanent
pacemaker implantation. Other clinical endpoints which included vascular complications, AKI, as well
as life threatening and major bleeding; stroke and MIs did not differ between the two groups. The
use of ACURATE neo procedures were significantly longer and required a greater amount of contrast
volume. Device success and early safety combined endpoints, as defined by VARC-2 criteria, were,
however, similar regardless the type of valve implanted. Importantly, the current study revealed
significantly higher rates of both mild and moderate-to-severe PVL with ACURATE neo as compared
to SAPIEN 3 and the latter were indirectly associated with worse survival observed in ACURATE
neo group.
Previous observational studies [15–21] and, among them, the SAVI-TF (Symetis ACURATE neo
Valve Implantation Using Transfemoral Access) registry [29,30] reported on excellent short-term
outcomes with low complications and, in particular, PPI rates in ACURATE neo valve attributable to
the design of the prosthesis. The particularly low gradients also contributed to the similar or better rates
of device success for ACURATE neo and SAPIEN 3 in propensity matched comparisons. Whether the
abovementioned benefits would hold true in randomized populations and further translate into
improved clinical outcomes was investigated in the Safety and Efficacy of the Symetis ACURATE
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Neo/TF Compared to the Edwards SAPIEN 3 Bioprosthesis trial (SCOPE I) [14]. Interestingly, the
ACURATE neo valve failed to meet noninferiority for its primary endpoint of combined at 30 days
against the balloon-expandable SAPIEN 3 (Edwards Lifesciences) valve. Moreover, secondary analyses
demonstrated SAPIEN 3 to be superior for the composite safety and efficacy endpoint, driven by
less stage 2 or 3 acute kidney injury and less paravalvular leak. Valve dysfunction requiring repeat
interventions was also less common at 30 days. In particular, findings on device success need to be
addressed, since the rates varied largely between RCT and the remaining PS-matched studies driven
by higher patient prosthesis mismatch in the SAPIEN 3 group (P < 0.00001). Indeed, median mean
transvalvular gradient was lower, and the median mean aortic valve area was larger, in the ACURATE
neo, compared to the SAPIEN 3 group, at follow-up echocardiography in the SCOPE I trial. This
may have been partially due to the fact that sizing and thus the choice of the valve process were
different in the SCOPE I and the remaining studies. Some residual bias despite propensity score
matching also cannot be excluded. In fact, Mauri et al. [18] reports on the sizing category was based on
perimeter for ACURATE neo and annular area for SAPIEN 3, then all patients received ACURATE
neo size S or SAPIEN 3 23 mm. In the study by Husser et al. [17] after PS-matching, there remained
a P = 0.003 difference in aortic annular area; Schaefer et al. [19] reports aortic annulus size to have
presented significant differences for area derived aortic annulus diameter (23.9 ± 2.8 vs. 24.8 ± 2.6
mm; P = 0.02) and perimeter-derived aortic annulus diameter (24.5 ± 2.5 vs. 25.3 ± 2.6 mm; P = 0.02),
which, in consequence, led to oversizing in the ACURATE neo and undersizing SAPIEN 3 (1.5 ± 6.6
vs. −0.9 ± 6.4; P = 0.01 for cover index). Further, only in the SCOPE I trial, both the clinical events
and functional assessment details were adjudicated by independent core lab. Independently, there
were fewer PPI necessary after ACURATE neo in the PS-matched studies; since not confirmed in the
SCOPE I, the supra-annular positioning of the valve must have had played, however, a much less
important role than expected, and the lower PPI rates originating from skewed valve-size selection
and positioning of the valve in the annulus [29]. More importantly, though, SCOPE I trial, by design,
excluded over 300 patients with excessive calcification of aortic valve or left ventricular outflow tract
(LVOT), which was not the case in remaining studies included in the current analysis. Presence of
calcifications in both aortic annulus and LVOT could have accounted for much higher rates of PPI
in the SAPIEN 3 arms across included PS-matched studies (average PPI incidence rate of 15.8%) as
compared to SCOPE I trial with 9.3% rate, similarly to what has been already demonstrated for SAPIEN
3 in another meta-analysis by the same group [30].
Conversely to the abovementioned, yet still contributing to device success rates, was the higher
incidence of moderate-to-severe PVL in the ACURATE neo valve, which was confirmed also in the
current meta-analysis. In the next-generation devices, improved by addition an external sealing cuff or
a skirt, the frequencies of mild and moderate-to-severe PVL became significantly lower as compared
with the earlier-generation valves. The pooled occurrence of more than mild PVL decreased from 6.9%
SAPIEN XT to 1.6% in SAPIEN 3 valve, as in a meta-analysis by Ando et al. with 2498 patients [31].
The PARTNER II SAPIEN-3 trial, which assessed early outcomes after TAVR in inoperable, high-risk
and intermediate-risk patients with severe aortic stenosis, showed moderate-to-severe PVL in 3.4%
and mild in 40.7% of the cases [32]. The abovementioned improvements seen in next-generation
devices seem not to be the case with ACURATE neo; in the meta-analysis, we found 11.7% incidence
of moderate-to-severe PVL in the ACURATE neo arm, nearly fourfold higher than in SAPIEN 3 and
mild PVL in 45.5% cases, translating into 60% increased risk. Unlike the current findings, SAVI TF
registry showed 4.1% of >mild PVL in 1000 patients treated with ACURATE neo which is within ranges
observable for other devices [33–38]. Postdilatation was performed in 44.8% of the patients in that
series, and this percentage is also comparable to 40.4%–51.9% in the current analysis, and therefore,
theoretically, should not influence the outcome; on the other hand, Barth et al. [15] reports lower >mild
PVL rates in one of participating centers (C) that used “zero tolerance of more than mild paravalvular
leak” policy and postdilated more frequently than other centers (52.7% as compared to 12.3% and
33.3%), which translated to 3.4% rate of >mild PVL (as compared to 6.0% and 34.1% in the remaining
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centers). Interestingly, this center was the one to demonstrate highest one-year survival (87.4% (95% CI:
79.6–92.3) compared to 75.4% (95% CI: 60.4–85.3) and 81.3% (95% CI: 70.1–88.6)). Corroborating these
estimates on larger scale and also in shorter follow-up, the current meta-analysis found an indirect link
between increased rates of >mild PVL and higher mortality in the ACURATE neo arm at 30 days. While
the presence of residual >mild PVL has been long shown to be associated with increased mortality in
the long-term [39,40], the link between >mild PVL and 30-day mortality appears less clear, particularly
for next-generation devices [12]. The abovementioned may be of importance given the fact that acute
aortic insufficiency of various degree in patients with prior pure aortic stenosis and diminished LV
compliance is often a cause of heart-failure exacerbation early in the sequelae [41].
An indirect link to increased mortality with ACURATE neo, as found also in meta-regression
of annular area; indeed, lower between-devices mortality risk ratios between ACURATE neo and
SAPIEN 3 were shown in patients with smaller annuli. An important hypothesis generated by present
meta-analysis is that ACURATE neo performs differently in this setting; since we could not demonstrate
excess of annual ruptures, cardiac tamponades, conversions to surgery or other periprocedural
complications in either group, the explanation of this phenomenon remains to be elucidated.
Several inherent limitations to the current analysis need to be acknowledged; firstly, the majority
of included studies are of an observational nature. Despite accounting for differences in the patients’
baseline populations by propensity matching in all of the non-randomized reports, there remain other
confounders, like learning curve, operators’ experience and decision as of valve size and type that
add to the risk of bias. Indeed, it cannot be refused that ACURATE neo was the preferred valve in
smaller aortic annuli in PS-matched studies. Secondly, one study [15] reports on outcomes with both
transfemoral ACURATE neo and transapical ACURATE TA systems. While similar in stent design and
technological features, there are certain, albeit minor, differences in delivery system and biological
tissue used in both devices [42]. Thirdly, only half of included studies reported follow-up longer than
one month; paucity of data regarding long-term clinical and functional outcomes significantly impedes
interpretation of ACURATE neo and SAPIEN 3 clinical suitability. Lastly, all but one study [14] lacked
of an external core lab assessment and adjudication of echocardiographic outcomes. Finally, to better
visualize the relative advantages of the contemporary-use valve systems, the results of a second similar
study, SCOPE II (NCT03192813), will compare the ACURATE neo to the EVOLUT R system with
respect to a composite of all-cause death and stroke at one year.
5. Conclusions
Contemporary evidence shows good short-term implantation outcomes of both ACURATE neo
and SAPIEN 3 valves, with no differences in combined endpoints of device success and early safety.
Implantation of ACURATE neo was associated with lower transvalvular gradients and lower risk
of permanent pacemaker implantation. Moderate-to-severe PVL rates were, however, higher in
ACURATE neo valve and were indirectly associated with increased 30-day all-cause mortality.
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Days Post TAVR for PPI
Reported
Barth S et al. 2019 [15] No no In-hospital
Costa et al. 2019 [16] Yes no NA
Husser O et al. 2017 [17] Yes no In-hospital and 30 days
Lanz J et al. 2019 [14] Yes no 30 days
Mauri V et al 2017 [18] No no 30 days
Schaefer A et al. 2017
[19] No
Atrioventricular block




TAVR, transcatheter aortic valve replacement; PPI, permanent pacemaker implantation; NA, not available.
Figure 1. Procedural outcomes. Individual and summary risk ratios with corresponding 95% confidence
intervals for the comparison of ACURATE neo vs. SAPIEN 3 in the analysis of predilatation.
Figure 2. Procedural outcomes. Individual and summary risk ratios with corresponding 95% confidence
intervals for the comparison of ACURATE neo vs. SAPIEN 3 in the analysis of postdilatation.
Figure 3. Procedural outcomes. Detailed analysis of individual weighted mean differences (MDs) with
corresponding 95% CIs on contrast volume used for the comparison of ACURATE neo vs. SAPIEN 3.
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Figure 4. Procedural outcomes. Detailed analysis of individual weighted mean differences (MDs) with
corresponding 95% CIs on procedure duration for the comparison of ACURATE neo vs. SAPIEN 3.
 
Figure 5. Clinical outcomes. Individual and summary risk ratios with corresponding 95%
confidence intervals for the comparison of ACURATE neo and SAPIEN 3 in the analysis of major
vascular complications.
 
Figure 6. Clinical outcomes. Individual and summary risk ratios with corresponding 95% confidence
intervals for the comparison of ACURATE neo and SAPIEN 3 in the analysis of acute kidney injury.
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Figure 7. Clinical outcomes. Individual and summary risk ratios with corresponding 95% confidence
intervals for the comparison of ACURATE neo and SAPIEN 3 in the analysis of periprocedural
myocardial infarction.
 
Figure 8. Clinical outcomes. Individual and summary risk ratios with corresponding 95% confidence
intervals for the comparison of ACURATE neo and SAPIEN 3 in the analysis of periprocedural
myocardial infarction taking into account “0 events”.
 
Figure 9. Clinical outcomes. Individual and summary risk ratios with corresponding 95% confidence
intervals for the comparison of ACURATE neo and SAPIEN 3 in the analysis of stroke.
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Figure 10. Clinical outcomes. Individual and summary risk ratios with corresponding 95% confidence
intervals for the comparison of ACURATE neo and SAPIEN 3 in the analysis of stroke taking into
account “0 events”.
 
Figure 11. Clinical outcomes. Individual and summary risk ratios with corresponding 95% confidence
intervals for the comparison of ACURATE neo and SAPIEN 3 in the analysis serious bleeding events.
 
Figure 12. Clinical outcomes. Individual and summary risk ratios with corresponding 95% confidence
intervals for the comparison of ACURATE neo and SAPIEN 3 in the analysis of 30-day all-cause
mortality taking into account “0 events”.
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Abstract: (1) Background: Knowledge about predictors for the long-time patency of recanalized
chronic total coronary occlusions (CTOs) is limited. Evidence from invasive follow-up in the absence
of acute coronary syndrome (routine surveillance coronary angiography) is scarce. (2) Methods: In a
monocentric-retrospective analysis, we obtained baseline as well as periprocedural data of patients
undergoing routine invasive follow-up. We defined target vessel failure (TVF) as a combined primary
endpoint, consisting of re-occlusion, restenosis, and target vessel revascularization (TVR). (3) Results:
We included 93 consecutive patients (15.1% female) from October 2013 to May 2018. After a follow-up
period of 206 ± 129 days (median 185 (IQR 127–237)), re-occlusion had occurred in 7.5%, restenosis in
11.8%, and TVR in 5.4%; the cumulative incidence of TVF was 15.1%. Reduced TIMI-flow immediately
after recanalization (OR for TVR: 11.0 (95% CI: 2.7–45.5), p = 0.001) as well as female gender (OR for
TVR: 11.0 (95% CI: 2.1–58.5), p = 0.005) were found to be predictive for pathological angiographic
findings at follow-up. Furthermore, higher blood values of high-sensitive troponin after successful
revascularization were associated with all endpoints. Interestingly, neither the J-CTO score nor the
presence of symptoms at the follow-up visit could be correlated to adverse angiographic results.
(4) Conclusions: In this medium-sized cohort of patients with surveillance coronary angiography, we
were able to identify reduced TIMI flow and female gender as the strongest predictors for future TVF.
Keywords: chronic total occlusion; target vessel failure; re-occlusion; surveillance
coronary angiography
1. Introduction
Coronary chronic total occlusion (CTO) is defined as either absent or minimal antegrade coronary
blood flow diagnosed by coronary angiography that had existed for >12 weeks [1]. According to
registry data, this distinct subtype of coronary artery disease has a prevalence of up to 20% of all
invasive coronary diagnostics [2]. Nevertheless, expert opinion on the optimal treatment strategy
(conservative, interventional, or surgical) is still controversial. According to contemporary data on
clinical practice, only about one third of all patients with a CTO are treated by revascularization
J. Clin. Med. 2020, 9, 178; doi:10.3390/jcm9010178 www.mdpi.com/journal/jcm41
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(percutaneous coronary intervention (PCI) or coronary artery bypass grafting surgery (CABG)) [2].
In contrast to non-CTO PCIs with a procedural success rate of 98%, interventional CTO procedures
are more complex and have a significantly lower periprocedural revascularization rate of 60% to 70%
in non-specialized centers [2,3], which can exceed 90% in highly specialized units [4,5]. As a tool to
assess and grade lesion difficulty as well as predicting successful guidewire crossing within 30 min in
interventional recanalization, the J-CTO (Multicenter CTO Registry in Japan) score was developed
and validated. The presence of five specific lesion characteristics in CTO vessels that are known
to hamper revascularization success (blunt stump, occlusion length > 20 mm, calcification, vessel
bending > 45 degrees, and previously failed PCI) are assigned to one point each and summarized [6].
Vessel revascularization in CTO lesions has been associated with clinical improvement of angina and a
prognostic benefit regarding a lower rate of subsequent myocardial infarction and longer survival in
clinical registries [7–10]. However, evidence on long-term angiographic results as well as potential
predictors for vessel patency and re-occlusion post CTO-PCI is scarce. Results from other registries
imply that a higher pre-interventional J-CTO score—beyond acute success—might have an impact
on an increased probability for future adverse events [11,12]. Thus, the objectives of this study were
(i) to investigate the incidence of long-term target vessel failure (re-occlusion, restenosis, and target
vessel revascularization) as assessed by invasive follow-up in an all-comer retrospective monocentric
analysis, and (ii) to identify potential predictors of future target vessel failure after successful CTO
recanalization, including the J-CTO score.
2. Methods
Data of all patients consecutively treated with successful PCI for CTO-lesions in our center
between October 2013 to September 2017 that had an elective control coronary angiography until
May 2018 were included in this retrospective analysis. Surveillance angiography after a follow-up
period of 3 to 12 months was routinely recommended after successful recanalization of a CTO vessel
in accordance with the guidelines for high-risk lesions [13]. Patients primarily undergoing urgent
invasive control for acute coronary syndrome at a follow-up instead of the elective control coronary
angiography were excluded from the analysis. From October 2013 to September 2017, recanalization
of CTO lesions by PCI was successfully performed in 201 cases in our center. For this retrospective
analysis, data of 100 patients of this cohort with an invasive follow-up in our center were available
(49.8%). Seven patients were excluded because of either an extremely long latency from the index
procedure to follow-up (n = 3) and/or because of acute coronary syndrome as an indication for
repeated invasive coronary angiography (n = 5) in order to prevent potential bias by findings not
solely grounded on previously recommended routine control. All subjects were adult individuals (≥18
years) with pre-existing fluoroscopic evidence of a chronically occluded coronary vessel. The choice of
the interventional approach (antegrade vs. retrograde recanalization, radial or femoral access) and
material for intervention at the index visit (e.g., guiding catheters, guidewires, PCI balloons, and stents)
was subject to the discretion of the operator.
Patients’ characteristics, clinical features (angina pectoris: Defined as chest discomfort as classified
by Canadian Cardiovascular Society (CCS) class >2; symptoms: Defined as the presence of angina
pectoris CCS class>2 and/or dyspnea NYHA (New York Heart Association) class>1; echocardiographic
baseline parameters; proof of vitality of the region of the CTO), comorbidities, cardiovascular risk
factors, as well as features of the PCI procedure (e.g., treated vessel, dose of contrast dye and radiation,
fluoroscopy and procedural duration, J-CTO score and its subfactors (lesion entry, length, bending, and
previously failed PCI attempt) of the lesion, number and length of used stent material), periprocedural
levels of biomarkers (e.g., high-sensitive troponin I, creatinine, C-reactive protein), and clinical and
angiographic findings at the invasive follow-up visit were gathered and analyzed. For a detailed
protocol to quantify the J-CTO score, see [6]. Adipositas was defined as BMI (Body mass index)
≥ 30 kg/m2, according to the WHO definition. Renal impairment was defined as a glomerular
filtration rate < 60 mL/min*1.73m2. The grade of a potential restenosis at the follow-up coronary
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angiography was retrospectively reassessed and the diameter loss in comparison to the reference
vessel diameter was quantified in a semi-automatic manner by the Quantitative Coronary Analysis
(QCA) tool (Philips Healthcare, Andover, MA, USA) for this study. Additionally, TIMI flow—as
defined by the Thrombolysis in Myocardial Infarction Trial, quantified in Grades 0–3—was recorded
semi-quantitatively for the time points directly after the index procedure and at the follow-up visit.
The primary endpoints of the retrospective analysis of our patient cohort study were defined as
follows:
(1) Re-occlusion: Defined as TIMI flow grade 0, as assessed by fluoroscopy of the treated vessel at
the timepoint of surveillance coronary angiography.
(2) Restenosis: Defined as the recurrence of lumen loss >50% in the CTO vessel as quantified
retrospectively by QCA (including re-occlusion).
(3) Target vessel failure (TVF): Defined as a combined endpoint by the presence of re-occlusion,
restenosis, or target vessel revascularization (defined as a necessity for a repeated PCI within the
former CTO vessel).
We compared baseline parameters and values of clinical, fluoroscopic, and laboratory findings
during index hospitalization (CTO PCI procedure) and at the timepoint of invasive follow-up and
assigned patients to groups dependent on the presence of each singular endpoint as well as the
combined endpoint at the time of follow-up surveillance coronary angiography. Continuous variables
are presented as a mean ± standard deviation or as a median and interquartile range and categorial
variables are expressed as percentages. Continuous variables found not to follow a normal distribution
when tested with the modified Kolmogorov–Smirnov test (Lilliefors test) and Shapiro–Wilk-test were
compared using the Wilcoxon matched-pairs signed rank test or the Wilcoxon–Mann–Whitney test for
comparison between each two groups. Normally distributed continuous variables were compared
using the Students’ t-test and categorical variables with Fisher’s exact or Chi2 test, as appropriate.
Logistic regression analyses were performed in order to identify potential predictors for the
occurrence of endpoints. Odds ratios (ORs) are given with the corresponding 95% confidence intervals
(CIs). Logistic regressions were calculated by a univariate and a multivariate model, which was
adjusted for age, diabetes, hyperlipidemia, smoking, hypertension, and a positive family history
of cardiovascular disease. Receiver operating characteristics (ROCs) curves were calculated for the
sensitivity and specificity of the J-CTO score to predict each individual endpoint, and the areas under
the curve (AUC) are presented with the corresponding 95% CI. p values < 0.05 (two-sided) were
considered to be statistically significant. Statistical analysis was conducted using SPSS software version
24 (SPSS Inc., Chicago, IL, USA).
Since the study involved only an anonymized, retrospective analysis of diagnostic standard data,
ethics approval was not required according to German law.
3. Results
At the time of the index procedure, the 93 patients included in our analysis had a mean age of
65.6 ± 11.0 years old, 15.1% of them were female, and they had been symptomatic (angina or dyspnea)
before intervention in 81.7% of the cases. The predominant target vessel for CTO intervention was
the right coronary artery in 54.8% of the cases and the mean J-CTO score was 1.49 ± 1.09. Most
predominant cardiovascular risk factors comprised arterial hypertension (79.6%), smoking (57.0%),
and hyperlipidemia (59.1%) as well as a history of previous PCI (74.2%). A detailed overview of the
baseline characteristics of all included subjects is displayed in Table 1. A mean of 2.2 ± 1.1 stents were
implanted over an average lesion length of 56.6 ± 30.5 mm. One patient (1.1%) received treatment with a
drug-eluting balloon alone without additional stent implantation; in all other patients, second-generation
drug-eluting stents or scaffolds (in 76 cases (82.8%), everolimus-eluting stents (EESs); in 4 cases (4.3%),
biolimus eluting stents; in 9 cases (9.7%), everolimus-eluting bioresorbable vascular scaffolds (BVSs),
and in 3 cases (3.2%), a combination of EESs and BVSs) were used to treat the lesion. No patient was
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treated by POBA (plain old balloon angioplasty). Three patients (3.2%) encountered periinterventional
acute renal failure, and one patient (1.1%) had relevant bleeding at the site of vascular access; in all
other patients, no relevant major adverse events during the index visit were recorded. In total, 95.7% (n
= 89) of the recanalizations were performed via the antegrade approach and primary vascular access
was via the radial artery in 62.4% of cases (n = 58). In accordance with the guidelines [8], 89.2% (83
patients) were treated with dual anti-platelet therapy alone, and 10 cases (10.8%) with a combination of
antiplatelet therapy and an oral anticoagulant. The time elapsed from the index procedure to invasive
follow-up was, on average, 206 ± 129 days (median 185 (IQR 127–237 days)).
Table 1. Baseline characteristics (n = 93).
Parameter n (%) Mean ± SD Median (IQR)
Age at procedure (years) 65.6 ± 11.0 66.5 (58.2/74.6)
female gender 14 (15.1%)
Angina before intervention 53 (57.0%)
Symptoms before intervention 76 (81.7%)
multivessel disease 80 (86.0%)
previous CABG 10 (10.8%)




Family history of CAD 24 (25.8%)
arterial hypertension 74 (79.6%)
peripheral artery disease 9 (9.7%)
cerebral artery disease 8 (8.6%)
renal insufficiency 6 (6.4%)
hyperthyroidism 13 (14.0%)
weight (KG) 90.2 ± 20.3 87.3 (78.0/100.8)
height (meters) 1.74 ± 0.10 1.76 (1.68/1.80)
Body mass index (kg/m2) 25.8 ± 4.8 24.9 (22.8/28.4)
Adipositas 14 (21.2%)
mean LVEF (%) 50.5 ±9.6 55.0 (45.0/55.0)
reduced LVEF at baseline 19 (29.7%)






J-CTO Score 1.49 ± 1.09 1.0 (1.0/2.0)
Components of the J-CTO Score
Entry 27 (29.0%)
Calcification 47 (50.5%)
Bending > 45◦ 25 (26.9%)
Lesion Length > 20 mm 29 (31.2%)
Retry Lesion 12 (12.9%)
Abbreviations: CABG: coronary artery bypass grafting, PCI: percutaneous coronary intervention, CTO: chronic total
occlusion, LVEF: left ventricular ejection fraction. LAD: left anterior descending artery, LCX: left circumflex artery,
RCA: right coronary artery. IQR: Interquartile Range, SD: standard deviation.
We compared patients’ clinical and periinterventional characteristics, including gender, coronary
vascular risk factors, renal impairment, left ventricular ejection fraction, duration and cumulative
fluoroscopy dose, stent length and number, periinterventional biomarkers, and symptoms, at baseline
and follow-up for each individual endpoint, and the cumulative endpoint. The incidence of re-occlusion
was low (7.5%, n = 7) and re-stenosis of the former CTO lesion (including re-occlusion) was observed
in 11.8% (n = 11). In five patients (5.4%), TVR was performed (two patients with treatment within the
former CTO lesion, in three patients with de novo stenosis adjacent to the former CTO lesion). Thus,
the incidence of the combined endpoint TVF was 15.1% (n = 14). Detailed results are presented in
Table 2 (for enhanced results, see Supplementary Materials Table S1).
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When comparing baseline characteristics as well as periprocedural factors of the index procedure
of patients encountering endpoints to those without adverse outcomes at the time of follow-up, we
identified several parameters with statistically significant differences between the patient groups.
Patients with reduced TIMI flow of the target vessel directly at the end of the index procedure were
statistically significantly overrepresented in the groups encountering each of the endpoints. We
observed a significantly greater incidence of re-occlusion (100% vs. 8.1%, p < 0.001), restenosis (90.9%
vs. 4.9%, p < 0.001), and the combined endpoint (71.4% vs. 5.1%, p < 0.001). Furthermore, the patients
reaching the endpoints had higher periprocedural levels of high-sensitive troponin I (1126.3 ± 1560.6
vs. 412.0 ± 1391.4, p = 0.006 for re-occlusion, 771.4 ± 1255.7 vs. 420.7 ± 1425.5, p = 0.013 for restenosis,
and 662.4 ± 1124.7 vs. 425.5 ± 1451.3, p = 0.044 for TVF), and the cumulative length of implanted
stents was significantly shorter (36.3 ± 41.1 vs. 58.3 ± 29.2, p = 0.044 for re-occlusion, 38.2 ± 36.2 vs.
59.1 ± 29.0 mm, p = 0.020 for restenosis, 43.0 ± 35.9 vs. 59.0 ± 29.0 mm, p = 0.042 for TVF). Other
factors with statistically significant differences between the groups encountering endpoints were a
lower number of implanted stents for restenosis, as well as a longer cumulative duration of the CTO
index procedure both for re-occlusion and restenosis. Patients with female gender were significantly
overrepresented in the target vessel failure group at follow-up (35.7% vs. 11.3%, p = 0.034)—a similar
trend could also be observed for restenosis and re-occlusion, although this did not reach statistical
significance (for details, see Table 2).
We performed logistic regression analyses to assess the odds ratios of independent predictors for
each individual endpoint, including TVF, and adjusted those further for general cardiovascular risk
factors (age, diabetes, hyperlipidemia, smoking, hypertension, and family history of cardiovascular
disease) in a multivariate model. The results are presented in Table 3 (for further detailed calculations,
see online Supplementary Materials Table S1). Individual factors as potential predictors for TVF
comprised—as expected—reduced TIMI flow at the end of the index procedure all endpoints for
re-occlusion (OR: 20.36 (95% CI: 3.21–129.00), p = 0.001), restenosis (OR: 21.29 (95% CI: 4.28–105.97),
p < 0.01), and the combined endpoint/TVF (OR: 11.00 (95% CI: 2.66–45.45), p = 0.001). Female gender
proved to be a predictor for the occurrence of restenosis (OR: 8.88 (95% CI: 1.58–49.89), p = 0.013) as
well as target vessel failure (OR: 11.03 (95% CI: 2.08–58.47), p = 0.005). Of note, a lower BMI was
assessed to be predictive regarding the endpoints of restenosis (OR: 0.73 (95% CI: 0.55–0.98), p = 0.037)
and TVF (OR: 0.80 (95% CI: 0.65–0.99), p = 0.037).
The J-CTO score at the index procedure as well as the presence of its singular factors could not
be correlated with the later occurrence of any of the singular endpoints or TVF. Neither was there
any statistically significant difference between the groups reaching the endpoints and those without
adverse events, nor were any ORs statistically significant (Figure 1). In order to further determine
the sensitivity and specificity to predict each individual end point by the J-CTO score, we computed
ROC curves. The AUC for re-occlusion was calculated as 0.61 (95% CI 0.40–0.82), for restenosis as 0.52
(95% CI 0.32–0.71), and for TVF as 0.51 (95% CI 0.33–0.70) (see online Supplementary Materials Figure
S1), further documenting that the J-CTO score could not predict later adverse outcomes in our cohort.
Interestingly, the presence of typical angina pectoris and/or dyspnea at the time of follow-up did also
not have any correlation with the co-incidence of re-occlusion, restenosis, or TVR (see Table 2).
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Figure 1. Distribution of the J-CTO score in all patients in the groups reaching endpoints. J-CTO scores
were calculated for the whole study group and stratified for all single endpoints and the combined
endpoint. In our study, the distribution of J-CTO scores did not differ significantly between groups (for
details, see the text).
4. Discussion
Over the last years, percutaneous recanalization procedures of CTO lesions have been introduced
into daily clinical practice in most PCI centers. Successful intervention in CTO lesions has been
attributed to clinical as well as prognostic benefit [7–9]. Yet, follow-up data, including invasive control
coronary angiography, as well as evidence on potential predictors for long-term success are rare.
The key findings of this retrospective study are as follows: In a monocentric retrospective analysis
with routinely recommended invasive follow-up of intermediate to difficult CTO lesions (mean J-CTO
score 1.49 ± 1.09), re-occlusion rates tended to be low. Yet, the incidence of adverse findings, like
restenosis, target lesion revascularization, and the combined endpoint target vessel failure, was
moderate but still relevant. Of all clinical parameters entered in the analysis, reduced TIMI flow of
the target vessel at the end of the index procedure was the strongest predictor of the endpoints at the
follow-up visit. Furthermore, patients with higher periinterventional levels of high-sensitive troponin
I as well as a shorter cumulative length of implanted stents were overrepresented in the groups with
a later occurrence of adverse events at the timepoint of surveillance coronary angiography. Female
patients were at a higher risk for TVF. Interestingly, the pre-procedural J-CTO score was not predictive
of the occurrence of later restenosis, re-occlusion, or TLV in our cohort.
Other retrospective analyses have aimed to identify potential predictors for later cardiac adverse
events in cohorts of patients that underwent PCI for CTO lesions. In a retrospective analysis of 249
patients with a mean (non-invasive) follow-up of 19.8 ± 13.1 months, a higher J-CTO score was found
to be associated with a higher rate of major adverse cardiovascular events (MACEs) [11]. Although
the baseline characteristics in this cohort were mainly comparable (age 63 ± 11 years vs. 65.6 ±
11.0 years in our study, 70.3% vs. 84.9% male, right coronary artery as the target vessel in 49.4% vs.
54.8%, J-CTO score 1.8 ± 1.0 vs. 1.49 ± 1.09), the study design was distinctly different, which might
account for the controversial findings. The follow-up was also survey based without surveillance
coronary angiography and the endpoints were also determined differently by MACEs (cardiovascular
or unknown cause of death, myocardial infarction, TVR by PCI or CABG). In another large European
multi-center retrospective analysis of a total of 1395 patients with a mean follow-up of 23 months,
female sex, high J-CTO score ≥ 3, and prior PCI as well as reduced left ventricular function were found
to be correlated with a higher incidence of MACEs [12].
In our analysis, we identified female gender as a risk factor for TVF. Although some registries
generated evidence that women derive the same benefit from CTO-PCI as men in regard to clinical
benefit [14], female gender was found to be a predictor of PCI-related complications as well as MACEs
in other retrospective studies too [12,15,16]. The reason for this observation remains unclear but
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may include differences in the hormonal status between men and women. Yet, this finding might
strengthen the recommendation on optimal patient pre-selection. This should comprise of routine use
of non-invasive testing for myocardial ischemia prior to recanalization attempts, especially in female
patients who appear to be at elevated risk for future TVF.
Only a very few studies have assessed the mechanisms and predictors of target vessel failure in
CTO patients. In a prospective multicenter noninferiority trial comparing the use of a sirolimus-Eluting
stent (SES) to an Everolimus-eluting stent (EES) on 330 patients with total coronary occlusions, the
incidence of re-occlusion (2.2% in the SES vs. 1.4% in the EES group) and re-stenosis (8.0% vs. 2.1%)
was distinctly lower than in our study group [17]. The follow-up rate was high, with 85% in comparison
to nearly 50% in our study. Yet, a less strict definition of total coronary occlusion (estimated duration of
occlusion ≥ 4 weeks) was utilized for this trial, which might partially account for the different findings.
In a monocentric retrospective Korean registry on 235 patients with PCI for CTO with an invasive
follow-up rate of 61.3% after 6 months, a longer occlusion length was found to be predictive for a
higher incidence of TVR [16].
In our PCI center from which we recruited the study population, surveillance invasive follow-up
was routinely recommended but only opted for in nearly 50% of the individuals. According to
European Guidelines [13], follow-up coronary angiography might be routinely performed in high-risk
coronary setups. The strategy of routine invasive follow-up is discussed controversially because
of limited evidence and—in contrast to the situation in Europe—American guidelines abstain from
a recommendation [18]. One prospective randomized multicenter study in Japan ((Randomized
Evaluation of Routine Follow-up Coronary Angiography after Percutaneous Coronary Intervention
Trial) ReACT Trial) on 700 patients could not find evidence of a clinical benefit for a general angiographic
follow-up at least in a normal risk patient cohort [19]. Of course, it remains controversial whether
CTO-PCIs resemble a high-risk PCI collective (not further explained in the European guidelines) and,
furthermore, an impact on further clinical benefit by this strategy of an early invasive follow-up and
treatment of probably non-symptomatic re-stenosis remains hypothetic up to now. Nevertheless, our
study provides evidence that surveillance coronary angiography might be justified after recanalization
of CTO lesions, especially in the presence of specific factors predictive of TVF. Clinical findings, such
as ongoing symptoms alone, with definite exclusion of acute coronary syndrome, might not be helpful
to stratify patients at risk of potential TVF.
Some limitations of our study merit consideration: First, the design is a monocentric retrospective
analysis with a mid-term follow-up. Due to the observational nature of the study, the follow-up rate
was only 49.8%, which might further account for a potential selection bias, which has to be taken
into account in the interpretation of our results. BVS were used for treatment in some cases, which
are not available anymore. Although routine surveillance invasive follow-up was recommended
in all patients, symptomatic individuals could be overrepresented at the follow-up visit, as the
prevalence of angina pectoris and dyspnea at the time of follow-up was higher in comparison to other
registries [12]. Indication for TVR was based on individual assessment of the interventional operator
and not mandatorily grounded on further non-invasive or invasive evaluation of the stenosis (e.g.,
measurement of fractional flow reserve, intracoronary imaging like optical coherence tomography
or intravascular ultrasound) and a potential clinical and prognostic benefit of these interventions
has not been studied. Larger prospective randomized studies with defined protocol, including
intracoronary imaging or flow measurements, for surveillance coronary angiography would be
desirable. Furthermore, patients with female gender were relevantly underrepresented (15.1%), yet at
a comparable extent to most published CTO registries [11,12,14–16].
5. Conclusions
In this retrospective monocentric cohort of patients undergoing routine follow-up coronary
angiography after CTO recanalization, we found evidence that reduced TIMI flow at the end of
the index procedure as well as female gender could be predictors of later angiographic adverse
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outcome (TVF). Furthermore, patients with a shorter cumulative length of implanted stents and higher
periinterventional levels of high-sensitive troponin I were overrepresented in the group of patients
encountering re-occlusion, restenosis, and TVF at the timepoint of invasive follow-up. In contrast
to other registers, we could not prove any correlation between the initial J-CTO score of the treated
CTO lesion and the later occurrence of any of the endpoints. Remarkably, symptoms at the time of
follow-up coronary angiography could not be attributed to adverse angiographic results. Based on the
still relevant rate of TVF, even in populations of intermediate lesion complexity, such as ours, routine
invasive follow-up after CTO procedures appears to be justified and should rather be guided by the
presence of risk predictors, and not by the occurrence of angina (with the exception of acute coronary
syndrome). Thus, our present work might stress a potential beneficial value of routine surveillance
coronary angiography after CTO interventions, especially for females and patients with reduced TIMI
flow at the end of the index procedure.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/1/178/s1,
Figure S1: ROC (receiver operating characteristics) curves for the J-CTO score vs. endpoints, Table S1: Detailed
results for baseline, periprocedural, and follow-up data as well as uni- and multivariate regressions analysis
stratified for the incidence of endpoints.
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Abstract: In this study, we used a single commercially available software solution to assess global
longitudinal (GLS) and global circumferential strain (GCS) using cardiac computed tomography
(CT) and cardiac magnetic resonance (CMR) feature tracking (FT). We compared agreement and
reproducibility between these two methods and the reference standard, CMR tagging (TAG).
Twenty-seven patients with severe aortic stenosis underwent CMR and cardiac CT examinations.
FT analysis was performed using Medis suite version 3.0 (Leiden, The Netherlands) software.
Segment (Medviso) software was used for GCS assessment from tagged images. There was a trend
towards the underestimation of GLS by CT-FT when compared to CMR-FT (19.4± 5.04 vs. 22.40 ± 5.69,
respectively; p = 0.065). GCS values between TAG, CT-FT, and CMR-FT were similar (p = 0.233).
CMR-FT and CT-FT correlated closely for GLS (r = 0.686, p < 0.001) and GCS (r = 0.707, p < 0.001),
while both of these methods correlated moderately with TAG for GCS (r = 0.479, p < 0.001 for CMR-FT
vs. TAG; r = 0.548 for CT-FT vs. TAG). Intraobserver and interobserver agreement was excellent in
all techniques. Our findings show that, in elderly patients with severe aortic stenosis (AS), the FT
algorithm performs equally well in CMR and cardiac CT datasets for the assessment of GLS and GCS,
both in terms of reproducibility and agreement with the gold standard, TAG.
Keywords: systemic disease; cardiac computed tomography; cardiac magnetic resonance; feature
tracking; tagging; myocardial deformation; strain
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1. Introduction
Multiple systemic and neuromuscular diseases can affect the cardiovascular system at some
point in their course. A wide variety of pathological processes fall under these definitions, some of
which have pathognomonic cardiovascular manifestations [1]. However, non-specific manifestations,
such as a subtle decline in regional or global myocardial function, are also common [2]. It can often go
unnoticed until the ejection fraction (EF) starts to decline or clinical symptoms of heart failure begin
to develop. Recently, myocardial strain has emerged as an imaging technique that adds information
about myocardial function beyond the left ventricular ejection fraction (LVEF) [3]. Furthermore, recent
studies have shown early reduction in myocardial strain in multiple systemic and neuromuscular
disorders, such as amyloidosis [4], systemic sclerosis [5], rheumatoid arthritis [6], and Duchenne
muscular dystrophy [7]. These data suggest that deformation imaging could become an important tool
for the early identification of cardiac involvement in these patients.
Due to its availability, speckle tracking echocardiography (STE) is the most widely used method
for strain assessment. However, the accuracy and feasibility of STE is highly dependent on image
quality [8], warranting the need for alternatives in certain patients. Cardiac magnetic resonance (CMR)
not only allows for myocardial strain assessment, overcoming the shortcomings of echocardiography,
but also offers tissue characterization ability that is second to none. Thus, it is an important tool in the
diagnostic work-up of patients with systemic connective tissue disorders [9]. A recently developed
cardiac magnetic resonance feature tracking (CMR-FT) technique has been validated against the
gold standard myocardial tagging (TAG) and is now considered a preferred CMR tool for strain
assessment [10]. The main advantage of CMR-FT is that it can be applied to steady-state free precession
(SSFP) cine loops that are used in routine clinical practice, therefore not requiring additional image
acquisition. Interestingly, although developed for CMR, the FT algorithm can also be applied to cardiac
computed tomography (CT) datasets to assess myocardial strain [11,12]. Naturally, strain assessment
from cardiac CT datasets has started to gain popularity.
In this study, we used a single commercially available software solution to acquire global strain
parameters via computed tomography feature tracking (CT-FT) and CMR-FT in a cohort of patients with
severe aortic stenosis (AS). We compared agreement and reproducibility of global longitudinal (GLS)
and global circumferential strain (GCS) between both these methods and the reference standard, TAG.
2. Experimental Section
2.1. Study Population
Twenty-six patients (14 females and 12 males, mean age 80.59 ± 5.87 years) with severe AS
referred to our institution for transcathether aortic valve replacement (TAVR) were enrolled in this
study. Further demographic and clinical data of the study population are listed in Table 1. AS was
diagnosed and graded echocardiographically according to the latest European Society of Cardiology
and European Association for Cardiothoraic Surgery guidelines [13]. All subjects underwent clinically
indicated CMR and cardiac CT examinations. This study complies with the Declaration of Helsinki.
Institutional Review Board approval was not necessary because it was a retrospective analysis of
clinical data. According to local law, all individuals signed an informed consent form before entering
the clinical CMR and cardiac CT. None of the observers could identify patient information when
analyzing the data.
2.2. Cardiac Computed Tomography Acquisition
Contrast-enhanced, retrospectively electrocardiography (ECG)-gated cardiac scans were
performed using a 2 × 128-slice multi-detector computed tomography scanner (Somatom Definition
Flash, Siemens AG, Erlangen, Germany). The following study protocol was used: tube voltage 100,
120 kV, tube current 320 ref. mAs/rotation, rotation time 280 ms, slice collimation of 128 × 0.6 mm,
with a temporal resolution of 75 ms, slice width of 0.75 mm, reconstruction increment of 0.4 mm,
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and reconstruction kernel B30f. Images were acquired in a cranio-caudal direction, from above the
aortic sinuses to below the diaphragm.
Table 1. Demographic and clinical data of the study population.
Variables.
n = 27
Mean ± SD or n (%)
Age 22.40 ± 5.69
Male 18.91 ± 5.97
Body mass index (kg/m2) 26.60 ± 3.60




Myocardial infarction 6 (22.22%)
History of CABG 5 (18.51%)
Stroke 4 (14.81%)
Diabetes mellitus type 2 6 (22.22%)
COPD 5 (18.51%)
Abbreviations: CAD: coronary artery disease; CABG: coronary artery bypass graft;
COPD: chronic obstructive pulmonary disease.
2.3. Cardiac Magnetic Resonance Acquisition
CMR acquisitions were made using a 1.5 Tesla magnetic resonance imaging (MRI) scanner
(Achieva, Philips Healthcare, Best, The Netherlands). Signals were received using a five-element
phased array cardiac coil. A four-lead vector ECG was used for R-wave triggering. A balanced
steady-state free precession (bSSFP) sequence with breath hold was acquired in long-axis (LAX) two-,
three-, and four-chamber views, as well as a short-axis (SAX) stack. This was used for volumetric
and FT analysis. Acquisition parameters used were a repetition time (TR) of 3.3 ms, echo time (TE)
of 1.6 ms, flip angle of 60◦, acquisition voxel size of 1.8 × 1.7 × 8.0 mm3, and 30 phases per cardiac
cycle. The complementary spatial modulation of magnetization (CSPAMM) technique was used to
acquire tagging images in three short-axis planes (basal, medial, and apical) with a temporal resolution
of 35 ms, spatial resolution of 1.4 × 1.4 mm, and a slice thickness of 8 mm.
2.4. Cardiac CT Data Analysis
Original three-dimensional (3D) datasets were analyzed offline using the commercially available
Medis Suite version 3.0 (Leiden, The Netherlands) software package to generate two-dimensional
(2D) cine loops of three LAX slices (i.e., two-, three-, and four-chamber), three SAX slices (i.e., basal,
mid, and apical), and a SAX stack with a slice thickness of 0.75 mm and a reconstruction increment
of 0.4 mm. Images were generated with temporal resolution of 10 phases per cardiac cycle in 10%
increments from early systole (0% cardiac cycle) to end-diastole (90% cardiac cycle). Care was taken
to make sure that 2D cardiac CT reconstructions closely matched the anatomical locations of the
images used for CMR analysis. End-systolic and end-diastolic cardiac phases were chosen visually.
Endocardial and epicardial borders in the SAX stack were outlined manually to calculate the volumetric
parameters, which were indexed to body surface area (BSA). Left ventricular mass index (LVMi),
left ventricular end-diastolic volume index (LVEDVi), left ventricular end-systolic volume index
(LVESVi), left ventricular stroke volume index (LVSVi), and left ventricular ejection fraction (LVEF)
were calculated. Global longitudinal strain (GLS) was assessed by averaging the peak systolic strain
values of 17 segments extracted from three LAX images, while global circumferential strain (GCS) was
acquired from three SAX images using a 16-segment model.
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2.5. CMR Data Analysis
bSSFP images were analyzed using Medis Suite version 3.0 (Leiden, The Netherlands) software
in the same manner as cardiac CT images to determine LVMi, LVEDVi, LVESVi, LVSVi, LVEF, GLS,
and GCS. Tagged images were analyzed using commercially available software Segment version 2.2
R6960. Endocardial and epicardial borders were manually outlined at an end-systolic timeframe in
three short-axis slices (i.e., basal, mid, and apical). After applying an automatic propagation algorithm,
quality of tracking was visually assessed, and changes were made as needed. GCS was derived using
a 16-segment model by averaging the peak systolic values. TAG data of one of the subjects could not
be analyzed due to breathing artefacts, therefore 26 patients were used for GCS comparisons.
Due to the counter-intuitive increase of strain in more diseased subjects, we chose to report
absolute values for easier interpretation.
2.6. Statistics
Data analysis was performed using commercially available software (GraphPad Prism 8, GraphPad
Software, San Diego, CA, USA). The Shapiro–Wilk test was used to assess the normality of distribution
of continuous variables. Unpaired Student’s t-test was used to compare differences between cardiac CT
and MRI derived volumetric parameters and GLS. One-way ANOVA was used to compare differences
in GCS between the three modalities. Pearson’s correlation coefficient and Bland–Altman analysis
were used to assess inter-method agreement. Intra- and interobserver variability were assessed using
two-way mixed intra-class correlation coefficient (ICC), Bland–Altman analysis, and coefficient of
variance (CoV). This was defined as the standard deviation of the differences divided by the mean, in
keeping with previous studies [14]. Agreement levels were defined according to previous studies [15]
as follows: excellent if ICC > 0.74, good if ICC = 0.6-0.74, fair if ICC = 0.4–0.59, poor if ICC < 0.4.
p-values of <0.05 were considered statistically significant.
3. Results
3.1. Volumetric Assessment
Values of volumetric assessment are represented in Table 2. LVEDVi, LVESVi, LVSVi, LVEF, and
LVMi values were similar between CMR and cardiac CT. There was excellent correlation between
the two techniques in LVEDVi (r = 0.913, p < 0.001), LVESVi (r = 0.879, p < 0.001), LVEF (r = 0.791,
p < 0.001), and LVMi (r = 0.971, p < 0.001), with good correlation for LVSVi (r = 0.619, p < 0.001). Results
of the Bland–Altman analysis of volumetric measurements are shown in the figures (Figures 1a–d
and 2).
Table 2. Values of volumetric assessment of the LV by CMR and CCT.
Measurement CMR CCT p-Value
LVEF (%) 64.57 ± 14.55 59.15 ± 14.82 0.181
LVEDVi (mL/m2) 72.60 ± 27.22 80.35 ± 26.42 0.374
LVESVi (mL/m2) 28.62 ± 21.21 35.79 ± 23.39 0.293
LVSVi (mL/m2) 43.98 ± 11.65 44.56 ± 8.13 0.933
LVMi (g/m2) 62.13 ± 20.51 66.04 ± 19.42 0.471
Values are expressed as mean ± SD. Abbreviations: CCT: cardiac computed tomography; CMR: cardiac
magnetic resonance; LVEF: left ventricular ejection fraction; LVEDVi: left ventricular end-diastolic volume
index; LVESVi: left ventricular end-systolic volume index; LVMi: left ventricular mass index; LVSVi: left
ventricular stroke volume index.
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Figure 1. Bland–Altman analyses of (a) LVEDVi, (b) LVESVi, (c) LVSVi, and (d) LVEF assessment
between CMR and CCT. Abbreviations: CCT: cardiac computed tomography; CMR: cardiac magnetic
resonance; LVEF: left ventricular ejection fraction; LVEDVi: left ventricular end-diastolic volume index;
LVESVi: left ventricular end-systolic volume index; LVSVi: left ventricular stroke volume index.
 
Figure 2. Bland–Altman analysis of LVMi assessment between CMR and CCT. Abbreviations: CCT:
cardiac computed tomography; CMR: cardiac magnetic resonance; LVMi: left ventricular mass index.
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3.2. Strain Assessment
Figures 3 and 4 show examples of GLS and GCS assessment in the same patient using different
strain-assessment techniques. Strain values from each technique are represented in Table 3. GLS showed
a trend towards being lower in CT-FT vs. CMR-FT (19.40 ± 5.04 vs. 22.40 ± 5.69, p = 0.065). GCS values
were similar between all techniques (p = 0.233). There was good correlation between CMR-FT and
CT-FT derived GLS (r = 0.686, p < 0.001) and GCS (r = 0.707, p < 0.001), while both of these methods
had moderate correlation with TAG for GCS (r = 0.479, p < 0.001 for CMR-FT vs. TAG; r = 0.548 for
CT-FT vs. TAG). Bland–Altman analysis revealed similarly wide limits of agreement (LOA) between
all techniques in both GLS and GCS (Figure 5a–d and Table 4).
 
Figure 3. Assessment of GLS from the four-chamber long-axis (LAX) view in the same subject using
CMR-FT (left) and CT-FT (right).
 
Figure 4. Assessment of GCS in the same subject from the mid-ventricular short-axis (SAX) view using
CMR-FT (left), CT-FT (middle), and TAG (right).
Table 3. Values of strain assessment of the LV by CMR and CCT.
Measurement CMR-FT CT-FT TAG
GLS (%) 22.40 ± 5.69 19.4 ± 5.04 N/A
GCS (%) 18.91 ± 5.97 18.13 ± 4.63 16.66 ± 3.38
Values are expressed as mean ± SD. Abbreviations: LV: left ventricular; CCT: cardiac computed tomography;
GLS: global longitudinal strain, GCS: global circumferential strain, CMR-FT: cardiac magnetic resonance
feature tracking, CT-FT: computed tomography feature tracking; TAG: myocardial tagging.
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Figure 5. Bland–Altman analysis of the (a) GLS assessment between CT-FT and MR-FT; (b) GCS
assessment between CT-FT and MR-FT; (c) GCS assessment between MR-FT and TAG; and (d) GCS
assessment between CT-FT and TAG. Abbreviations: MR-FT: magnetic resonance feature tracking;
CT-FT: computed tomography feature tracking; TAG: myocardial tagging; GLS: global longitudinal
strain; GCS: global circumferential strain.
Table 4. Tabular representation of Bland–Altman and Pearson’s correlation analyses for
strain assessment.
Measurement Comparison Bias (%) LOA (%) Pearson’s R




CMR-FT vs. CT-FT 0.888 ±8.16 0.7067
CMR-FT vs. TAG 2.250 ±10.31 0.4799
CT-FT vs. TAG 1.468 ±7.77 0.5484
Abbreviations: GLS: global longitudinal strain; GCS: global circumferential strain; CMR-FT: cardiac magnetic
resonance feature tracking; CT-FT: computed tomography feature tracking; LOA: limits of agreement;
TAG: myocardial tagging.
3.3. Intraobserver and Interobserver Reproducibility
The results of the reproducibility analyses are presented in Table 5. Intraobserver and interobserver
agreement was excellent for all techniques. CMR-FT had worse intraobserver reproducibility for GLS
(LOA ±2.4% vs. ±4.36%; CoV 6.8% vs. 10.1%) but performed better in interobserver comparison
(LOA ±3.16% vs. ±5.5%; CoV 7.4% vs. 16.1%). TAG had superior reproducibility compared to the
FT-based imaging technique for GCS, while FT-based techniques had similar results in interobserver
and intraobserver comparisons.
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Table 5. Reproducibility comparison of GLS and GCS between CMR-FT, CT-FT, and TAG.
Bias (%) Limits of Agreement (±) CoV (%) ICC (95% CI)
Intraobserver reproducibility
CMR-FT
GLS 0.09 4.36 10.1 0.960 (0.837–0.990)
GCS −2.44 4.8 13.1 0.931 (0.439–0.985)
CT-FT
GLS −0.08 2.4 6.8 0.983 (0.932–0.996)
GCS −0.05 5.0 14.4 0.949 (0.801–0.987)
TAG
GCS −0.08 1.26 3.9 0.992 (0.969–0.998)
Interobserver reproducibility
CMR-FT
GLS 0.03 3.16 7.4 0.982 (0.926–0.995)
GCS −2.3 6.6 18.1 0.922 (0.629–0.981)
CT-FT
GLS 1.25 5.5 16.1 0.866 (0.501–0.966)
GCS 0.39 5.1 14.6 0.940 (0.759–0.985)
TAG
GCS 0.48 1.72 5.4 0.981 (0.918–0.995)
Abbreviations: GLS: global longitudinal strain; GCS: global circumferential strain; CMR-FT: cardiac magnetic
resonance feature tracking; CT-FT: computed tomography feature tracking; TAG: myocardial tagging; CoV: coefficient
of variance; ICC: intra-class correlation coefficient.
4. Discussion
4.1. Main Findings
To our knowledge, this is the first study that compared CT-FT derived strain values to CMR-FT
and TAG. The main findings of our study were as follows.
i. There was good correlation between CMR-FT and CT-FT for GLS and GCS assessment,
while GCS derived from both CMR-FT and CT-FT had a moderate correlation with TAG;
ii. The intra- and interobserver reproducibility of CMR-FT and CT-FT were excellent;
iii. There were no significant differences between cardiac CT and CMR for the volumetric assessment
of the LV.
In the past decade, multiple methods to assess myocardial strain parameters from cardiac
CT datasets have emerged. Most use tissue tracking algorithms originally developed for CMR or
echocardiography to track either endocardial or epicardial borders of the left ventricular (LV) in 2D
cine loops generated from 3D cardiac CT datasets. As with CMR and echocardiography, these methods
allow for the quantification of well-studied global strain parameters, GLS, GCS, and global radial strain
(GRS). In 2010, Helle-Valle et al. used a multimodality tissue tracking algorithm, originally developed
for analysis of echocardiographic images, to assess GRS in a cohort of ischemic heart disease patients
(n = 20). They demonstrated that the results of this method had good correlation with GRS derived
from TAG (r = 0.68) and that the method has the ability to discern scarred LV segments [16]. Buss et al.
used a similar feature tracking algorithm in a cohort of congestive heart failure patients (n = 27) to
obtain and compare global strain parameters from cardiac CT and transthoracic echocardiography
datasets. They found close correlation for GRS (r = 0.97), GCS (r = 0.94), and GLS (r = 0.93) between
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these modalities [12]. In the largest study to date (n = 123), Fukui et al. compared FT-derived GLS in a
cohort of severe AS patients and found moderate correlation between cardiac CT and transthoracic
echocardiography (TTE) (r = 0.62) [11].
Another method, developed specifically for cardiac CT, allows for the quantification of a cardiac
CT-specific 3D principal strain. First, images of neighboring phases are interpolated using a motion
coherent algorithm to reduce noise and improve motion coherence. Interpolated images are then
analyzed using image and model matching algorithms to create a 3D motion-vector matrix of the
LV [17]. Voxels of interest can then be chosen within this matrix to derive either a regional or global
principal strain. Unlike 2D strain parameters, 3D principal strain encompasses deformation in all
directions. It, thus, incorporates longitudinal, circumferential, and radial components. It is expressed
as a positive value [18]. In a recent study, Ammon et al. found a close correlation (r = −0.8) between
3D principal strain and STE-derived GLS in a cohort (n = 35) of severe AS patients [19].
As previously noted, in the present study, we used a commercially available feature tracking
software to measure GLS and GCS from cardiac CT datasets and compared it to CMR-FT and TAG in a
cohort of patients with severe AS. We found a strong correlation between CT-FT and CMR-FT, but CT-FT
tended to underestimate both GLS (22.40 ± 5.69 vs. 19.4 ± 5.04, p = 0.065) and GCS (18.91 ± 5.97 vs.
18.13 ± 4.63, p = 0.233). Previous authors have noticed a similar underestimation when comparing
cardiac CT-derived strain to STE [12,19]. This underestimation could be driven by low temporal
resolution of cardiac CT-derived cine loops. As shown by Rösner et al., accuracy of STE-derived strain
measurements is dependent on the temporal resolution of the recordings [20]. They found systematic
underestimation of strain parameters at temporal resolutions of less than 30 frames/cardiac cycle.
Indeed, our 2D cine cardiac CT reconstructions had a temporal resolution of 10 frames/cardiac cycle,
while CMR cine loops were acquired at 30 frames/cardiac cycle. To our knowledge, the performance
of feature tracking at lower temporal resolutions has not been investigated yet, thus further studies
are needed.
Interestingly, despite having a lower temporal resolution, when compared with TAG (the reference
standard strain assessment technique), CT-FT and CMR-FT had similar correlation and LOA for GCS
assessment. Additionally, reproducibility analysis revealed similar results for both FT-based techniques.
If TAG data are taken as the ground truth, these findings suggest that FT algorithm performs equally
well on both CMR and cardiac CT datasets.
Additionally, due to its angle independency and high temporal and spatial resolutions, CMR is the
gold standard technique for the functional assessment of the heart [21]. However, despite having the
worse temporal resolution, cardiac CT has been shown to have a close correlation and good agreement
with CMR for the assessment of LV volumes in multiple studies [22–24], indicating that these methods
can be used interchangeably for volumetric assessment. Our results agree with these findings.
4.2. Clinical Implications
There is an increasing number of patients who have implanted cardiac devices, and this decreases
the feasibility of CMR due to potential artefacts or the inability to condition these devices. Our
results imply that cardiac CT datasets are non-inferior to CMR datasets for the assessment of GLS
and GCS using the FT algorithm. Furthermore, ours and multiple previous studies have shown
potential interchangeability of volumetric measurements between cardiac CT and CMR. With further
advancements in technology and an increase in temporal resolution, a cardiac CT might be used as a
convenient follow-up tool to previous CMR assessments for both volumetric and strain measurements
in patients with implanted cardiac devices.
4.3. Limitations
Naturally, there are certain limitations in our study. Firstly, this was a small-scale single-center
trial. Secondly, we only had TAG acquisitions for short-axis slices, therefore we could not compare
FT-derived GLS to a reference standard imaging technique. However, previous studies suggest that
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CMR-FT has similar correlation and agreement to TAG for both GCS and GLS [25]. Thirdly, we
did not have STE-derived strain parameters for a more comprehensive inter-modality comparison.
Finally, given the retrospective nature of this trial and limited availability of high quality CT and CMR
acquisitions that were made within a short timeframe in other populations, the trial was performed in
a highly selected population of patients with severe AS. Thus, further studies are required to confirm
these findings in more diverse cohorts.
5. Conclusions
Our findings show that the FT algorithm performs equally well in both CMR and cardiac CT
datasets for the assessment of GLS and GCS, both in terms of reproducibility and agreement with the
gold standard, TAG. In the clinical routine, cardiac CT might be used as a convenient follow-up tool to
previous CMR assessments for both volumetric and strain measurements in patients with implanted
cardiac devices.
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Abstract: Human cardiac progenitor cells isolated from the same host may have advantages over other
sources of stem cells. The aim of this study is to establish a new source of human progenitor cells collected
from a waste product, pericardiac effusion fluid, after open-heart surgery in children with congenital
heart diseases. The fluid was collected every 24 h for 2 days after surgery in 37 children. Mononuclear
cells were isolated and expanded in vitro. These pericardial effusion-derived progenitor cells (PEPCs)
exhibiting cardiogenic lineage markers, were highly proliferative and enhanced angiogenesis in vitro.
Three weeks after stem cell transplantation into the ischemic heart in mice, cardiac ejection fraction was
improved significantly without detectable progenitor cells. Gene expression profiles of the repaired
hearts revealed activation of several known repair mechanisms including paracrine effects, cell migration,
and angiogenesis. These progenitor cells may have the potential for heart regeneration.
Keywords: congenital heart disease; cardiac surgery; open heart; progenitor cells; regeneration;
stem cells
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1. Introduction
Despite the recent advances in molecular medicine and health care; cardiac diseases, including
both adult and congenital heart diseases, are still the leading cause of morbidity and mortality
throughout the world [1]. Congenital heart disease (CHD) is the most common congenital anomalies in
newborns [2]. Globally, there are around 1.35 million neonates born with CHD every year over the last
15 years. The highest CHD birth prevalence is reported in Asian countries with 9.3 per 1000 live births
which is one of the leading causes of perinatal and infant death from congenital malformations [3].
Approximately 25 percent of these neonates require surgery or catheter-based intervention in the first
year of life [4]. The prognosis of CHD is good with 83% of patients are free from reoperation for
20 years and the overall survival rate was 86%, including early mortality [5]. However, multiple-stage
operations are needed to correct the defects in cases with complex CHD. Lui et al. pointed out the
misperception that CHD is cured by surgery [6]. CHD patients are at increased risk of developing
myocardial ischemia or premature coronary artery disease (CAD) while growing up. The number of
adult CHD patients continues to increase by 5% per year, there are now more than 1 million patients in
the United States [6]. Owing to the lack of effective treatment strategy after severe cardiac injury in
these patients, stem cell-based therapies may be a potential therapeutic strategy [7,8].
A variety of stem cell populations have been explored for their potential to promote cardiac
repair and regeneration. The results are controversial since each type of stem cell has its own profile
of advantages, limitations, and translational practicability. The most frequently studied stem cell
populations in cardiac diseases include embryonic stem cells (ESC), bone marrow-derived stem cells
(BMSC), tissue-specific stem cells (TSSC), and the most recently inducible pluripotent stem cells (iPS).
ESCs are conceptually attractive for cardiac repair because of the potential to differentiate into different
cell types in a damaged heart. Despite the recent success of ESCs engraftment and repairing injured
myocardium in a primate model of myocardial infarction [9], translation into clinical use has been
hindered by ESCs’ genetic instability, potential tumorigenic and immunogenic properties, and ethical
considerations related to the origin of these cells [7]. BMSCs are composed of several cell populations
that have the capacity to differentiate into various cell types, including hematopoietic stem cells (HSC),
mesenchymal stem cells (MSC), endothelial progenitor stem cells (EPC), and others. Each cell type
has been reported to improve cardiac function on top of standard therapy in cardiac diseases. Most
clinical trials to date have used total bone marrow mononuclear cells, which comprise HSCs, MSCs,
and monocytes [7]. Promising results from Cochrane Heart Group enrolled more than a thousand
patients with heart diseases but debates continued because of a high degree of heterogeneity in the
results [10,11]. It is still too early to draw conclusions on the efficacy of BMSCs [12]. TSSC, such as
adipose tissue-derived stem cells (ADS) [13] and umbilical cord blood-derived stem cells (UBS) [14],
appeared to be attractive in the treatment of cardiac diseases. Early promising results in clinical trials
have been shown in ADS treated cardiac damages [13]. However, the tumorigenic potential of these
cells cannot be totally excluded [13]. UBS is still in the early recruitment stages of the clinical trial [14].
Resident cardiac progenitor cells expanded from heart biopsy in the early clinical trial showed
promising results [15]. These cells have exhibited robust cardiovascular differentiation potential.
However, an invasive heart biopsy is not easily accepted by parents of CHD patients. Human iPS cells
provide new revenue for sufficient stem cells in the treatment of heart failure. Yet the safety in clinical
applications remains to be determined [16]. Taken together, while multiple clinical trials of stem cell
therapy worldwide on adult or congenital heart diseases suggest that stem cell therapy is safe with
modest improvement in cardiac functioning and structural remodeling [7,16], the right source of stem
cells remains one of the major challenges in this field. A new source of stem cells, which is free of
ethical conflict, easy to isolate and propagate, and with cardiac regenerative potential, is desirable for
cell-based therapy in the treatment of CHD.
Draining of blood and effusion from the mediastinum and pleural space following open-heart
surgery is critical to establish adequate evacuation of fluid after surgery [17]. Surgical drainage is
usually left in place for 3 to 4 days until the fluid is decreased to less than 50 ml per day with stable
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hemodynamic and respiratory functions. In this study, we explored the possibility of the isolation and
expansion of progenitor cells from pericardial effusion drained after open-heart surgery in children
with congenital heart diseases. We named these cells pericardial effusion-derived progenitor cells
(PEPCs).
2. Materials and Methods
2.1. Isolation and Expansion of Progenitor Cells from Open-Heart Surgery Drain Fluids
All human studies were conducted according to the principles expressed in the Helsinki Declaration
and approved by the institutional review board. Thirty-seven patients with congenital heart diseases
aged 3 days to 43 months (mean 9.7 ± 9.2 months, Table S1) and scheduled for open-heart surgery were
recruited after signing informed consent by their parents. Immediately after cardiac surgery, drain tubes
were inserted into pericardial space to relieve fluid accumulation around the heart. Drain fluids were
collected every 24 h for 2 days after the operation in an aseptic container (Figure 1) containing 300 mL of
cold saline and was kept at 4 ◦C. Cells were centrifuged at 1500 rpm for 10 min at 4 ◦C and re-suspended
in 30 ml cold RPMI medium (Gibco, Invitrogen, Carlsbad, CA, USA). Mononuclear cells were isolated
with Ficoll-Paque (GE Healthcare, Buckinghamshire, UK) by following the manufacturer’s instruction.
They were cultured directly without sorting on a fibronectin-coated 48-well plate with cardiosphere
medium [15] (300 μL/well) consisting of 35% IMDM and 65% DMEM/F-12 Mix (Gibco, Invitrogen,
Carlsbad, CA, USA), 3.5% FBS, 1% penicillin-streptomycin, 1% L-glutamine, 0.1mM 2-mercaptoethanol,
thrombin, 1× B-27, 80 ng/mL bFGF, 25 ng/mL EGF, and 4 ng/mL cardiotrophin-1. On the second and
third day, 200 μL of the supernatant with RBCs and white blood cells were replaced carefully with
freshly prepared medium without disturbing the loosely attached cells. The procedure was repeated
every 3 days to completely remove the RBCs and unattached cells. Cells were expanded in a ratio of
1:2 in 5–7 days thereafter.
Figure 1. Schematic drawing of the isolation and expansion procedures for human pericardial
effusion-derived progenitor cells (PEPCs). (A) Drain fluid was collected on the first and second day
after open-heart surgery in a drain bottle containing 300 mL of 4 ◦C normal saline. The bottle was
kept at 4 ◦C during collection. (B) Mononuclear cells were collected by density gradient centrifugation
with Ficoll-Paque. (C) The mononuclear cells with red blood and white blood cells were plated on a
fibronectin-coated plate and cultured in cardiosphere medium. (D) The red blood and white blood
cells were removed by serial medium supplement every 3 days. (E) Spindle-like cells were noted as
early as 3 days while cardiospheres appear around 7 days after seeding. (F) Further cell expansions to
obtain sufficient cell number for transplantation. (G) PEPCs were injected into peri-infarction regions
of a mouse heart.
67
J. Clin. Med. 2019, 8, 1028
2.2. Flow Cytometry
Cells isolated on day 1 and day 2 from cardiac surgery drain fluid were analyzed with flow
cytometry to study the early surface marker expression. Cells with a higher passage (>5) were used to
study the chronological changes of surface markers. All experiments were done with a FACSCalibur
(BD Biosciences, San Jose, CA, USA) flow cytometer. Data were analyzed with free software WinMDI
2.8. Monoclonal antibodies used for cell surface markers analyses included fluorescein isothiocyanate
(FITC)-conjugated anti-human CD34, phycoerythrin (PE)-conjugated anti-human CD133 (MACS,
Bergisch Gladbach, Germany), allophycocyanin (APC)-conjugated anti-human CD117, PE-conjugated
anti-human CD31, and CD45 (BD Pharmingen, San Diego, CA, USA), FITC-mouse IgG2aκ, APC-mouse
IgG1κ, and PE-mouse IgG1κ isotype controls (BD Pharmingen, San Diego, CA, USA).
2.3. Cell Culture and Conditioned Medium for Angiogenesis Assay
Human fibroblasts from neonatal foreskin (HS68, Bioresource Collection and Research Center,
Taipei, Taiwan) were cultured in DMEM with 10% fetal calf serum, 5% streptomycin and penicillin.
Primary human umbilical vein endothelial cells (HUVEC) were purchased from the same center and
were cultured in Medium 199 (Life Technologies, Taipei, Taiwan). Conditioned medium (CM) was
collected 48 h in serum-free DMEM for fibroblasts, serum-free Medium 199 for HUVEC, and serum-free
culture medium for PEPCs, respectively. CM was pooling from 100 μL of medium with 2 × 104 cells
in each well of a 96-well plate and stored at −20 ◦C until used. Twenty thousand HUVEC cells were
seeded on a 96-well plate pre-coated with basement membrane matrix (Matrigel Matrix Growth Factor
ReducedTM, BD Biosciences, Taipei, Taiwan). They were plated either with 100 μL complete Medium
199 as the positive control, with 100 μL FBS-free Medium 199 as the negative control, or with 100 μL
CM. To evaluate the mechanism of angiogenesis elicited by PEPCs, neutralizing antibodies 0.04 μg/100
μL anti-VEGF (R&D, Minneapolis, MN, USA), or 0.8 μg/100 μL anti-HGF (Abcam, Billerica, MA, USA),
or 50 μg/mL thalidomide (Sigma-Aldrich, St. Louis, MO, USA) was added to CM on a shaker for 1
hour at room temperature. Cells were imaged after 18 h with a digital camera coupled to a microscope.
Five different areas were taken from one well. Images were analyzed with Image J software (Version
1.52p, National Institutes of Health, Bethesda, MD, USA) and the total vessel length was measured
with AngioTool Software (version 0.6a, National Cancer Institute, Bethesda, MD, USA) [18]. Each
condition was triplicated and at least three independent experiments were performed.
2.4. Cardiac Infarction in Mice
All animal studies were performed in compliance with the US Department of Health and Human
Services Guide for the Care and Use of Laboratory Animals and approved by the institutional review
board. Adult male SCID-beige mice, aged 10 to 20 weeks, were purchased from the animal center of
National Taiwan University, Taipei, Taiwan. The left main descending branch of the coronary artery
was ligated with a 7-0 prolene suture [15]. To minimize the number of mice used for the experiments
and to compare results from different assays, PEPCs at passage 6 from three randomly selected patients
were used in all following experiments. Either PEPCs or lentivirus-transduced PEPCs (105 cells in a
total volume of 10 μL phosphate-buffered saline (PBS)) were injected at two sites bordering the infarcts
(5 μl each) immediately after vessels ligation. 8 mice were injected with PEPCs, while the other 6 mice
were injected with lentivirus-transduced PEPCs for in vivo bioluminescence imaging. Transduced or
non-transduced (both n = 8) human fetal skin fibroblasts (WS1, Bioresource Collection and Research
Center, Taipei, Taiwan) and PBS (n = 11) were used as both positive and negative controls, respectively.
WS1 is a normal skin fibroblast cell line originated from a 12-week gestation fetus. The embryonic
nature of these cells is expected to have partial effects on tissue repair. These cells were grown in
Eagle’s Minimum Essential Medium with 10% FBS.
All mice underwent echocardiography (Philips Sonos 5500, 15 MHz probe, Eindhoven,
Netherlands) to evaluate the ventricular function on the day before operation (baseline, day 0),
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2 days, 1 week, 2 weeks, and 3 weeks after surgery. Ventricular wall thickness and chamber dimensions
were measured using a short-axis parasternal view at the level of the papillary muscles. Left ventricular
ejection fraction (LVEF) and fractional area were calculated from 2D long-axis views taken through
the infarcted area. Mice were sedated with isoflurane during all procedures. Data were collected by
averaging three separate measurements during each examination. Mice were euthanized at 3 weeks.
2.5. Transplanted Cell Tracing with Optical Bioluminescence Imaging and Alu Sequence
Cardiac bioluminescence imaging was performed using the Xenogen IVIS 50 system (Hopkinton,
MA, USA). After intraperitoneal injection of reporter probe D-luciferin (150 mg luciferin/kg), animals
were imaged for 1–10 min under anesthesia. The same mice were scanned weekly for 3 weeks. Imaging
signals were quantified in units of maximum photons per second per square centimeter per steradian
(photons/sec/cm2/sr) as described [19]. To test the possibility that a small population of PEPCs might
survive but not be detected by in vivo imaging, the human Alu repeat [20], acted as a marker to detect
human PEPCs from infarcted hearts, was amplified by PCR.
2.6. Virus Production and Cell Transduction
PEPCs were transduced with luciferase gene as a tracer. The plasmid pLLB13 was constructed by
inserting the Mef I-and Xba I-digested luciferase DNA fragment, PCR-amplified from pGL4.10 (Promega,
USA) using both the 5’-primer (5′-CGAACTCAATTGCCACCATGGAAGATGCC-3′) and 3’primer
(5′-CCCGACTCTAGAATTATTACACGGC-3′), into pLenti6/Ubc/V5-DEST (Invitrogen, Carlsbad, CA,
USA) from which the 1752-bp fragment between EcoR I and Xba I restriction enzyme sites had been
removed. Lentivirus production and transduction of PEPCs were performed as suggested by the
manufacturer. Briefly, lentivirus was produced by transfecting 293FT cells (Invitrogen, Carlsbad,
CA, USA) with both pLLB13 and ViroPower Packaging Mix (Invitrogen, Carlsbad, CA, USA) in the
presence of Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The lentivirus was harvested three
days later with a titer of 2 × 106 transducing units. They were then used to transduce PEPCs in the
presence of 6 μg/mL polybrene and 0.5 μg/mL blasticidin.
2.7. Immunocytochemistry and Histological Analysis
Spindle shape PEPCs and cardiosphere-like cell clusters were collected for immunostaining.
Cells were fixed with 3.7% buffered paraformaldehyde, permeabilized with 0.5% Triton X-100 for
15 min and then blocked with goat serum (Zymed, San Diego, CA, USA) for 30 min at 37 ◦C. Cells
were incubated with antibodies including mouse anti-CD105 (R&D Systems, Inc., Minneapolis, MN),
anti-CX43 (Chemicon, Temecula, CA, USA), anti-sarcomeric actin (Abcam, Cambridge, UK), rabbit
anti-CD117, anti-Ki67 (Abcam, Cambridge, UK) for 12 h at 4 ◦C, followed by an hour room temperature
incubation with Alexa 488 or Alexa 489 conjugated secondary anti-mouse/anti-rabbit IgG antibodies
(Molecular Probes, Eugene, OR, USA). Cell nucleus was stained with 4’, 6-diamidino-2-phenylindole
(DAPI) (Sigma). The fluorophore was excited by a laser at 405 nm; 488 nm or 543 nm and detected by a
scanning confocal microscope (Olympus FV-1000, Tokyo, Japan). The specificity of all antibodies used
in this study was examined with isotype-specific immunoglobulins at the same protein concentration
as a negative control. Mouse hearts were excised, fixed in 10% formaldehyde or fresh frozen, and
sectioned in 5-μm slices. Tissue sections were stained with a hematoxylin-eosin reagent or Masson’s
trichrome. Tissue infarct zone was calculated from Masson’s trichrome-stained sections by tracing the
infarct borders manually [15] and then by using ImageJ software to calculate the percent of infarct
myocardium by a researcher who blinded to the study.
2.8. Gene Expression in Mouse Heart after Cell Transplantation
To realize the crosstalk between implanted PEPCs and mouse cardiomyocytes, mouse hearts
treated with PBS, human fibroblasts, and PEPCs were collected 3 weeks after surgery for DNA
microarray analysis. Each group contained at least 3 mice. Mouse hearts were excised and frozen
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stored at −80 ◦C. The whole ventricular portion of each ischemic heart was used for RNA extraction.
RNA was extracted after stabilizing in RNA later-ICE (Ambion, Foster City, CA, USA) by following
the manufacturer’s instruction. Affymetrix cDNA microarray (Mouse Gene 1.0 ST Array GeneChip,
Santa Clara, CA, USA) with 28,853 genes was used for whole-genome analysis. Gene expression level
differences were analyzed with methods developed by Tusher VG et al. [21]. SYBR green master mix
and 7500 Fast Real-Time PCR systems were used to confirm the gene expression (Applied Biosystems,
Foster City, CA, USA). 18s RNA or GAPDH was used as an internal control.
2.9. Statistics Analysis
The Pearson product–moment correlation coefficient method was used to identify the patient
parameter that might be independently associated with cell growth and cell isolation. One-way
analysis of variance (ANOVA) was performed to determine whether there were significant differences
between the different treatments. Bonferroni t-test was applied for multiple pairwise comparisons
among individual groups. The Student’s t-test was used to compare differences in two groups when the
variables were normally distributed and Mann–Whitney rank sum test when data were not normally
distributed. Data were analyzed using SigmaStat (Systat Software Inc. San Jose, CA, USA) version 3.11.
A p-value less than 0.05 was considered significant. Data were calculated with at least three separated
independent experiments.
3. Results
3.1. Isolation of PEPCs from Drain Fluid after Open-Heart Surgery
Figure 1 depicts the methods of collection and propagation of PEPCs from the drain fluids. The
average cells yield for the first 24-hour drain fluid was 6.3 ± 3.0 × 106, and 2.2 ± 1.4 × 106 for the second
24-hour. On 6–7 days-in-vitro (DIV), the morphology of the loosely attached cells changed. Spindle-like
cells spread out on the culture dish while loosely attached cells began to form cell clumps resembling
the morphology of a cardiosphere (Figure 2A). Subsequently, the culture showed robust growth.
Spindle-like cells became confluent with cardiospheres growing on top on 14 DIV (Figure 2B). Of note,
initial cell density affected cell growth [22]. With a higher culture density (2 × 104/μL), spindle-like
cells appeared on day 3 while cardiospheres appeared around day 7 after seeding. However, with a
lower density (2 × 102/μL), spindle-like cells appeared around day 7 while cardiopspheres emerged
around 2–3 weeks. Importantly, PEPCs culture could be established from all 37 patients (3-day-old to
43-month-old, median 9-month-old) included in the study (Table S1), suggesting that this protocol was
reproducible regardless of the patient’s sex, age, and disease conditions (r= 0, Pearson product–moment
correlation coefficient). The doubling time of these cells was 4.56 ± 1.8 days.
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(H) 
Figure 2. PEPCs are highly proliferating cells and express cardiac lineage potential after in vitro culture.
(A) Spindle-like cells and cardiosphere-like cell clusters appeared 7 days after cell seeding. (B) Day 14
culture showed robust growth of spindle cells and cardiospheres. (C) FACS analysis, either from day
1 (D1) or day 2 (D2) drain fluid collections, showed increased expression of stem cell factor receptor
(CD117), CD90, and CD105 after 6 cell passages (D1–P6, D2–P6) compared with their corresponding
primary cells (D1 and D2). (D) The expression of CD31, CD34, CD45, and CD133 decreased with
increased cell passages (* p < 0.05, ** p < 0.01, *** p < 0.001). (E) Differential interference contrast (DIC)
image of cultured human PEPCs showed two distinct cell morphologies: cardiosphere-like (CS) and
spindle-like cell (SC) on the fibronectin-coated plate. (F) and (G) Confocal immunofluorescence images
of CS and SC cells stained with CD117, connexin (CX) 43, Ki67, CD105, (H) α-sarcomeric actin. Nuclei
were counterstained with 4’, 6-diamidino-2-phenylindole (DAPI). Scale bar = 200 μm in E and G, and
scale bar = 50μm in H.
3.2. PEPCs Differentiate toward Cardiovascular Lineage
PEPCs collected directly from patients’ day 1 or day 2 (n= 11 in each group) after surgery expressed
similar, if not all, cell surface markers including CD31, CD34, CD45, CD90, CD105, CD117 (c-kit), and
CD133 (Figure 2C,D) at variable levels (no significant difference, p > 0.05). Day 1 PEPCs contained
surface markers including CD31 (4.4 ± 2.4%), CD34 (1.4 ± 1.2%), CD45 (6.4 ± 3.7%), CD90 (15.8 ±
12.3%), CD105 (1.8 ± 1.8%), CD117 (20.7 ± 18.1%), and CD133 (0.5 ± 0.4%), CD31/CD34 (1.6 ± 1.1%),
CD34/CD133 (0.3 ± 0.4), CD45/CD117 (2.4 ± 2.5%), CD90/CD105 (0.7 ± 0.6%), CD117/CD133 (0.7 ±
0.7%). After six in vitro passages, the expressions of CD45 decreased to 1.4% while no expression of
CD31, CD34, and CD133. CD90 (68.9%), CD105 (90.6%), and CD117 (40.6%) increased dramatically.
Co-expression of surface markers CD45/CD117 was about the same (2.2 ± 1.0%) while CD90/CD105
increased significantly to 68.9 ± 4.7%. The present in vitro culture and passage condition might favor
the expansion of a distinct population progenitor cells.
PEPCs including cardiospheres (CS) and spindle-like cells (SC) (Figure 2E) proliferated rapidly
by a doubling time of 5–7 days during in vitro expansion. Consistent with this observation,
immunofluorescence staining of Ki67 showed strong signals in both CS and SC (Figure 2G). PEPCs
also expressed various cardiac stem cell and lineage-specific cell surface markers. In general, SC
exhibited antigenic markers similar to those of the CS. As shown in Figure 2F, cells from both CS and
SC populations express CD117, indicating the presence of progenitor cells [23]. The majority of PEPCs
expressed markers indicative of cardiovascular lineages including CD105 [24], connexin (CX) 43 [25],
and α-sarcomeric actin [15] (Figure 2F–H).
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3.3. In Vitro Angiogenesis of PEPCs
Conditioned medium from PEPCs enhanced angiogenesis of HUVEC in vitro. Figure 3 shows
PEPCs condition medium significant enhanced HUVEC to form tubes (Figure 3C) in comparison to
serum-free medium control (Figure 3A) or serum-free conditioned medium from fibroblasts (Figure 3B).
The efficacy of PEPCs conditioned medium promoting tube formation was the same as medium
supplemented with 10% serum (Figure 3D). The enhancement was inhibited by anti-HGF, anti-VEGF,
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Figure 3. PEPCs conditioned medium enhanced angiogenesis in vitro. (A) Twenty thousand HUVEC
cells were seeded on a 96-well plate pre-coated with basement membrane matrix. Cells were imaged
after 18 h with a digital camera coupled to a microscope. HUVEC cells cultured in serum-free medium
showed no tube formation. (B) Few vascular networks formed in serum-free conditioned medium
from fibroblasts. (C) Well-formed vascular networks developed in cells cultured in PEPCs conditioned
medium. (D) Cells cultured in completed medium (positive control) showed vascular networks as
in PEPCs conditioned medium. (E) The total vessel length in pixels under different conditions. Data
were pooled from three independent experiments expressed as average ± SD. (F) The enhancement
was inhibited by anti-HGF, anti-VEGF and thalidomide (* p < 0.05; *** p < 0.001).
3.4. Therapeutic Potential of PEPCs and Cell Fate in Ischemic Heart Repair
Three weeks after injection of PEPCs into the margins of ischemic myocardium in mice,
echocardiography revealed a significant improvement of cardiac ejection fraction compared to the
PBS and fibroblast treated mice (Figure 4A,B; * p < 0.05). The regeneration ability was further
quantified in sections stained with Masson trichrome to discriminate viable from fibrous tissue
(Figure 4C–F). Ischemic hearts with PBS (negative control, Figure 4C) or fibroblasts (positive cell
control, Figure 4D) transplantation showed significant heart dilatation. PEPC transplanted hearts
had a smaller blue-stained (fibrous) infarct zone (25 ± 9%) compared to the hearts transplanted with
fibroblasts (35 ± 7%; p < 0.01) or PBS-treated hearts (49 ± 17%; *** p < 0.001, Figure 4F).
In vivo luciferase signals from injected PEPCs declined from day 3 to day 15, and completely
undetectable at day 22 after transplantation, advocating human PEPCs might not survive in injured
mice hearts (Figure 4G,H). It may of interest to analyze whether any difference in cardiac repair ability
between luciferase-transduced cells and non-transduced cells. However, the small sample size limited
further subpopulation analysis. The absence of human cells was further confirmed by undetectable
human Alu repeats in PEPC-treated infarct mouse heart (Figure 4I).
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Figure 4. PEPCs restore cardiac functions and initiate tissue regeneration after transplantation into
an ischemic heart. (A) Long-axis views from an echocardiogram performed 21 days post-infarction
showed improvement of cardiac contractility after PEPCs transplantation (n = 14) compared to
fibroblasts (n = 16) and PBS (n = 11). (B) Left ventricle ejection fractions were improved in mice injected
with PEPCs (* p < 0.05). (C) Masson trichrome stain of ischemic heart in which viable tissue stains
red whereas fibrous tissue stained blue, representative heart 3 weeks after PBS injection (n = 11);
(D) fibroblasts transplanted (n = 10); and (E) PEPCs transplanted (n = 10). (F) Percent of infarction
area in ischemic heart (** p < 0.01, *** p < 0.001) 3 weeks after cell transplantation. (G) In vivo imaging
of PEPCs fate after transplantation. A representative mouse injected with 1 × 105 PEPCs showed
significant bioluminescence activity on day 3, which decreased progressively over the following
3 weeks. (H) Quantitative analysis of signals from all animals transplanted with PEPCs (signal activity
is expressed as photons/sec/cm2/sr), n = 8 in PEPCs transplanted mice. (I) No human Alu sequence
was detected in mouse heart 3 weeks after PEPCs transplantation.
3.5. Paracrine Effects of PEPCs on Ischemic Heart Repair
To define the key components involved in the sustain effect of PEPCs on cardiac repair in the
ischemic heart mouse model, we performed a whole genome microarray pooled from three ventricles
of the mouse hearts in each group treated with PBS, human fibroblasts or PEPCs 22 days after
transplantation. The heat map (baseline cutoff of ± 1.5fold change) indicated there are 95 genes
regulated in the PEPCs-treated ischemic heart compared to human fibroblast-injected and PBS-injected
controls (Figure 5A). Of these, 54 genes were upregulated and 41 genes were downregulated (Table S2).
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(A) 
(B) 
Figure 5. The difference of microarray gene expression profile after PEPCs-injected ischemic heart.
(A) Hierarchical clustering heatmap displaying genes that were upregulated (red) or downregulated
(green) in response to PEPCs, fibroblasts or PBS exposure (>1.5-fold change). (B) Gene ontology
enrichment analysis of 95 differentially expressed genes revealed the enriched biological process and
molecular function. Representative gene ontology terms listed on the bar plot have enrichment p values
< 0.05 and the horizontal axis was the gene count.
Gene ontology analysis revealed several pathways to be significantly overrepresented in the
PEPCs-treated group, including pathways involved in the immune and inflammatory response,
cytokine and chemokine activity as well as paracrine signaling (Figure 5B). Particularly, genes involved
in neutrophil chemotaxis such as chemokine ligands and cell adhesion such as integrins and cluster
of differentiation molecules, were upregulated in PEPCs-treated ischemic hearts. Various cytokines
including integrin subunit beta 2 (ITGB2) and matrix metalloproteinase-3 (MMP-3), which have been
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implicated in promoting angiogenesis and cell migration in the ischemic hearts [26] were increased
in the PEPCs-treated group. The increased immune complements and chemokine receptors induced
by PEPCs at a later time point when PEPCs were physically absent in the ischemic site suggested
an enhanced homing or recruitment of host stem cells and other cell types that might contribute to
ischemic heart repair [27].
4. Discussion
In this study, we found cells isolated from congenital heart disease patients’ own pericardial
effusion for pressure relief after cardiac surgery may have potential to treat their heart disease in the
future. We named these cells as PEPCs because the drainage tube was inserted in this space to relieve
pressure after the operation. The PEPCs may be originated from heart, bone marrow or fibroblasts.
Further studies are needed to clarify their origin. Agarwal U et al. found an age-dependent effect
of human pediatric cardiac progenitor cells isolated from juvenile heart failure patients in repairing
right ventricular heart failure in a rat [28]. They divided children undergoing reconstructive surgeries
into three groups based on age: neonate (1 day to 1 month), infant (1 month to 1 year), and child
(1 to 5 years). Injection of neonatal cardiac progenitor cells exerting the maximum beneficial effect
compared with cells from infant and child. All patients in our study are younger than 4 years old
(median 9 months). PEPCs could be established from all 37 patients regardless of age, sex, and disease
types in our study. However, more patients are needed to confirm age effects in the future.
During the process of PEPCs culture, two critical points could determine the efficiency of PEPCs
expansion: (1) initial cell density affects the cell growth and the formation of cardiospheres, and (2) a
mixed cell population at the beginning of culture benefits cell growth. Initially, we tried to culture
PEPCs after purifying the CD117+ cells through FACS cell sorting. Although CD117+ cells have
been demonstrated to represent cardiac stem cells, this subpopulation of cells grew very slowly and
failed to form cardiospheres. The unfavorable cell growth of this subpopulation might attribute to a
low cell density and lack of cytokines/growth factors release from other cells. We decided to culture
PEPCs without cell sorting. The suspended RBC and white blood cells were removed gradually
by serial changing of the medium. A highly heterogeneous population of cells, possibly including
inflammatory cells, mesenchymal stem/progenitor cells, and endothelial stem/progenitor cells at the
initiation of PEPCs culture might provide a better milieu for subsequent PESCs expansion by mimicking
host environment. This is in line with the observation by Smith RR et.al. in the establishment of
cardiosphere-derived cells from cardiac biopsy without antigenic selection. The authors speculate that
a mixed cell population might be advantageous for progenitor cell proliferation and function more
potent than CD117 or CD90 purified stem cell subsets after injection into infarct areas [29]. It is also
true in adipose tissue-derived stem cells in vitro [22]. Sukho P. et al. showed a higher cell seeding
density in the presence of inflammatory cytokines enhances endothelial cell proliferation and fibroblast
migration [22].
This study is focusing on how to isolate potential progenitor cells from surgery byproduct. The
limitation of the present study is the lack of a sophisticated analysis of cell function and lineage assays
by differentiation PEPCs with different culture media and a head-to-head comparison with another
more established cardiac stem/progenitor cell. Nevertheless, PEPCs are heterogeneous in nature,
exhibiting a phenotypic signature distinct from that reported for cardiac resident stem cell [15] and
mesenchymal stem cells [16]. In the present study, day 1 and day 2 primary cells expressed CD117,
the receptor for stem cell factor; and CD105, the regulatory component of the transforming growth
factor-beta receptor complex which is important for angiogenesis [24]. A small portion (<5%) of cells
expressed CD31. CD31 is also known as platelet/endothelial cell adhesion molecule-1 (PECAM-1) and
can be found on the surface of platelets, monocytes, neutrophils, and some types of T-cells [30]. Less
than 2% of cells expressed CD34 (hematopoietic progenitor cell antigen) which is associated with the
selection and enrichment of hematopoietic stem cells for bone marrow transplants clinically but may
express in different progenitor cells [31]. Around 7% PEPCs expressed CD45, a leukocyte common
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antigen and an essential regulator of T and B-cell antigen receptor signaling. The surface markers
data implies a mixed cell population in the fresh isolates. Around 3% PEPCs expressed CD105 and
7% expressed CD45 while cardiac resident stem cells express almost 100% CD105 and do not express
CD45 [15]. However, more than 70% PEPCs expressed CD90 and CD105 without expression of CD34
after in vitro expansion to passage 6. Our results are in agreement with recent studies that CD105+
MSC isolated from human heart improved ventricular ejection function in ischemic mouse heart and
improved functional recovery by an ischemic limb after cells implantation [24]. MSC usually reveals
a negative expression of CD34 and CD45 surface markers [32]. Colony-forming units-fibroblasts
(CFU-Fs) also can repair myocardial damages [33]. The fibroblasts we used for in vivo study were
originated from fetal skin. It was reasonable to expect some therapeutic effects in the ischemic heart as
we showed in Figure 4D. However, these cells are CD117 negative cells. Taken together, we conclude
that PEPCs may represent a distinct progenitor cell type. However, more studies are needed to clarify
PEPCs as a new progenitor cell.
The safety and efficacy of clinical trials of stem cell therapy in myocardial infarction patients are
encouraging yet remain in dispute [7,16]. Despite the potential uses of ideally matched autologous
cardiogenic cells from PEPCs transplantation, certain risks such as tumor formation and sudden death
need to be concerned before clinical application. No tumors formed or sudden death happened in
the PEPCs-treated mice. The use of cells with early passage (passage 6) for expansion may minimize
the risk of tumor transformation of PEPCs [34,35]. However, a long-term follow up in vivo and more
experiments are needed to confirm the results.
The delay of cell harvesting to cell transplantation is one of the practical limitations in cell therapy.
PEPCs expanded after six passages were used for cell therapy in eight ischemic hearts to achieve a
homogenous cell background in mice. After expansion in vitro, 90% PEPCs expressed CD105 which
may play a major role in therapeutic efficacy and cardiomyogenic differentiation [36]. The first 24
h drain fluid contained 6 million cells which may enough for cell therapy. It is of interest to study
if the primary cells without expansion or cells with a lower passage expansion will have better or
similar regenerative efficacy. We did not examine electrophysiology in PEPCs. The expression of
connexin 43, a gap junction protein which plays a crucial role in the synchronized contraction, and
α-sarcomeric actin, a major constituent of the contractile apparatus of cardiomyocytes [37,38] have been
used as indicators for the electrical coupling potential [15]. PEPCs express both proteins, suggesting
the potential to differentiate toward cardiomyocytes with electrically coupling potential. Nevertheless,
long-term engraftment of implant cells may be unnecessary for cell therapy in cardiac repair and
regeneration [29]. Indirect stimulation of the reparative response through paracrine effects has been
one of the major hypotheses of cardiac regeneration in the first and second-generation cell therapy for
myocardial infarction [16,39]. Bone marrow stem cell secretome analysis has revealed more than 100
soluble intrinsic paracrine factors, the restorative potential of which includes myocardial protection,
angiogenesis, modulation of remodeling, increase in cardiomyocyte proliferation, and activation of
resident progenitor cells [40]. The beneficial effects in reducing scars, reducing inflammation [41]
and enhancing heart regeneration were mainly derived from indirect mechanisms such as paracrine
effects [42], and exosomes secreted by cardiosphere-derived cells [43]. The recognition of dominant
indirect mechanism opens a new research paradigm that secretory factors from stem cells may have
potential in the regeneration of the ischemic heart [43]. However, the studying of the secretome of
PECPs in vitro may not reflect the long-term effects in vivo, though it may explain the enhanced
angiogenesis in Figure 3. The paracrine activity may require multiple cell type in the microenvironment.
Therefore, we have used microarray to probe for differential gene expression in the infarction site. The
microarray experiment at 3 weeks after transplantation revealed the upregulation of genes involved in
chemotaxis, angiogenesis, and cell migration in PEPCs-transplanted heart, indicating that the long-term
effect of PEPCs transplantation could trigger endogenous paracrine signaling that facilitates homing or
recruitment of host stem cells and other cell types for ischemic heart repair.
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5. Conclusions
In the present study, we have established a simple method for the isolation and propagation of
progenitor cells from pericardial effusion which supposed to be discarded after heart surgery. Results
from cardiac repair in mice suggested the potential of PEPCs in cell-based therapy in CHD. The
PEPCs isolated and expanded by this method appear to have some pragmatic advantages. First,
PEPCs are easy to harvest from drain fluids, the byproduct of open-heart surgery. Isolating and
propagating cells without the need for cell sorting makes this technique simple and reduces the risk
of contamination. Second, the yield of PEPCs is at least comparable, if not higher, to that previously
reported for cardiosphere-derived cells obtained from endomyocardial biopsy (average 3 million in
4 weeks). Third, PEPCs are isolated from the same patient that will not raise an ethical issue and
immune rejection for his/her future cell therapy. PEPCs may represent a new potential source for cell
therapy in treating CHD with its easy harvesting protocol and potential in cardiac repairs. However,
the functional characterization and differentiation of PEPCs into other cell types and the long-term
safety needs to be investigated before the future application of PEPCs in the clinic.
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Abstract: The limitations of the first-generation everolimus-eluting coronary bioresorbable vascular
scaffolds (BVS) have been demonstrated in several randomized controlled trials. Little data are
available regarding the outcomes of patients receiving hybrid stenting with both BVS and drug-eluting
stents (DES). Of 3144 patients prospectively enrolled in the GABI-Registry, 435 (age 62 ± 10, 19%
females, 970 lesions) received at least one BVS and one metal stent (hybrid group). These patients
were compared with the remaining 2709 (3308 lesions) who received BVS-only. Patients who had
received hybrid stenting had more frequently a history of cardiovascular disease and revascularization
(p < 0.05), had less frequently single-vessel disease (p< 0.0001), and the lesions treated in these patients
were longer (p < 0.0001) and more frequently complex. Accordingly, the incidence of periprocedural
myocardial infarction (p < 0.05) and that of cardiovascular death, target vessel and lesion failure and
any PCI at 24 months was lower in the BVS-only group (all p < 0.05). The 24-months rate of definite
and probable scaffold thrombosis was 2.7% in the hybrid group and 2.8% in the BVS-only group,
that of stent thrombosis in the hybrid group was 1.86%. In multivariable analysis, only implantation
in bifurcation lesions emerged as a predictor of device thrombosis, while the device type was not
associated with this outcome (p = 0.21). The higher incidence of events in patients receiving hybrid
stenting reflects the higher complexity of the lesions in these patients; in patients treated with a hybrid
strategy, the type of device implanted did not influence patients´ outcomes.
J. Clin. Med. 2019, 8, 767; doi:10.3390/jcm8060767 www.mdpi.com/journal/jcm87
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1. Introduction
A number of randomized controlled trials comparing the outcomes of drug eluting stents compared
to first-generation everolimus-eluting coronary bioresorbable vascular scaffolds (BVS) have shown
the limitations of this novel type of devices [1–4]. When compared with drug eluting stents (DES),
the mechanical limitations of BVS, including thicker and wider struts, lower radial strength, and
limited expansion capabilities [5,6] represent important limitations for the treatment of complex lesions,
including ostial or calcific ones, bifurcations, and lesions in small vessels. Supporting this concept,
a number of post-hoc analyses have shown that this type of lesions represents predictors for BVS
failure [7–9] unless a dedicated implantation technique is used [10,11]. Additionally, lesions in the left
main, in by-pass grafts, and restenotic lesions have been excluded from the CE certification from the
very beginning.
Based on these considerations, some authors have advocated for the use of a hybrid approach,
which consists of limiting the use of BVS to settings in which the use of BVS is allowed (or considered
to be safe) [12]. While this strategy is in conflict with the concept of “vascular regeneration” which
represents the foundation of the use of BVS, it might still have the theoretical advantage that vessels
(e.g., the proximal segments) in which long-term complications are clinically more relevant, would
be “stent-free” after device resorption. Independently of the clinical rationale supporting the use of
hybrid stenting, this setting however allows a direct head-to-head comparison of the outcomes of the
device types independently of patients´ characteristics and clinical presentation.
The multicenter German-Austrian ABSORB Registry (GABI-R) was designed to monitor the usage
of BVS in everyday practice. Details on this international registry have been published elsewhere [13].
In the current analysis, we set out to assess the incidence of clinical events in patients receiving hybrid
percutaneous coronary interventions.
2. Methods
Between November 2013 and January 2016, consecutive patients undergoing implantation of
at least one BVS (Absorb; Abbott Vascular, Santa Clara, CA, USA) were enrolled in a prospective
single-arm registry in 92 GABI-R centers. Details on the methods for patients’ inclusion and follow-up
in this observational registry have been previously published [13–15]. The study was conducted in
accordance with the provisions of the Declaration of Helsinki and with the International Conference
on Harmonization Good Clinical Practices, the protocol was approved by each local ethics committee
(first Vote: Ethic committee of the Justus Liebig Universität Giessen 190/13) and all patients provided
written, informed consent. Clinicaltrial.gov NCT02066623
2.1. Objective of the Study
The objective of this study was to investigate the outcome of patients receiving hybrid stenting
with at least one drug eluting stent and one bioresorbable scaffold.
2.2. Procedures
Lesion preparation, BVS implantation, postdilation and use of intracoronary imaging, as well
as medical therapy, were left to the operator’s discretion. The protocol recommended use of pre-
and postdilation. High-pressure dilation was defined as dilation with ≥14ATM. Antiplatelet therapy
consisted of aspirin (loading dose 250–500 mg and maintenance dose 100 mg/day) and clopidogrel
(loading dose at least 300 mg and maintenance dose 75 mg/day), prasugrel (loading dose 60 mg
and maintenance dose 10 mg), or ticagrelor (loading dose 180 mg and maintenance dose 90 mg bid).
Dual antiplatelet therapy was recommended for at least 12 months.
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2.3. Definitions
For the purpose of the present analysis, hybrid stenting was defined as implantation of at least
one Absorb BVS and one metallic stent (BMS or DES) in the same patient. The primary endpoint of the
present study was the incidence of definite/probable device thrombosis in lesions/patients treated with
BVS compared to metallic stents.
Procedural success was defined as visually estimated residual stenosis <30% with thrombolysis
in myocardial infarction flow grade III. Other definitions were based on the Academic Research
Consortium (ARC) criteria [16]. Scaffold thrombosis was defined as definite or probable. Cardiac
death was defined as death from immediate cardiac causes or complications related to the procedure
as well as any death in which a cardiac cause could not be excluded. Myocardial infarction (MI)
was defined according to the World Health Organization extended definition. Target lesion failure
(TLF) was defined as a composite of cardiac death, target vessel MI, and clinically-driven target lesion
revascularization (TLR). Target vessel failure (TVF) was defined as a composite of cardiac death,
target-vessel MI, and clinically driven target vessel revascularization (TVR).
2.4. Data Management and Outcomes of Interest
Data in the GABI-R were collected electronically via an internet-based application and centralized
by the IHF GmbH-Institut für Herzinfarktforschung (Ludwigshafen, Germany). Patients were
contacted by telephone at 30 days, six months and two years using standardized questionnaires.
Follow-up, source verification, quality controls were performed centrally. All events were adjudicated
and classified by an independent event adjudication committee.
2.5. Statistical Analysis
Data are presented as mean± standard deviation, absolute frequencies and percentages, or median
(lower, upper quartile) as appropriate. Data are presented per patient and per lesion. Odds-ratios (95%
confidence limits) are presented to characterize the differences in event frequencies among groups.
The incidence of events in the periprocedural interval and at each of the follow-up times was tested
with Pearson’s Chi-squared test. Concerning device thrombosis, testing for differences on patient level
had to face a highly unbalanced design: There was no reference group for DES/BMS-only treatment.
Thus, we implemented a loglinear model for an incomplete contingency table and three factors: BVS
thrombosis, stent thrombosis, and hybrid treatment, accounting for interactions between the treatment
and device type. To compare times to event (= device thrombosis) and assess the impact of the device
type and hybrid stenting on outcomes, a proportional-hazard model (“Cox regression”) on stent level
was implemented. Intra-subject correlations were considered by using a robust sandwich estimate
aggregating stent residuals to subject level. This multiple regression model included the device type as
a main factor and additional pre-defined predictor variables that have been previously shown to be
associated with scaffold/stent thrombosis in the GABI-R: Total stent length, lesion type, bifurcation
lesion, and time of implantation (before or after January 2015). Missing values were imputed either
by random drawing from the standardized empirical distribution (in case of missing times-to-event),
by modal values (binary) or by median values (metrical variables). A two-tailed p value <0.05 was
considered to indicate statistical significance. Statistical analyses were performed using the SAS®
software, version 9.4 for Windows. Copyright© 2002–2012 SAS Institute Inc. SAS and all other SAS




CONSORT flow diagrams are presented in Figure 1 (left and right panel). Of 3144 (4278 lesions)
patients included in the GABI-R registry who received at least one BVS and whose two-years vital
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status was known, 2709 (3308 lesions) were treated with scaffolds only (BVS-only group) while 435
(970 lesions) were treated with at least one additional metallic stent (hybrid group).
Patient characteristics are presented in Table 1. Patients in the hybrid group consistently showed
characteristics compatible with a higher complexity: Glomerular filtration rate was lower (p < 0.05),
the prevalence of prior PCI (p < 0.01), myocardial infarction (p < 0.01), multivessel disease (p < 0.0001),
male sex (p < 0.05) were all higher in the hybrid group and there was a trend towards older age
and higher diabetes prevalence in this group (both = 0.06). In line with this, procedure duration,
contrast use, radiation time, and the number of lesions treated per patient were larger in the hybrid
group (all p < 0.0001). DAPT with prasugrel was used more commonly in the hybrid group (p < 0.05).
The prevalence of smoking was higher in the BVS-only group (p < 0.05).
Table 1. Baseline characteristics of the cohort.





n = 2709 p Value
Female gender 22.9% (721/3144) 19.1% (83/435) 23.6% (638/2709) <0.05
Age (years, rounded) 60.87 ± 11.02 61.91 ± 10.36, 60.7 ± 11.11 0.06
Diabetes mellitus 20.9% (651/3117) 24.2% (105/433) 20.3% (546/2684) 0.06
Current smoker 34.9% (1039/2978) 30.4% (128/421) 35.6 % (911/2557) <0.05
Arterial hypertension 73.4% (2274/3100) 75.3% (324/430) 73% (1950/2670) 0.31
Hypercholesterolemia 56.5% (1702/3010) 59.6% (243/408) 56.1% (1459/2602) 0.19
Glomerular filtration rate 79.39 ± 23.68, n = 1590 75.33 ± 22.55, n = 165 79.86 ± 23.77, n = 1425 <0.05
History of myocardial
infarction 22.2% (687/3094) 27.4% (117/427) 21.4% (570/2667) <0.01
History of PCI 33.9% (1044/3079) 39.6% (169/427) 33% (875/2652) <0.01
History of aorto-coronary
bypass surgery 2.5% (79/3131) 3% (13/433) 2.4% (66/2698) 0.49
History of CAD 41.1% (1137/2768) 44% (178/405) 40.6% (959/2363) 0.20
History of stroke 2.7% (85/3143) 3% (13/435) 2.7% (72/2708) 0.69
Acute coronary syndrome at
presentation 51.4% (1617/3143) 47.8% (208/435) 52% (1409/2708) 0.10
Stable angina pectoris 33.5% (1053/3143) 33.1% (144/435) 33.6% (909/2708) 0.85
Left ventricular ejection
fraction 56.09 ± 10.5, n = 1930 54.84 ± 10.15, n = 282 56.31 ± 10.55, n = 1648 <0.05
1-vessel CAD 41.9% (1317/3144) 20% (87/435) 45.4% (1230/2709) <0.0001
2-vessels CAD 31% (974/3144) 35.6% (155/435) 30.2% (819/2709) <0.05
3-vessel CAD 27.1% (852/3144) 44.4% (193/435) 24.3% (659/2709) <0.0001
Values are mean ± SD or % (absolute number/number of available records); CAD = coronary artery disease; PCI =
percutaneous coronary intervention, CBR = clinical BVS restenosis.
 
Figure 1. Study flow per patient (left panel) and per lesion (right).
Lesion characteristics are presented in Table 2. A total of 4962 BVS/Stents (4349 BVS, 631 in the
hybrid group and 3718 in the BVS-only group, and 613 stents, all in the hybrid group) were implanted.
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The large majority of metallic stents were DES (total of DES used: 610), and only three BMS were
used. Interventions in the hybrid group were more frequent in the LAD, those in the BVS-only group
were more frequent in the RCA (p < 0.0001 and p < 0.05). Compatible with the above differences
between groups, all parameters expressing lesion complexity were more frequent in the hybrid group:
The prevalence of B2 (p < 0.05), C1 (p < 0.0001), C2 (p < 0.05) lesions, bifurcation lesions (p < 0.0001),
chronic total occlusions (p < 0.0001), lesions with severe tortuosity (p < 0.05), presence of calcium
(p < 0.05), and lesion length (p < 0.0001) were higher in the hybrid group than in the BVS only group.
Predilatation was performed in 93.5% of BVS-only treated patients and 85.7% of patients treated with
hybrid-PCI (p < 0.0001). The use of high-pressure inflations, scoring balloons, rotablator, was more
frequent in the hybrid group (p < 0.001). In contrast, postdilation was performed more frequently
(73.6% compared to 68.4% in BVS-only patients.
Table 2. Angiographic and procedural characteristics.
Total (Hybrid + BVS-Only) Hybrid Group BVS Only p Value
Procedure duration, minutes 58.90 ± 28.91, n = 3141 77.83 ± 35.96, n = 435 55.85 ± 26.38, n = 2706 <0.0001
Radiation time, minutes 11.84 ± 8.22, n = 3143 18.05 ± 10.64, n = 435 10.84 ± 7.28, n = 2708 <0.0001
Amount of contrast medium,
mL 174.76 ± 74.65, n = 3140 223.40 ± 91.21, n = 435 166.94 ± 68.50, n = 2705 <0.0001
IVUS 3% (94/3142) 2.8% (12/435) 3% (82/2707) 0.76
OCT 4.5% (141/3142) 4.6% (20/435) 4.5% (121/2707) 0.90
Per lesion
Treated segments 4278 970 3308
Lesions treated with BRS only 87.3% (3670/4204) 43.8% (417/951) 100% (3253/3253)
Lesions treated with stents
only 9.8% (410/4204) 43.1% (410/951) 0% (0/3253)
Intervention in LAD 74.7% (1582/2118) 84.7% (287/339) 72.8% (1295/1779) <0.0001
Intervention in LCX 59.6% (813/1363) 63.8% (153/240) 58.8% (660/1123) 0.15
Intervention in RCA 68.4% (1051/1537) 62.8% (155/247) 69.5% (896/1290) <0.05
Graft 23.8% (5/21) 0% (0/1) 25% (5/20) 0.57
Lesion type
A 26.5% (1133/4270) 19.4% (187/964) 28.6% (946/3306) <0.0001
B1 37% (1579/4270) 36.1% (348/964) 37.2% (1231/3306) 0.52
B2 19.6% (836/4270) 21.9% (211/964) 18.9% (625/3306) <0.05
C1 12.6% (539/4270) 17% (164/964) 11.3% (375/3306) <0.0001
C2 4.3% (183/4270) 5.6% (54/964) 3.9% (129/3306) <0.05
De novo lesion 94.2% (4025/4272) 92.9% (897/966) 94.6% (3128/3306) <0.05
Ostial lesion 0.8% (36/4272) 0.5% (5/966) 0.9% (31/3306) 0.21
Bifurcation lesion 2.9% (123/4272) 5.5% (53/966) 2.1% (70/3306) <0.0001
100% stenosis 5.6% (241/4272) 5.7% (55/966) 5.6% (186/3306) 0.94
Chronic total occlusion 37.3% (90/241) 63.6% (35/55) 29.6% (55/186) <0.0001
Severe tortuosity 1.2% (52/4263) 1.9% (18/961) 1% (34/3302) <0.05
No calcification 35.9% (1533/4270) 33.2% (320/964) 36.7% (1213/3306) <0.05
% Stenosis 86.30 ± 11.73, n = 4275 84.92 ± 11.93, n = 968 86.71 ± 11.65, n = 3307 <0.0001
Imaging 3.2% (136/4275) 1.8% (17/968) 3.6% (119/3307) <0.01
FFR 5.2% (223/4262) 6.7% (64/961) 4.8% (159/3301) <0.05
RVD 2.95 ± 0.63, n = 93 3.15 ± 0.43, n = 11 2.92 ± 0.64, n = 82 0.26
Lesion length 17.12 ± 9.30, n = 4258 18.84 ± 10.51, n = 956 16.62 ± 8.85, n = 3302 <0.0001
Lesion length >34 mm 5.6% (238/4258) 8.4% (80/956) 4.8% (158/3302) <0.0001
Any lesion preparation 91.7% (3921/4274) 85.7% (830/968) 93.5% (3091/3306) <0.0001
Pre-dilatation 100% (3920/3921) 100% (830/830) 100% (3090/3091) 0.60
High pressure balloon 43% (1680/3908) 49.3% (408/828) 41.3% (1272/3080) <0.0001
Non-compliant balloon 73% (1215/1665) 85.3% (348/408) 69% (867/1257) <0.0001
Use of scoring balloon 3% (116/3921) 5.4% (45/830) 2.3% (71/3091) <0.0001
Rotablation 0.2% (6/3921) 0.6% (5/830) 0% (1/3091) <0.001
Stent/BVS size, mm 3.07 ± 0.59, n = 4960 3.03 ± 0.45, n = 1243 3.08 ± 0.63, n = 3717 <0.001
Postdilatation performed 72.4% (3093/4271) 68.4% (660/965) 73.6% (2433/3306) <0.01
High-pressure Postdilation 89.5% (2766/3090) 86.9% (573/659) 90.2% (2193/2431) <0.05
PSP-technique 6.4% (244/3794) 12.6% (68/541) 5.4% (176/3253) <0.0001
Procedural success 99% (4229/4273) 98.7% (954/967) 99.1% (3275/3306) 0.27
Glycoprotein IIb/IIIa inhibitors 8% (252/3143) 6.7% (29/435) 8.2% (223/2708) 0.26
Medical therapy at discharge
Aspirin 97.3% (3056/3141) 95.9% (417/435) 97.5% (2639/2706) <0.05
P2Y12-receptor
inhibitorsClopidogrel 44% (1351/3068) 41.2% (175/425) 44.5% (1176/2643) 0.2
Prasugrel 34.1% (1045/3068) 38.6% (164/425) 33.3% (881/2643) <0.05
Ticagrelor 21.9% (672/3068) 20.2% (86/425) 22.2% (586/2643) 0.37
Values are mean ± SD, median (quartiles) or % (absolute number/number of available records); BVS = bioresorbable
vascular scaffold; CBR = clinical BVS restenosis; DES = drug eluting stent; PCI = percutaneous coronary intervention.
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Lesion and procedural characteristics in the hybrid group are presented in Table 3. Of the
970 lesions in patients in the hybrid group, 417 (43.8%) had been treated with BVS only, 410 (43.1%)
with DES/BMS only and there was a total of 124 lesions treated with overlapping hybrid strategy
(2.9% of the total, 12.8% of the lesions treated in patients who received hybrid revascularization).
An additional 19 were not classified in the database. When lesions treated with BVS-only were
compared to lesions treated with DES/BMS only, BVS-only lesions were longer, more frequently type
C2 (both p < 0.05), and there was a trend towards more frequent chronic total occlusions (p = 0.06).
Only the prevalence of bifurcation lesions was higher in the DES/BMS-treated lesions (p < 0.0001).
There was a total of 25 Medina 1,1,1 lesions, and 2 Medina 0,1,1 lesions in the hybrid group. There were
only three cases of hybrid bifurcation stenting (metallic stent + BVS in the same bifurcation lesion).
In terms of procedural parameters, larger predilation balloons, imaging and postdilation were used
more frequently in BVS-treated lesions (p < 0.01, p < 0.05 and p < 0.0001). Procedural success was 99%
in both groups.
Table 3. Lesion-level analysis, bioresorbable vascular scaffold (BVS)-treated lesions compared to lesions




p Value OR (95%-CI)
Number of lesions 827 417 410




n = 410 0.69




n = 3 1
Lesion length (mm) 18.01 ± 9.9, n = 815 18.6 ± 9.66, n = 411 17.41 ± 10.1, n = 404 <0.05
Lesion length >34 mm 6.5 % (53/815) 6.8% (28/411) 6.2% (25/404) 0.72 1.11(0.63–1.94)
Morphology
A 20.4% (168/823) 21.4% (89/416) 19.4% (79/407) 0.48 1.13(0.80–1.59)
B1 36.2% (298/823) 36.8% (153/416) 35.6% (145/407) 0.73 1.05(0.79–1.40)
B2 22.6% (186/823) 20% (83/416) 25.3% (103/407) 0.07 0.74(0.53–1.02)
C1 15.6% (128/823) 15.1% (63/416) 16% (65/407) 0.74 0.94(0.64–1.37)
C2 5.2% (43/823) 6.7% (28/416) 3.7% (15/407) <0.05 1.89(0.99–3.59)
De novo vessel 93% (767/825) 93.8% (391/417) 92.2% (376/408) 0.37 1.28(0.75–2.19)
In-stent re-stenosis 1% (8/825) 0.5 % (2/417) 1.5% (6/408) 0.15 0.32(0.06–1.61)
Bifurcation 5.9% (49/825) 2.4% (10/417) 9.6% (39/408) <0.0001 0.23(0.11–0.47)
Complete occlusion 5.3% (44/825) 6.2% (26/417) 4.4% (18/408) 0.24 1.44(0.78–2.67)
CTO 61.4% (27/44) 73.1% (19/26) 44.4% (8/18) 0.06 3.39(0.95–12.09)
Ostial lesion 0.6% (5/825) 0.2% (1/417) 1% (4/408) 0.17 0.24(0.03–2.18)
Severe tortuosity 2% (16/820) 1.2% (5/416) 2.7% (11/404) 0.12 0.43(0.15–1.26)
No calcification 33.7% (277/823) 36.3% (151/416) 31% (126/407) 0.11 1.27(0.95–1.7)
Mild 43.7% (360/823) 44.2% (184/416) 43.2% (176/407) 0.78 1.04(0.79–1.37)
Moderate 18.2% (150/823) 15.9% (66/416) 20.6% (84/407) 0.08 0.73(0.51–1.04)
Severe 4.4% (36/823) 3.6% (15/416) 5.2% (21/407) 0.28 0.69(0.35–1.35)
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p Value OR (95%-CI)
Procedural Characteristics
Pre-dilatation 100% (693/693) 100% (396/396) 100% (297/297) n.d.
High pressure balloon 51.1% (353/691) 52.3% (207/396) 49.5% (146/295) 0.47 1.12(0.83–1.51)
Maximum balloon
diameter (mm) 2.75 ± 0.46, n = 689 2.79 ± 0.41, n = 395 2.69 ± 0.5, n = 294 <0.01
Scoring balloon 5.8% (40/693) 6.8% (27/396) 4.4 % (13/297) 0.17 1.6(0.81–3.15)
Rotablation 0.6% (4/693) 0.5% (2/396) 0.7% (2/297) 0.77 0.75(0.10–5.35)
Post-dilatation 66.8% (551/825) 85.5% (355/415) 47.8% (196/410) <0.0001




1.6% (13/827) 2.6% (11/417) 0.5% (2/410) <0.05
Procedural success 99% (819/827) 99% (413/417) 99% (406/410) 0.98
Values are mean ± SD or % (absolute number/number of available records).
3.2. Clinical Outcomes
The incidence of periprocedural myocardial infarction (p < 0.05, OR 4.2(1.2–14.9)) and vessel
perforation (p < 0.001, OR 4.9(1.8–13.2)) was higher in the hybrid group. Otherwise, there was no
difference in the incidence of periprocedural events.
At 30 days (Table 4), the incidence of cardiovascular death, target vessel and target lesion failure
were higher in the hybrid group. Similarly, at 24-month follow-up (follow up available in 98.4% of the
patients), the incidence of cardiovascular death (p < 0.05, OR 2.3(1.0–5.2)), target vessel failure (p < 0.01,
OR 1.7(1.2–2.3)) and target lesion failure (p < 0.05, OR 1.6(1.1–2.3)), and that of any PCI (p < 0.05, OR
1.4(1.1–1.8)), were higher in the hybrid group.
There was no significant difference (p = 0.13) in the incidence of target lesion revascularization
(estimates and confidence limits presented in Figure 2).
A total of 17 definite/probable stent thromboses occurred in the hybrid group during the 24-months
follow-up: In six cases, they affected both (at least) a DES and a BVS in the same patient; in four cases,
they only affected a BVS, and in one case only one DES.
Figure 3A,B show the two-years incidence, as well as estimates and confidence limits for the
incidence of stent and BVS thrombosis in both the hybrid and BVS-only group. Before testing for
differences, effects of the device type and hybrid treatment had to be separated and adjusted for
possible interactions. Thereafter, with regard to treatment strategy, only a trend towards a higher
incidence of BVS thrombosis remained in the BVS-only group (p = 0.07). With regards to the device
type, BVS and stent thrombosis rates did not differ significantly, neither within the hybrid group
(p = 0.22), between hybrid and BVS-only group (p = 0.31), nor pooled over all treatments (p = 0.07).
In the multivariable analysis, only the implantation in bifurcation lesions emerged as an
independent predictor of device thrombosis (Table 5). In separate analyses neither acute coronary
syndrome at index nor the implantatation technique used modified this association (p = 0.241 and
p = 0.637, respectively).
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Table 4. Clinical Outcomes.
Total (n = 3144) Hybrid Stenting
(n = 435)
BVS Only
(n = 2709) p Value OR (95%-CI)
Periprocedural complications
Death 0% (0/3143) 0% (0/435) 0% (0/2708) n.d. -
MI 0.3% (10/3143) 0.9% (4/435) 0.2% (6/2708) <0.05 4.18(1.17–14.87)
CABG - emergency operation 0% (0/3143) 0% (0/435) 0% (0/2708) n.d. -
Coronary thrombosis 0.4% (12/3143) 0.9% (4/435) 0.3% (8/2708) 0.05 3.13(0.94–10.45)
Coronary perforation 0.5% (16/3140) 1.6% (7/435) 0.3% (9/2705) <0.001 4.9 (1.82–13.22)
30-days follow-up
All-cause mortality 0.51% (16/3144) 1.15% (5/435) 0.41% (11/2709) <0.05 2.85 (0.99–8.25)
Cardiovascular mortality 0.32% (10/3144) 0.92% (4/435) 0.22% (6/2709) < 0.05 4.18(1.18–14.88)
Scaffold thrombosis Definite 0.86% (27/3144) 1.15% (5/435) 0.81% (22/2709) 0.48 1.42 (0.53–3.77)
- Probable 0.35% (11/3144) 0.69% (3/435) 0.3% (8/2709) 0.20 2.34 (0.62–8.87)
Stent thrombosis Definite 0.23% (1/435) 0.23% (1/435) - -
- Probable 0.69% (3/435) 0.69% (3/435) - -
Any myocardial infarction 1.43% (45/3144) 1.84% (8/435) 1.37% (37/2709) 0.44 1.35 (0.63–2.93)
Target vessel related MI 1.18% (37/3144) 1.61% (7/435) 1.11% (30/2709) 0.37 1.46 (0.64–3.35)
Target lesion revascularization 1.08% (34/3144) 1.38% (6/435) 1.03% (28/2709) 0.52 1.34 (0.55–3.25)
Target lesion failure 1.49% (47/3144) 2.76% (12/435) 1.29% (35/2709) <0.05 2.17 (1.12–4.21)
Target vessel failure 1.72% (54/3144) 2.99% (13/435) 1.51% (41/2709) <0.05 2 (1.07–3.77)
24-months follow-up
Follow-up available 98.4% (3094/3144) 97.2% (423/435) 98.6% (2671/2709)
All-cause mortality 3.06% (96/3135) 4.37% (19/435) 2.85% (77/2700) 0.09 1.56 (0.93–2.6)
Cardiovascular mortality 0.96% (30/3135) 1.84% (8/435) 0.81% (22/2700) <0.05 2.28 (1.01–5.16)
Scaffold thrombosis Definite 2% (54/2694) 1.33% (5/375) 2.11% (49/2319) 0.32 0.63 (0.25–1.58)
- Probable 0.78% (21/2688) 1.33% (5/377) 0.69% (16/2311) 0.19 1.93 (0.7–5.29)
Stent thrombosis Definite 0.53% (2/374) 0.53% (2/374) - -
- Probable 1.33% (5/377) 1.33% (5/377) - -
Any myocardial infarction 5.07% (137/2703) 5.31% (20/377) 5.03% (117/2326) 0.82 1.06 (0.65–1.72)
Target vessel related MI 3.37% (91/2700) 3.19% (12/376) 3.4% (79/2324) 0.84 0.94 (0.51–1.74)
Target lesion revascularization 6% (162/2698) 7.71% (29/376) 5.73% (133/2322) 0.13 1.38 (0.91–2.09)
Target lesion failure 7.19% (195/2711) 10.24% (39/381) 6.7% (156/2330) <0.05 1.59 (1.1–2.3)
Target vessel failure 10.21% (277/2714) 14.7% (56/381) 9.47% (221/2333) <0.01 1.65 (1.2–2.26)
Any PCI 18.52% (505/2727) 23.02% (87/378) 17.79% (418/2349) <0.05 1.38 (1.06–1.79)
Values are mean ± SD or % (absolute number/number of available records); BRS = bioresorbable vascular scaffold;
CI = confidence interval; PCI = percutaneous coronary intervention; OR = Odds ratio.
 
Figure 2. Two-years rates of target lesion revascularization. Comparison of Patients treated with hybrid
vs. BVS-only strategy.
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Figure 3. (A) Two-years incidence of device thrombosis. There was no difference among lesions treated
with BVS only, metal stents only, or hybrid strategies; (B) cumulative incidence curves showing an
overlap of the confidence intervals.
Table 5. Multivariate analysis of the predictors of definite/probable device thrombosis.
Analysis of Maximum Likelihood Estimates
Parameter Parameter Estimate Standard Error Chi-Square Pr > ChiSq Hazard Ratio
Device type 0.44883 0.36030 1.5518 0.2129 1.566
Total stent length 0.21102 0.16178 1.7015 0.1921 1.235
Lesion type B2/C −0.32342 0.26101 1.5354 0.2153 0.724
Implantation after Jan. 2015 −0.33539 0.23905 1.9683 0.1606 0.715
Bifurcation 1.04114 0.48421 4.6233 0.0315 2.832
4. Discussion
The GABI-R is a large international registry on the use of BVS. In the present analysis, we investigate
the characteristics and outcomes of patients who received hybrid stenting (i.e., at least one BVS and at
least one metallic stent). The major findings of the current analysis include: (i) Patients treated with
hybrid stent/scaffold therapy had a more complex presentation and worse outcomes than those treated
with BVS alone; (ii) During a two-years follow-up, the incidence of adverse events at the level of the
lesions treated with BVS was not worse than that of the lesions treated with metallic stents.
The concept of a vascular scaffold that provides temporary mechanical support and is resorbed
during follow-up to avoid a permanent unnecessary foreign body remains an attractive concept for
percutaneous coronary intervention. Although initial randomized trials reported non-inferiority as
compared to metallic drug-eluting stents [17,18], with signals that these devices might also be used in
more complex lesion [19–22], more recent trials have consistently demonstrated a higher incidence of
adverse events both early and late after implantation [3,4,23]. Mechanistic evidence shows that these
increased rates might depend on the technique used at the time of implantation, inadequate selection
of lesions, and, importantly, on the mechanical limitations of the devices, including increased strut
thickness, reduced expansion limits, reduced radial resistance [6,8]. Further, particular settings, such
as chronic total occlusions, acute coronary syndromes, treatment of ostial lesions and a lack of care at
the time of implantation have all been associated with increased events, including thrombosis and
restenosis [3,24–28]. Based on these notions, the general recommendation is that patients who have
been treated with BVS should prolong their dual antiplatelet therapy until complete resorption of the
device. This recommendation is likely to be particularly important in patients treated for complex
lesions, such as those presented here. Knowledge of these limitations lead to the hypothesis that,
by avoiding implantation in the presence of adverse lesion characteristics (e.g., long lesions with
proximal or distal reference vessel diameters unsuitable for BVSs, very calcific or bifurcation lesions)
may represent an adequate compromise between the benefit of the BVS and the risk of adverse events.
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Interestingly, this setting also allows within-patients comparison of the outcomes, i.e., removes the
confounding influence of differences in patient-related risk factors among groups.
Beyond any consideration on the safety of the devices implanted, it might be hypothesized that
the use of BVS might be more advantageous in long and proximal segments, which might thereafter
regain the possibility to adjust their diameter in response to biochemical and physical stimuli. Calcific
lesions, in contrast, might have theoretically less potential for regeneration. Thrombotic lesions might
also represent a setting for BVS, allowing ”plaque stabilization“ as previously reported [29]. The use
of BVS in CTO lesions has also been reported, but no data are available regarding the capacity of
these lesions to regenerate [30]. In the present database, lesions treated with BVS-only were indeed
longer and more frequently of type C (thrombotic). There was a trend towards less calcific lesions
being treated with BVS-only, but this difference remains speculative. Finally, in theory there is also a
rationale for the use of BVS in ostial or bifurcation lesions to limit (in time) the risks associated with
malapposed struts, but the evidence on their (lack of) safety in these settings clearly discouraged their
use [31]. Based on the instructions for use, in the present database, bifurcation lesions were almost
exclusively treated with metallic stents.
Reports on the short-term outcomes of this so-called hybrid stenting strategy (the use of both
metallic stents and BVS in the same patient or lesion) have been previously published [32–35].
Collectively, these studies reported that the use of a hybrid approach might be an acceptable compromise
to overcome the limitations of BVS. In the present study, we report data from a larger database with
longer follow-up. In our study, the incidence of events was similar between BVS and metallic
stents, while treatment of complex patients and lesions (particularly bifurcation lesions) remained
an independent predictor of events. These findings confirm the hypothesis that a hybrid approach,
in which more complex settings are treated with DES, might be a feasible option, although its rationale
needs to be validated. While polymeric devices of the first generation (Absorb, Abbott vascular) have
been removed from the market following the evidence of increased adverse events, the present results
might also apply to other similar devices for which data from large databases are not available. Further,
they provide a perspective for novel devices of this type.
5. Limitations
The GABI-R was a prospective registry designed to provide information on the real-life use of BVS
and is therefore affected by the limitations of this type of study design. Centralized data monitoring,
quality assessment, and follow-up were however performed to limit these issues. With regards to the
present analysis, hybrid treatment of lesions complicates the adjudications of the events to one or the
other device type. For this reason, the comparison of the incidence of device thrombosis was limited
to lesions treated with only one type of device. Despite the size of the database, conclusions on very
rare subsets (e.g., bifurcation lesions treated with hybrid strategy) were not possible. As well, data on
the antiplatelet regimen at the time of the event are missing. The present data should not be directly
extrapolated to second-generation BVS. However, they provide an insight that a prudent strategy of
hybrid stenting might allow combining the benefit of bioresorbable devices with the safety of standard
metallic stents also in more complex settings. The impact of a correct implantation technique has been
demonstrated in a number of papers, including those from our group [8,18,24,25,27,28]. Unfortunately,
the absence of a central quantitative coronary analysis in the present database does not allow clear
conclusions to this regard. Finally, the comparison of the outcomes within hybrid patients removes
patient-related confounders but not lesion-related confounders, which would be better addressed in
trials with a randomization at lesion level.
6. Conclusions
We report on the outcome of patients undergoing BVS and DES implantation, a particularly
complex subset among patients treated with BVS. In this database, which is one of the largest ones
worldwide on the use of BVS, the type of device implanted did not influence patients´ outcomes.
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Hybrid stenting is a negotiation between the concept of “full vascular regeneration” and the mechanical
limitations of these novel devices. Whether the use of metallic stents, although limited as compared to
a full-metal strategy, compromises the benefits of BVS remains however to be discussed. Whether the
use of a hybrid strategy with newer (and safer) scaffolds will present any advantage as compared to a
full-DES strategy, will need to be studied in the future.
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Abstract: Malapposition is a common finding in stent and scaffold thrombosis (ScT). Evidence from
studies with prospective follow-up, however, is scarce. We hypothesized that incidental observations
of strut malapposition might be predictive of late ScT during subsequent follow-up. One hundred
ninety-seven patients were enrolled in a multicentre registry with prospective follow-up. Optical
coherence tomography (OCT), performed in an elective setting, was available in all at 353 (0–376) days
after bioresorbable scaffold (BRS) implantation. Forty-four patients showed evidence of malapposition
that was deemed not worthy of intervention. Malapposition was not associated with any clinical
or procedural parameter except for a higher implantation pressure (p = 0.0008). OCT revealed
that malapposition was associated with larger vessel size, less eccentricity (all p < 0.01), and a
tendency for more uncovered struts (p = 0.06). Late or very late ScT was recorded in seven of these
patients 293 (38–579) days after OCT. OCT-diagnosed malapposition was a predictor of late and very
late scaffold thrombosis (p < 0.001) that was independent of the timing of diagnosis. We provide
evidence that an incidental finding of malapposition—regardless of the timing of diagnosis of the
malapposition—during an elective exam is a predictor of late and very late ScT. Our data provide a
rationale to consider prolonged dual antiplatelet therapy if strut malapposition is observed.
Keywords: stent thrombosis; bioresorbable scaffold; optical coherence tomography
1. Introduction
Bioresorbable scaffolds (BRS) were introduced to offer transient vessel support after coronary
angioplasty while avoiding long-term risks associated with permanent metallic stents [1]. However,
the BRS with by far the most clinical experience, the everolimus-eluting Absorb BRS (Abbott Vascular,
Santa Clara, CA, USA), showed an unexpectedly high incidence of scaffold thrombosis (ScT) both early
and late after implantation in a number of single- and multicentre observational studies [2–6] and
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was ultimately removed from the market. Incomplete expansion of the BRS is believed to convey the
highest risk of early ScT and implantation techniques aimed to achieve full expansion of the device
were shown to reduce the incidence of early ScT [7]. In contrast, studies based on quantitative coronary
angiography provided evidence that undersizing (i.e., choice of a BRS smaller than the reference vessel)
is strongly associated with late adverse events [8,9]. The mechanism(s) of this association remain
speculative, however, it can be hypothesized that malapposition and the resulting disturbances in
blood flow dynamics might play a role.
While the mechanistic rationale for the association of malapposition and late stent/scaffold
thrombosis is solid [10,11], evidence to date is limited to observational studies in which malapposition
was frequently found in cases of ScT [12–16]. Therefore, the aim of this study was to investigate
whether incidental observation of scaffold malapposition would predict subsequent late and very
late ScT.
2. Methods
2.1. Objective of the Study
The hypothesis of the study was that incidental optical coherence tomography (OCT) evidence of
scaffold malapposition (observed in an elective setting and not deemed worthy of intervention at the
time of OCT) might predict the occurrence of ScT during subsequent follow-up.
2.2. Patients
Consecutive patients treated at three high-volume centres in Germany (University of Mainz;
University of Giessen; University of Erlangen) with Absorb BRS between April 2012 and March 2016
who satisfied the following criteria were included in this multicentre registry:
• Patients had undergone elective OCT at the end of the implantation procedure, during non-target
vessel-staged procedures, or in the setting of elective invasive exams.
• In none of these patients was there evidence of ischemia in the region perfused by the vessel
treated with BRS and OCTs had been performed as elective controls after implantation of these
novel devices.
• An experienced interventionalist (based on current experts´ recommendations [17]) reviewed the
OCT and saw no clinical indication for the re-treatment of these lesions.
Patient and procedural data were entered retrospectively after inclusion in the study. Follow-up
data were acquired prospectively by trained medical staff during clinical visits and telephone interviews.
Referring cardiologists, general practitioners, and patients were contacted whenever necessary for
further information. All data were internally audited at each centre by trained local staff and were
entered retrospectively into the multicentre database in an anonymized way according to national
privacy policies and laws and following the requirements of the local ethics committees. Data were
audited centrally for consistency and plausibility and queries were generated when necessary.
2.3. Definitions
Frequency domain-OCT was performed using the Ilumien Optis system (St. Jude Medical, Inc.,
Minneapolis, MN, USA). OCT imaging catheters were inserted distally to the treated segments and the
pullback was recorded until either the guiding catheter was reached or the maximum pullback length
was completed. If necessary, two sequential pullbacks were acquired to image the scaffolded segment.
OCT measurements were made offline using the QCU-CMS software (Medis, Leiden, Netherlands)
by trained staff using standardized operating procedures. Longitudinal cross-sections were analysed
at 1 mm intervals within the stented lesion and 5 mm proximally and distally to the scaffold. Among
others, the following quantitative parameters were determined: The percentage of incomplete strut
apposition (ISA) at 1 mm intervals calculated as a percentage of the total number of malapposed
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struts divided by the total number of struts; malapposition distance, length, and area; the eccentricity
index computed as the ratio between the minimum and maximum diameters; the symmetry index
defined as the difference between maximum scaffold diameter and minimum scaffold diameter divided
by the maximum scaffold diameter; presence of evaginations, peri-strut low intensity areas (PSLIA),
and microvessels. Evaginations were defined as any outwards protrusion in the luminal vessel contour
beyond the struts´ abluminal surface between well-apposed struts. Strut discontinuity/disruptions
were diagnosed if there was evidence of isolated (malapposed) struts or groups of struts that did not
fit the normal circular geometry of the scaffold in one or more than one cross section by more than 33%
of the distance between the centre of gravity and the lumen. Further, cases where there was evidence
of a clear gap (frames without any strut) were also diagnosed as strut discontinuity [18].
Definitions are described in detail in [19]. Briefly, malapposition was defined as a lack of contact
of at least 1 strut with the underlying vessel wall (at least 150 μm, in the absence of a side branch)
with evidence of blood flow behind the strut. It was classified as “major” malapposition if there was
evidence of at least 30% of the struts in one frame. Neovessels were defined as sharply delimitated,
signal-poor lacunae that extended over multiple contiguous frames. Peri-strut low intensity areas
(PSLIAs) were defined as homogeneous, non-signal-attenuating zones around struts that were of lower
intensity than the surrounding tissue. Peri-strut intensity was measured at the mid-strut at a depth
of 150 μm from the lumen and at equal distance between two contiguous struts based on intensity
of the “key” component of the CMYK (cyan, magenta, yellow, and key) colour model based on raw
cross-sectional images. Quantitative assessment was obtained at 5 mm proximal and distal to the BRS
to measure the proximal and distal reference vessel area (RVA). RVA was calculated as the mean of
the 2 largest luminal areas 5 mm proximal and distal to the BRS edge [20]. If no meaningful value for
proximal or distal RVA was obtained, the largest luminal cross-sectional area at either end was used.
Incomplete expansion was defined as a minimum scaffold area of at least 90% in both the proximal
and distal halves of the scaffold relative to the closest reference segment.
ScT was centrally adjudicated and classified as definite, probable, and possible according to the
Academic Research Consortium criteria based on the analysis of original documents [21]. Definite ScT
required angiographic or autopsy confirmation with thrombus originating in the BRS or in the segment
5mm proximal or distal to the BRS. Probable ScT was considered to have occurred after intracoronary
stenting in the following cases: any unexplained death within the first 30 days or any myocardial
infarction—irrespective of the time after the index procedure—that is related to documented acute
ischemia in the region of the implanted BRS without angiographic confirmation, in the absence of any
other obvious cause. Possible ScT was considered to have occurred with any unexplained death from
30 days after intracoronary stenting until the end of trial follow-up.
2.4. Statistical Analysis
Statistical analysis was performed using IBM SPSS Statistics (SPSS Statistics 23, IBM Deutschland
GmbH, Ehningen, Germany). Categorical data are presented as absolute numbers and percentages.
Continuous variables are given as mean (SD) or median (IQR). The frequencies of categorical variables
were compared by the Pearson chi-square test and the distribution of continuous variables was
compared by the Mann–Whitney–Wilcoxon test. No imputation was performed. A Kaplan–Meier
curve was used to plot time-to-event curves and the hypothesis that malapposition could be associated
with incident ScT was tested using a log-rank test. Exploratory univariate and multivariable Cox
regression analysis was performed to evaluate the impact of each of the above parameters on the
occurrence of ScT. Potential covariates were prioritized for data analysis (a list of the covariates is
presented in Supplementary Tables S4–S6). To address the impact of the timing of the OCT diagnosis
on the association between malapposition and ScT, the period until diagnosis of malapposition was
grouped into early (diagnosis within 48 h after implantation of BRS), mid (diagnosis from day 3 but
not later than 30 days after implantation of BRS), and late (later than 30 days after the implantation of
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A total of 197 patients (219 lesions) who underwent elective OCT within 353 (0–376) days after
BRS implantation were enrolled in the study (Table 1). One hundred and thirty-two patients were
treated in Mainz, 36 in Giessen, and 29 in Erlangen. Follow-up was complete (100%) at a median of
1059 (1009–1110) days, during which 7 patients presented with late or very late ScT 579 [341–623] days
after implantation and 293 (38–579) days after OCT. Diagnosis of ScT was supported by OCT-imaging
in 5 cases and was based on angiography alone in two patients.
Table 1. Baseline characteristics of the cohort.
Baseline Characteristic
Late or Very Late
Scaffold Thrombosis
ScT (n = 7)
No ScT (n = 190) p
Age (years) 58.3 ± 9.1 61.8 ± 11.9 0.37
Male Sex (%) 85.7 81.6 0.78
Hypertension (%) 100 77.9 0.16
Diabetes mellitus (%) 14.3 20.5 0.69
Current smoker (%) 43.9 36.8 0.74
Family history (%) 14.3 30.0 0.37
Hyperlipoproteinaemia (%) 43.9 47.4 0.81
Prior revascularization (%) 71.4 34.7 0.04 *
Prior bypass surgery (%) 0 3.7 0.06
Prior percutaneous intervention (%) 71.4 33.2 0.04 *
Prior stroke/TIA (%) 0 3.2 0.63
eGFR (mean ± SD, ml/min) 91.4 ± 30.8 85.4 ± 20.2 0.74
Left ventricular ejection fraction (mean ± SD, %) 54.3 ± 7.9 54 ± 8.2 0.96
Acute coronary syndrome (%) 71.4 51.4 0.30
Clinical indication
- Stable angina (%) 28.6 37.4 0.57
- ST-elevation myocardial infarction (%) 42.9 22.1 0.29
- Non-ST-elevation myocardial infarction (%) 28.6 24.9 0.82
- Unstable angina (%) 0 13.8 0.20
Number of vessels treated 1.6 ± 0.8 1.1 ± 0.4 0.01 *
Number of scaffolds per lesion 1.0 ± 0 1.2 ± 0.5 0.25
Number of scaffolds per patient 1.7 ± 1.1 1.3 ± 0.7 0.23
Chronic total occlusion (%) 0 6.8 0.47
Lesion type AHA/ACC classification B/C2 (%) 85.7 63.5 0.22
Dual antiplatelet therapy (DAPT) 0.58
- Clopidogrel (%) 14.3 31.2
- Prasugrel (%) 14.3 52.4
- Ticagrelor (%) 71.4 16.4
* = statistically significant; eGFR = estimated Glomerular filtration rate; AHA/ACC = American Heart
Association/American College of Cardiology.
Patients with late or very late ScT showed similar characteristics with respect to age, sex, and
cardiovascular risk profile. A history of prior revascularization was more frequent in ScT patients
(71.4% vs. 34.7%; p = 0.04). The majority of BRS were implanted in the setting of an acute coronary
syndrome (71.4% vs. 51.4%; p = 0.30) with no difference between the groups. While control patients
tended to have a higher number of scaffolds per lesion (1.0 ± 0 vs. 1.2 ± 0.5; p = 0.25), the number
104
J. Clin. Med. 2019, 8, 580
of treated vessels (1.6 ± 0.8 vs. 1.1 ± 0.4; p = 0.01) was higher in the ScT group. Parameters of lesion
complexity were comparable between the groups.
Procedural characteristics divided by the incidence of ScT are shown in Table S1. The strategy
used for implantation was not different between ScT patients and reference patients; pre-dilatation was
performed in almost all cases (100% vs. 99.5%; p = 0.85) with comparable inflation pressures (13.4 ± 1.9
vs. 13.2 ± 2.3 atm; p = 0.75). All ScTs (except for one, occurring during clopidogrel therapy at 38 days
after index) were observed after scheduled cessation of dual antiplatelet therapy (DAPT).
3.2. Optical Coherence Tomography (OCT) Characteristics
The timing of OCT from the index procedure is presented in Figure 1. OCT characteristics are
shown in Table 2. Total scaffold length did not differ significantly between ScT patients and reference
patients (35.4 ± 29.2 vs. 27.4 ± 16.5 mm; p = 0.96). At the patient level, there was no difference in
scaffold nominal diameter, however, at lesion level, scaffolds that displayed an ScT during follow-up
had a greater minimum (3.2 ± 0.22 vs. 3.0 ± 0.35 mm; p = 0.01) and maximum scaffold diameter
(3.4 ± 0.24 vs. 3.1 ± 0.34 mm; p = 0.04). In line with this, the maximum (12.3 ± 2.5 vs. 9.1 ± 3.1 mm2;
p = 0.005) and minimum (6.3 ± 1.0 vs. 4.8 ± 1.9 mm2; p = 0.82) lumen areas were significantly larger
in ScT patients. The incidence of PSLIA and neovessels as well as BRS asymmetry and eccentricity
were similar between ScT and reference patients (Table 2). Strut discontinuities were more frequently
observed in the ScT patients (42.9% vs. 5.9%; p < 0.001). Furthermore, uncovered (42.9% vs. 5.9%;
p < 0.001) and malapposed struts (85.7% vs. 20.1%; p < 0.001) were observed significantly more
frequently in BRS that later developed ScT. Malapposition area, distance, and length were not different
in patients with compared with those without ScT.
Figure 1. Timing of OCT from index procedure. There was no difference between patients with or
without malapposition (p = 0.871).
Baseline characteristics and procedure-related parameters of patients with and without
malapposition can be found in Tables S2 and S3 (supplementary materials). The presence of
malapposition was not associated with any of the other OCT characteristics. Patients with malapposition,
however, showed a larger lumen area (8.4 ± 2.5 vs. 11.6 ± 3.8 mm; p < 0.001) and more eccentricity
(0.68 ± 0.09 vs. 0.61 ± 0.12; p < 0.001) and tended to have uncovered struts more frequently (p = 0.06,
Table S8, supplementary materials).
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Table 2. Optical coherence tomography (OCT) findings.
Optical Coherence Finding
Late or Very Late ScT
(n = 7)
No ScT
(n = 190) p
Number of struts 1080 ± 485 1059 ± 837 0.38
Number of frames 116.1 ± 84 120.4 ± 49 0.24
Pullback length (mm) 19.1 ± 8.1 21.1 ± 5.4 0.35
Maximum lumen area (mm2) 12.3 ± 2.5 9.1 ± 3.1 0.005 *
Minimum lumen area (mm2) 6.3 ± 1.0 4.8 ± 1.9 0.02 *
Average lumen area (mm2) 8.96 ± 1.03 6.6 ± 2.20 0.003 *
Maximum lumen asymmetry 0.28 ± 0.10 0.27 ± 0.11 0.82
Maximum scaffold asymmetry 0.24 ± 0.012 0.24 ± 0.09 0.91
Maximum lumen eccentricity 0.62 ± 0.11 0.66 ± 0.10 0.29
Maximum scaffold eccentricity 0.66 ± 0.10 0.72 ± 0.08 0.07
Peri-strut low intensity area (PSLIA) (%) 20.0 5.4 0.18
Microvessels (%) 42.9 31.0 0.51
Fractures (%) 57.1 33.5 0.20
Uncovered scaffold struts (%) 42.9 5.8 <0.001 *
Malapposition (>30% in one frame, without side) (%) 71.4 15.3 <0.001 *
Any malapposition per patient (%) 85.7 20.1 <0.001 *
Malapposition length (mm) 2.33 ± 1.5 2.76 ± 1.8 0.67
Malapposition maximum area (mm2) 1.56 ± 0.69 2.3 ± 1.9 0.64
Number of malapposed segments 1.83 ± 1.17 1.7 ± 0.99 0.88
Malapposition distance (mm) 0.52 ± 0.25 0.89 ± 0.77 0.22
Evagination (%) 57.1 27.5 0.08
* = statistically significant.
3.3. Analysis of the OCT Predictors of Scaffold Thrombosis
Figure 2 illustrates the relationship between OCT evidence of malapposition and subsequent ScT.
The log rank test p was <0.001.
Figure 2. Kaplan–Meier curve illustrating the association between incidental finding of malapposition
during elective follow-up OCT and incidence of late and very late ScT.
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Multivariable Cox regression identified both malapposition diagnosed early (within 48 hours)
after the index procedure (HR = 24.1, 95% CI = 1.5–387.6, p = 0.03) and later than day 30 (HR =
20.9, 95% CI = 2.5–179.7, p < 0.001) as independent predictors of ScT. Further exploratory univariate
and multivariable Cox regression analysis (Tables S4–S7, supplementary materials) showed that the
presence of malapposition (p = 0.049, hazard ratio (HR) 10.56 (1.0–110.68)) was the only independent
predictor of ScT. The presence of uncovered struts and the number of vessels treated showed a threshold
association (p = 0.05).
3.4. OCT Evidence at the Time of ScT
OCT observations at the time of ScT were collected in a separate retrospective registry. These data
are presented in Appendix A.
4. Discussion
The principal findings of this study are: (1) Malapposition was identified as predictor of late
and very late ScT in patients treated with BRS; this association was demonstrated for both “major”
malapposition (defined as evidence of at least 30% of the struts in one frame) and for any degree of
malapposition. This association was valid when malapposition was diagnosed either at implantation
or >30 days thereafter. (2) The presence of uncovered struts showed a threshold association with the
incidence of ScT during follow-up in multivariate analysis. (3) In an analysis of thrombi detected by
OCT (see supplementary materials), evidence of malapposition was more frequent in late/very late ScT
than in early ScT. This evidence was associated with larger vessel and scaffold sizes.
BRS were introduced to overcome long-term limitations of metallic stents; however, evidence from
a number of registries and randomized controlled studies showed BRS to be associated with increased
risk of both early and late ScT [2,4,22]. Importantly, early ScT was often shown to be associated with
procedural issues (including suboptimal vessel sizing and incomplete scaffold/vessel expansion) [23].
In line with this, improvement in implantation techniques proved to be associated with reduced
rates of such events [24,25]. Later, evidence was reported of late and very late ScT, i.e., at a time
when the benefits of the resorbable device over metallic stents were supposed to be realized [2,4,22].
Importantly, malapposition, often associated with strut discontinuity and uncovered struts, emerged
as the strongest association of very late ScT in OCT case series [13,15,16]. Although the mechanisms of
this form of disruption in the geometry of the scaffold remain unknown and are probably different
from case to case, the persistence of early malapposed (often uncovered) struts, or the development
of late malapposition/evaginations, both resulting in struts not being embedded in the vascular wall,
appear to be a prerequisite for evolution of adverse scaffold geometry. Similar data are also available
for metallic stents; malapposition was the leading finding in the Bern and PESTO registries of stent
thrombosis and among the three leading mechanisms in the PRESTIGE registry [26,27].
Stent malapposition results in disturbances in blood flow dynamics, adluminal areas of high shear
stress, and abluminal areas of low shear stress and recirculation [10,11]. These disturbances are in turn
associated with impaired strut coverage by endothelial cells (“strut healing“), strongly influence the
local levels of blood viscosity, and stimulate platelet activation and neointima formation [28,29] that
might amplify the supposedly higher thrombogenicity of scaffolds [30].
Despite this rationale and retrospective evidence, prospective follow-up data on the role
of malapposition in determining an increased risk of late thrombosis in BRS remain limited to
first-generation drug-eluting stents, in which the occurrence of late acquired malapposition at any time
between imaging assessment and stent thrombosis complicates any assessment. In a meta-analysis by
Hassan et al, the odds ratio for the risk of stent thrombosis in patients with diagnosed late acquired
malapposition was 6.51 (1.34–34.91); however, the data were heterogeneous, with three trials supporting
this conclusion and the other two leaning in the other direction. These considerations have a further
level of complexity with respect to BRS use, where it would be expected that the resorption of the
malapposed struts would limit their thrombogenic potential. Gomez-Lara et al. [31] performed an
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OCT sub-study of the ABSORB trial Cohort B, in which BRS having a 3 mm diameter were deployed.
The incidence of malapposed struts in vessels with a final distal maximal lumen diameter >3.3 mm
was higher than in cases in which the final lumen diameter was smaller. In addition, we previously
reported that undersizing at the time of implantation and BRS implantation in vessels larger than
3.5 mm are predictors of late/very late ScT. In contrast, oversizing and small reference vessel diameters
(RVDs) were predictors of early ScT [18]. The current data provide a possible mechanism related to
this observation, suggesting that malapposition, even when it is diagnosed incidentally and regardless
of the length of time from implantation, is a predictor of late and very late ScT and should therefore
trigger mechanical/pharmacological intervention.
In our database, total scaffold length, uncovered struts, minimum lumen area, and the number of
vessels treated did not affect the chances of ScT in our cohort, although the regression model should be
analyzed with caution as the covariate/case ratio may have led to overmodeling [32].
5. Limitations
There are several limitations associated with this study. First, its registry nature, with retrospective
collection of patients´ data and prospective follow-up, has clear inherent limitations, and the evidence
provided here (particularly given the small sample size and event rate) should be seen as hypothesis
generating, particularly with regard to the exploratory multivariate analysis. A strictly prospective
study design to investigate malapposition as a causal factor of scaffold thrombosis would be complex
from an ethical perspective. OCT follow-up was not performed at fixed time points and was not
repeated, so any conclusion on the nature (early versus late acquired) of malapposition was impossible.
Further, the Bern registry emphasized the importance of the longitudinal extent of malapposition
(>1 mm) and suggested a cut-off >300 μm for the strut-vessel wall distance [33]. These cases are
usually treated in the clinical routine and were not included in the present database. The present study
expands this evidence to suggest that findings of scaffold malapposition, even those that appear as
“minor” and not worthy of intervention, are indeed associated with ScT. Importantly, fluid dynamic
models demonstrate that, particularly for thick struts with quadratic profile, a smaller malapposition
distance might actually have the largest hemodynamic effect [28,29]. ScT is a complex phenomenon
in which vessel, scaffold architecture, structure, and a number of patient characteristics play a role
and it is likely that larger cohorts would have allowed identification of other clinical or procedural
parameters and possible causes and mechanisms. For our analysis, late and very late ScT were pooled.
However, all late ScT occurred at a time at which resorption would have already started and the two
groups of patients did not differ in any of the key features. The definition of strut fracture has not
yet been validated and an analysis of different types of fractures goes beyond the scope of this study.
We therefore limited the definition of fracture to cases where discontinuity, altered geometry (see
example in the supplement data), and/or a gap within the scaffold was evident. Our data apply to
“thick strut” scaffolds; no conclusion on the importance of malapposition in (thin-strut) metallic stents
can be inferred. Finally, the cross-sectional nature of our observation does not allow mechanistic insight.
The (non-significantly) higher incidence of ST-segment elevation myocardial infarctions (STEMIs) at
index in the patients presenting with malapposition points out the importance (and complexity) of
vessel sizing in this setting.
6. Conclusions
We provide the first evidence that an incidental finding of malapposition—regardless of the timing
of diagnosis of the malapposition—during an elective exam is a predictor of late and very late ScT.
Whether mechanical correction of this finding also reduces events is unknown and will require further
studies. However, this evidence suggests that prolonging dual antiplatelet therapy in these cases
would be a prudent strategy.
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Appendix A
A.1. Retrospective Cohort: Malapposition at the Time of Scaffold Thrombosis (ScT)
Optical coherence tomography (OCT) recordings of consecutive patients with ScT were collected
in an additional retrospective registry study (Figure A1). Observations in cases of late/very late ScT
were compared with those in patients with early ScT.
 
Figure A1. Representative images of cases of late/very late scaffold thrombosis (ScT) (n = 9). The panels
are numbered according to the patient number. Case 1: ScT 563 days after index. The patient presented
with ST-segment elevation myocardial infarction (STEMI). Optical coherence tomography (OCT) shows
a homogeneous layer within the bioresorbable scaffold (BRS), suggestive of neointima, evidence of
white thrombus (7 o’clock), and a large signal-poor, peri-strut, low intensity area (from 1 to 5 o’clock)
with increased attenuation compatible with oedema/immature neointima. The architecture of the struts
appears to be disrupted, but no gap was evident. Case 2: ScT 349 days after index. The patient presented
with non-ST-segment elevation myocardial infarction (NSTEMI). OCT revealed malapposition (2a)
immediately contiguous to white-red thrombus (2b). In this case, the strut architecture was also altered
(2b; 1 o’clock) and there was evidence of incompletely covered struts (2a).
A.2. Results: OCT Evidence at the Time of ScT
All patients presenting with ScT in whom an OCT was performed at the three institutions were
included in a separate retrospective registry. A total of 16 patients with OCT acquisition at the time
of the ScT were identified. Five of these patients were also included in the prospective follow-up
observational group (31.3%). Seven patients of the retrospective cohort were classified as acute or
subacute and nine as late or very late ScT (563 (49) days after implantation). Representative images of
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the thrombi are presented in Figure A1. All ScTs were classified as definite. Patients with late or very late
ScT were more frequently female and more frequently had a history of prior revascularization. Further
baseline and procedural characteristics were similar (Tables S9 and S10, supplementary materials).
OCT findings are listed in Table S11 (supplementary materials). The majority of frames showed
evidence of thrombus (78 ± 37 vs. 55% ± 66%; p = 0.18). Incomplete expansion was seen predominantly
in cases of early ScT (83.3% vs. 12.4%; p = 0.008). Scaffold discontinuities (0% vs. 50%; p = 0.04) and
malapposition (16.7% vs. 87.5%; p = 0.008) were features of late or very late ScT. OCT parameters
expressing vessel and scaffold geometry did not differ between early and late ScT (Table S11,
supplementary materials). The initial dual antiplatelet therapy (DAPT) regimen in use when implanting
bioresorbable scaffold (BRS) was also not different (p = 0.66); however, 83% of patients developed late
or very late ScT while not on DAPT (p = 0.006 compared to early ScT cases, Table S12, supplementary
materials).
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Abstract: Studies are extremely limited for the investigation of the clinical outcome of da Vinci
robot-assisted bilateral internal mammary artery (BIMA) grafting in coronary artery bypass grafting
(CABG) surgery. This study aimed to explore the short-term outcome of da Vinci robot-assisted BIMA
grafting through the left pleural space. Relevant data were collected from patients with multi-vessel
coronary artery disease receiving two kinds of CABG: a group of patients receiving da Vinci
robot-assisted CABG with BIMA grafting, and another group of patients receiving sternotomy CABG
with BIMA grafting. Primary endpoints, which included cardiovascular and renal endpoints, were
analyzed between the groups using the chi-square test, analysis of variance test, and Kaplan–Meier
analysis. Compared with the conventional group (n = 22), the robotic group (n = 22) had a significantly
longer operation time (12.7 ± 1.7 vs. 8.5 ± 1.5 hours; p < 0.01) and a marginally lower mean of serum
creatinine at baseline (1.2 ± 0.3 vs. 2.0 ± 1.7 mg/dL; p = 0.04). Primary endpoints (5, 22.7% vs. 12,
54.5%; p = 0.03) and renal endpoints (1, 4.5% vs. 7, 31.8%; p = 0.02) at six months were significantly
reduced in the robotic group compared with the conventional group. There were no differences
in cardiovascular endpoints at six months between the groups (1, 4.5% vs. 0; p = 1.00). The data
showed that da Vinci robot-assisted BIMA grafting was safe, with equal cardiovascular events and
lowered renal events at six months, as compared to conventional sternotomy BIMA grafting, despite
the longer procedure time. The short-term study suggests that da Vinci robot-assisted BIMA grafting
may be considered a favorable surgical option for patients with severe coronary artery disease.
Keywords: bilateral internal mammary artery; coronary artery disease; coronary artery bypass
grafting; da Vinci; sternotomy; outcome
1. Introduction
International guidelines recommend coronary artery bypass grafting (CABG) surgery as a
treatment option in patients with left main disease and/or multi-vessel coronary artery disease
(CAD) [1–3]. Conventional CABG surgery requires sternotomy, which generates a long mid-sternal
wound scar and potentiates sternal wound infection, particularly in patients receiving bilateral internal
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mammary artery (BIMA) grafting [4–6]. On the other hand, numerous studies have documented
the clinical benefit of BIMA grafting, including prolonged graft patency [7,8], lowered adverse
cardiovascular events [8,9], and improved survival [9–13]. A conflicting result obtained from a registry
study showed that BIMA grafting was not associated with better outcomes compared with single
internal mammary artery grafting [14]. In order to minimize surgical trauma and avoid sternotomy,
a robot-assisted technique using a da Vinci operator system (Intuitive Surgical, Mountain View, CA,
USA) was introduced into the field of CABG surgery. A few studies showed that robotic CABG
surgeries had favorable cardiovascular outcomes [15–18]. In addition, a meta-analysis of 16 pooled
studies exhibited that there were significantly fewer renal failure events in robot-assisted endoscopic
CABG, as compared to conventional CABG [19]. However, no studies have reported on the composite
endpoints of cardiovascular and renal events between da Vinci robot-assisted BIMA grafting and
conventional BIMA grafting. Therefore, this retrospective study was designed to investigate the
primary endpoints of cardiovascular and renal events between the two patient groups with severe
CAD receiving robot-assisted BIMA graft via the left pleura or conventional sternotomy BIMA grafting.
The present results were expected to elucidate the short-term primary outcome and help guide surgical
decision in patients with severe CAD.
2. Materials and Methods
2.1. Study Design and Patient Selection
The study was a single-center, retrospective, non-randomized, and non-controlled observational
study based upon the analysis of the database of a single medical center, and was designed to detect
the differences in adverse events between two patient groups: Group 1 of patients receiving da Vinci
robot-assisted CABG with BIMA grafting via left pleura and Group 2 of patients receiving conventional
sternotomy CABG with BIMA grafting. Consecutively collected patients were those who had been
angiographically diagnosed with left main disease and/or multi-vessel CAD, and thereafter received
two kinds of CABG surgeries. They were matched by age. For both groups, femoral artery and
vein cannulations were performed for the preparation of cardiopulmonary bypass with systemic
heparinization. Beating heart CABG with BIMA skeletonization and mobilization was routinely
conducted in all patients, with an on- or off-pump according to the patient’s hemodynamic status
and the operator’s discretion. A radial artery (RA) or great saphenous vein (GSV) was harvested as a
conduit with the right internal mammary artery (RIMA) for anastomosis of the left circumflex artery
(LCX) and of the right coronary artery (RCA). The procedures of the two kinds of CABG surgeries
are detailed below. Patients were excluded if they received an urgent CABG, received a hybrid of
percutaneous coronary intervention (PCI) and CABG, received left internal mammary artery (LIMA)
grafting or RIMA grafting alone, presented with ST-segment elevation myocardial infarction, or had
previously been enrolled in another clinical study. All patients received a daily dose of 100 mg aspirin
indefinitely, in combination with a daily dose 75 mg clopidogrel as dual antiplatelet therapy with an
expected duration of at least one year after the index surgeries. Clinical follow-up was scheduled
in hospital, three months, and six months after discharge for data collection. Primary endpoints
consisted of a composite of cardiovascular and renal endpoints. Relevant data were recorded for
patient characteristics, clinical presentations, and adverse events during the follow-up period. All
patients in the two groups were thoroughly informed about the procedure preoperatively and provided
written consent. The study protocol had been examined and approved by the committee of the
hospital. The present study was performed in accordance with the Declaration of Helsinki and local
regulatory guidelines.
2.2. Da Vinci Robot-Assisted CABG with BIMA Grafting via Left Pleura
Each beating-heart da Vinci robot-assisted CABG with unilateral BIMA grafting was performed
with an on- or off-cardiopulmonary pump according to a patient’s hemodynamic status by an
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experienced team led by a well-trained CABG surgeon with more than 15 years of CABG surgery
experience. After general anesthesia and aseptic procedures, a double-lumen was intubated for single
right-lung or bilateral low-volume ventilation in order to mobilize the BIMA grafts. A BIMA graft was
mobilized through the left pleura using the da Vinci robot-assisted operation system, with the left chest
elevated at approximately 30 degrees and with the patient in supine position. The chest cavity was
insufflated with carbon dioxide to expand the surgical space. An RIMA was first mobilized through
the left pleural and pre-mediastinal space with two-lung low-volume ventilation. Then, an LIMA was
mobilized with single right-lung ventilation. The vessels were anastomosed by direct-vision through a
left thoracotomy in the second intercostal space with a surgical wound of about 6–12 cm in length.
The mobilized LIMA was anastomosed with the left anterior descending artery (LAD); the RA or GSV
served as an additional conduit for connection with the RIMA and for anastomoses of the LCX-obtuse
marginal branch (LCX-OM) and/or the RCA-posterior descending artery (RCA-PDA).
2.3. Conventional Sternotomy CABG with BIMA Grafting
Patients received a full mid-sternotomy for conventional CABG surgeries with BIMA grafting.
The mobilized BIMA and harvested RA or GSV in each patient were anastomosed with native coronary
arteries by direct-vision through a mid-sternal exposed surgical wound of about 20–30 cm in length.
Similar to the da Vinci robot surgery, the RA or GSV served as an additional conduit for connection
with RIMA and for anastomoses with LCX-OM and/or RCA-PDA. All patients in the two groups were
treated and monitored postoperatively at the intensive care unit.
2.4. Definitions
Adverse events in hospitals were defined as wound infection, severe blood loss requiring blood
transfusion, pleural effusion, pulmonary edema, and pneumonia. The definition of CAD was coronary
stenosis exceeding 50% in diameter of an adjacently normal segment. Estimated glomerular filtration
rate (eGFR) was calculated using the modification of diet in renal disease equation. The definition of
CKD stages was according to stratified values of eGFR recommended by the guidelines [20]. Consumed
units of packed red blood cells or fresh frozen plasma were defined as the sum of the blood units
used in hospital. Each operator determined the use of an intra-aortic balloon pump (IABP) according
the hemodynamics in the peri-operative period. Myocardial infarction (MI) was defined according
to the clinical symptoms, the level of serum troponin I >5 μg/L, new eletrocardiographic changes,
or echocardiographic evidence of new regional wall motion abnormality. Operation room time was
defined as the time interval between the patient’s arrival at the operation room and the patient’s
departure from the recovery room.
2.5. Primary Endpoints at Six Months
Primary endpoints in the study included cardiovascular and renal endpoints. Cardiovascular
endpoints including all-cause mortality, non-fatal MI, repeated revascularization, and non-fatal
hemorrhagic and ischemic stroke; renal endpoints included a rise of serum creatinine >0.5 mg/dL above
the baseline value, creatinine doubling (at least a 100% raise from the basal level of serum creatinine),
and occurrence of CKD stage 4 or 5. An endpoint event was confirmed by two independent physicians
according to the clinical symptoms and signs, laboratory data, electrocardiographic findings, and/or
diagnostic images. The follow-up period was six months.
2.6. Statistical Analysis
All variables were statistically analyzed using SPSS software version 22 (SPSS Inc., Chicago, IL,
USA). All categorical data and rates are displayed as numbers (percentages), and the continuous
data are shown as means ± standard deviation. Baseline and outcome data between the groups were
compared using chi-square test (χ2) or Fisher exact test for categorical variables, and the analysis of
variance test for continuous variables. Kaplan–Meier analysis with log-rank test was used to detect
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differences in cumulative event-free survival at six months between the two groups. A p value < 0.05
with two-sided 95% confidence interval was considered statistically significant for all tests. Analysis
was conducted as time to the first event involving primary endpoints, without double counting
of events.
3. Results
3.1. Patient Demographic and Characteristic Data
Data for a total of 44 patients were collected from November 2010 to January 2016 (Figure 1). In this
cohort, 22 patients with left main disease and/or multi-vessel CAD received da Vinci robot-assisted
CABG with BIMA grafting through the left pleura. The 22 age-matched patients received conventional
sternotomy CABG with BIMA grafting. Figure 2A,B show endoscopically mobilized BIMA and the
minimal surgical scars after robot-assisted surgery. Figure 2C,D show a large sternotomy wound and
BIMA anastomosed with coronary arteries, and a larger surgical scar after conventional sternotomy
surgery. The operation time was significantly longer in robotic CABG as compared with sternotomy
CABG (12.7 ± 1.7 vs. 8.5 ± 1.5 h; p < 0.01). The mean serum creatinine at baseline was marginally lower
in robotic CABG compared with sternotomy CABG (1.2 ± 0.3 vs. 2.0 ± 1.7 mg/dL; p = 0.04), whereas
the mean eGFR was identical between groups (57.9 ± 31.5 vs. 65.4 ± 13.6 mL/min/1.73 m2; p = 0.32).
The baseline characteristics of the two groups are shown in Table 1.
 
Figure 1. The patient flow chart. LM = left main; CABG = coronary artery bypass grafting;
CAD = coronary artery disease; PCI = percutaneous coronary intervention; LIMA = left internal
mammary artery; RIMA = right internal mammary artery; STEMI = ST-segment elevation myocardial
infarction; BIMA = bilateral internal mammary artery.
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Figure 2. Wound healing in robotic and conventional sternotomy-assisted bilateral internal mammary
artery grafting via the left pleura in coronary artery bypass grafting surgery. (A) Endoscopy shows
that the left internal mammary artery (LIMA) (upper) and the right internal mammary artery (RIMA)
(lower) were mobilized using the da Vinci operator system. (B) Surgical wounds (white arrows) of
da Vinci robot-assisted CABG are small. (C) Finished anastomoses of LIMA (right) and RIMA (left)
with coronary arteries are displayed in an explored sternal area of a sternotomy CABG. (D) A long
mid-sternal wound scar (white arrow) is shown in a patient who had received a sternotomy CABG.
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Table 1. Baseline characteristics between two surgical modalities.
Da Vinci Robotic Surgery
(n = 22)
Sternotomy Surgery
(n = 22) p Value
Male 20 (90.9) 21 (95.5) 1.00
Age (years) 61.2 ± 12.0 62.9 ± 10.5 0.63
Body mass index (kg/m2) 26.9 ± 4.0 27.3 ± 3.2 0.70
Risk factors for CAD
Diabetes mellitus 11 (50.0) 10 (45.5) 1.00
Hypertension 17 (77.3) 18 (81.8) 1.00
Dyslipidemia 13 (59.1) 12 (54.5) 1.00
Hyperuricemia 1 (4.5) 0 (0) 1.00
Drug allergy 5 (22.7) 1 (4.5) 0.19
Alcohol drinking 6 (23.7) 1 (4.5) 0.95
Cigarette smoking 10 (45.5) 11 (50.0) 1.00
Family history of CVD 8 (36.4) 2 (9.1) 0.03
CAD condition
LM 10 (45.5) 13 (59.1) 0.55
TVD 17 (77.3) 20 (90.9) 0.41
DVD 5 (22.7) 2 (9.1) 0.41
Grafting conduit
BIMA 22 (100.0) 22 (100.0) 1.00
Radial artery 19 (86.4) 19 (86.4) 1.00
GSV 3 (13.6) 3 (13.6) 1.00
Anastomosis number 3.0 ± 0.6 3.4 ± 0.7 0.34
On pump 10 (45.5) 16 (72.7) 0.12
On pump time (min) 123.9 ± 96.2 131.4 ± 59.8 0.81
Operation room time (h) 12.7 ± 1.7 8.5 ± 1.5 <0.01
Biomarkers at admission
Hemoglobin (g/dL) 13.7 ± 1.6 12.7 ± 2.4 0.11
Creatinine (mg/dL) 1.2 ± 0.3 2.0 ± 1.7 0.04
eGFR (mL/min/1.73 m2) 65.4 ± 13.6 57.9 ± 31.5 0.32
CKD stage 0.11
I/II 15 (68.2) 10 (45.5)
III 7 (31.8) 7 (31.8)
IV 0 (0) 3 (13.6)
V 0 (0) 2 (9.1)
Continuous data are presented as mean ± standard deviation; category data are presented as number
(percentage); CABG = coronary artery bypass grafting; BMI = body mass index; CAD = coronary artery disease;
CVD = cardiovascular disease; LM = left main; TVD = triple vessel disease; DVD = double vessel disease;
LIMA = left internal mammary artery; RIMA = right internal mammary artery; eGFR = estimated glomerular
filtration rate; CKD = chronic kidney disease.
3.2. In-Hospital Adverse Events
In-hospital adverse events did not differ between the groups (p > 0.05), except for a significantly
lower incidence of CKD stages 4 and 5 in patients who received da Vinci robot-assisted CABG with
BIMA grafting (1, 4.5% vs. 10, 45.4%, respectively; p < 0.01). In-hospital cardiovascular events were
equal between the two groups, including death, non-fatal MI, repeated revascularization, and non-fatal
stroke (p > 0.05). The adverse events in hospital are outlined in Table 2.
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Table 2. Adverse events in hospital between two surgical modalities.
Da Vinci Robotic Surgery
(n = 22)
Sternotomy Surgery
(n = 22) p Value
Hospital stay (days) 21.0 ± 8.8 24.4 ± 14.0 0.34
ICU stay (days) 4.8 ± 3.5 5.0 ± 3.3 0.90
Ventilator weaning (days) 2.2 ± 1.8 2.3 ± 2.3 0.94
Renal events
CKD stages IV/V 1 (4.5) 10 (22.7) <0.01
Creatinine change >0.5 mg/dL 5 (22.7) 7 (31.8) 0.50
Doubling creatinine (mg/dL) 1 (4.8) 3 (13.6) 0.61
eGFR (mL/min/1.73 m2) * 58.5 ± 22.1 45.5 ± 31.6 0.12
Hemodialysis 0 (0) 1 (4.5) 1.00
The lowest hemoglobin (g/dL) 11.9 ± 1.5 12.1 ± 1.5 0.57
Blood transfusion (U)
FFP 5.3 ± 3.8 3.8 ± 4.3 0.28
PRBC 2.1 ± 2.0 1.4 ± 2.2 0.30
Adverse events 4 (18.2) 5 (27.8) 0.70
Death 0 (0) 0 (0) 1.00
Myocardial infarction 0 (0) 0 (0) 1.00
Stroke 0 (0) 0 (0) 1.00
Wound infection 1 (4.5) 1 (5.6) 1.00
Pneumonia 1 (4.5) 0 (0) 1.00
Pleural effusion 1 (4.5) 2 (11.1) 1.00
Post-operation IABP 2 (9.1) 3 (13.6) 1.00
Continuous data are presented as mean ± standard deviation; category data are presented as number (percentage);
CABG = coronary artery bypass grafting; CKD = chronic kidney disease; eGFR = estimated glomerular filtration
rate; FFP = fresh frozen plasma; PRBC = packed red blood cells; ICU = intensive care unit; eGFR * = indicate the
lowest value of eGFR in hospital; IABP = intra-aortic balloon pump.
3.3. Primary Endpoints at Six Months
Primary endpoints at six months were significantly reduced in robotic CABG compared with
sternotomy CABG (5, 22.7% vs. 12, 54.5%; p = 0.03) (Table 3). The finding was reinforced by the
Kaplan–Meier analysis (p = 0.03 by log-rank test) (Figure 3). The significant reduction was mainly
contributed by the fewer renal events in robotic surgery (1 vs. 7; p = 0.02). The cumulative rates of
cardiovascular endpoints at six months were identical, including all-cause mortality (0 vs. 0; p = 1.0),
non-fatal MI (0 vs. 1; p = 1.0), and non-fatal stroke (0 vs. 0; p = 1.0).
Table 3. Clinical outcomes at six months between two surgical modalities.
Da Vinci Robotic Surgery
(n = 22)
Sternotomy Surgery
(n = 22) p Value
Finished six months follow-up 19 (86.5) 21 (95.5)
Primary endpoints 5 (22.7) 12 (54.5) 0.03
Cardiovascular events 1 (4.5) 0 (0) 1.00
Mortality 0 (0) 0 (0) 1.00
Myocardial infarction 1 (4.5) 0 (0) 1.00
Stoke 0 (0) 0 (0) 1.00
Renal events 1 (4.5) 7 (31.8) 0.02
CKD stages IV/V 0 (0) 7 (31.8) 0.02
Creatinine doubling 0 (0) 1 (4.5) 1.00
Creatinine change >0.5 mg/dL 1 (4.5) 5 (22.7) 0.18
Hemodialysis 0 (0) 1 (4.5) 1.00
eGFR (mL/min/1.73 m2) 72.1 ± 19.0 56.9 ± 34.0 0.08
Re-hospitalization * 4 (18.2) 6 (27.3) 0.47
Continuous data are presented as mean ± standard deviation; category data are presented as number (percentage);
CABG = coronary artery bypass grafting; * = re-hospitalizations due to any cause; primary endpoint = all-cause
mortality, myocardial infarction, stock, CKD stages IV/V, and creatinine change >0.5 mg/dL.
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Figure 3. Kaplan–Meier survival analysis shows a significant reduction in the cumulative incidence of
the composite of cardiovascular and renal endpoints at six months (p = 0.03 by log-rank test), including
all-cause mortality, non-fatal myocardial infarction, repeated revascularization, non-fatal stroke, the
presence of chronic kidney disease stage 4 or 5, creatinine doubling, and a raise of the baseline creatinine
>0.5 mg/dL in patients receiving da Vinci CABG as compared with those receiving conventional CABG.
CABG = coronary artery bypass grafting.
4. Discussion
The study generated three major findings: (1) primary endpoints were significantly reduced in
patients receiving da Vinci robot-assisted BIMA grafting via the left pleura at six months, as compared
with patients receiving sternotomy CABG with BIMA grafting; (2) the significant reduction in primary
endpoints was contributed by the fewer renal events in robotic CABG. Cardiovascular endpoints were
equal between the groups; (3) robotic CABG compared with conventional CABG had smaller surgical
wounds but longer operation times, and identical hospital and ICU stay. The da Vinci robot-assisted
CABG with BIMA grafting via the left pleura is considered a new surgical treatment option for patients
with severe CAD.
Robotic CABG had a significant reduction in the rate of primary cardiovascular and renal
endpoints as compared to sternotomy CABG. The relatively better renal function at baseline in da
Vinci robot-assisted CABG with BIMA grafting may partially account for the significant reduction in
adverse renal events in hospital and at six months. Renal dysfunction was reported to independently
predict post-CABG adverse events, such as mortality and/or morbidity [21–23], and advanced renal
diseases [24,25]. Compared with robotic CABG with BIMA grafting, the poorer renal function in
conventional CABG possibly resulted in renal deterioration after CABG surgeries. In addition, the
finding was consistent with the result obtained from a meta-analysis of 16 pooled studies which
showed that robot-assisted CABG versus conventional CABG was associated with fewer renal failure
events [19]. Furthermore, renal function may be preserved in off-pump CABG surgeries [26], despite
the equality of cardiopulmonary pump use observed between the groups. A shorter elapsed time
from coronary angiography until off-pump CABG was also reported to deteriorate renal function [27].
Nevertheless, the reason why there were fewer renal events in robotic CABG versus conventional
CABG remains unclear. The finding needs to be further confirmed.
On the other hand, the two groups had identical rates of adverse cardiovascular events in hospital
and at six months. The finding implicated that the da Vinci robot-assisted unilateral BIMA grafting
was not inferior to the conventional BIMA grafting in terms of short-term cardiovascular outcome.
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Furthermore, the data displayed satisfactory results with freedom from subsequent wound infection
and post-operative ischemic stroke. A few trials indicated that BIMA harvesting may lead to a decline
in blood supply to the sternum and increase the risk of sternal wound infection [4–6]. A BIMA
graft-sparing aortic clamp and aortic anastomosis may reduce the risk of peri-operative ischemic
stroke [8,17].
The present results disclosed that robotic CABG compared with conventional CABG had longer
operation times but without longer ICU and hospital stays, and ventilation times. Similar to
conventional BIMA mobilization, robot-assisted BIMA mobilization requires a longer procedure
time [28,29], especially in RIMA mobilization through the left pleural and pre-mediastinal space.
Unilateral BIMA grafting minimizes the surgical wounds but prolongs the operation times. The
robot-assisted operation time may be shortened through collaborative team-work in a learning-curve
manner [28]. This will increase operator comfort, reduce fatigue, and allow patients receiving da Vinci
robot-assisted CABG with BIMA grafting to have safer interventional procedures, therefore greatly
improving patient outcomes [30].
Several limitations have to be emphasized: (1) as the study had few case numbers, low event
rates, short follow-up, and primary selection bias, its results should be interpreted with caution; (2) the
heterogeneity at baseline and unmeasured confounders between the two different surgeries may have
affected the outcomes; (3) other factors, such as hemodynamics, angiographically-proven coronary
lesions, and systolic function at baseline, that differed between the two groups could have potentially
influenced the outcomes, as these were not investigated in the study; (4) in the study, it was not
mandatory to routinely check coronary angiograms to survey the graft patency.
In conclusion, the data showed that da Vinci robot-assisted CABG with left-pleural BIMA grafting
compared with conventional sternotomy CABG with BIMA grafting did not increase in-hospital and
short-term cardiovascular events but possibly lowered adverse renal events. The study suggests that
the robot-assisted CABG with left-pleural BIMA grafting can be considered a new surgical option for
patients with severe CAD. Further larger studies are needed to investigate long-term outcomes.
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Abstract: Background: The aim of this study was to evaluate the benefit of standard practice
Optical Coherence Tomography (OCT) imaging, as a complement to coronary angiography (CA),
for optimizing the indications, strategy, and results of percutaneous coronary interventions (PCI).
Methods: We retrospectively analyzed 182 patients with OCT imaging in a single tertiary center.
Results: OCT use had a low prevalence (3.1% of 4256 CAs and 1.7% of 3027 PCIs). OCT was used
post-CA in 71.5% and post-PCI in 28.5% of cases, mainly in acute coronary syndromes—95.6%.
OCT was performed for borderline lesions in 43.4% of cases; lesion severity was reassessed as severe
and led to PCI in 64.5% of them. OCT was performed for nonsignificant lesions in 17% of cases;
lesion severity was reassessed as severe and led to PCI in 38.7% of them. OCT provided optimal
selection for PCI strategy in 11% of cases. OCT identified suboptimal PCI results in 54% left main
PCIs and in 48% bifurcation PCIs with optimal CA; PCI optimization was performed. In the only
seven patients with suboptimal PCI, OCT revealed an optimal result in four cases, thus avoiding
unneccessary optimization. In 27.3% of patients with post-CA OCT and PCI result “systematic” OCT
control, a PCI optimization was indicated. Conclusion: OCT supplied a major benefit in 86.2% of
cases, especially by identifying significant coroanry stenosis in CA borderline and nonsignificant
lesions; OCT led to PCI indication in two-thirds and, respectively, one-third of these cases. In the
post-PCI context, OCT led to an indication of PCI optimization in half of the complex left main and
bifurcation lesions, as well as in a quarter of “systematic” post-PCI OCT controls.
Keywords: optical coherence tomography; percutaneous coronary interventions; borderline lesions;
nonsignificant lesions; left main; bifurcations
1. Introduction
Cardiovascular diseases represent a major health burden, with coronary artery disease (CAD) as
the most important cause of morbidity and mortality [1,2]. Every effort is made for improving CAD
diagnosis, identifying patients with an indication for revascularization and optimal revascularization
treatment through either interventional cardiology or cardiac surgery, resulting in a progressive
decrease in CAD mortality [3,4].
Coronary angiography (CA) is the gold standard invasive procedure currently used for CAD
diagnosis, decision-taking and assessing efficacy of percutaneous coronary interventions (PCIs) [5].
CA limitations are related to suboptimal ability to identify complicated atherosclerotic plaques and
sometimes even to incorrect grading of the severity of coronary stenosis [5].
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Optical coherence tomography (OCT) further improves invasive intracoronary imaging, offering
new insights on the coronary wall and lumen, due to its high resolution (10 micrometers) [3,6].
OCT provides accurate characterization of atherosclerotic plaques, in terms of severity and extension,
and identifies high-risk and complicated plaques, as well as coronary thrombi [5,6].
Over the last ten years, fast acquisition OCT devices and software allowed this method to be
used safely, in everyday practice, as a complement to CA. OCT is therefore not only a very well
recognized in vivo CAD research tool [6–8], but also an increasingly used real-life tool. Various
indications have been proposed for OCT use in current clinical practice [9–11], as experience with OCT
use has grown [12–14]. Recent guidelines already recommend OCT use for optimizing stent-related
PCI procedures [15].
The aim of this study is to evaluate the benefit of standard practice OCT imaging, as a complement
to CA for optimizing the indications, strategy and results of percutaneous coronary interventions.
The study covers five years of practice of a single tertiary center from Romania.
2. Methods
2.1. Study Population
This study retrospectively analyzes the indications and benefit of OCT use in 182 patients,
evaluated in a single tertiary center from Romania (Cluj County Emergency Hospital, Department
of Interventional Cardiology), over a period of 5 years (January 2012–September 2017). During this
interval, 4256 patients underwent CA for suspected CAD, of whom, 3027 patients also had PCI.
No exclusion criteria were considered. Informed consent was obtained before the invasive
procedure. Clinical data and angiographic examinations were stored in the hospital database and in
a dedicated catheterization laboratory database.
Data regarding cardiovascular risk factors [2] were obtained from patients history, physical
examination, and medical records. Arterial hypertension was defined as known or newly diagnosed
blood pressure values above 140/90 mmHg. Diabetes mellitus was defined as known or newly
diagnosed blood fasting glucose above 126 mg/dL or glycated haemoglobin >6.5%. Dyslipidemia
was defined as low-density lipoprotein cholesterol >130 mg/dL and/or triglycerides >150 mg/dL.
Renal insufficiency was defined as a glomerular filtration rate <60 mL/min. Smoking habit was
defined by current or recent smoking. Overweight was defined as body mass index >25 kg/m2.
CA was performed via right radial artery in 143 (78.6%) patients, via femoral artery in 35 (19.2%)
patients and transbrachial in the remaining four (2.2%) patients, on Siemens Coroskop T.O.P and
Siemens Artis Zee angiographs (Siemens Healthineers, Erlangen, Germany). Severity of coronary
stenosis was assessed visually and by quantitative coronary analysis (QCA). The highest degree of
stenosis severity, usually the area stenosis severity provided by QCA, was considered. After CA,
coronary arteries were classified as normal (without plaques), with nonsignificant lesions (<50%),
with borderline lesions (50–70%) or with significant stenosis (>70%).
2.2. OCT Acquisition Technique, Analysis, and Indications
OCT images were acquired with a commercially available system (ILUMIEN OPTIS OCT
Intravascular Imaging System, St. Jude Medical, St. Paul, MN, USA), using an over the wire OCT
catheter (C7 Dragonfly™ and Dragonfly™ OPTIS™, St. Jude Medical, St. Paul, MN, USA). The entire
length of the region of interest was scanned using the integrated automated pullback device at
20 mm/s. During image acquisition, coronary blood flow was replaced by continuous flushing
of contrast medium directly from the guiding catheter. All images were recorded digitally, stored,
and analyzed using proprietary software (St. Jude Medical, St. Paul, MN, USA) in concordance with
standard consensus of OCT use [5].
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OCT was performed by all three senior interventional cardiologists, using the predefined
indications in Table 1, during working hours and, two days each week, 24/24 h, for emergency
situations like acute coronary syndromes (ACS).
Table 1. Indications for OCT use, adapted from Tearney G.J. et al. [5], Räber L. et al. [10] and
Karanasos A. et al. [16]. OCT: optical coherence tomography; PCI: percutaneous coronary intervention;
ACS- acute coronary syndrome.
OCT Indication Specific Area of Interest
Post-Coronary Angiography and before a first PCI procedure
Lesion evaluation
Culprit lesion evaluation in ACS patients without coronary angiography
significant stenosis
Evaluation of lesions with angiographic haziness
(suspected dissection/thrombus/calcification)
Pre-PCI assessment
Measurements of lumen diameter and lesion length for PCI devices selection
(balloon/stent dimensions)
Lesion assessment for PCI technique/strategy selection
(for left main and large bifurcations)
Evaluation of “landing zones”
Evaluation of guide wire position




Evaluation of stent expansion
(identification of under-expansion/residual stenosis)
Evaluation of potential vascular injury
(identification of edge dissection/intra-stent thrombus/tissue protrusion)
Late evaluation of
suspected stent failure
Identification and characterization of restenosis
Identification of in stent thrombosis
Identification of neoatherosclerosis
Indications for OCT use were the ones generally accepted at the time of the investigation
(Table 1) [5,10,16]. OCT was performed either after CA, for lesion evaluation or pre-PCI strategy
assessment, or after PCI, for result assessment. OCT quantification of coronary lesion severity was
made using the proprietary software, as area stenosis compared to largest pre-lesion reference area.
An OCT area stenosis of at least 70% was considered as significant stenosis, with an indication for PCI.
The study complies with the Declaration of Helsinki on human research.
2.3. Statistical Analysis
Categorical variables were expressed as frequencies and compared with χ2 test. A two-sided
p-value of 0.05 was considered significant.
3. Results
3.1. Demographic, Clinical and Angiographic Data
The investigated population includes 174 (95.6%) patients with ACS, of which 50 had ST-elevated
myocardial infarction (STEMI), 39 had non-ST elevated myocardial infarction (NSTEMI), 85 had
unstable angina (UA), and eight had stable CAD (SCAD). Demographic, clinical and angiographic
data of OCT investigated patients are presented in Table 2 and data regarding their cardiovascular risk
factors are presented in Table 3.
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Table 2. Demographic, clinical and angiographic data of patients investigated by OCT (LAD—left











50 39 85 8 182
Gender
Male 34 29 55 6 124 (68.1%)
Female 16 10 30 2 58 (31.9%)
Age
<40 2 0 3 0 5 (2.7%)
≤40–49 22 3 10 2 37 (20.3%)
≤50–59 9 13 20 2 44 (24.2%)
≤60–69 8 10 36 3 57 (31.3%)
≤70–79 8 12 16 1 37 (20.3%)




Normal 2 1 3 1 7 (3.8%)
LM 5 6 11 0 22 (12.1%)
1 Vessel Disease 29 8 30 2 69 (37.9%)
2 Vessels Disease 6 7 17 3 33 (18.1%)




LM 9 18 30 2 59 (32.4%)
LAD 31 18 49 6 104 (57.1%)
LCX 3 2 2 0 7 (3.8%)
RCA 7 0 4 0 11 (6.1%)
Venous Graft 0 1 0 0 1 (0.5%)
Table 3. Study population cardiovascular risk factors.
Hypertension 143 (78.6%)
Diabetes mellitus 46 (25.3%)
Dyslipidemia 105 (57.7%)
Renal Insufficiency 11 (6%)
Smoking habit 52 (28.6%)
Overweight 35 (19.2%)
3.2. Post Coronarography OCT
OCT was performed in two main instances: first, as a complemmentary imaging method after
CA—130 patients (71.5% of the OCT investigations) and second, as an imaging method just used
first after PCI—52 patients (28.5% of the OCT investigations) (Figure 1). Post-CA OCT was made
in 3.1% of the total 4256 CAs performed in CAD patients, while post-PCI OCT was done in 1.7%
of the total 3027 PCIs. OCT had two main indications, in the 130 patients post-CA group: OCT to
provide accurate diagnosis and therapeutic decisions for revascularization (“decision-making OCT
group”)—110 patients (60.4% of the OCT investigations)—and, respectively, OCT to provide optimal
selection of PCI strategy—20 patients (11% of the OCT investigations) (Figure 1).
3.2.1. “Decision-making OCT Group”
In the “decision-making OCT group” (110 patients), there were 79 patients (43.4% of the OCT
investigations) with borderline (50–70%) CA lesions and 31 patients (17% of the OCT investigations)
with nonsignificant lesions (<50%) or with a normal aspect on CA (Figure 1).
Borderline CA Lesions
In the 79 patients with a high clinical and electrocardiogram suspicion of CAD and with borderline
CA lesions, in 77 of them with ACS (43 UAs, 17 STEMIs, and 17 NSTEMIs) and only two with SCADs
an accurate decision for revascularisation could not be made based on CA alone, so OCT was performed.
After performing OCT, the severity of coronary artery lesions was reassessed and graded as severe
(>70%) (Figure 2A/a), with an indication for revascularization in 51 patients (64.5% of the 79 cases)
(Table 4).
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Figure 1. OCT indications. Pts: patients.
Nonsignificant Lesions or Normal Coronary Aspect
In the 31 patients with nonsignificant lesions (<50%) (Figure 2B/b and 2C/c) or with a normal
coronary arteries aspect on CA (Figure 2D/d), there were 29 patients with ACS (15 STEMIs, 10 UAs,
and four NSTEMIs). These ACS pts represented 15.3% of the total 189 ACS patients with nonsignificant
lesions or normal coronary arteries investigated in our center, during the investigated time interval.
There also were two SCAD patients. OCT identified 12 patients with significant (>70%) lesions (38.7%
of the 31 cases), leading to PCI revascularization (Table 4).
When performed after CA, OCT led to revascularization in significantly more patients with
borderline lesions than in ones with nonsignificant lesions or normal coronary arteries (64.5 vs. 38.7%,
p = 0.013).
3.2.2. OCT for Optimal Selections of PCI Strategy
The second main indication for OCT, after CA, was represented by patients in whom a decision for
PCI revascularization was taken after CA, but OCT was still needed on top of CA, in order to provide
optimal selection of PCI strategy (Figure 1). In these 20 patients (11% of the OCT investigations),
there were three indications for OCT:
- identification of stent failure mechanism (10 patients, 5.5% of the OCT investigations);
OCT proved restenosis in eight and neoatherosclerosis in two patients (Figure 2E/e);
- selection of PCI devices features (seven patients, 3.8% of the OCT investigations); there were
three cases of long lesions PCI (Figure 2F/f), two of left main (LM) PCI and another two of
bifurcation PCI;
- comprehensive assessment of native lesions suspected of complications (three patients, 1.6% of
the OCT investigations); OCT confirmed complicated atherosclerotic plaques in all three of them,
with identification of thrombus in one patient.
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Figure 2. (A)—Anterior STEMI previously treated with fibrinolytic therapy—angiographically
borderline lesion on proximal LAD, a—OCT shows massive red thrombus, with significant lumen
stenosis; (B)—UA patient—angiographically nonsignificant lesion on ostial LAD, b—OCT shows signs
of culprit lesion (white and red thrombus), with permeable lumen; (C)—Anterior STEMI patient—ostial
LAD haziness of nonsignificant lesion, c—OCT shows coronary dissection, with significant lumen
stenosis; (D)—Anterior STEMI patient—angiographically normal coronary aspect, d—OCT shows
a dissection and hematoma originating from a vasa vasorum hemorrhage, being probably the
underlying physiopathology of the ACS; (E)—NSTEMI patient at 10 years after a LCX bare metal
stent implantation—angiographically intra-stent haziness, e—OCT shows neoatherosclerosis as the
mechanism for stent failure; (F)—Inferior STEMI female patient—angiographically long, double lumen
pattern, RCA stenosis, f—OCT confirms spontaneous dissection as the underlying physiopathology
and guides PCI (guide wire presence in the true lumen and choice of stent’s “landing zones”); (G)—LM
PCI with excellent angiographic result, g—OCT shows significant malapposition; (H)—Suboptimal
angiographic result of proximal LAD stent placement, h—OCT shows excellent result.
3.3. Post-PCI OCT Group
The “post-PCI” OCT group included 52 patients, with two main indications for imaging (Figure 1):
assessment of complex lesions PCIs, with an optimal angiographic result—45 cases (24.7% of the OCT
investigations) and assessment of suboptimal PCI results—seven cases (3.8%).
3.3.1. Assessment of Complex Lesions PCIs with Optimal Angiographic Result Included:
Left Main Lesions PCI Assessment
This group included 24 patients with LM PCI, representing 13.2% of OCT indications and 19.8%
of the 121 LM PCIs performed in our center, during the investigated time interval; there were mainly
ACS (nine UA, eight STEMI, and six NSTEMI) patients, while two had SCAD; OCT was performed for
LM PCI control in cases of technically challenging procedures (15 cases), two stents technique (seven
cases), and for important LM, LAD, or LCX decalibration (two cases); optimal OCT results were found
in 11 patients, without need for LM PCI optimization; OCT imaging found malappositions (10 patients)
(Figure 2G/g) and edge dissections (three patients), leading to a decision for PCI optimization (with
new balloon dilatation or, respectively, new stent implantation) in these 13 out of the 24 patients (54%
of the LM PCIs with optimal angiographic results) (Table 4).
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Bifurcation Lesions PCI Assessment
This group included 21 patients with bifurcation PCI, representing 11.5% of OCT indications
and 2.2% of the 955 bifurcation PCIs performed in our center, during the investigated time interval;
there were only ACS (11 UA, seven NSTEMI, and three STEMI) patients; OCT was performed for
bifurcation PCI control in cases of technically challenging procedures (11 cases) and two stents
techniques (10 cases); optimal OCT results were found in 11 patients, without need for PCI optimization;
OCT imaging found malappositions (six patients) and edge dissections (four patients), leading to
a decision for PCI optimization in these 10 out of the 21 patients (48% of the bifurcation PCIs with
optimal angiographic results) (Table 4).
3.3.2. Assessment of Suboptimal PCI Results
This group included seven patients (three STEMI, two NSTEMI, and two UA), representing only
0.23% of the 3027 PCIs performed in our center in the investigated time interval. The indication for
OCT imaging was represented by
- angiographic suspicion of edge dissection (three cases); only one was confirmed by OCT, leading
to PCI optimization;
- angiographic suspicion of extensive coronary dissection (one case)—unconfirmed by OCT;
- angiographic suspicion of coronary thrombus (two cases), confirmed by OCT in both cases and
followed by PCI optimization;
- angiographic suspicion of significant residual stenosis in the native coronary, proximal to the
stented lesion (one case), unconfirmed by OCT (Figure 2H/h).
In this group, OCT imaging revealed the presence of an optimal PCI result in four of the seven
patients (57.1%), thus avoiding unneccessary PCI optimization. There were only three out of seven
patients (42.8%) in whom PCI optimization was really needed.
3.4. Decision Change after OCT
For the entire group of 182 patients investigated by OCT, intracoronary imaging had a decisive
benefit for optimizing interventional cardiology indications and strategy, in 157 patients (86.2%),
as follows
- in all the 130 patients having OCT imaging as a complement to CA, for assessing the indication
of revascularization and
- in 27 of the 52 patients investigated post-PCI (51.9% of this subgroup).
3.5. OCT Investigations not Included in This Study
There also were 44 OCT investigations performed after PCI, out of 77 cases, in patients from the
“post-CA” group. In these patients, OCT catheter was already used before PCI, OCT investigations
were therefore performed for PCI result control. In this group of patients, all post-PCI angiographic
results were optimal, but OCT found suboptimal result and led to optimization in 12 cases (27.3%):
10 with balloon post-dilatation for stent underexpansion and two with new stent implantation for
edge dissections.
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Borderline lesions 28(35.5%) 51(64.5%) 79
Nonsignificant lesions or normal coronaries 19(61.3%) 12(38.7%) 31
Stent failure mechanism 10 10
Native lesion assessment 3 3
Selection of PCI devices 7 7
LM PCI control, after optimal angiography 11 (45.8%) 13 (54.2%) 24
Bifurcation PCI control, after optimal angiography 11 (52.3%) 10 (47.7%) 21
Suboptimal PCI result on angiography 4 (57.1%) 3 (42.9%) 7
4. Discussion
Multiple centers use OCT in a variety of clinical scenarios for diagnosis and therapeutic
optimization in coronary interventions [9–14]. A recently issued European Association of
Percutaneous Cardiovascular Interventions (EAPCI) expert consensus document on clinical use of
intracoronary contained a broad array of OCT indications [10]. The ESC guidelines on myocardial
revascularization [15] recommend OCT use for PCI optimization (Class IIa, Level of evidence B) and
for identifying stent failure mechanism (Class IIa, Level of evidence C). A recent clinical practice
survey [11] offered the perception of interventional cardiologists on the indications for OCT use
and their relative prevalence. Our study provides actual evidence on real-life OCT use in a tertiary
interventional cardiology center, allowing analysis of its indications and highlighting its benefits.
The main benefit proved to be the identification of significant coronary stenosis, with an indication for
PCI, in patients with borderline and nonsignificant coronary lesions on CA. Our study also proved
OCT interest for optimizing imaging results after PCI, in complex LM and bifurcation lesions, as well
as in a “systematic” post-PCI OCT control approach. This imagistic PCI optimization would translate
into a better clinical outcome [5,10].
In our study, OCT proves particularly useful in the clinical setting of ACS (95.6% of the
investigated patients), with 71.5% of OCTs performed as a complementary imaging method to CA,
representing 3.1% of CAs in our center.
We mainly used OCT to provide accurate diagnosis and therapeutic decisions concerning
revascularization (60.4% of the OCT investigations). A moderate proportion (43.4%) of the OCT
investigations were performed for borderline lesions, and 17% for assessment of coronary arteries
with nonsignificant lesions or with a normal aspect. Our approach is in consensus with the
recent european recommendation [15] of OCT use in the up to 25% of NSTE-ACS patients with
angiographically normal epicardial arteries, for identifying culprit lesions or rule out mechanisms
such as dissection and haematomas (MI with nonobstructive coronary arteries, MINOCA). In ACS
patients, physiological evaluation with fractional flow reserve has a limited value, with contradictory
reports on safety [15,17,18] and unknown prognostic value [15].
A very important finding in our study is that OCT, performed complementary to CA, in ACS,
reassessed the severity of coronary lesions and led to the indication of revascularization in 64.5% of
borderline lesions, and in 38.7% of nonsignificant lesions or normal coronary arteries. This result
would support inclusion of OCT imaging in the practice guidelines, in this setting.
In our study, OCT also proved useful for the control of LM PCI patients with optimal angiographic
results, which accounted for 13.2% of OCT indications. In these patients, suboptimal OCT findings
as malappositions and edge dissections led to PCI optimization in not less than 54% of the cases.
This finding underlines the limits of angiography for LM PCI assessment and may support the need for
a systematic OCT imaging in this setting. In our study, OCT was used in only 19.8% of LM PCI patients,
with technically challenging procedures, a two-stent technique, or important LM, LAD, or LCX
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decalibration.This was in contrast to the survey on intravascular imaging use, where participants
reported a 77% use for LM PCI guidance [11].
OCT was useful for optimization of bifurcation PCI, in difficult, technically challenging procedures
and two-stent techniques. Despite a very good angiographic result in these patients, OCT found
suboptimal results in 48% of the cases, with need for optimization. These findings support the limited
existing data [19–21] regarding the need for more than angiography in bifurcation PCI. Other clinical
practitioners reported a 53.5% use of IVI for guiding bifurcation PCI [11]. However, we used OCT for
only 2.19% of our bifurcation PCIs (11.5% of total OCTs).
While other authors report that 79.6% of IVI evaluations are done for PCI strategy planing,
in selected cases [11], this indication accounted for only 11% of OCTs, in our center. We used
pre-PCI OCT for identifying stent failure mechanisms, selecting PCI devices features, and assesing
native lesions.
OCT provided support in cases with suboptimal angiographic PCI results, in whom imaging
proved in fact to correspond to a good PCI result, in four of the seven investigated patients. This is
a rare OCT indication but its results further support that OCT imaging may overcome CA limitations.
While being available during the whole 5-year period of our study, OCT was used in only 1.7% of
patients undergoing PCI. Our findings are comparable to the results of a recent large observational
study, which showed a 1.3% prevalence of OCT use for PCI guiding [22].
Our relatively low prevalence of OCT use (3.1% of CA and 1.7% of PCIs) is similar to the approach
of 16.6% of interventionalists in the recent clinical practice survey, that used intravascular imaging in
less than 5% of their patients [11]. It is however to be noted that, in this same survey [11], 51.3% of
the participants use IVI in more that 15% of patients, another 18% of participants use IVI in 5–15% of
patients, and 10.3% of participants use IVI only in highly selected cases, while 3.9% of interventional
cardiologists do not use any IVI [11].
Our study reports that OCT, while used in a limited number of pts submitted to CA and
PCI, offer a substantial benefit for 86.2% of the investigated patients, leading to optimization of
interventional cardiology indications and strategy. This is true in all patients in the post-CA group and
in 51.9% of the post-PCI group.
Our results concerning OCT-related decision changes in the post-PCI LM and bifurcations complex
lesions group (51.9%) are similar to the ones reported by the DOCTORS [23] trial, namely, a 50% change
in procedural strategy in the OCT group. The ILUMIEN I study [24] reported 27% decision change in
the post-PCI group. This low prevalence of OCT-related decision change post-PCI in the ILLUMIEN
I study, can be explained by the systematic use of OCT, both pre- and post-PCI [24]. In our study,
the systematic post-PCI use of OCT, in patients already having had OCT pre-PCI, led to identification
of suboptimal PCI results, mainly underexpansion and edge dissection, with an indication for PCI
optimization, in 27.3% of the cases, similar to the one in ILLUMIEN I study [24].
5. Study Limitations
Our study is an observational, retrospective, single-center one, with a limited sample size, without
a statistical power calculation; thereby, our results should be interpreted with caution and considered
hypothesis generating. Clinical follow-up of our patients is beyond the purpose of our study. Long term
clinical benefit of a dual imagistic approach, using both CA and OCT, and not only CA, for the selection
of PCI indications, strategy and result assessment and optimization, would require either a randomized
study, or a comparison between centers using these two approaches.
6. Conclusions
The main OCT benefit is in borderline and nonsignificant lesions on CA, in whom OCT identifies
significant coronary stenosis and leads to PCI indication in two-thirds and, respectively, one-third of the
patients. In the post-PCI context, OCT leads to an indication of PCI optimization in half of the complex
left main and bifurcation lesions, as well as in a quarter of “systematic” post-PCI OCT controls.
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Abstract: To analyse the predictive ability and incremental value of left ventricular longitudinal
axis strain (LAS) and late gadolinium enhancement (LGE) using standard cardiovascular magnetic
resonance (CMR) imaging for the diagnosis and prognosis of severe aortic stenosis (AS) in patients
with an indication for aortic valve replacement. We conducted a prospective study on 52 patients
with severe AS and 52 volunteers. The evaluation protocol included standard biochemistry tests,
novel biomarkers of myocardial fibrosis, 12-lead electrocardiograms and 24-hour Holter, the 6-minute
walk test and extensive echocardiographic and CMR imaging studies. Outcomes were defined as
the composite of major cardiovascular events (MACEs). Among AS patients, most (n = 17, 77.2%) of
those who exhibited LGE at CMR imaging had MACEs during follow-up. Kaplan–Meier curves for
event-free survival showed a significantly higher rate of MACEs in patients with LGE (p < 0.01) and
decreased LAS (p < 0.001). In Cox regression analysis, only reduced LAS (hazard ratio 1.33, 95% CI
(1.01 to 1.74), p < 0.01) and the presence of LGE (hazard ratio 11.3, 95% CI (1.82 to 70.0), p < 0.01) were
independent predictors for MACEs. The predictive value increased if both LGE and reduced LAS
were added to left ventricular ejection fraction (LVEF). None of the biomarkers of increased collagen
turnover exhibited any predictive value for MACEs. LAS by CMR is an independent predictor of
outcomes in patients with AS and provides incremental value beyond the assessment of LVEF and
the presence of LGE.
Keywords: severe aortic stenosis; longitudinal axis strain; late gadolinium enhancement; cardiac
magnetic resonance imaging
1. Introduction
Aortic stenosis (AS) is currently the most often encountered valvular heart disease in adults. The
overall prevalence of this condition has recently increased as a consequence of progressive ageing of
the population, reaching a maximum in patient’s ≥75 years of age (2.8% of the general population) [1].
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Severe AS is associated with changes in left ventricular (LV) geometry and function induced by
increased afterload [2,3]. In the early stages, the constant exposure to elevated afterload leads to
progressively increasing LV wall thickness, a compensatory change that temporarily relieves wall
stress. At this point, LV systolic function is preserved. In later stages, compensatory mechanisms are
overwhelmed by the constant exposure to increased afterload, leading to maladaptive remodelling
and impaired LV systolic function [4,5]. Chronic inflammation, osteoblast activation, active valve
mineralization, valvular and myocardial fibrosis occur due to the continuous exposure to increased
pressure overload and are important factors in the evolution of AS [6]. Myocardial cell apoptosis [7] and
the secretion of excess extracellular matrix proteins [8] favour the development of myocardial fibrosis
and lead to systolic and diastolic LV dysfunction and increased ventricular stiffness [9]. Such changes
are associated with a higher risk of major adverse cardiovascular events (MACEs) [10,11] and poorer
outcomes in terms of clinical status and long-term survival after aortic valve replacement [12]. Changes
in LV mechanics usually occur before the overt impairment of the LV systolic function, as assessed
by the left ventricular ejection fraction (LVEF). Moreover, LVEF has a high inter- and intra-observer
variability (14%) [13] and only becomes impaired in the late stages of the disease [14]. By contrast,
global longitudinal strain has increased reproducibility, and is altered from the early stages of severe
AS [15,16]. Although echocardiography is valuable, it has some limitations, and additional imaging
techniques may provide incremental value for diagnostic and prognostic purposes in severe AS
patients. Cardiac magnetic resonance (CMR) imaging is widely accepted as the non-invasive modality
of choice for visualizing and quantifying myocardial fibrosis by late gadolinium enhancement (LGE)
techniques [17]. A mid-wall pattern of fibrosis has been observed in the myocardium of up to 38%
of patients with moderate or severe AS and has been associated with a more advanced hypertrophic
response [10], and an eight-fold increase in mortality [10].
Recently, left ventricular longitudinal axis strain (LAS) by CMR imaging has been validated as a
fast and reliable method for quantifying global LV longitudinal function [18], which does not require
additional pulse sequences and off-line processing using dedicated software tools. The aim of the
current pilot study was to assess the incremental value of LAS and LGE using standard CMR images
for the diagnosis and prognosis of patients with severe AS undergoing aortic valve replacement.
2. Material and Methods
2.1. Study Patients
We conducted a prospective study on 128 patients with severe AS undergoing aortic valve
replacement and who were examined in the 5th Department of Internal Medicine of the Iuliu Hatieganu
University of Medicine and Pharmacy, Cluj-Napoca, Romania, between March 2016 and August 2018.
Severe AS was defined as (1) peak aortic jet velocity ≥ 4 m/s, and/or (2) mean transvalvular gradient
≥ 40 mmHg, and/or (3) aortic valve area (AVA) ≤ 1.0 cm2 [19,20].
Patients who had contraindications for CMR (including incompatible metallic devices,
significant chronic renal disease with estimated glomerular filtration rate < 30 mL/min/1.73 m2,
or claustrophobia), other significant valvular disease, rheumatic valve disease with significant
(at least moderate) mitral stenosis, post-irradiation AS, history of previous myocardial infarction
with or without coronary revascularization by percutaneous coronary intervention and/or bypass,
previous surgery for valvular disease, active inflammatory, infectious diseases, or neoplasia, cirrhosis,
pulmonary fibrosis, poor echocardiographic window or those who did not agree to participate were
excluded. The total number of excluded patients was 76 (Figure 1). Finally, 52 patients with severe
AS (test group) were compared to 52 volunteers (control group), matched for age and sex, who
responded to a questionnaire excluding any history of chronic heart disease, other than systemic arterial
hypertension, without ongoing symptoms, normal clinical examination and normal electrocardiogram,
chest radiographs, echocardiography, Holter ECG monitoring for 24 h and CMR imaging. Volunteers
in the control group were recruited during the same enrolment interval as test group patients.
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Figure 1. Patient selection and study design.
The current study was approved by the Ethics Committee of the Iuliu Hatieganu University of
Medicine and Pharmacy, Cluj-Napoca—decision number 196/10.03.2016. The research was conducted
in compliance with the Declaration of Helsinki. All patients were informed about the investigation
protocol and signed a written consent form before being assigned to either the test or control
group. Each patient underwent the same investigation protocol, including medical history, clinical
examination, the recording of a 12-lead electrocardiogram, 24-h Holter monitoring, 6-min walk test
(6MWT), biochemical analysis, echocardiography and CMR imaging, which were all performed during
the same hospital visit.
2.2. Medical History and Clinical Examination
We recorded the medical history and cardiovascular risk factors of all enrolled subjects, including
active smoking, systemic arterial hypertension, dyslipidemia, diabetes, and obesity. Coronary
artery disease was considered present if myocardial infarction, angina pectoris, or revascularization
(by either angioplasty or coronary artery by-pass) were performed. The New York Heart Association
(NYHA) functional classification was used to assess the severity of dyspnoea. Patients with severe
AS were considered symptomatic if they experienced dyspnoea, angina and/or syncope. A 12-lead
electrocardiogram was recorded at enrolment and 24-h Holter monitoring was performed. The 6MWT
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was performed in the presence of adequately trained medical personnel following the American
Thoracic Society guidelines, and the 6-min walk distance (6MWD) was reported. The risk of mortality
after cardiac surgery was assessed by the EuroScore II [21] software available on www.euroscore.org.
2.3. Biochemical Analysis
Two peripheral venous blood samples were collected at enrolment from each participant and
serum was separated by centrifugation. One sample was used for standard biochemistry tests,
including high sensitive C reactive protein (hs-CRP) measurements, with a Beckman Coulter AU480
Chemistry Analyzer. The other serum sample was preserved at −80 ◦C until the end of the study and
used for measuring procollagen type I C-terminal propeptide (PICP), procollagen type III N-terminal
propeptide (PIIINP) and N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) levels. All biomarker
levels were determined by the Sandwich ELISA technique according to the manufacturer’s instructions
(Elabscience Biotechnology Co., Ltd., WuHan, China) For determining PICP, we used Human PICP
ELISA Kits, Elabscience Biotechnology Co. PIIINP was determined using Human PIIINP ELISA Kits,
and for NT-proBNP levels, Elabscience Biotechnology Co., Ltd., kits were used. Measurements were
performed by a single investigator who was blinded to all clinical and imaging data. Renal function
was estimated by the glomerular filtration rate (eGFR), using the Chronic Kidney Disease Epidemiology
Collaboration equation, considering age, race, gender, and plasma creatinine concentration. Renal
function was considered impaired at eGFR < 60 mL/min/1.73 m2.
2.4. Echocardiography
Transthoracic echocardiography was performed in all participants to the study using a General
Electric Vivid E9 (GE Health Medical, Horten, Norway) echocardiograph with a M5S 1.5/4.6 MHz
active matrix-phased array transducer. Examinations were performed by two physicians (L.S. and
C.O.), each with more than 10 years of experience in the field, and blinded to all clinical and laboratory
data. Echocardiography data was collected and reported according to guidelines from the European
Association of Echocardiography and the American Society of Echocardiography [19,20,22,23].
The severity of AS was quantified by continuous wave Doppler measurements of peak aortic flow
velocity and mean transaortic gradients; AVA was calculated using the continuity equation and indexed
to body surface area (BSA). LV systolic function was quantified by the LVEF (bi-plane Simpson’s
modified rule). LV diastolic function and right chambers dimensions and functions were assessed
following global recommendations.
2.5. Cardiac Magnetic Resonance Imaging
All CMR imaging examinations were performed by two experienced examiners, one cardiologist
and one radiologist (L.A.C. and C.C.), blinded to all clinical data, using specialized software (Syngo.Via,
VB20A_HF04, Argus, Siemens Healthineers Global, Erlangen, Germany), as recommended [24], on
a 1.5 T MR scanner (Magnetom Symphony, Siemens Medical Solutions, Erlangen, Germany) with a
dedicated surface coil for radio frequency signal detection. Standard localized views and contiguous
short-axis and 4-chamber cine views covering both ventricles from base to apex were first acquired by
ECG-gated steady-state free precession (SSFP) sequences, in apnea (Figure 2). Pre-contrast imaging
parameters were selected at the beginning of the study and a standard protocol was applied for each
examination: repetition time 3.6 ms; echo time 1.8 ms; flip angle 60◦; slice thickness 6 mm; field of
view 360 mm; image matrix of 192 × 192 pixels; voxel size 1.9 × 1.9 × 6 mm; 25–40 ms temporal
resolution reconstructed to 25 cardiac phases. The imaging plane of the aortic valve was defined
by the acquisition of a systolic three-chamber view and an oblique coronal view of the aortic valve
and proximal aorta. Post-contrast, standard LGE images were acquired 10 minutes after intravenous
injection of 0.2 mmol/kg gadolinium contrast agent (Gadoterate meglumine or Dotarem, Guerbet,
Roissy CdG, France) in long- and short axis-views, using a segmented inversion-recovery gradient-echo
sequence. Inversion time was adjusted to optimize nulling of apparently normal myocardium. Brachial
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blood pressure was monitored during CMR SSFP acquisitions. LV end-diastolic volume (LVEDV) and
end-systolic volume (LVESV), LVEF and end-diastolic LV mass (LVM) were measured on short-axis
cine-SSFP images. Epicardial and endocardial borders were traced semi-automatically at end-diastole
and end-systole using specialized software (Syngo.Via VB20A_HF04, Argus, Siemens Medical
Solutions). AVA was measured on cross-sectional planimetric images during systole by drawing
the region of interest. LV longitudinal function was assessed by LAS, defined as the difference in mitral
annular displacement at end-systole vs. end-diastole, and expressed in percentages. The presence
and distribution of LGE in the LV were assessed from short-axis images, using the 17-segments
model, recommended by the American Heart Association [24].The pattern of LGE distribution was
characterized as mid-wall, subepicardial, focal or diffuse.
 
Figure 2. Cardiovascular magnetic resonance (CMR) imaging in aortic stenosis (AS) patients.
(A) cine-SSFP (steady-state free precession) imaging of a stenotic bicuspid aortic valve; (B) coronal
left ventricular outflow tract view acquired through-plane showing the aortic valve leaflet tips and
restricted leaflet motility and resultant high velocity jet; (C) three-chamber view acquired through-plane
showing the aortic valve leaflet tips, restricted leaflet mobility, and high velocity jet; (D,E) four-chamber
view at end-diastole and end-systole acquired for longitudinal axis strain (LAS); (F) late gadolinium
enhancement (LGE) in short-axis views of left ventricle showing focal hyper-enhancement (arrow).
2.6. Clinical Outcomes
Patients were followed-up over a median time interval of 386 days (interquartile range: 60 to
730 days) by completing a questionnaire either on hospital visits, telephone house-calls, or both.
Survival analysis was performed for the combined end-point. The study end-point was a combination
of major adverse cardiac events (MACE), including sudden cardiac death, non-fatal myocardial
infarction, sustained ventricular arrhythmias, third-degree atrioventricular block and hospitalization
for heart failure. If more than one event occurred, the most severe was selected. Hospitalizations due
to non-cardiac causes were not considered in the analysis. The duration of follow-up was determined
from the CMR study date until the occurrence of a MACE. The last evaluation of patient survival status
was performed in August 2018 (the follow-up closing date). Complete follow-up was available for
all patients.
2.7. Statistical Analysis
The normal distribution of data was tested by the Kolmogorov-Smirnoff test. Data were reported
as mean and standard deviation, or median and interquartile range (IQR). Relative frequencies for
categorical variables were reported as percentages. The Chi-square or Fisher’s exact tests were used to
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compare variables between the two groups. Multiple comparisons were made using one-way ANOVA
variance analysis or the Kruskall–Wallis test. Univariable and stepwise multivariable logistic regression
analyses were performed to determine the association between LAS and LGE, and other variables
derived from imaging modalities. The hazard ratio (HR) for the prediction of events was calculated for
each of the outcomes using a Cox regression model. For each outcome of interest, we considered all
of the significant variables in the univariate analysis and sought the best overall multivariate models
for the composite end point, by stepwise-forward selection, with a probability to enter set at p < 0.05
and to remove the effect from of regression at p < 0.05. Event-free survival (time to first event) was
generated by the Kaplan–Meier method and statistical significance was determined by the log-rank
test. Receiver operating characteristic curve analysis was performed to study the predictive ability of
LAS and LVEF for adverse cardio-vascular events. Results were considered statistically significant for
p < 0.05. Cohen’s Kappa inter- and intra-observer coefficient calculation was performed. Retrospective
test power calculation and prospective sample size were estimated, with type I and type II variation




The present study was designed as a pilot study to serve as data for sample size calculation. Based
on LAS numeric values and considering the threshold of alpha = 0.05, our estimation of type II beta
risk stands below 0.05. However, in order to ensure the best power for inter-group tests, we have
calculated a minimum necessary sample of 50 subjects /group (for type I alpha = 0.05). The study will
be continued up to this limit for enabling us to decrease the type II error up to 0.05 (95% power).
All baseline characteristics of patients with AS and healthy volunteers are reported in Table 1.
There were no statistically significant differences in age, gender, body surface area, systemic artery
pressures, active smoking or presence of diabetes between the two groups. Patients in the test group
had a poorer exercise capacity as assessed by the 6MWT.
Table 1. Baseline characteristics of patients in the test and control group.
Test Group Control Group p-Value
Clinical characteristics n = 52 n = 52
Age, years 66 (7.5) 66 (7.8) NS
Male gender, n (%) 29 (55.7) 29 (55.7) NS
Body surface area, m2 1.90 (0.24) 1.97 (0.13) NS
Body-mass index, kg/m2 28.5 (4.1) 30.2 (4.9) NS
Heart rate, bpm 73 (11.6) 72 (8.6) NS
Systolic blood pressure, mmHg 132 (18.1) 133 (20.3) NS
Hypertension, n (%) 37 (71.1) 28 (53.8) NS
Diabetes mellitus, n (%) 22 (42.3) 14 (26.9) <0.01
Dyslipidemia, n (%) 35 (67.3) 24 (46.1) NS
Smoking, n (%) 19 (36.5) 13 (25) NS
6MWD, m 406 (138.1) 592 (103.9) <0.001
Coronary artery disease, n (%) 18 (32.6)
Chronic obstructive lung disease, n (%) 7 (11.5)
Peripheral vascular disease, n (%) 27 (51.9)
NYHA functional class ≥ III, n (%) 15 (28.8)
Logistic EuroScore, % 3.8 (1.3–5.9)
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Table 1. Cont.
Test Group Control Group p-Value
Medications
β-blockers, n (%) 40 (76.9) 14 (26.9) <0.001
ACEIs or ARBs, n (%) 45 (86.5) 10 (19.2) <0.001
Calcium channel blockers, n (%) 6 (11.5) 13 (25) <0.01
Statins, n (%) 38 (73) 15 (28.8) <0.001
ASA or other antiplatelet therapy, n (%) 32 (61.5) 13 (34.6) <0.01
Diuretics, n (%) 37 (71.1) 5 (9.6) <0.001
Echocardiography
Peak aortic velocity, m/s 4.45 (0.47) 1.31 (0.36) <0.001
Peak transaortic gradient, mmHg 82.1 (17.9) 7.2 (2.7) <0.001
Mean transaortic gradient, mmHg 52.9 (14.7) 3.6 (0.75) <0.001
AVA index, cm2/m2 0.52 (0.08) 2.9 (0.08) <0.001
E/E’ ratio 9.8 (3.2) 6.5 (0.8) <0.001
DT, ms 223 (52.2) 185 (8.8) <0.001
sPAP, mmHg 33.4 (7.3) 26.2 (7.2) NS
Cardiovascular magnetic resonance
LVEDV index, mL/m2 82.4 (21.6) 61.8 (15.0) <0.001
LVESV index, mL/m2 35.7 (16.6) 20.9 (5.8) <0.001
LVM index, g/m2 96.2 (24.3) 62.1 (16.5) <0.001
LVEF, % 58.4 (9.7) 66.1 (4.7) <0.001
LVM/LVEDV, g/mL 1.22 (0.35) 1.04 (0.29) <0.01
LAV index, mL/m2 49.1 (11.6) 25.5 (3.7) <0.001
LAS (%) −17.7 (3.9) −20.5 (1.5) <0.001
TAPSE, mm 14.9 (2.5) 19.8 (3.6) <0.001
LGE, n (%) 30 (57.7)
Biomarker levels
PICP, ng/mL, IQR 1.2 (0.37–7.3) 0.42 (0.38–4.6) <0.001
PIIINP, ng/mL, IQR 13.6 (2.5–68.3) 9.7 (2.4–29.7) <0.01
hs-CRP, pg/mL, IQR 1.1 (0.49–1.9) 0.74 (0.16–1.1) <0.001
NT-proBNP, pg/mL, IQR 1960 (170–9893) 210 (60–390) <0.001
eGFR, ml/min/1.73 m2 88.1 (24.1) 89.2 (19.6) NS
Abbreviations: n, number of patients; IQR, interquartile range; NYHA, New York Heart Association; NT-proBNP,
N-terminal pro-Brain Natriuretic Peptide; hs-CRP, high sensitive C reactive protein; PICP, procollagen type I
C-terminal propeptide; PIIINP, procollagen type III N-terminal propeptide; eGFR, estimated glomerular filtration
rate; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid;
LAS, left ventricular longitudinal-axis strain; LGE, left ventricular late gadolinium enhancement; LVEDV, left
ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVM, left ventricular mass; LVEF, left
ventricular ejection fraction; LAV, left atrial volume; E, peak mitral flow velocity; E’, early diastolic peak myocardial
velocity; DT, early diastolic filling deceleration time; sPAP, systolic pulmonary artery pressure; 6MWD, six minute
walk distance; TAPSE, tricuspid annular plane systolic excursion; AVA, aortic valve area. Data are reported as mean
(standard deviation) or median (IQR) or n (%).
Patients in the AS group had significantly higher levels of PICP (p < 0.001), PIIINP (p < 0.01),
hs-CRP (p < 0.001) and NT-proBNP (p < 0.001) than patients in the control group.
The cause of AS in test group patients was calcification of a trileaflet valve (n = 39), presence of
a bicuspid aortic valve (n = 6), rheumatic disease (n = 4), or undetermined (n = 3). 47 (90%) patients
with AS were symptomatic. LVEF was preserved in most test group patients (n = 38; 73%). Indexed
LVM was increased ≥92 g/m2 in 28 patients (53.8%) and reduced LAS < −18% was documented in
20 patients with AS (38.4%). LGE was found in 30 patients with AS (57.7%). LGE was distributed
mid-wall in 12 patients (23%), in the sub-epicardial myocardium in 5 patients (9.6%), was focal in 10
patients (19.2%), and diffuse in 3 patients (5.7%).
3.2. Reproducibility of CMR Measurements
CMR measurements were repeatedly performed on the same set of images, acquired from all
patients in the study group. Intra- and inter-observer reproducibility of LVEF and LAS measurements,
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and the assessment of LGE by CMR were excellent. The kappa coefficients of agreement were 0.89
(inter-reader) and 0.91 (intra-reader) for the assessment of LGE, and 0.93 (inter-reader) and 0.96
(intra-reader) for LAS (Table 2).
Table 2. Reproducibility inter and intra-reader agreement of CMR measurements.
Parameter Coefficient Kappa 95% Confidence Interval Standard Error
Inter-reader
LVEF 0.95 0.907 to 0.974 0.023
LAS 0.93 0.912 to 0.962 0.027
LGE 0.89 0.795 to 0.940 0.078
Intra-reader
LVEF 0.99 0.989 to 0.998 0.002
LAS 0.96 0.953 to 0.985 0.014
LGE 0.91 0.905 to 0.942 0.033
Abbreviations: LAS, left ventricular longitudinal-axis strain; LGE, left ventricular late gadolinium enhancement;
LVEF, left ventricular ejection fraction.
3.3. Survival Analysis
All patients underwent surgery and aortic valve replacement was performed. During a median
follow-up period of 386 (60 to 730) days, 22 patients (42.3%) had MACEs: non-fatal myocardial
infarction (n = 2), sustained ventricular arrhythmias (n = 2), third-degree atrioventricular block (n = 3)
and hospitalization for heart failure (n = 15). In three patients, MACEs (ventricular tachycardia and
hospitalization for heart failure, respectively) occurred before surgery. One patient developed third
degree atrio-ventricular block during surgery and required permanent pacing. Nineteen other patients
experienced MACEs after aortic valve replacement. Most patients (n = 17, 77.2%) with LGE on CMR
imaging had MACEs during follow-up.
The discriminative performance of additional markers for MACEs was calculated by receiver
operating characteristic curve analysis for the combined end-point: LVEF (optimized cut-off value,
<50%; AUC, 0.759; p < 0.01) and LAS (optimized cut-off value, <−18%; AUC, 0.883; p < 0.0001) (Table 3).
Interestingly, the biomarkers for enhanced collagen turnover had no discriminative ability for MACEs
in severe AS patients.
Table 3. Predictive ability of biological markers and imaging parameters for outcomes in severe AS
patients considered for aortic valve replacement surgery.
Variables Sensibility Specificity PPV NPV ROC Threshold AUC
LVEF 0.67 0.90 0.87 0.73 <50 0.759
LGE 0.75 0.68 0.66 0.76 + 0.717
LAS 0.77 0.90 0.85 0.84 <−18 0.883
PICP 0.56 0.73 0.64 0.67 >0.84 0.535
PIIINP 0.50 0.79 0.67 0.65 >16.1 0.572
Abbreviations: PICP, procollagen type I C-terminal propeptide; PIIINP, procollagen type III N-terminal propeptide;
LAS, left ventricular longitudinal axis strain; LGE, left ventricular late gadolinium enhancement; LVEF, left
ventricular ejection fraction.
Kaplan–Meier curves for event-free survival showed a significantly higher rate of MACEs in
patients with LGE (p < 0.01) and decreased LAS (p < 0.001) at CMR imaging (Figure 3).
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Figure 3. Kaplan–Meier curves for event-free survival for (A) Longitudinal Axis Strain (LAS); (B) late
gadolinium enhancement (LGE).
3.4. Uni- and Multivariate Analysis
Several clinical parameters were predictors for the combined end-point in univariate analysis: the
6MWD, E/E’ ratio, LVEDV indexed, LVESV indexed, LVEF, LGE and LAS (Table 3).
In multivariate Cox regression analysis, only LGE and LAS (adjusted HR = 9.86, 95% CI 1.77 to
54.0, p < 0.01, respectively, HR = 1.32, 95% CI 1.01–1.71, p < 0.01) remained independent predictors for
MACEs (Table 4).
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Subsequently, a stepwise multivariate Cox regression model was constructed, including age,
6MWD, E/E’ratio, LVEF, LAS and the presence of LGE. Only reduced LAS (HR 1.33 (95% CI 1.01–1.74;
chi-square: 15.1, p < 0.001) and LGE (HR 11.3 (95% CI 1.82–70.2); chi-square: 24.3, p < 0.001) were
independent predictors for the combined end-point (Table 5).
Table 5. Stepwise Multivariate Proportional Hazard Model for the Combined End Point.
Variables
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
HR 95% HR 95% HR 95% HR 95% HR 95% HR 95%
Age 1.01 (0.95–1.08) 0.96 (0.89–1.03) 1.01 (0.95–1.08) 1.00 (0.95–1.06) 1.00 (0.95–1.06) 1.01 (0.96–1.07)
6MWD 0.99 (0.98–1.00)
E/E’ 1.24 (1.01–1.54) **
LVEF 0.94 (0.88–1.01)
LAS 1.33 (1.01–1.74) **
LGE 11.3 (1.82–70.2) *
Abbreviations: 6MWD, six minute walk distance; E, peak mitral flow velocity; E’, peak myocardial velocity at
the mitral valve annulus; LAS, left ventricular longitudinal-axis strain; LGE, left ventricular late gadolinium
enhancement; LVEF, left ventricular ejection fraction. * p < 0.001; ** p < 0.01.
3.5. Incremental Predictive Value for the Combined End-Point
Sequential Cox proportional-hazards models yielded significantly increased predictive power for
the combined end-point of MACEs when both LGE and LAS were used in addition to LVEF (chi-square
= 19.74, one degree of freedom). Neither LGE, nor LAS provided incremental predictive power when
used alone, in addition to LVEF (Figure 4).
Figure 4. Incremental predictive value of longitudinal axis strain (LAS) and late gadolinium
enhancement (LGE) added to left ventricular ejection fraction (LVEF) for the combined end-point
in AS patients.
4. Discussion
In this prospective pilot study, we aimed to establish whether advanced CMR imaging techniques
provide additional value in identifying patients with severe AS at risk for MACEs.
We have shown that both LAS and the presence of LGE are more reliable than LVEF for predicting
MACEs in patients with severe AS, and that their combined use, in addition to LVEF, provided
incremental value to any marker used alone.
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Earlier echocardiography-based studies have demonstrated that global longitudinal strain is a
reliable marker of cardiovascular events in different categories of patients [25,26] and is superior to
traditional measurements of LVEF for predicting MACEs in patients with cardiovascular diseases [27].
Two relatively recent studies confirmed that CMR feature tracking with SSFP is a robust
method for assessing LV mechanics and compares well to global longitudinal strain assessed by
echocardiography [28,29]. Also, studies have recently emerged showing that impaired myocardial
strain at CMR identifies ventricular function impairment in preclinical arrhythmogenic right ventricular
dysplasia [30] and light chain amyloidosis, even if LVEF is preserved [31]. Considering these findings,
myocardial strain assessment by CMR might become a valuable tool for the early identification of
myocardial impairment.
Currently, data on the use of strain assessment by CMR in patients with AS is scarce. Al Musa et al.
reported that strain by CMR is significantly decreased in patients with severe AS and preserved LVEF
by comparison with healthy volunteers, and is even more impaired if patients are symptomatic [32].
To our knowledge, there is currently no other published data on the prognostic use of LAS in such
patients, and our research is the first to address the relation with cardiovascular events.
By contrast, the presence of LGE has already been validated by previous studies as a marker of
poor prognosis in severe AS. The presence of LGE was associated with poorer outcomes after aortic
valve replacement, including the lack of improvement in symptoms and increased mortality [12,33].
Moreover, in the study by Dweck et al., LGE provided incremental value to LVEF for survival in
patients with moderate to severe AS [10]. The quantitative assessment of LGE also seems useful for
predicting functional improvement and all-cause mortality after aortic valve replacement [10].
Although LGE assessment is obviously a valuable tool for risk stratification, in our study the
predictive power for MACEs was increased when LAS was added to the model. By contrast, PICP
and PIIINP did not contribute at all, which is consistent with previously published research [34].
Considering the results of our research and previously published data, LAS might become an important
part of LV function assessment at CMR, particularly considering that it does not require contrast
administration. Further research is needed to validate this hypothesis.
Firstly, the study was conducted in a single institution and has the inherent limitations of that
approach. Secondly, endomyocardial biopsies were not performed during surgery to assess the
presence or absence of myocardial fibrosis in AS patients. Also, we were unable to acquire T1 mapping
sequences, and therefore extracellular volume and diffuse myocardial fibrosis could not be quantified.
Finally, LAS, as a marker of longitudinal contractile function, is an independent predictor of
outcomes in patients with AS and provides incremental value beyond the assessment of LVEF and the
presence of LGE.
We hypothesise that, if more data is collected to endorse it, LGE and LAS at CMR should provide
incremental value to current risk scores for stratifying prognosis in patients undergoing surgical aortic
valve replacement.
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Abstract: A definitive conclusion regarding whether on-pump or off-pump coronary artery bypass is
preferable in young patients is lacking. The aim of our study was to perform a long-term comparison
of the two approaches in young patients. We analyzed the National Health Insurance Research
Database, using data for patients between 18 and 45 years of age who had undergone isolated
coronary artery bypass between 2001 and 2011. The study endpoints were: all-cause death, major
adverse cardiac and cerebrovascular events, and repeat revascularization within 30 days, 1 year,
5 years, and the entire 10-year follow-up period. A total of 344 patients received off-pump surgery
and 741 patients received on-pump surgery. Preoperative characteristics and comorbidities were
similar in both groups, and all-cause mortality was almost equal (p = 0.716). The 5-year survival rates
were 93.9% and 92.2% in the off-pump and on-pump groups, respectively, and the 10-year survival
rates were 86.3% and 82.1%, respectively. The repeat revascularization rate was significantly lower
in the on-pump group (p = 0.0407). Both the on-pump and off-pump methods offer equally good
long-term outcomes in terms of mortality and major adverse cardiac and cerebrovascular events.
However, the need for repeat revascularization is a concern in the long term after off-pump surgery.
Keywords: coronary artery bypass; on-pump coronary artery bypass; off-pump coronary artery
bypass; young patients
1. Introduction
The efficacy and appropriate indications for off-pump coronary artery bypass grafting (CABG)
have been a source of contention since its enthusiastic re-emergence in the 1990s [1]. Recently, several
large randomized trials have compared on-pump with off-pump CABG [2–6]. They showed the
superiority, or at least non-inferiority, of on-pump CABG to off-pump CABG for most patients and in
the hands of most surgeons [7]. However, the main participants in these trials were elderly patients.
In most of the trials the average age was approximately 60 years, and in some trials patients under
45 years were even excluded [2–6].
Young patients account for 3% of all patients with coronary artery disease (CAD) and have a
different background and propensity to elderly patients [8]. They are more likely to be male, smokers,
obese, have a family history, and some of them have non-atherosclerotic diseases [8–17]. Although the
appropriateness of CABG in young patients is currently being considered [8–14,16], there is insufficient
data to form a definitive conclusion. In particular, there have been no studies comparing long-term
outcomes between on-pump and off-pump CABG in young patients.
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The aim of our study was to perform the first long-term, high-volume comparison of on-pump
versus off-pump CABG in young patients using the Taiwan Nationwide Database.
2. Experimental Section
2.1. Materials and Methods
The Taiwanese National Health Insurance (NHI) program has been operating since 1995. By 2014,
approximately 99.9% of the Taiwanese population was enrolled in the NHI program [18]. For the
current analysis, we used a data subset of the NHI Research Database, namely the registry for patients
with catastrophic illness, which contains the records of all prevalent cases of patients who have
major illnesses.
From the database, we included patients between 18 and 45 years of age who had undergone
isolated on-pump or off-pump CABG between 2001 and 2011, as shown in Figure 1. We searched the
database to determine the presence of comorbidities such as hypertension, diabetes mellitus, peripheral
vascular disease, chronic obstructive pulmonary disease stroke, myocardial infarction (MI), implanted
cardiac pacemaker, or atrial fibrillation. The extent of CAD (single, double, or triple vessel disease)
and renal function were also compared. The study endpoints were all-cause death, major adverse
cardiac and cerebrovascular events (MACCE; defined as all-cause death, MI, and stroke); and repeat
revascularization within 30 days, 1 year, 5 years, and over the entire follow-up period.
Figure 1. Flowchart of patient enrollment. We included 1282 patients, who were 45 years old or younger,
and had isolated on-pump arrest or off-pump coronary artery bypass grafting (CABG). Among them,
197 patients were excluded for the surgeons’ adopted on-pump beating techniques. Mean follow up
time was 5.53 years and longest follow up time was 16 years, with 100% complete follow up.
2.2. Statistical Analysis
The characteristics of patients were analyzed using the chi-square test for categorical variables
and t-tests for continuous variables to identify potential differences between the two groups. We used
standardized difference to measure the balance of covariates, whereby an absolute standardized
difference of greater than 10% represented meaningful imbalance.
The survival was compared between the groups of patients using Kaplan–Meier survival curves
and log-rank tests. The factors affecting survival were analyzed by univariate and multivariate
Cox’s proportional hazard models to estimate the hazard ratio (HR) with a 95% confidence interval
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(95% CI). All the analyses were performed with SAS 9.3 software (SAS Institute Inc, Cary, NC, USA).
A p-value <0.05 was considered statistically significant.
3. Results
There were 31,448 patients that had undergone CABG in the database. From these, we included
1282 patients who were 45 years old or younger and had isolated on-pump or off-pump CABG. Among
these, 197 patients were excluded due the use of an on-pump beating heart technique, as shown in
Figure 1. The average overall follow-up time was 5.3 years and the longest was 16 years, with 100%
complete follow up. The mean follow-up times were 4.79 years for off-pump CABG and 5.53 years for
on-pump CABG.
A total of 344 patients received off-pump surgery and 741 patients received on-pump surgery,
as shown in Table 1. Both groups were comprised of predominantly male patients, and mean age
was similar in both groups (approximately 41 years in both; p = 0.18). The distribution of one-vessel
disease was greater in the off-pump group (15.99% off-pump vs. 6.34% on-pump). Before the operation,
both groups had a similar incidence of diabetes mellitus, hyperlipidemia, familial hypercholesterolemia,
chronic obstructive pulmonary disease, stroke, peripheral vascular disease, hypertension, previous
myocardial infarction, atrial fibrillation, implanted pacemaker, and presence of renal dysfunction,
as shown in Table 1. In the off-pump group, there were 28.19% of them that received previous
percutaneous coronary intervention and in the on-pump group it was 26.85% (p = 0.63). The emergent
operations of both groups were similar; they accounted for 13.95% in the off-pump and 13.76% in the
on-pump group (p = 0.41).
Regarding the completeness of revascularization, we used graft number/disease vessels as a
marker; if the number is more than 1, we deem this as complete revascularization in our database.
By doing so, the completeness of revascularization in one vessel disease was 100% in both groups.
The completeness of revascularization in two-vessel disease was 93% in the off-pump group and 95%
in the on-pump group. The completeness of revascularization in three-vessel disease was 91% in the
off-pump group and 92% in the on-pump group.
Table 1. Baseline characteristics of the patients.
Characteristic
Age ≤ 45 Year (N = 1282)
Off-Pump CABG On-Pump CABG
P Value
Standardized
Difference (%)N % N %
Patients, total No.—no. (%) 344 741
Female sex 34 9.88 94 12.69 0.18 8.86
Age—year Mean/Std. Dev. 41.04 ± 4.15 40.95 ± 4.13 2.17
Extent of coronary
artery disease
One-vessel disease 55 15.99 47 6.34 <0.0001 30.99
Two-vessel disease 72 20.93 113 15.25 14.80
Three-vessel disease 217 63.08 581 78.41 34.18
Number of grafting
1 57 16.56 45 6.07 <0.0001 25.14
2 42 12.20 61 8.23 9.63
3 and >3 245 71.22 635 85.69 8.14
Comorbidity
Diabetes Mellitus 116 33.72 236 31.85 0.54 3.99
Hyperlipidemia 65 18.89 131 17.67 0.62 4.21
Familial hypercholesterolemia 6 1.74 15 2.02 0.31 5.11
Insulin-dependent
diabetes mellitus 8 2.33 7 0.94 0.07 10.90
Chronic obstructive
pulmonary disease 8 2.33 16 2.16 0.86 1.12
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Table 1. Cont.
Characteristic
Age ≤ 45 Year (N = 1282)
Off-Pump CABG On-Pump CABG
P Value
Standardized
Difference (%)N % N %
Previous stroke 23 6.69 45 6.07 0.70 2.51
Peripheral vascular disease 9 2.62 19 2.56 0.96 0.33
Hypertension 195 56.69 400 53.98 0.40 5.44
History of
myocardial infarction 107 31.10 214 28.88 0.45 4.86
History of atrial fibrillation 5 1.45 6 0.81 0.32 6.09
Implanted pacemaker 7 2.03 8 1.08 0.21 7.72
Normal renal function 322 93.60 698 94.20 0.70 2.48
Chronic kidney disease 5 1.45 8 1.08 0.60 3.34
Renal-replacement therapy 17 4.94 36 4.86 0.95 0.39
Prior percutaneous
coronary intervention 97 28.19 199 26.85 0.63 5.23
Surgical Timing—emergency 48 13.95 102 13.76 0.91 0.41
CABG: coronary artery bypass grafting; Std. Dev.: Standard Deviation.
The 30-day outcomes, as shown in Table 2, and the 1-year outcomes, as shown in Table 3, in terms
of death, myocardial infarction, and stroke were not different between the groups. The operative
outcome, as shown in Table 2, including transfusion amount, post-operative atrial fibrillation,
ICU (intensive care unit) stay, and hospital stay were no different. The incidence of post-operative
atrial fibrillation was 10.46% in the off-pump and 13.76% in the on-pump groups (p = 0.535). Further,
at 5 years and 10 years, there were no differences in death, MI, stroke, and MACCE, as shown in Tables
4 and 5. The Kaplan–Meier curve shows that the rates of all-cause mortality were almost equal in both
groups (p = 0.716), as shown in Figure 2A. The 5-year survival rate was 93.9% in the off-pump group
and 92.2% in the on-pump group and the 10-year survival rates were 86.3% and 82.1%, respectively.
There was no significant difference in freedom from MACCE at 5 and 10 years in patients receiving
on-pump versus off-pump surgery (79.1% vs. 81.8% and 64.8% vs. 70.0%, respectively; p = 0.3310),
as shown in Figure 2B.














Transfusion—pRBC (unit) 2.56 ± 1.45 3.12 ± 1.63 0.93 0.34 2.42 0.672
Post-OP atrial fibrillation—no. (%) 36 (10.46) 102 (13.76) 1.32 0.41 2.16 0.535
ICU stay (days) 1.4 ± 0.82 1.5 ± 0.93 1.02 0.81 1.32 0.812
Hospital stay (days) 8.2 ± 3.58 9.1 ± 4.21 1.15 0.36 4.21 0.781
Components of primary outcome—no. (%)
Death 2 (0.58%) 3 (0.4%) 1.43 0.15 13.75 0.7581
Myocardial infarction 4 (0.11%) 7 (0.94%) 0.84 0.25 2.87 0.7805
Stroke 2 (0.58%) 2 (0.28%) 0.41 0.03 6.63 0.5266
New renal failure requiring dialysis 5 (1.45%) 12 (1.62%) 1.10 0.39 3.14 0.8596
Other specified outcomes—no. (%)
Cardiovascular-related death 1 (0.29%) 1 (0.13%) 0.46 0.03 7.29 0.5781
pRBC: Red blood cell; ICU: intensive care unit; CABG: coronary artery bypass grafting; HR: hazard ratio; C.I.:
confidence interval.
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Components of primary outcome—no. (%)
Death 7 (2.03%) 12 (1.62%) 0.80 0.32 2.03 0.6392
Myocardial infarction 11 (3.2%) 36 (4.86%) 1.46 0.73 2.89 0.2819
Stroke 6 (1.74%) 11 (1.48%) 0.87 0.31 2.41 0.7879
New renal failure requiring dialysis 13 (3.78%) 35 (4.72%) 1.59 0.83 3.05 0.1622
Other specified outcomes—no. (%)
Cardiovascular-related death 13 (3.78%) 11 (1.48%) 0.98 0.23 4.22 0.9738













Components of primary outcome—no. (%)
Death 16 (4.65%) 45 (6.07%) 1.27 0.72 2.25 0.4109
Myocardial infarction 28 (8.14%) 67 (9.04%) 1.11 0.71 1.74 0.6420
Stroke 18 (5.23%) 37 (4.99%) 1.00 0.56 1.77 0.9909
New renal failure requiring dialysis 29 (8.43%) 68 (9.18%) 1.18 0.76 1.84 0.4650
Other specified outcomes—no. (%)
Cardiovascular-related death 5 (1.45%) 13 (1.75%) 1.14 0.41 3.21 0.7996
Cerebrovascular disease death 2 (0.58%) 2 (0.27%) 1.18 0.10 13.64 0.8945













Components of primary outcome—no. (%)
Death 25 (7.27%) 70 (9.45%) 1.15 0.73 1.83 0.5492
Myocardial infarction 35 (10.17%) 90 (12.15%) 1.12 0.75 1.67 0.5737
Stroke 22 (6.4%) 48 (6.48%) 0.99 0.60 1.65 0.9731
New renal failure requiring dialysis 32 (9.3%) 79 (10.66%) 1.14 0.75 1.72 0.5533
Other specified outcomes—no. (%)
Cardiovascular-related death 5 (1.45%) 15 (2.02%) 1.30 0.47 3.58 0.6113
Cerebrovascular disease death 2 (0.58%) 2 (0.27%) 1.18 0.10 13.64 0.8945
Repeat revascularization was defined by further admission intervention of coronary artery or
repeat coronary artery bypass surgery 6 months after first operation. The reason we defined repeat
revisualization by 6 months after first operation was to eliminate the scheduled hybrid procedures,
because most of the hybrid procedures were performed within 3 months.
The repeat revascularization rate was significantly lower in the on-pump group (p = 0.0407),
as shown in Figure 2C. Freedom from revascularization at 5 years was 86.2% in the on-pump versus
80.8% in the off-pump group, and at 10 years was 76.1% versus 65.9%, respectively.
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Figure 2. Kaplan–Meier survival curve. (a) All cause of death in both groups. The 5-year survival rate
was 93.9% in the off-pump and 92.2% in on-pump groups; the 10-year survival rate was 86.3% in the
off-pump and 82.1% in the on-pump groups. (b) Major cardiac and cerebrovascular events (death,
myocardial infarction, and stoke). The 5-year free from major adverse cardiac and cerebrovascular
events (MACCE) rate was 79.1% in the off-pump and 81.8% in the on-pump groups; the 10-year free
from MACCE rate was 64.8% in the off-pump and 70.0% in the on-pump groups. (c) Kaplan–Meier
survival curve of repeat revascularization. Off-pump carries concern of repeat revascularization in the
long term. Free from revascularization at 5 years was 86.2% in on-pump vs. 80.8% in off-pump, and at
10 years, 76.1% vs. 65.9%, respectively.
4. Discussion
In our study, we compared the outcomes of on-pump and off-pump CABG in 1085 young patients.
There was no difference in the 30-day, 1-year, and 5-year outcomes in terms of death, MI, stroke,
and new renal failure. Kaplan–Meier and long-rank analysis showed that all-cause mortality and
MACCE were not significantly different. Off-pump surgery was not inferior to on-pump surgery in
terms of death, MI, and MACCE. However, the repeat revascularization rate was significantly higher
in the off-pump group. The long-term survival was excellent in both groups.
For young coronary artery bypass patients, the long-term durability of the vascular graft and
the long-term survival benefit are the major concerns. Young patients have less comorbidities than
older patients. They have better renal function, less incidence of diabetes, and less renal impairment
compared with older patients. Therefore, in both groups, young patients have less surgical risk [19].
The characteristics of coronary artery disease in young patients are different from older patients:
80% is atherosclerotic and 20% is non-atherosclerotic (e.g., coronary embolism, thrombosis, congenital
anomalies, vessel inflammation, spasm) [9–17].
Compared with older patients, coronary heart disease in young patients is more closely associated
with male sex, smoking, obesity, and family history. Conversely, the proportion of patients with
diabetes mellitus and hypertension is smaller [8–13,17]. In our patients, the prevalence of diabetes was
33.72% and 31.85% in the off-pump and on-pump groups, respectively; in contrast, in our previous
nationwide study where the mean age of patients was 62 years, the incidence was approximately
70% [19]. The overall prevalence of hypertension was 55%, and 90% of the cohort were males.
Young patients with coronary artery disease have fewer comorbidities than older patients [10,12].
In our study, the incidence of stroke, peripheral vascular disease, chronic obstructive pulmonary
disease, and atrial fibrillation were low, and renal function was preserved in most patients.
Triple vessel disease was the predominant pathology in our cohort, in accordance with similar
findings reported recently by Saraiva et al. [10].
Kaplan–Meier analysis in this study revealed excellent survival in young patients, and there
were no significant differences between on-pump and off-pump CABG. However, the repeat
revascularization rate was significantly higher after off-pump CABG. As recognized in the European
Society of Cardiology/European Association for Cardiothoracic Surgery 2014 guidelines, there is
substantial evidence indicating that on-pump CABG provides superior or equal short-and-long term
outcomes compared with off-pump CABG in elderly patients [2–7]. However, the more frequent need
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for revascularization may be a major concern when treating younger patients who would be expected
to live longer, and their rates of revascularization may keep rising in parallel to their follow-up.
Previous studies had suggested that the higher rate of repeat revascularization in off-pump CABG
patients was related to incomplete revascularization and the surgeon’s experience [20]. In addition,
the rapid progression of atherosclerosis in young patients [15] might also have precipitated the high
rate of repeat revascularization in our study. Regarding the completeness of revascularization, we used
graft number/disease vessels as a marker; if the number is more than 1, we deem this is complete
revascularization in our database. By doing so, the completeness of revascularization in one vessel
disease was 100% in both groups. The completeness of revascularization in two-vessel disease was
93% in the off-pump group and 95% in the on-pump group. The completeness of revascularization in
three-vessel disease was 91% in the off-pump group and 92% in the on-pump group. In our national
database, the completeness of revascularization in coronary artery patients was more than 91% in all,
and there were no differences in both groups. However, we cannot trace specific surgeon’s experience
in the registry database. Presuming that both groups have an equal completeness revascularization
rate, we could say that the repeat revascularization was not due to incomplete surgery at the first
operation. The differences might come from the procedure itself.
Actually, both methods offer good immediate results and provide also good long-term outcomes
in terms of death, myocardial infarction, and stroke. We thought the choice of off-pump and on-pump
procedures in the young patient should be decided by the patient’s lesion anatomy, and the surgeon’s
experience and preference.
Several possible limitations to our study must be addressed. Because the study analysis was
retrospective and only clinical events and services regulated by reimbursement were recorded, factors
such as the extension of diseased coronary arteries and the completeness of revascularization, left
ventricular ejection fraction or patients’ functional capacity, choice of conduit (percentage of bilateral
internal mammary arteries or total arterial grafting), conversion between on-pump and off-pump,
and surgeon experience were not evaluated. The decision to perform off-pump versus on-pump CABG
was dependent on the patients’ clinical characteristics and the surgeons’ preferences. Unmeasured
confounders or detection bias may thus have affected our results.
5. Conclusions
We compared on-pump and off-pump CABG in young patients using a nationwide database.
There was no significant difference in short-and-long term outcomes in terms of death and MACCE.
However, the need for repeat revascularization might be a concern over the long term after
off-pump surgery.
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Abstract: Percutaneous coronary interventions with stent-based restorations of vessel patency have
become the gold standard in the treatment of acute coronary states. Bioresorbable vascular scaffolds
(BVS) have been designed to combine the efficiency of drug-eluting stents (DES) at the time of
implantation and the advantages of a lack of foreign body afterwards. Complete resolution of the
scaffold was intended to enable the restoration of vasomotor function and reduce the risk of device
thrombosis. While early reports demonstrated superiority of BVS over DES, larger-scale application
and longer observation exposed major concerns about their use, including lower radial strength and
higher risk of thrombosis resulting in higher rate of major adverse cardiac events. Further focus
on procedural details and research on the second generation of BVS with novel properties did not
allow to unequivocally challenge position of DES. Nevertheless, BVS still have a chance to present
superiority in distinctive indications. This review presents an outlook on the available first and second
generation BVS and a summary of results of clinical trials on their use. It discusses explanations for
unfavorable outcomes, proposed enhancement techniques and a potential niche for the use of BVS.
Keywords: bioresorbable vascular scaffold; drug-eluting stent; percutaneous coronary intervention;
angioplasty; acute coronary syndrome
1. Introduction
Cardiovascular disease is the most common cause of death, and by the year 2030, up to 44% of the
adult US population is projected to suffer from some form of it, including ischaemic heart disease and
acute coronary syndromes [1]. The effective restoration and maintenance of coronary vessel patency
is a major problem requiring evaluation [2]. The idea of vascular restoration after the implantation
of coronary stents has projected the development of bioresorbable vascular scaffolds (BVS) at the
forefront of technological advancement in the field of coronary devices [3–6]. The design of BVS was
prompted in an attempt to solve the limitations of durable drug eluting stents (DES), including (i) the
occurrence of very late stent thrombosis (VLST), (ii) late expansive and adaptive vessel remodelling,
(iii) anatomical limitations in case of surgical revascularization and (iv) impairment of computer
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tomography imaging [7,8]. After the initial excessive enthusiasm around BVS, the community was
overly disappointed by the results of clinical trials. Complete resorption and improved vasomotor
response of first generation of BVS which were believed to result in a reduced risk of target lesion failure
(TLF) and stent thrombosis (ST) have been largely questioned [9–13]. In particular, the resorption
time for the first commercially available BVS, ABSORB, has turned out to be substantially longer
than initially thought. Therefore, it has been hypothesized that the resorption process itself or its
delay can trigger complications [14–16]. A poor safety profile, especially in terms of target vessel
myocardial infarction (TVMI) and an ST of 3 year follow up in ABSORB, as well as the negative
results of the Amsterdam Investigator-Initiated ABSORB Strategy All-Comers Trial (AIDA) induced
the manufacturer, Abbott Vascular, to halt the commercialization of ABSORB BVS [17–19]. Similarly,
despite good outcomes of the BIOSOLVE I trial, the DREAMS BVS is still not ready for clinical use as
the sparse data available stem from a small number of nonrandomized studies, conducted on a small
number of patients [20–23]. Nevertheless, thanks to the encouraging results from the BIOSOLVE II
and III studies which report very good outcomes in the 184 patients enrolled, with a more complex
anatomical setting, we are facing a steady rise in the clinical use of the Magmaris stent within the
ongoing prospective registry BIOSOLVE IV [24,25].
Overall, BVS appear to be a ‘critical’ development phase, and the currently clinically available
BVS were given a class III indication for clinical use outside of studies in the current European Society
of Cardiology (ESC) guidelines [26]. However, the disappointing outcomes mentioned above derive
from studies in which optimal implantation strategies, proper imaging and long and potent platelet
inhibition have not been extensively applied. On the contrary, it is proved that proper assessment of
the target vessel segment with intravascular ultrasonography (IVUS) or optical coherence tomography
(OCT) together with pre- and/or post-dilation can efficiently improve safety profile of BVS [27–29].
Thus, it is highly possible that refined second generation scaffolds with optimized implantation
technique and proper imaging may restore the position of BVS and be competitive towards DES.
Our systematic review discusses the hypothetical advantages of BVS in the light of disappointing
results obtained so far in clinical trials. Additionally, we aimed to explore possible methods to improve
BVS performance starting from the design of next generation BVS and ending with procedural and
pharmacological highlights.
2. Potential Advantages of BVS over Current Generation DES
Fully bioresorbable stents consist of synthetic biodegradable polymers that are intended to initially
display functions similar to DES, and then dissolve within months after implantation, which may
lead to the restoration of vasomotor function. In order to hold their promise, BVS should provide all
potential advantages without sacrificing too much in terms of performance in comparison to DES.
Another noticeable phenomenon (unrealistic using a solid metal stent) is the restoration of endothelial
function with secondary reduction of atherosclerotic plaque [30,31]. After dissolving, it allows to
maintain the integrity of the artery and return to its physiological properties (systolic and diastolic),
thereby facilitating a beneficial remodeling and, consequently, causing a reduced passage for persistent
inflammation (Figure 1) [31,32]. Therefore, a hypothesis has been put forward regarding the benefits
of BVS, especially in younger patients or those with acute coronary syndromes, in which the metal
stain is less likely to heal [33]. Among other features, the unfailing of the covered side branches
after resorption, as well as avoiding the effect of a ‘full metal coat’, especially during diffuse disease,
were also foreseen, providing early treatment of restenosis in the stent without additional layers of
metal stents occupying the space [34]. BVS also give the possibility of a surgical revascularization
procedure [31]. Moreover, this new technology also has significant benefits in the patient’s personal
preferences to avoid having a permanent foreign body [32]. However, data available so far show
us that most promises associated with the advantage of resorption had been overestimated. In fact,
an ultimate demonstration of most potential advantages of BVS, such as restoration of the physiological
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function of vessels and endothelium, and the possibility of future surgical interventions within the
same lesion, are still lacking [35].
Figure 1. Timeline of bioresorbable vascular scaffolds (BVS) resorption and its interactions with vessel
wall [6,16]. Presented course of phases and events is a generalization for available BVS. Certain time
points are specific for ABSORB BVS-see Table 1. Abbreviations: BVS, bioresorbable vascular scaffold;
OCT, optical coherence tomography.
3. Overview of First and Second Generation BVS
The first generation of BVS was initiated by ABSORB and DESolve scaffolds based on poly-L-lactic
acid (PLLA) and DREAMS G1 scaffold based on magnesium [36,37]. Second generation of BVS
embraces constantly expanding variety of scaffolds with enhanced properties and novel features.
PLLA-based ART (Terumo, Tokyo, Japan) and DESolve Cx plus, the tyrosine analogue-based Fantom
(REVA Medical, Inc., San Diego, CA, USA) and the magnesium-based Magmaris (Biotronik, Berlin,
Germany) were introduced to clinical practice. The general characteristics of BVS are presented in
Table 1. Yet, the variety of other devices based on polymers, metallic alloys or their combination remains
in development [38,39]. Their development originates from an attempt to arrange a scaffold with
thinner struts. The diameter of struts may not exceed 100 μm, whereas in the first generation it ranged
from 150 μm [40]. The reduced thickness is believed to cause less blood flow disturbances and therefore
to be associated with a lower risk of in-ST and a shorter requirement of dual antiplatelet therapy
(DAPT). Additionally, tiny meshes become covered with a thinner layer of neointima and protected
from the narrowing of the vessel lumen [41]. The newest devices are made of either magnesium alloy or
polymers, including derivatives of PLLA and deaminotyrosine polycarbonate. These materials ensure
greater resistance to fractures during post-implantation dilation and attain mechanical properties
comparable to ordinary DES [30,42–44].
The ABSORB stent has a PLLA backbone, strut thickness is about 150 μm, with a bioresorbable
coating of poly-D,L-lactic (PDLLA) with a thickness of 7 μm, secreting everolimus with a similar
pharmacokinetics to the Xience DES [31,34,35,45–49]. Due to the presence of ester bonds between
the PLLA and PDLLA monomers, degradation occurs by stepwise hydrolysis. In the final stage,
either PLLA or PDLLA particles degrade entirely to lactic acid, or remnants smaller than 2 μm are
phagocytized by macrophages [31,50]. Degradation is a mild, progressive process with minimal
inflammatory reaction [51]. In order to obtain the appropriate mechanical framework of these stents,
it became necessary to increase the thickness of the strut, because of lower tensile strength, reduced
stiffness and the chance of deformation [35,52]. Studies have shown that in order to avoid strut rupture
or abnormal decomposition, ABSORB stents require accurate lesion, judicious patient selection and
an appropriate implantation technique, as they are able to stretch up to 0.7 mm beyond the nominal
diameter [36,53]. ABSORB stents are radiolucent and therefore may not be visualized in fluoroscopy.
For this reason, the stent at both ends was provided with two platinum markers, present to allow
165
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radiographic recognition. However, due to their tiny dimensions they identification requires high
quality fluoroscopic imaging [52].
Table 1. Summary of efficacy and safety of the bioresorbable vascular scaffolds in clinical trials.










ABSORB PLLA 2012 everolimus 156 >36
DESolve PLLA 2014 novolimus 150 <24
DESolve Cx plus PLLA 2017 novolimus 120 <24
DREAMS 1G Magnesium alloy 2015 paclitaxel 120 9–12
Second generation
Magmaris (DREAMS 2G) Magnesium alloy 2016 sirolimus 120 9–12
Fantom Tyrosine polycarbonate 2017 sirolimus 125 36
ART PDLLA 2015 none 170 6
DESolve has a similar strut thickness (150 μm in the first generation), is composed of a PLLA-based
scaffold and equipped with two platinum-iridium markers to enable radiographic visualization.
The second generation, DESolve Cx plus, has a strut thickness of 120 μm, with a length of 14 to 28 mm
and a diameter of 2.5 to 4.0 mm [54]. In the initial version, it eluted novelists at a rate of 80% during
a month after implantation [55–57]. High flexibility enables extension up to 5 mm, without risk of
breakage and provides greater radial strength in the vessel during the critical period of up to 4 months
after implantation. In addition, DESolve scaffolds presents were observed of passively expand within
1 h after implantation, whereas ABSORB stents present a tendency to recoil [56,57]. However, under
experimental conditions it was noticed that this ‘autocorrect’ feature is able to generate only small
radial forces, so that it improves stent positioning, but does not exert a relevant impact on the vessel
wall [58]. It has been hypothesized that it may either contribute to the reduced risk of malfunction of
the stent immediately after implantation or may prove to be a beneficial feature in acute myocardial
infarction, where the stent may be undersized. However, there is no data to support this concept [54].
The new model also promises biodegradation in the first year by as much as 95% with the assumption
of full resorption of the stent up to 2 years [54,56,59]. After this period, the polymer is replaced with
a loose net mainly composed of proteoglycan, followed by a new connective tissue [54]. DESolve
scaffolds differ, therefore, from ABSORB stents due to the properties of self-expansion and increased
tolerance to excessive stretching.
DREAMS G1 stent is based on a frame made of absorbable magnesium alloy. Magnesium attains
better mechanical properties such as a higher capacity of elongation and an increased tensile strength,
allowing to use a thinner strut structure [54,60]. Due to the intrinsic radiolucency of magnesium
and lack of markers mounted, the first generation stents are not visible in conventional imaging,
but at the same time they are compatible with magnetic resonance imaging (MRI). These stents have
bioresorbable coating of poly-lactic-co-glycolic acid (PLGA) eluting paclitaxel, and decompose in
approximately 3–4 months [20,22,61–63]. The absorption of the magnesium alloy is a two-stage process,
starting on the luminal surface of the scaffold, progressing towards the layers, until only the trace of
hydroxyapatite remains at the site of implantation. In addition, magnesium reacts with water to form
magnesium hydroxide, which starts the corrosion process [56]. Corrosion, however, does not proceed
to the same extent on all sides, preferring the lateral surfaces of the struts. The initial crystal structure
of magnesium hydroxide is gradually transformed into an amorphous body with a high-water content.
After a time, the material is absorbed again through the core-infiltration of the cells [20]. In addition,
some in vitro studies have shown that elevated magnesium concentrations in the coronary arteries per
se reduce smooth muscle cell proliferation and increased endothelial cell proliferation [60,64]. Another
advantage of these devices was the evidence of lower thrombogenicity in animal studies [60]. Despite
the anti-arrhythmic properties of magnesium and its inhibitory effect on the release of endothelin-1,
no adverse effects have been observed due to stent degradation [20,65]. The next generation, DREAMS
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2 BVS (Magmaris), was enhanced in following ways: (i) its coating was thickened from 1 μm to 7 μm
and converted from PLGA to PLLA, (ii) paclitaxel was substituted with sirolimus with greater elution
(1.4 μg/mm2), and (iii) the strut thickness increased to 150 μm × 140 μm [61].
The main highlight of the Fantom scaffold is its intrinsic radio-opacity. The presence of iodinated
tyrosine analogue polymer enables more precise deployment and non-invasive radiological assessment
throughout the whole degradation time. The content of iodine in a single device is negligible in
comparison with the amount administered in a contrast media [38].
4. Real-World BVS Performance—Outcomes and Evaluation
The safety and efficacy of BVS devices in clinical trials are presented in Figure 2 and Table 2. As for
now, the superiority of any BVS over DES has not been shown in a randomized trial.
Figure 2. Comparison of incidence rate of major adverse events in randomized trials: (a) target lesion
failure, (b) myocardial infarction, (c) cardiac death and (d) all device thrombosis. Figure presents data
from ABSORB, AIDA, EVERBIO II and TROFI II trials. The circle diameter represents the number of
patients in respective trials [17,19,66–70].
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The first data describing BVS performance stems from a single arm ABSORB I study comprising
of a 5 year observation of 130 patients in total. Safety and efficacy were assessed by observing events
of ST and occurrence of major adverse cardiac effects (MACE). MACE was defined as nonfatal stroke,
nonfatal myocardial infarction and cardiovascular death. The 5 year results were promising, inasmuch
as in both cohorts no ST was observed, and the MACE rate ranged from 3.4% to 11% in cohorts A and
B, respectively. It indicated that ABSORB BVS has a potential to overtake DES in the terms of safety
profile and led to trials directly comparing ABSORB BVS with Xience V DES [31,72]. ABSORB II and
ABSORB III studies were prospective, randomized, single-blind, multi-center trials which aimed on
proving the non-inferiority of ABSORB BVS versus drug eluting Xience V DES. The primary endpoints
of the study enclosed comparison of cardiac death (CD), TVMI and target lesion revascularization
(TLR) rates one year after implantation, while secondary endpoints included the assessment of primary
endpoint parameters at 2–5 years’ time and the assessment of ST, VLST and cost-related data.
The ABSORB II trial was the first to report inferiority of ABSORB BVS. 3 year follow-up
was associated with a two-fold greater risk of TLF in comparison with Xience V (10% vs. 5%;
p = 0.0425) [17,80]. Later, 2 year and 3 year observations in ABSORB III trials demonstrated ABSORB
BVS inferiority in terms of overall ST and TLF driven mainly by TVMI [66,67]. Finally, the preliminary
30 day results of the most up to date and most populous ABSORB IV study revealed lower acute
device success rate (94.6% vs. 99.0% (P < 0.0001)), greater risk of TLF (5.0% vs. 3.7%; p = 0.02) and
greater ischemia-driven target vessel revascularization rate (ID-TVR) (1.2% vs. 0.2%; p = 0.003) [68].
Simultaneously, cumulative meta-analyses embracing ABSORB II, III, AIDA, EVERBIO II and TROFI
II trials indicated the superiority of DES in the terms of both TLF and overall ST [9,10,69,70]. So far,
only two country-specific trials (ABSORB JAPAN and ABSORB CHINA) demonstrated superiority of
ABSORB BVS over Xience V DES [71,74]. The published meta-analyses and the results of the ABSORB
IV trial formed the basis of the decision to cease production of ABSORB BVS in late 2017.
DREAMS G1 performance was assessed in 1 and 3 years’ long observation in the course of the
BIOSOLVE I study [21,23]. The BIOSOLVE I trial included 46 patients with silent ischemia, stable or
unstable angina and assessed angiographic and IVUS follow-up at 6 and 12 months together with
3 years’ clinical follow-up. In opposition to ABSORB trials, proper implantation strategy elements
such as pre-dilatation were compulsory [20]. TLF occurrence at 6 months and 12 months is presented
in Table 3. While no cardiac deaths or ST events were observed, the final results available in 3 year
follow-up indicated 6.6% of TLF, 4.3% ischemia driven target lesion revascularization (ID-TLR) and
2.2% TVMI. Based on the angiographic results, it was assumed that DREAMS still could not compete
with the 3rd generation of DES. BIOSOLVE-II and BIOSOLVE-III trials have been designed to observe
its performance 3 years after implantation. As for now, data is available for 184 patients with single and
multiple lesions in up to 2 years’ follow-up. Pooled analysis concluded with no trace of thrombosis, and
TLF occurred in 3.3% and 5.9% of patients in the BIOSOLVE-II and BIOSOLVE-III groups respectively.
It is worth noting that four cardiac deaths were observed among both groups [22,24].
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BIOSOLVE-IV—a prospective, observational trial—is currently ongoing and aims at enrolling
2054 patients to be followed-up for 5 years. First year outcomes for the first 400 patients were recently
published [25]. Procedural success was achieved in all but three patients. Target lesion failure (TLF)
(primary endpoint) was registered in 4.3% of patients, and was exclusively composed of target lesion
revascularizations. The rate of target vessel myocardial infarction was 0.88% and a single definite
scaffold thrombosis was reported (0.3%) 10 days after implantation in a calcified lesion after a 5 day
interruption of DAPT to perform a surgical minimally invasive revascularization of a non-target vessel.
Despite DESolve’s greater self-expansion properties and its unique self-correction property, which
helps to avoid malapposition, no study proved its superiority over DES [54]. In addition, recent
observational studies indicated propitious results [76,77]. Nevertheless, a non-complete follow-up
represents the study’s limitations in long-term DESolve performance and the risk of late complications,
e.g., VLST has not been properly investigated yet. As a consequence, the first generation of DESolve
did not find application on the market. As such, the next generation, DESolve CX plus, has been halted.
The performance of Fantom scaffolds has been examined in two studies: Fantom I and Fantom
II, including 7 and 117 patients respectively. The Fantom I pilot trial resulted in preserved patency
in target vessels observed in IVUS after four months and no cardiac events after six months [78].
The multi-centre Fantom II trial observed short-term procedural success in 99.1% of cases, a 2.8% rate
of MACE and one event of in-ST after six months. Investigators and commenters find these results
comparable with other BVS. More encouraging results are anticipated from Cohort B of the Fantom II
study, including 240 patients and nine month follow-up [79,82].
5. Anatomy of Failure: Explanation for Unfavorable Outcomes
As for now, the superiority of BVS over DES has not been shown in a randomized trial. A series
of large-scale, post-registration studies showed long-term performance to be influenced by factors on
every step of application of BVS, i.e., from device design to procedural specifics and vascular properties
at the site of implantation (Figure 3) [83,84]. Optical analysis of intraluminal changes brings closer an
explanation of the inferiority of BVS in clinical trials. Firstly, BVS implantation correlates with a greater
asymmetry index (AI) and eccentricity index (EI) of the vessel in long term follow-up [85]. EI is defined
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as the ratio of minimum and maximum scaffold/stent diameter per cross section, while AI is defined
as the ratio of minimal to maximal device diameter [85]. The greater the AI and EI value, the less
symmetric the vessel section. Greater AI and EI were the consequence of the fact that ABSORB BVS is
‘less forgiving’ in case of inadequate deployment technique. Improper implantation, and consequently
greater AI and EI, was determined to have a direct and significant impact on TLF occurrence in the
ABSORB group [85,86]. Additionally, in numerous trials, the implantation of ABSORB correlated with
lower minimal lumen diameter than Xience V, more extensive vessel remodeling, greater late luminal
loss and decreased mean lumen area [17,87,88].
Figure 3. Comparison of the causes of device thrombosis in drug eluting stents (DES) and bioresorbable
vascular scaffolds (BVS) [12].
Furthermore, as shown by randomized studies, after the implantation of bioresorbable stents,
a lower minimal diameter of the vessel lumen significantly increased initial stenosis which results in
a greater risk of recoil in vivo [53,81,89]. The mentioned phenomena were caused by an increased
strut thickness, greater than in DES; bulky, discontinuous, malapposed struts; structural disruption;
and finally, incomplete resorption (even in 3 year observation time (the PRAGUE-19 trial)) [73,86].
Mentioned factors led to greater neointimal hyperplasia, greater volume of intraluminal masses and
eventually greater coronary artery lumen narrowing, resulting in device failure [90,91]. Thus, it is
highly probable that the failure of ABSORB was caused by a combination of faulty device design and a
far from optimal implantation technique.
BVS are much more demanding in terms of the implantation technique and require specific protocol
called the ‘PSP technique’ (Prepare the lesion, Size adequately, Post-dilate). Prior to implantation, it is
necessary to perform an in-depth target segment imaging, in order to accurately assess the dimensions
of the vessel and detect the presence of possible calcification [20,32,35,92,93]. Recent studies and
reconsideration of the results of five ABSORB studies correlate with accurate adjustment of a scaffold
and optimal post-dilation with a lower risk of TLF, and excessive pre-dilation with a lower risk
of ST [94–96]. Therefore, BVS should not be implanted in places which cannot be accessed with a
pre-dilating balloon. In next step, the scaffold should be expanded gradually by means of a five second
pressure increase by two atmospheres, and the target pressure should be maintained for 30 s [32].
On the contrary, proper positioning of DES is a one-step procedure with limited time of ischemia [20].
However, prolonged ischemia appears not to impact BVS efficacy, and their use may be warranted
even in chronic total coronary occlusions [97].
Recent studies have identified clinical scenarios which require particular attention. Desirable
post-dilation steps cannot be performed safely on scaffolds longer than 28 mm, due to the risk of
breakage. Therefore, long lesions demand a specific ‘scaffold to scaffold’ technique to avoid overlapping,
resulting in impaired radial strength [98]. The use of BVS in lesions located on vessel bifurcations is
associated with an acceptable risk of TLR, however, still greater than in use of DES [99]. Eventually, BVS
are contraindicated in aorto-ostial lesions [100]. Acute coronary syndromes seemed to be a propitious
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target for BVS due to feature of restoration of the native vessel lumen and vasomotor function. This
indication is supported by the results of randomized TROFI II and ISAR- ABSORB MI trials on STEMI
patients treated with either ABSORB BVS or DES, which concluded with a comparable healing score
and risk of adverse events [70,75].
The first-generation BVS ABSORB seems to increase the risk of ST and TVMI as shown by recent
meta-analyses [101–105]. Furthermore, analysis of the data collected by several registries shows that
this BVS associates with a high rate of early (within 30 days) definite or probable ST of 1.3–1.5% [106,107].
Moreover, 1 year after implantation, the definite or probable ST rates are markedly higher (up to 3.1%)
than the rates detected by the randomized trials [108–114]. This apparently higher thrombogenicity
may be caused by two major limitations of the first-generation thick-strut poly-lactic acid BVS. First,
mechanical limitations of the BVS demand a more elaborate percutaneous coronary intervention (PCI)
technique [115]. This may increase the risk of suboptimal scaffold implantation. Second, structural
limitations of the BVS lead to the creation of laminar flow disruptions [116]. This may serve as a nidus
for inter-strut thrombus formation.
The mean number and length of BVS implantation and its relation to the incidence of ST is
illustrated in Figure 3, based on data from randomized controlled trials and registries with ≥100
patients that report a 6–12 month follow-up and BVS details [81,101–104,106–114,117–123]. Only the
ASSURE registry, which included 183 patients, reported no cases of ST at 1 year follow-up [119].
However, the mean number and length of the implanted BVS in the ASSURE registry were comparable
to those in the selected patient populations of the randomized controlled trials. Thus, it suggests that
the cohort of the ASSURE registry was rather a low risk population and that this may account for
the low event rate that has been observed [102]. Figure 4 illustrates that there is a trend toward an
association between the stent length/number of implanted stents per patient and the incidence of ST.
Since late ST is a crucial concern in the use of BVS, a long-term (at least 3–5 years) observation period
should be warranted in upcoming trials.
Figure 4. Bubble graph showing the relationship between the mean number and length of the implanted
scaffolds and the incidence of scaffold thrombosis at the 6–12 month follow-up. Only randomized
controlled trials, or registries with ≥100 patients that reported the required scaffold implantation details
and had a follow-up duration of 6–12 months were included. The circle diameter indicates the reported
percentage of definite or probable scaffold thrombosis [19,80,81,102,107,112–114,117,119,120,124].
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6. Niche for BVS and Optimization of BVS Action
The excellent performance of DES makes them a tough benchmark to beat. The current generation
of DES provides a very good vascular scaffolding with excellent radial strength. In fact, their use is
associated with low rates of restenosis, ST or MACE [125–128]. Nevertheless, there are still concerns
about their use [20,43,129]. The constant presence of a durable metallic prosthesis impairs vasomotor
response vasodilation and causes a prolonged inflammatory reaction, which may eventually manifest
in clinical observation [71,130–133]. Hence, BVS are believed to be distinctively beneficial in younger
patients [73]. BVS may also serve patients’ personal preferences to avoid carrying a permanent foreign
body [32]. BVS theoretically enable surgical revascularization at the site of implantation, however this
concept has not been yet appraised in a clinical trial [31]. On the other hand, the group of preferred
candidates is limited to those who clearly take advantage of the resolution of the scaffold. BVS are
still discouraged in patients with limited life expectancy, inasmuch as a still uncertain safety profile
prevails over the possible benefits associated with biodegradation [60].
The next generations of BVS resolving without antiproliferative drugs may overcome recent
concerns about the use of DES in the management of peripheral artery disease. After years of
satisfactory performance, the elution of paclitaxel is currently suspected to increase late mortality [134].
Despite the lack of an exact mechanism linking the action of an antiproliferative drug and all-cause
mortality, the Vascular Leaders Forum convened by physicians, manufacturers and the Food and
Drug Administration (FDA) in March, 2019 recommends cautious monitoring and reconsideration of
alternative treatment options [135]. These circumstances may facilitate further development and show
new indications for BVS.
The importance of routine pre-procedural imaging and strict compliance to the PSP technique
should be highlighted [136,137]. The PSP technique is distinctively beneficial in the case of aggravated
risk of thrombosis, e.g., in diabetic patients [124,138]. In line with this concept, the use of a longer
inflation time, as suggested by the producer, allows better for device expansion and a more homogeneous
apposition [53]. In order to select the proper size of BVS, the measurement of the target’s diameter was
observed to be equally accurate under the guidance of either angiography or OCT [139]. Eventually,
MRI enables non-invasive and non-radiative assessment of BVS patency after implantation and may
be an alternative for patients with recurrent angina after angioplasty [140]. Despite the design of
comparable radial strength of BVS to DES, it was noted that excessive stretching decreases its radial
strength and elasticity and consequently leads to breakage [32,115,141]. This observation was confirmed
in an experiment performed on a computational model. An arrangement of a mesh and the dimensions
of a single strut determine the specific post-dilation size of a scaffold at which optimal mechanical and
drug release properties are attained [142]. It is worth noting that available BVS devices are not equal in
terms of their mechanical properties. PLLA-based scaffolds attain greater bending stiffness but lower
radial strength, and tend more to recoil than magnesium-based scaffolds [58]. Among polymer-based
scaffolds, the DESolve device attains greater flexibility and adapts better adaptation to the shape of the
vessel [57,143]. These features are likely to contribute to upcoming studies as specific indications for
certain devices. Greater radial strength may be utilizable in large vessels, while greater elasticity in
tortuous vessels.
Another important issue is the residual high platelet reactivity (HPR) under DAPT, which
represents one of the major determinants for worse outcomes of patients after PCI [144–147]. Therefore,
the existence of a therapeutic window of platelet reactivity for P2Y12 pathway inhibition was
proposed [148]. Indeed, it has been shown previously in an all-comer PCI population that if both the
P2Y12 and cyclooxygenase-1 pathway inhibition of DAPT are personalized using Multiplate (a “point
of care” platelet function assay which determines multiple electrode platelet aggregometry), HPR rates
improve along with the clinical outcomes of patients [149–151]. Therefore, it would be interesting
to know whether personalizing DAPT, by intensifying the treatment in the case of HPR to P2Y12
receptor blocker and/or aspirin, would have an impact on the rates of ST after BVS implantation.
Personalization of DAPT remains a controversial issue because the randomized trials on this subject
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had considerable shortcomings [152,153]. Nevertheless, it has been already shown that strict peri-
and post-interventional optimization of platelet reactivity improves patient outcomes at 30 days in
an all-comers PCI population who underwent metallic stent implantation [149–151]. It might be
that optimizing platelet reactivity may be of even greater importance in BVS implantation, primarily
because the thicker struts of the first-generation scaffold disrupt laminar flow and thereby increase the
risk of thrombus formation [116]. In our opinion, not even the best implantation technique is capable
of completely counteracting this inherent limitation of the current BVS. This suggests that to improve
patient outcomes after PCI with this BVS, it might be necessary to optimize the platelet reactivity.
Several catheterization laboratories intensify platelet inhibition through the routine prescription of the
newer potent P2Y12 receptor blockers for a longer duration (up to 3 years) to reduce the rates of ST
after BVS implantation. A currently ongoing study on the administration of ticagrelor after the use of
BVS in coronary vessels is believed to elucidate this matter [154,155].
7. Conclusions
After the initial excessive enthusiasm around BVS stemming from the dream of disappearing
stents, clinical trials brought a great disillusionment. Existing DES devices still remain first choice in
majority of cases and at the moment it is hard to believe that the current BVS could jeopardize their
position. The next generations of BVS are anticipated to overcome the limitations which emerged
in the initial clinical experiences. In particular, the procedural complexity and higher than expected
restenosis and thrombosis represent major limitations. In fact, both technological advances and clinical
expertise are about to shed new light on application of BVS devices.
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Abstract: Percutaneous cardiovascular interventions have changed dramatically in recent years,
and the impetus given by the rapid implementation of novel techniques and devices have been
mirrored by a refinement of antithrombotic strategies for secondary prevention, which have been
supported by a significant burden of evidence from clinical studies. In the current manuscript, we aim
to provide a comprehensive, yet pragmatic, revision of the current available evidence regarding
antithrombotic strategies in the domain of percutaneous cardiovascular interventions. We revise
the evidence regarding antithrombotic therapy for secondary prevention in coronary artery disease
and stent implantation, the complex interrelation between antiplatelet and anticoagulant therapy
in patients undergoing percutaneous coronary intervention with concomitant atrial fibrillation,
and finally focus on the novel developments in the secondary prevention after structural heart disease
intervention. A special focus on treatment individualization is included to emphasize risk and
benefits of each therapeutic strategy.
Keywords: dual antiplatelet therapy; antiplatelet; coronary artery disease; structural heart disease
1. Introduction
The link between percutaneous cardiovascular intervention and antithrombotic therapy begins
right at the time of the first coronary angioplasties performed by Andreas Grüntzig. After the
introduction of this technique in 1977, post-procedural warfarin therapy was initiated for 6–9 months
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after intervention to reduce the risk of post-procedural ischemic complications [1]. A few years later,
the same group tested whether aspirin (ASA), with its secondary inhibition capacity of platelet’s
thromboxane A2 pathway, was superior to the oral anticoagulation in decreasing the incidence of
reintervention after PCI [2]. While the techniques and the devices were improved in the following
years, the introduction of the coronary stent and its first-in-man implantation in 1986 by Jacques
Puel, dramatically improved early and late results of percutaneous coronary intervention (PCI), yet
introducing a novel clinical issue: stent thrombosis. This complication occurred in up to 10% of cases
at that time, and while a treatment with warfarin alone or warfarin plus aspirin was common after PCI
and stent implantation, the rate of stent thrombosis remained high. Only in 1998 two randomized
trials demonstrated that dual antiplatelet therapy (DAPT), constituted by the combination of ASA
and a platelet P2Y12 inhibitor, was more effective than warfarin and aspirin therapy in reducing
the risk of stent thrombosis [3,4]. These studies have established DAPT the as the gold standard
therapy after angioplasty and stent implantation [5–7]. At the same time, similar antithrombotic
practices were implemented for other percutaneous cardiovascular interventions such as atrial septal
defect [8,9] or patent foramen ovale (PFO) closure [5,10], and more recently transcatheter aortic valve
implantation (TAVI) [11] and transcatheter mitral valve repair (TMVR), in which the evidence coming
from the coronary intervention field has been extrapolated to structural heart interventions. The
aim of the current review is to summarize the evidence that established the current standards and
recommendation for DAPT type and duration after coronary intervention, comment on the current
standards for personalized treatment decision-making, and discuss the most recent advances in terms
of treatment combination of antiplatelet and direct acting oral anticoagulants (DOAC) for the secondary
prevention of high ischemic risk patients and patients with concomitant PCI and non-valvular atrial
fibrillation. Finally, we touch upon the current evidence, recommendations and future perspectives for
antithrombotic therapy in patients undergoing structural heart interventions.
2. Type of Antithrombotic Treatment after PCI
2.1. Evidence for Clopidogrel
While ticlopidine was the first P2Y12 inhibitor to be associated with ASA for DAPT, its worse
safety profile made it obsolete after the introduction of clopidogrel. In 2000, the CLASSIC study
was the first comparative trial in which clopidogrel in association with ASA was compared with
ticlopidine in association with ASA after PCI [12]. In this study, which randomized 1020 patients to the
combination of clopidogrel and ASA vs. ticlopidine and ASA, clopidogrel provided better safety and
tolerability (i.e., less allergy, skin or gastrointestinal disorders and neutropenia) with a similar bleeding
and efficacy profile. The CURE trial compared clopidogrel vs. placebo in addition to ASA in patients
who presented with acute coronary syndromes without ST-segment elevation undergoing invasive or
non-invasive management. The first primary outcome—a composite of death from cardiovascular
causes, nonfatal myocardial infarction, or stroke—was significantly reduced in the clopidogrel group
by 20% as compared to placebo (relative risk (RR) 0.80; 95% CI 0.72–0.90; p < 0.001) [13]. The evidence
provided by the landmark CURE trial established DAPT with clopidogrel as the standard of care
after acute coronary syndrome (ACS) and after coronary stent implantation. However, its high
inter-individual variability in platelet inhibition and a sizable proportion of non-responders patient [14]
highlighted the need for more potent and consistent platelet inhibition that would be introduced with
novel generation P2Y12 inhibitors.
2.2. Evidence for Prasugrel
Similar to clopidogrel, prasugrel is a prodrug which requires conversion to an active metabolite to
ultimately irreversibly bind to the P2Y12 receptor and achieve antiplatelet effect (Figure 1). different
from clopidogrel, prasugrel has a more rapid and greater antiplatelet effect [15,16]. These drugs have
been tested head-to-head in TRITON TIMI 38 trial. In this study, 13,608 patients with moderate to
high-risk ACS and a scheduled invasive strategy were randomized to receive either prasugrel or
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clopidogrel. The primary efficacy endpoint of death from cardiovascular causes, nonfatal myocardial
infarction, or nonfatal stroke occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients
receiving prasugrel (HR 0.81; 95% confidence interval (CI)), 0.73–0.90; p < 0.001). There was also a
significant reduction of myocardial infarction (9.7% for clopidogrel vs. 7.4% for prasugrel; p < 0.001),
urgent target-vessel revascularization (3.7% vs. 2.5%; p < 0.001), and stent thrombosis (2.4% vs. 1.1%;
p< 0.001) related to the use of Prasugrel. However, the higher efficacy of prasugrel was counterbalanced
by an increased risk of major bleeding, including fatal bleeding. Patients with previous stroke or
transient ischemic attack were harmed by prasugrel use (hazard ratio, 1.54; 95% CI, 1.02–2.32; p = 0.04),
while patients with 75 years of age or older and patients weighing less than 60 kg had had no benefit
from prasugrel compared to ticagrelor [17]. TRITON TIMI 38 did not include patients with ACS
undergoing medical-management. This population was specifically evaluated in the TRILOGY ACS
trial. In TRILOGY ACS, patients were randomly allocated to prasugrel or clopidogrel and managed
exclusively with medical therapy without revascularization. Prasugrel ultimately failed to show
superiority for the primary study outcome compared to Clopidogrel in ACS patient treated medically
without revascularization [18].
 
Figure 1. Antiplatelet and anticoagulant treatment strategies for secondary prevention of
ischemic events.
Finally, the recent SASSICAIA trial (NCT02548611) explored the impact of prasugrel in patients
undergoing elective PCI. In this study, patients with stable CAD and undergoing PCI were randomized
to a loading dose with prasugrel or clopidogrel at the time of PCI. All patients after PCI were
treated with clopidogrel alone and the primary outcome of all-cause death, any myocardial infarction,
definite/probable stent thrombosis, stroke, or urgent vessel revascularization at 30 days was evaluated.
Ultimately, there was no difference for the primary endpoint in the two study arms; hence, SASSICAIA
trial failed to demonstrate that a prasugrel loading dose in elective patients reduces ischemic events as
compared to an initial loading dose of clopidogrel.
2.3. Evidence for Ticagrelor
Ticagrelor is a P2Y12 inhibitor which binds reversibly the platelet receptor with a shorter plasma
half-life. This has a more rapid onset and more pronounced platelet inhibition compared to clopidogrel
(Figure 1) [19]. In the PLATO trial, 18,624 patients with acute coronary syndrome were randomized to
Ticagrelor or Clopidogrel. In this study ticagrelor significantly reduced the rate of death from vascular
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causes, myocardial infarction, or stroke (9.8% vs. 11.7%; HR 0.84; 95% CI, 0.77–0.92; p < 0.001), but also
increased non-coronary artery by-pass graft (CABG) related major bleeding [20]. In the ST Elevation
Myocardial Infarction to Open the Coronary Artery (ATLANTIC) [21] study, 1862 patients with STEMI
were randomized to pre-hospital administration of the loading dose of ticagrelor administered directly
in the ambulance vs. in-hospital administration in the catheterization laboratory [21]. The two
co-primary endpoints explored in the study (>70% resolution of ST-segment elevation before PCI and
proportion of TIMI flow grade 3 at initial angiography) did not differ significantly between the two
groups. The rates of definite stent thrombosis were lower in the pre-hospital administration group
than in the in-hospital group (0% vs. 0.8%, p = 0.008 in the first 24 h; 0.2% vs. 1.2%, p = 0.02 at 30 days).
No difference for major bleeding was observed with the two strategies.
2.4. Evidence for the Direct Comparison of Prasugrel and Ticagrelor
Despite having different pharmacological characteristics, prasugrel and ticagrelor demonstrated a
similar efficacy profile in terms of platelet inhibition and percentage of patients with high on-treatment
platelet reactivity [22]. On a clinical standpoint, while the two P2Y12 inhibitors proved superiority
compared to clopidogrel in the two registration studies [17,20], a direct comparison between the
two drugs has been provided only recently [23]. In the PRAGUE-18 study, 1230 patients with acute
myocardial infarction (MI) treated with primary PCI were randomized to prasugrel or ticagrelor. The
intended treatment duration was 12 months [24]. At one-year follow-up (although the study was
ended prematurely for futility), the combined endpoint of cardiovascular death, MI, or stroke occurred
in 6.6% of prasugrel and in 5.7% of ticagrelor patients (HR: 1.167; 95% CI: 0.742–1.835; p = 0.503). No
significant differences for all bleeding (10.9% vs. 11.1%; p = 0.999) and TIMI major bleeding (0.9%
vs. 0.7%; p = 0.754) were observed [24]. Rafique et al. explored the direct comparison of two P2Y12
inibhitors in the setting of primary PCI executing a network metanalysis of 37 studies: at one-year
follow-up, prasugrel compared to ticagrelor was associated with a lower rate of MACE (OR: 0.77, 95%
CI: 0.61–0.97), death for all causes (OR: 0.63, 95% CI: 0.46–0.87), but not CV death, MI or ST, with a
similar rate of major bleeding [25]. While prior studies and meta-analysis have been inconclusive
in unraveling possible differences in clinical outcomes between the two treatments, ISAR-REACT
5 was the first trial properly designed and sized to evaluate the direct comparison of ticagrelor vs.
prasugrel [26]. In this multicenter, investigator-initiated, open-label trial 4018 patients with ACS
undergoing invasive management were randomly assigned to either ticagrelor or prasugrel at the
standard loading and maintenance doses. Importantly, according to guideline recommendations,
patients randomized to the prasugrel arm were loaded only after angiography and to be assigned to a
reduced maintenance dose if body weight was <60 kg or age >75 years. The primary endpoint of the
study was a composite of death, myocardial infarction, or stroke at one year. The major secondary
endpoint was bleeding according to BARC 3, 4 or 5 definition. At 12-month follow-up, the primary
endpoint occurred 9.3% in the ticagrelor group and in 6.9% in the prasugrel group (HR, 1.36; 95%
confidence interval (CI), 1.09–1.70; p = 0.006). The individual elements of the primary endpoint were all
numerically in favor of prasugrel (death, 4.5% vs. 3.7%; MI, 4.8% vs. 3.0%; stroke, 1.1% vs. 1.0%). Stent
thrombosis was similar between the two treatments. Surprisingly, no difference in terms of bleeding
was observed among the two treatment arms, with a rate of BARC 3, 4 or 5 of 5.4% in the ticagrelor
arm and 4.8% the prasugrel arm (HR 1.12; 95% CI, 0.83–1.51; p = 0.46) [26].
3. Duration of DAPT after PCI and Major Determinants for Treatment Selection
Randomized Trials
Numerous studies have tried in recent years to clarify which temporal window could be ideal
after PCI or ACS (Table 1), and in general two major strategies have been presented relative to what
was considered the standard of care for DAPT duration of 12 months [27]. A short DAPT encompasses
a strategy of less than 12 months of treatment, and a long DAPT extends its duration beyond 12 months.
With respect to a strategy of shortening DAPT duration, the first randomized study testing this
188
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assumption was the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting
(EXCELLENT). In this study, 1443 patients treated with drug-eluting stent (DES) implantation and
randomized to 6 vs. 12 months DAPT, were evaluated to test the non-inferiority of the short DAPT
strategy compared to the standard of care for the primary endpoint of cardiac death, myocardial
infraction (MI), or ischemia-driven target vessel revascularization. Ultimately, six-month DAPT
demonstrated non-inferior compared to the standard of care. In addition, TIMI major and minor
bleeding were numerically higher in the 12-month group, but this difference was not statistically
significant (HR 0.40; 95% CI: 0.13–1.27; p = 0,12) [28]. A similar hypothesis of non-inferiority of 6
vs. 12 months DAPT was also tested and observed in The Second Generation Drug-Eluting Stent
Implantation Followed by Six-Versus Twelve-Month Dual Antiplatelet Therapy (SECURITY) [29]
and in the Intracoronary Stenting and Antithrombotic Regimen: Safety and Efficacy of Six-month
Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) [30]. A different design was
implemented in the Impact of Intravascular Ultrasound Guidance on Outcomes of XIENCE PRIME
Stents in Long Lesions study [31]. In this case a factorial design was implemented and the first
randomization was based on the routinely use of intravascular ultrasound PCI guidance, while the
second randomization was for DAPT duration (6 vs. 12 months). At 12-month follow-up the composite
of Cardiac death, MI, stroke, and TIMI major bleeding was similar between patients treated with 6-
or 12-month DAPT (2.2% vs. 2.1%; p = 0.85). Interestingly, in the subgroup analysis for the primary
endpoint patients treated with intravascular ultrasound guided stent implantation benefitted more
from a shorter DAPT treatment as compared to those treated with angiographic guidance alone. In the
specific setting of ACS, two randomized trials tested the feasibility of a shorter DAPT duration of six
months as compared to the standard of care 12 months strategy: the SMART-DATE trial randomized
2712 patients to a DAPT for 6 or 12 months. At 18 months, the primary endpoint, a composite of
all-cause death, MI, or stroke was recorded equally in the two study arms (4.7% vs. 4.2%) meeting
the pre-specified non-inferiority hypothesis. However, a significant excess of MI was recorded in
the short DAPT cohort [32]. A more specific setting was explored in the DAPT-STEMI trial where
870 patients with STEMI treated with primary PCI and second-generation DES that after six months
of treatment with DAPT were randomized to another 12 months of DAPT therapy or to stop P2Y12
inhibitor and continue with aspirin only. The primary study endpoint was a composite of death, MI,
revascularization, stroke, and major bleeding at 24 months after primary PCI. Short DAPT was found
to be non-inferior as compared to the standard 12-month treatment duration (short DAPT 4.8% vs.
long DAPT 6.6%; p = 0.004). However, these results should be interpreted with caution as the study
enrolled a small sample size, and the event rate recorded was low compared to other studies in the
literature [33]. The short DAPT therapy in high ischemic risk patient was the goal of the REDUCE
trial (NCT02118870), which selected a population with a higher baseline ischemic risk to explore the
non-inferiority of 3 vs. 12 months of DAPT in patients with ACS treated with PCI. The 1496 patients
included in the study have been treated at index procedure exclusively with a bioabsorbable polymer
DES. The primary endpoint was a composite of all cause death, MI, stent thrombosis, stroke, target
vessel revascularization, or bleeding, with a wide, 5%, non-inferiority margin. The study reached
non-inferiority with an event rate of 8.2% in the short DAPT arm and 8.4% in the long DAPT arm
(p < 0.001). However, among secondary ischemic endpoints, stent thrombosis (1.2% vs. 0.4%; p = 0.08)
and all-cause mortality (1.9% vs. 0.8%; p = 0.07) were numerically higher in the short DAPT arm, a
trend which was consistent with that observed in the SMART-DATE trial [32]. Different temporal
strategies have been considered in the design of the studies ITALIC [34] and NIPPON [35], respectively,
6 vs. 24 months of DAPT and 6 vs. 18 months of DAPT. These trials reached non-inferiority, but, again,
the results from these studies should be interpreted with caution due to the study early termination
and the wide non-inferiority margin selected.
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The rationale for a long DAPT strategy derives from the residual thrombotic risk during secondary
prevention, which remains high despite potent P2Y12 inhibition [36]. Maintaining on a longer
term a more potent and consistent platelet inhibition with DAPT should reduce the rate of ischemic
complication due to plaque progression and rupture, yet may increase the risk of bleeding complications
that have an equal negative impact on mortality [37,38]. The Dual-Antiplatelet Treatment Beyond
one Year After Drug-Eluting Stent Implantation (ARCTIC INTERRUPTION) trial [39], an extended
follow-up of the ARCTIC study, tested the superiority of ≥18 months DAPT vs. 12 months after
stent implantation after an elective PCI. The primary efficacy endpoint occurred in 4% of patients in
both study arms, while a significant excess of bleeding was detected in the prolonged DAPT arm.
The PROlonging Dual antIplatelet treatment after Grading stent-induced intimal hYperplasia study
(PRODIGY) trial [40], randomly allocated patients to a long DAPT strategy for 24 months vs. a short
DAPT for six months showing no difference between the two strategies with respect to the study
primary efficacy endpoint of death, MI, stroke, whereas an excess of actionable BARC 2, 3 or 5 bleeding
was noted among patients allocated to the 24 month DAPT arm. The Dual Antiplatelet Therapy (DAPT)
study was the first study with the adequate power to detect a difference for more rare ischemic events
including stent thrombosis [41]. The study was funded by the American Food and Drug Administration
and randomized 9961 patients who tolerated an uneventful course of DAPT of 12 months after stenting
to two treatment strategies: interrupting DAPT at 12 months or continuing treatment up to 30 months.
Extended DAPT resulted in a 1% absolute reduction in very late stent thrombosis and a 1.6% absolute
reduction of major adverse cardiovascular and cerebrovascular events (MACCE). A total reduction
of 2% of MI was also noted and this was ascribed in half of the cases to a different vessel from the
one treated on a first place. Despite the sound reduction of ischemic events with a prolonged DAPT,
this strategy was also burdened by a significant excess of major bleeding, with a doubtful or even
negative impact on all cause mortality [41,42]. A landmark trial that further supported the potential
extension of DAPT to the long term is the Prevention of Cardiovascular Events in Patients with Prior
Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in
Myocardial Infarction 54 (PEGASUS-TIMI 54) study. PEGASUS investigated the potential benefit of
extended DAPT therapy in patients with a prior myocardial infarction implementing two different
Ticagrelor doses (90 mg twice daily and 60 mg twice a daily) on top of aspirin compared to placebo
plus aspirin. The primary outcome was cardiovascular death, MI, or stroke, which occurred in 7.8% of
the ticagrelor 90 mg bid group (hazard ratio (HR) vs. placebo 0.85, p = 0.008), 7.8% of the ticagrelor
60 mg bid group (HR vs. placebo 0.84, p = 0.004), and 9.0% of the placebo group. Ticagrelor was
also associated with a significant increase in TIMI major bleeding, but no increase in intracranial
hemorrhage [43]. Similar results were also observed, in a different population in THEMIS-PCI trial.
This study evaluated the impact of DAPT with ticagrelor plus aspirin in patients with stable ischemic
heart disease, type 2 diabetes, and prior PCI, compared to aspirin alone. At a median follow-up of 39.9
months, ticagrelor on top of aspirin was associated to a reduction of the primary efficacy outcome of
cardiovascular death, MI, or stroke, which occurred in 7.3% of the ticagrelor/aspirin group and in 8.6%
of the placebo/aspirin group (p = 0.013). The higher treatment efficacy was counterbalanced by an
excess of bleeding, in fact the primary safety outcome of the study, TIMI major bleeding, occurred
in 2.0% of the ticagrelor/aspirin group compared to 1.1% of the placebo/aspirin group (p < 0.0001).
No difference in intracranial hemorrhage was observed. When the exploratory composite outcome
of so-called “net irreversible harm”—a composite of all-cause death, MI, stroke, fatal bleeding, or
intracranial hemorrhage—was explored, this occurred in 9.3% of the ticagrelor/aspirin group and in
11.0% of the placebo/aspirin group (p = 0.005) [44].
While DAPT type and duration selection is clearly associated with a trade-off between ischemia
and bleeding [36,45], the optimal strategy, maximizing efficacy and safety should be individualized
based on the patients’ characteristics [46–50]. The type of clinical presentation (i.e., SCAD, unstable
angina, non-STEMI, or STEMI) at the time of PCI is a major determinant of a patient’s mortality risk,
and may profoundly impact the probability of ischemic recurrences [51–53]. In the DAPT trial, 30.7%
192
J. Clin. Med. 2019, 8, 2016
presented with an acute coronary syndrome at the time of PCI. Long DAPT compared with standard
DAPT regimen significantly reduced definite or probable stent thrombosis in patients both with MI
(0.5 vs. 1.9%; p = 0.001) and without MI (0.4 vs. 1.1%; p = 0.001), yet the magnitude of the reduction of
MACCE from longer DAPT was bigger among patients with MI (3.9 vs. 6.8%; p = 0.001) than among
those without MI (4.4 vs. 5.3%; p = 0.08) at the time of presentation (Pint = 0.03) [41,54]. The ischemic
risk after PCI is also associated to several anatomical or procedural characteristic [55]. The concept
of PCI complexity is quantifiable using previously validated and guideline-endorsed criteria: PCI
with ≥3 stents implanted and 3 ≥ lesions and/or coronary vessels treated; and/or bifurcation with 2
stents implanted, total stent length >60 mm, and/or treatment of a chronic total occlusion [56]. In these
patients, long-term DAPT (≥12 month) compared with a short period of DAPT (three or six months),
significantly reduced the risk of cardiac ischemic events with a greater effect in patients undergoing
PCI with more complex features. On the other hand, the risk of bleeding, estimated through risk
scores, is also a potent driver for treatment selection [57–60]. The PRECISE-DAPT score based on
five-items (age, creatinine clearance, hemoglobin, white blood cell count, and prior spontaneous
bleeding) showed potential to guide DAPT duration decision-making: individuals deemed at high
bleeding risk (PRECISE-DAPT score ≥ 25), prolonged DAPT was associated with no ischemic benefit
but a significant bleeding hazard, whereas, on the other side, among patients not deemed at high
bleeding risk (PRECISE-DAPT score < 25) a long DAPT treatment was associated with a significant
reduction in the composite ischemic endpoint of MI, definite stent thrombosis, stroke, and target
vessel revascularization without a significant increase in bleeding events [58]. It is interesting to
note that according to a recent retrospective study, patients who underwent complex PCI would
benefit long-term DAPT only if not at high risk of bleeding at baseline (PRECISE DAPT < 25) [61,62].
Ultimately, international guidelines agree on the fact that coronary stent type is no more a driver
mandating different DAPT duration, and preferential BMS use for anatomical [63] or clinical [64–67]
reasons mandating shorter DAPT duration are no longer recommended [48].
4. From DAPT to Single Antiplatelet Therapy (SAPT), Evidence for Aspirin Withdrawal and
Monotherapy with P2Y12 Inhibitor
Several clinical studies have been designed to test efficacy and safety of a strategy of early
withdrawal of aspirin after PCI (Figure 2). In the One-Month Dual Antiplatelet Therapy Followed by
Clopidogrel Monotherapy vs. Standard 12-Month Dual Antiplatelet Therapy With Clopidogrel After
Drug-Eluting Stent Implantation (STOPDAPT-2) study, 3045 patients undergoing PCI (62% SCAD)
were randomized to one month of DAPT followed by clopidogrel monotherapy for five years versus
12 months of DAPT followed by Aspirin monotherapy for five years. After the first year of follow-up,
the primary endpoint of cardiovascular death, myocardial infarction (MI), definite stent thrombosis,
stroke, or TIMI major/minor bleeding occurred in 2.4% of the one-month DAPT group and in 3.7% of the
12-month DAPT group (HR 0.64; 95% CI 0.42–0.98), reaching both non-inferiority and superiority of the
experimental treatment compared to the 12 month DAPT arm (p non-inferiority < 0.001; p superiority
= 0.04). This result was mostly driven by a significant 74% reduction of TIMI major or minor bleeding
among patients treated with shorter DAPT (HR 0.26 95% CI 0.11–0.64; p = 0.002) [68]. However, since
this study was exclusively conducted in an Asian population and with specific procedural standards
(e.g., imaging guided PCI was carried out in >97% of patients) the external validity of these results
may be limited.
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Figure 2. Design of clinical trials exploring aspirin withdrawal after percutaneous coronary intervention.
Similarly, the Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet
Therapy After DES (SMART-CHOICE) study compared a short treatment arm of three months of DAPT
followed by P2Y12 inhibitor monotherapy with the standard 12-month duration of DAPT. The primary
study hypothesis was the non-inferiority of the experimental treatment as compared to the standard
treatment for the primary ischemic endpoint. In total, 2993 patients undergoing PCI (58% with ACS
at presentation) were ultimately included. At 12-month follow-up, the primary outcome of all-cause
death, MI, or stroke occurred in 2.9% of patients in the three-month DAPT arm and in 2.5% in the
12-month DAPT arm, meeting the pre-specified non-inferiority margin (p for non-inferiority = 0.007;
p for superiority= 0.46). Actionable bleeding events accounted according to bleeding academic research
consortium (BARC) Type 2, 3 or 5 criteria were significantly less in the short DAPT arm, mostly due to
a reduction of minor bleeding [32].
The GLOBAL LEADER trial included 15,968 patients who underwent PCI for stable or unstable
coronary disease that were randomized to DAPT of aspirin plus ticagrelor for one month, followed
by ticagrelor monotherapy for 23 months versus DAPT for 12 months (aspirin/clopidogrel for stable
coronary disease or aspirin/ticagrelor for unstable coronary disease), followed by aspirin monotherapy
for 12 months [69]. The primary outcome was a composite of all-cause death or nonfatal myocardial
infarction). The primary study hypothesis was to demonstrate the superiority of the experimental
treatment for the composite ischemic endpoint at 24-month follow-up. Ultimately, at 24-month
follow-up, there was an equipoise for the two treatment strategies for the primary study endpoint
(p = 0.073). Importantly, adherence to the assigned treatment was as low as 78% at 24 months in the
experimental arm, which may have reduced the pre-specified statistical power of the study [69,70].
Finally, the most recent TWILIGHT trial tested the impact of aspirin withdrawal at three months
after PCI in 7119 high-risk patients who were randomized at three months after PCI to ticagrelor
monotherapy for additional nine months or continuing standard DAPT with aspirin and ticagrelor.
The trial specifically included patients that were deemed both at high ischemic and bleeding risk. At
12 months after PCI, the primary safety endpoint, a composite of BARC 2, 3 or 5 bleeding was reduced
by 44% in the ticagrelor monotherapy arm (4.0% vs. 7.1%; HR 0.56; 95% CI 0.45–0.68; p < 0.001). No
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significant differences in MACE were observed in the two study arms, consistently to what observed
in other studies of aspirin withdrawal.
Taken together, all the studies exploring aspirin withdrawal presented to date, show a consistent
reduction of bleeding events by removing aspirin at different timepoints after PCI, with no apparent
trade-off in ischemic events. However, some consideration regarding these studies should be
highlighted. First, the STOP-DAPT 2 trial and SMART-CHOICE were exclusively conducted in an
Asian population with very high usage of intravascular imaging for optimizing stent implantation,
potentially limiting external validity of these findings to other centers with different practice. Second,
the timing to randomization and effective aspirin withdrawal was of one month in three trials and three
months in another. In addition, the baseline ischemic risk of the populations explored was different
among trials; hence, it is not clear which is the optimal timing for safe aspirin withdrawal. In addition,
whether potent P2Y12 inhibition should be preferred over a treatment with clopidogrel, in which high
prevalence of drug non-responders may pose concerns for aspirin withdrawal should be clarified. In
light of the recent results of the ISAR-REACT 5 trial, whether monotherapy with ticagrelor or with
prasugrel should be preferred has not yet been studied.
5. Combination of Oral Anticoagulants and Antiplatelet Therapy in Patients at Higher Ischemic
Risk or with Non-Valvular Atrial Fibrillation
5.1. Direct-Acting Oral Anticoagulants (DOAC) in Association to Antiplatelet Therapy in Patients at High
Ischemic Risk
Despite the great progress in reducing the rate of events in patients at high ischemic risk, there is
still a significant residual thrombotic risk in patients with coronary artery disease and prior vascular
events, which is as high as 10% at 12 months after the occurrence of an ACS. [71] Novel pharmacological
strategies focused on the long-term association of antiplatelet and anticoagulant drugs to further
reduce the ischemic burden have been tested (Table 2). The Anti-Xa Therapy to Lower Cardiovascular
Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in
Myocardial Infarction 51 (ATLAS ACS 2-TIMI 51) study was based on this assumption and was the
first testing the hypothesis that additional factor Xa inhibition on top of standard DAPT could further
reduce the residual ischemic risk of patients after an acute coronary syndrome. The ATLAS ACS
2-TIMI 51 included a total of 15,526 patients with a recent ACS to receive twice-daily doses of either
2.5 mg or 5 mg of Rivaroxaban or placebo on top of standard DAPT with Aspirin and Clopidogrel. The
primary efficacy end point was a composite of death from cardiovascular causes, myocardial infarction,
or stroke, while the safety outcome was TIMI major bleeding not related to coronary-artery bypass
grafting (CABG). After a mean treatment of 13 months, rivaroxaban significantly reduced the primary
end point, as compared with placebo (HR in the rivaroxaban group, 0.84; 95% confidence interval,
0.74–0.96; p = 0.008), with a significant improvement observed for both the twice-daily 2.5-mg dose
(9.1% vs. 10.7%, p = 0.02) and the twice-daily 5-mg dose (8.8% vs. 10.7%, p = 0.03). As compared
with placebo, Rivaroxaban increased the rates of major bleeding not related to coronary-artery bypass
grafting (2.1% vs. 0.6%, p < 0.001) and also of intracranial hemorrhage (0.6% vs. 0.2%, p = 0.009), yet
not increasing fatal bleeding (0.3% vs. 0.2%, p = 0.66) [72]. Despite the promising results showed in the
ATLAS ACS 2-TIMI 51, Rivaroxaban 2.5 mg was not widely introduced in practice with this indication
mostly for the safety concerns due to the higher bleeding risk and most importantly to the introduction
of the more potent P2Y12 inhibitors prasugrel and ticagrelor which are now preferred over clopidogrel
in patients with ACS.
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The APPRAISE-2 study tested the effect of Apixaban, at a dose of 5 mg twice daily in addition
to standard antiplatelet therapy as compared with placebo in patients with a recent acute coronary
syndrome and with high ischemic risk. The study was terminated prematurely after inclusion of
7392 patients because of an increase in clinically important bleeds, including fatal bleeds. The impact
of apixaban on ischemic events could not be evaluated, because only 68% of the expected number of
participants required to reach the pre-specified sample size was enrolled [73].
In the most recent Cardiovascular Outcomes for People Using Anticoagulation Strategies [74]
trial, the role of factor Xa inhibition with Rvaroxaban was tested among chronic and stabilized patients
with coronary artery disease (CAD) and in peripheral arterial disease (PAD) [74]. In this double-blind
trial, the investigator randomly assigned 27,395 patients with stable atherosclerotic vascular disease
to receive Rivaroxaban (2.5 mg twice daily) plus Aspirin (100 mg once daily), Rivaroxaban alone
(5 mg twice daily), or Aspirin alone (100 mg once daily). The primary outcome was a composite of
cardiovascular death, stroke, or myocardial infarction. The safety outcome was a modification of the
International Society on Thrombosis and Haemostasis (ISTH) criteria for major bleeding and included
fatal bleeding, symptomatic bleeding into a critical organ, bleeding into a surgical site requiring
reoperation, and bleeding that led to hospitalization. With respect to the study primary endpoint,
a treatment with rivaroxaban-plus-aspirin was associated to a significant 24% reduction of events
as compared to aspirin-alone (379 patients vs. 496 patients; HR, 0.76; 95% CI, 0.66–0.86; p < 0.001),
yet major bleeding were also more common in the rivaroxaban-plus-aspirin group (288 patients vs.
170 patients; HR, 1.70; 95% CI, 1.40–2.05; p < 0.001), mainly driven by nonfatal and non-intracranial
bleedings. Rivaroxaban alone was not associated with lower rates of the primary endpoint compared
with aspirin alone, but led to an excess of major bleeding events.
5.2. DOAC and Antiplatelet Therapy in Patients with Non-Valvular Atrial Fibrillation (AF) Undergoing PCI
The association of anticoagulant and antiplatelet therapies is needed in the case of the concomitant
presence of atrial fibrillation and percutaneous coronary intervention or recent acute coronary syndrome.
Multiple studies demonstrated on one side that anticoagulant is inferior to antiplatelet therapy after
stenting, and on the other side that antiplatelet therapy is inferior to anticoagulant therapy for the
prevention of thromboembolic events in patients with atrial fibrillation [75]. However, the prolonged
association of these two treatments expose patients to a hazard of serious bleeding, which is 3–4-fold
higher than the two treatments taken singularly [76]. Hence, multiple studies focused on the reduction
of duration or intensity of the antithrombotic therapy in this setting (Table 3 and Figure 3). The What is
the Optimal antiplatElet and anticoagulant therapy in patients with OAC and coronary StenTing [77]
WOEST trial randomized 573 patients with an indication to long-term oral anticoagulation (of whom
69% of patients had AF) and who underwent PCI to a dual therapy of oral anticoagulants vitamin k
antagonists plus clopidogrel or to a triple therapy of OAC plus Clopidogrel and Aspirin. Treatment
was continued for one month after bare metal stent (BMS) placement and for one year after DES
placement (65% of patients). The primary endpoint was the occurrence of any bleeding episode at
one-year follow-up. Dual as compared to triple therapy was associated with a substantial reduction
of all bleeding events at one year (19.4 vs. 44.4%; HR 0.36, 95% CI 0.26–0.50; p < 0.001) and also to a
reduction of the combined secondary endpoint of death, myocardial infarction, stroke, target-vessel
revascularization, and stent thrombosis (11.1 vs. 17.6%; HR 0.56, 95% CI 0.35–0.91; p= 0.025) [77]. While
the study was not powered to detect differences among rare ischemic events, a significant reduction
of all-cause death was observed among patients treated with a dual therapy strategy. Nevertheless,
this result should be taken with caution due to the open-label design of the study. More recently,
multiple studies evaluated both the impact of aspirin withdrawal among patients with indication
to triple therapy and the concomitant effect of DOAC vs. the traditional treatment with Vitamin k
antagonists. The PIONEER AF-PCI was the first to study this scenario and randomized 2124 patients
with non-valvular AF who had undergone PCI with stenting to receive, in a 1:1:1 ratio, low-dose
rivaroxaban (15 mg o.d.) plus a P2Y12 inhibitor (and no ASA), very-low-dose rivaroxaban (2.5 mg
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b.i.d.) plus DAPT, or standard therapy with a dose-adjusted VKA plus DAPT. The primary study
endpoint consisted of clinically relevant bleeding according to the TIMI definition. At 12 months, the
rate of the primary endpoint was lower in the two groups receiving rivaroxaban than in the group
receiving standard therapy (16.8% for rivaroxaban 15 mg + P2Y12i, 18.0% for rivaroxaban 2.5 mg +
DAPT, and 26.7% for VKA + DAPT). The lowest rate of bleeding was observed among patients treated
with rivaroxaban 15 mg + P2Y12 inhibitor, and this strategy was associated with a 41% reduction of
bleeding as compared to triple therapy (HR 0.59, 95% CI 0.47–0.76; p < 0.001) [78]. Rates of ischemic
events were similar in the three groups. While the lowest dosage of rivaroxaban is not approved for
thromboembolic protection in AF, rivaroxaban 15 mg may be preferred over the 20 mg od dosage in
patients recently treated with PCI and treated with concomitant antiplatelet therapy as endorsed by
international guidelines [7].
Figure 3. Design of clinical trials exploring the combination of oral anticoagulants and antiplatelet
agents in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention.
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Similarly, the Randomized Evaluation of Dual Antithrombotic Therapy with Dabigatran versus
Triple Therapy with Warfarin in Patients with Nonvalvular Atrial Fibrillation Undergoing Percutaneous
Coronary Interventio trial [79], randomized 2725 patients with AF who had undergone PCI to triple
therapy with warfarin plus a P2Y12 inhibitor (clopidogrel or ticagrelor) and aspirin, or to dual therapy
with dabigatran (110 mg or 150 mg twice daily) plus a P2Y12 inhibitor (clopidogrel or ticagrelor, at
the discretion of the treating physician) and no aspirin (110-mg and 150-mg dual-therapy groups).
Different from the PIONEER AF-PCI trial, the RE-DUAL PCI trial randomized patients to both the
approved doses of dabigatran for thromboembolic protection in AF. In addition, the triple therapy
duration in this study was much shorter than observed in the previous WOEST and PIONEER AF-PCI,
in which a significant proportion of triple therapy patients continued treatment up to 12 months. The
primary end point was a composite of major or clinically relevant nonmajor bleeding according to
the ISTH definition. The RE-DUAL PCI trial was designed to test both the non-inferiority and the
superiority of the experimental treatment (i.e., dual therapy with DOAC) for the primary bleeding
endpoint and also its non-inferiority with respect to the incidence of a composite of thromboembolic
events and coronary ischemic events (myocardial infarction, stroke, or systemic embolism, death, or
unplanned revascularization). After a mean follow-up of 14 months, the primary endpoint occurred in
15.4% of patients in the dual-therapy group with dabigatran 110-mg as compared with 26.9% in the
triple-therapy group (HR, 0.52; 95% CI, 0.42–0.63; p < 0.001 for both non-inferiority and superiority)
and in 20.2% of patients in the dual-therapy group with dabigatran 150-mg as compared to 25.7% in
the triple-therapy group (HR, 0.72; 95% CI, 0.58–0.88; p < 0.001 for non-inferiority). Non-inferiority for
the composite ischemic endpoint was also confirmed with both doses of dabigatran.
On the same line as in the previous two trials, the antithrombotic Therapy after Acute Coronary
Syndrome or PCI in Atrial Fibrillation (AUGUSTUS) study evaluated the impact of a treatment with
apixaban as compared to VKA in patients undergoing stenting or with a recent ACS. Different from
the previous three studies, this used a two-by-two factorial design, i.e. not only the type of oral
anticoagulant but also aspirin treatment was randomized. AUGUSTUS is thus the first trial to test
both the concept of OAC type and dual vs. triple therapy separately. In total, 4614 patients were
randomly allocated to apixaban 5 mg bid or VKA, and to aspirin or placebo, on top of a P2Y12 inhibitor
(mostly clopidogrel) after a mean of seven days after the PCI/ACS occurrence. At six-month follow-up,
the primary outcome of major or clinically relevant nonmajor bleeding was reported in 10.5% of
the patients receiving apixaban, as compared with 14.7% of those receiving a vitamin k antagonist
(HR, 0.69; 95% CI, 0.58–0.81; p < 0.001 for both non-inferiority and superiority) reaching both the
prespecified non-inferiority and superiority of the experimental treatment. With respect to the second
randomization, the primary endpoint occurred in 16.1% of those assigned to aspirin, as compared to
9.0% with placebo (HR, 1.89; 95% CI, 1.59–2.24; p < 0.001). A lower incidence of death or hospitalization
was observed in patients treated with apixaban compared to vitamin k antagonists (23.5% vs. 27.4%;
hazard ratio, 0.83; 95% CI, 0.74–0.93; p = 0.002). With respect to the secondary endpoint exploring
ischemic events, this was similar among patients treated with apixaban or VKA and also for patients
randomized to aspirin or placebo. Ischemic stroke was significantly reduced by 50% among patients in
the apixaban arm. Despite the fact that this study was not powered to evaluate differences among
study arms for the rare ischemic endpoints, a trend towards an excess of myocardial infarction and
definite or probable stent thrombosis was observed among patients randomized to placebo (dual
therapy) as compared to those assigned to aspirin (triple therapy) [80].
Finally, the recent Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial
Fibrillation Undergoing Percutaneous Coronary Intervention (ENTRUST-AF-PCI) evaluated the safety
and efficacy of edoxaban plus single antiplatelet therapy vs. VKA plus DAPT in subjects with atrial
fibrillation following PCI with stent placement. Participants were randomly assigned (1:1) from
four hours to five days after PCI to edoxaban (60 mg once daily) plus a P2Y12 inhibitor (mostly
clopidogrel) for 12 months or a VKA in combination with a P2Y12 inhibitor and aspirin (100 mg once
daily, for 1–12 months). The edoxaban dose was reduced to 30 mg per day if one or more factors
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were present (creatinine clearance 15–50 mL/min, bodyweight ≤60 kg, or concomitant use of specified
potent p-glycoprotein inhibitors). The primary endpoint was a composite of major or clinically relevant
non-major (CRNM) bleeding within 12 months. In the intention-to-treat analysis, major or CRNM
bleeding events occurred in 128 (17%) patients randomized to Edoxaban and 152 (20%) patients to the
VKA regimen; the relative risk reduction of 17% for the safety endpoint was enough to demonstrate
the non-inferiority of the experimental treatment, but did not reach superiority (95% CI 0.65–1.05;
p = 0.0010 for non-inferiority, p = 0.12 for superiority). In a post-hoc landmark analysis in which events
occurring during the first two weeks after randomization were censored, experimental treatment
with Edoxaban was associated to a significant 32% reduction of bleeding compared to triple therapy
with VKA. No difference for ischemic events was observed, yet the study was not powered to detect
differences for ischemic endpoints [81]. As already reported, none of these RCTs taken singularly was
powered for ischemic endpoints, hence meta-analysis could provide important insights on this matter.
However, the meta-analysis currently available in the literature drafted different conclusions. A first
study-level network meta-analysis of four RCT and 10,026 patients, not including the more recent data
from the ENTRUST trial, showed that dual therapy with both VKA or DOAC was associated to lower
TIMI major or minor bleeding compared to triple therapy with VKA, and a similar risk of MACE, MI
and ST [82]. On the contrary, a more recent patient-level meta-analysis including the recent results of
the ENTRUST trial, showed a trend (although not significant) towards higher risk for stent thrombosis
with dual therapy. Reconciling these inconsistencies will be a priority of future research to inform
international practice guidelines. Ideally, more robust data may come from patient-level meta-analysis,
which could also provide important insights on the subgroups that most benefit from each treatment.
Leveraging on the new evidence in the field, in particular the REDUAL-PCI and PIONEER-AF-PCI,
a recent North American consensus statement on the management of antithrombotic therapy in
patients with atrial fibrillation undergoing percutaneous coronary intervention [83] suggests a
double-therapy approach as the default strategy for most patients. Instead, in selected patients
at high ischemic/thrombotic and low bleeding risks, extending low-dose aspirin therapy (triple therapy)
up to one month after PCI appear reasonable. In addition, in this setting, clopidogrel remains the
P2Y12I of choice.
Finally, whether antiplatelet therapy should be stopped 12 months after PCI, leaving patients
on treatment with OAC alone was a matter of debate. The recent Atrial Fibrillation and Ischemic
Events with Rivaroxaban in Patients with Stable Coronary Artery Disease (AFIRE) trial compared
rivaroxaban monotherapy compared with rivaroxaban/antiplatelet therapy after 12 months from PCI
or CABG and up to 24 months in patients with atrial fibrillation and stable coronary artery disease.
The study was prematurely interrupted for an excess of mortality in the combination therapy group
treated with rivaroxaban plus antiplatelet therapy. The primary efficacy outcome of all-cause mortality,
myocardial infarction, stroke, unstable angina requiring revascularization, or systemic embolism,
occurred in 4.1%/patient-year in the rivaroxaban monotherapy group compared with 5.8%/patient-year
in the rivaroxaban/antiplatelet therapy group (p for non-inferiority <0.0001). As expected, ISTH major
bleeding occurred in 1.6%/patient-year in the rivaroxaban monotherapy group and in 2.8%/patient-year
in the rivaroxaban/antiplatelet therapy group (p = 0.01).
6. Current Evidence for the Type and Duration of Antithrombotic Therapy in Percutaneous
Structural Heart Interventions
6.1. Transcatheter Aortic Valve Implantation (TAVI)
Transcatheter Aortic Valve Implantation (TAVI) has been established as the method of choice
for the treatment of severe aortic stenosis in patients with increased surgical risk [84,85]. Due to the
vibrant activity in clinical trials, which is extending the indications of this treatment to different and
lower risk clinical indications, TAVI could become the treatment of choice for most patients with aortic
valve disease [86]. Secondary prevention with antithrombotic therapies after TAVI is primarily meant
to reduce the risk of thrombosis of the valve components and prevent subsequent systemic thrombus
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embolization. While most of the events occurs during the first 48 h after valve implantation and are
likely related to acute embolization of fibro-calcific valve material after valve implantation or catheter
manipulation potentially damaging aortic wall, later ischemic events may be linked to thrombosis of
the prosthesis surface or to unrecognized/new-onset of atrial fibrillation [87].
Current guidelines, mostly based on expert consensus extrapolated from the coronary stent
experience, suggest as standard treatment strategy DAPT with aspirin and clopidogrel for 3–6 months
after valve implantation, followed by a lifelong treatment with ASA. However, in patients with
low hemorrhagic risk, a therapy with vitamin k antagonists in the first months after the procedure
is also considered reasonable [84]. This latter indication is extrapolated from the experience with
surgically-implanted valves, in which a short-term anticoagulation after bioprothetic valve implantation
is common [84]. Despite the paucity of high-quality evidence in the field, several studies are evaluating
possible antithrombotic treatment strategies after TAVI (Figure 4).
 
Figure 4. Clinical studies testing antithrombotic strategies for secondary prevention of percutaneous
structural heart interventions. TAVI: transcatheter aortic valve implantation; TMVR: transcatheter
mitral valve repair; LAAO: left atrial appendage occlusion; PFO: patent foramen ovale.
In the randomized Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve
Implantation Trial, 222 TAVI patients undergoing a balloon-expandable device implantation were
randomized to DAPT (i.e., aspirin plus clopidogrel) or to aspirin alone. The primary endpoint of death,
MI, stroke or transient ischemic attack, or major or life-threatening bleeding was similar between the
two treatment groups but trended higher among patients assigned to DAPT (15.3% vs. 7.2%, p = 0.065)
mostly due to an excess of major or life-threatening bleeding among patients treated with DAPT (10.8%
vs. 3.6%, p = 0.038) [88]. Sherwood et al. tried to describe contemporary practice patterns of antiplatelet
therapy and their relationship to outcomes post-TAVI trough a retrospective analysis of the NCDR
STS/ACC TVT Registry. This analysis of 16,694 patients undergoing transfemoral TAVI reported that
81.1% patients were discharged on DAPT and 18.9% were discharged on SAPT. There was no difference
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in the main baseline characteristics among those assigned to DAPT or SAPT, whereas those assigned to
DAPT had more CAD (64.6% vs. 52.3%; p < 0.01) and PAD (25.2% vs. 22.3%; p < 0.01). No difference in
mortality (HR 0.92; 95% CI 0.81, 1.05) stroke (HR 1.04; CI 0.83, 1.31) or MI (HR 1.00; CI 0.72, 1.39) at one
year was observed between DAPT and SAPT, but a significantly higher risk for major bleeding (HR
1.48; CI 1.10, 1.99) was observed with DAPT [89]. Current TAVI population carries an exaggerated
bleeding risk, hence more potent platelet inhibition has to be justified by other concomitant indications
rather that procedural alone. Whether the type and not only the number of the antiplatelet drugs
implemented may have an impact in patients with TAVI is under investigation in the TICTAVI study
(NCT02817789), which will evaluate the impact of ticagrelor monotherapy for 30 days after valve
implantation vs. DAPT with clopidogrel and the soluble salt of aspirin lysine Acetylsalicylate.
Apart from antiplatelet therapy, various regimens of anticoagulant therapy are currently under
investigation for secondary prevention after TAVI in patients without further indication to OAC.
Based on the fact that valve thrombosis may be associated to a low shear stress thrombosis and that
the current TAVI population has a high risk of new onset AF which was registered in up to 50%
after valve implantation [90], use of OACs in this population may appear sound. The Global Study
compares a rivAroxaban-based Antithrombotic Strategy with an antipLatelet-based Strategy After
Transcatheter aortIc vaLve rEplacement to Optimise Clinical Outcomes (GALILEO) trial (NCT02556203)
compared rivaroxaban 10 mg combined with aspirin for three months followed by rivaroxaban 10 mg
monotherapy versus DAPT for three months followed by aspirin monotherapy in patients without an
established indication for OAC [91]. The trial has been prematurely terminated due to an excess of
death or thromboembolic events (11.4% vs. 8.8%), bleeding (4.2% vs. 2.4%) and all-cause death (6.8% vs.
3.3%) in patients allocated to rivaroxaban. Similarly, the ongoing DAPT versus OAC for a Short Time to
Prevent Cerebral Embolism After TAVI (AUREA) trial (NCT01642134) will compare VKA with DAPT
in patients without further indication to OAC. The primary study endpoint is the detection of new
areas of cerebral infarction by MRI three months after TAVI. Further ongoing studies are evaluating the
safety and efficacy of DOACs in patients undergoing TAVI. The ATLANTIS (Anti-Thrombotic Strategy
After Trans-Aortic Valve Implantation for Aortic Stenosis trial) (NCT02664649) is testing the safety and
efficacy of apixaban 5 mg bid compared to VKA in patients with an established indication for OAC,
and apixaban 5 mg bid compared to DAPT/SAPT in patients without an indication for OAC. Similarly,
the ENVISAGE AF trial (NCT02943785) is testing Edoxaban 30 and 60 mg vs. VKA in patients with AF
and an indication for OAC.
Apart from secondary prevention of thromboembolic events, the evidence of clinically-evident
valve thrombosis after biologic valve implantation has been described and require specific treatment to
reduce the risk of embolization or prosthesis dysfunction. Prosthetic valve thrombosis is characterized
by thrombus formation on the leaflets and metallic frames, with subsequent valve dysfunction with or
without thromboembolism. Latib et al. reported in 4266 patients undergoing TAVI a total of 26 cases
of PV thrombosis (0.61%) at a median timing from implantation of 181 days (interquartile range:
45–313 days) [92]. The most common clinical findings in these cases were presentation with progressive
dyspnea, signs of heart failure or systemic embolization. Valve thrombosis could also be an incidental
finding at the time of echocardiographic follow-up, detected by an increase transprosthetic gradient [93].
Valve thrombosis after TAVI could be acute (up to one day), subacute (ten days to one month), or
late (more than one month) and its risk appears higher in the first three months post-implantation.
Although the mechanisms are not completely clear, risk factors such as systemic pro-thrombotic state,
valve malposition, prosthesis size, and the presence of low/high velocity flows after implantation [94]
have been suggested as potential risk factors for this phenomenon. In addition, subclinical valve
thrombosis has also been describing using novel imaging techniques but its clinical implications are
still unclear. Makkar et al. showed that in patients with stroke after valvular implantation there was
a reduction in the mobility of leafleats identifiable by CT scan as a hypo-attenuation on the valve
leaflets after administration of contrast medium. In all cases, the reduction of leaflet motion was not
related to an alteration of the valvular hemodynamics but seems to be related with an in increased
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risk of TIA/stroke (in the analysis of pooled RESOLVE and SAVORY cohorts). A treatment with OAC
resolved leaflet hypomobility in all the patients treated, while other antithrombotic regimens did
not prove effective [95]. Several observational studies showed a lower risk of valve thrombosis in
patients on OAC treatment [96,97]. Latib et al. showed that, of 26 patients with valve thrombosis,
23 (88%) were treated with medical therapy, such as oral vitamin k antagonists with/without bridging
heparin (unfractionated heparin or low-molecular–weight heparin). Anticoagulation was effective and
resulted in significant decrease of the trans-prothesic aortic valve gradient or disappearance of the
thrombotic mass in all patients [92]. The upcoming Comparison of a Rivaroxaban-based Strategy With
an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and
Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography
(GALILEO-4D) (NCT02833948) will also evaluate if anticoagulation compared to the usual double
platelet inhibitor therapy after TAVRI may have an impact in reducing the risk of leaflet thrombosis,
and its results are expected soon.
6.2. Evidence for MitraClip, Transcatheter Mitral Valve Interventions
Transcatheter mitral valve repair is indicated in moderate-to-severe or severe mitral insufficiency
in patients with high surgical risk [98]. The MitraClip is currently the only system approved by the
FDA and is based on the concept of “edge to edge” surgical repair to reduce valve insufficiency [99].
The procedure involves the passage of large bore catheter from the venous system, through atrial
septal puncture in the left atrium, which may expose patients to peri-procedural and post-procedural
ischemic events [100]. An incidence of 0.9% of ischemic stroke was documented on 30-day follow-up
in the EVEREST RCT trial [98], 2.6% in the EVEREST-HRR and 2.4% in the EVEREST-REALISM
registries [101] (Figure 4). Currently, neither international guidelines nor manufacturers provide
precise recommendations for the type and duration of the antithrombotic therapy after the procedure
and no specific studies have been yet carried out in this field. The current most commonly adopted
antithrombotic treatments derive from the protocol recommendations of the first pivotal trials of
the device. This generally consist of one month of DAPT with aspirin and clopidogrel followed by
aspirin alone for 6–12 months. Transcatheter mitral valve replacement is flourishing and it is still at its
inception. Multiple devices have been tested in first-in-man studies and the approach to antithrombotic
therapy is still anecdotic and should be individualized based on the specific device used. Given the
slow blood flow on the atrial side of the prosthesis together with the high rate of AF in these patients,
the risk of device thrombosis is potentially high and merits consideration at the time of antithrombotic
treatment selection.
6.3. Percutaneous Patent Foramen Ovale (PFO) Occlusion
Patent foramen ovale (PFO) and atrial septal defects [8] represent the most prevalent cardiac
anomaly in the general population [102,103]. The presence of PFOs may predispose to paradoxical
right-to-left atrium embolism, of which the most dreadful consequence is cryptogenic stroke,
representing a major cause of embolic stroke in younger patients. Several devices have been developed
in the last 20 years to physically occlude the PFO and prevent right-to-left shunt embolism [104,105] and
systemic embolization. While these devices are effective for the scope, several procedural and long-term
complications exist, including atrial rupture, pericardial tamponade, septal perforation, and acute/late
thrombus formation of the device [106]. Thrombus formation can be a consequence of the incorrect
measurement of the device [107,108]. More typically thrombosis could be triggered by the metal
structure of the device, owing to endothelialization defects within the first four weeks [109]. However
experimental studies in vivo have shown that the endothelialization process can last up to three
months [110], or even up to five years post implantation [111] in some reports. Independent predictors
of thrombotic formation are atrial fibrillation and presence of septal aneurysm [109]. Antithrombotic
therapy is therefore crucial after device implantation, but the strategies remain controversial, and no
randomized studies have been published to assess the optimal antithrombotic strategy in this scenario
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(Figure 4). In many centers, the antithrombotic strategy of choice is DAPT with ASA plus clopidogrel
for 6–8 weeks followed by ASA alone for an additional 4–8 months. DAPT for 1–6 months followed
by single antiplatelet therapy for at least five years is recommended in a recent consensus document
endorsed by the EAPCI [112]. In contrast, the latest American Academy of Neurology guidelines
recommended lifelong antithrombotic therapy after PFO closure [113]. In the REDUCE trial, 664
patients with previous cryptogenic stroke were randomized in a 2:1 ratio to undergo PFO closure
with the Gore Occluder. Antiplatelet therapy consisted of ASA alone (59%), clopidogrel alone (25.9%)
or a combination of aspirin and P2Y12 inhibitor (i.e., clopidogrel or dypiridamole, <10%) and was
similar in the two study groups. Follow-up was continued during a median of 3.2 years after the
procedure, and in this period antiplatelet was maintained. The risk of recurrent stroke was significantly
lower with PFO closure plus antiplatelet therapy than with antiplatelet therapy alone (1.4% vs. 5.4%,
p = 0.002) [114]. Device thrombosis was reported in two patients in the closure group. In the CLOSE
trial, 663 patients with a recent stroke attributed to PFO were assigned in a 1:1:1 ratio to PFO closure
(11 different devices were used) plus long-term antiplatelet therapy, oral anticoagulation alone or
antiplatelet therapy alone. The PFO closure group received DAPT for three months, followed by SAPT
for a median follow-up of 5.5 years. Among patients assigned to oral anticoagulation, 93% received
VKA and 7% DOACs. In the antiplatelet therapy group, 87% received ASA alone, 10% Clopidogrel
alone and 3% ASA plus dipyridamole throughout the study period. At 12-month echocardiography
evaluation, 93% of patients who underwent closure had no or minimal residual shunt. The rate of
recurrent stroke at five years was significantly lower with PFO closure plus long-term antiplatelet
therapy than with antiplatelet therapy alone (0% vs. 4.9%, p < 0.001) [115]. Within the comparison of
antiplatelet therapy or anticoagulant therapy, recurrent stroke at five years was observed in 3.8% of
patients assigned to antiplatelet therapy vs. 1.5% of patients assigned to oral anticoagulant therapy,
however statistical significance was not analyzed because the study was not powered to compare
outcomes in these groups, hence any conclusion regarding the indirect comparison of PFO closure and
anticoagulant therapy cannot be extrapolated from this study. One device thrombosis was reported, and
no significant differences in terms of major bleeding were recorded. In the RESPECT trial, 980 patients
with previous cryptogenic ischemic stroke were randomly assigned to undergo PFO closure (Amplatz
PFO occluder) or receive medical therapy for a median follow-up of 5.9 years. Patient undergoing PFO
closure received ASA plus clopidogrel daily for one month, followed by ASA alone for five months.
In the medical-therapy group, four regimens were allowed: ASA alone, clopidogrel alone, warfarin
with a goal INR of 2–3, and ASA plus dipyridamole. After a median follow-up of 5.9 years, closure
of PFO was associated with a lower rate of recurrent ischemic stroke than medical therapy (3.6% vs.
5.8%, p = 0.007). There were two cases of device thrombosis treated successfully with intravenous
heparin. Wintzer-Wehekind et al. in a retrospective analysis 453 patient after PFO closure reported
a low but clinically relevant risk of bleeding, which exceeded the risk of ischemic events in their
cohort. As expected, all major bleeding events occurred in patients receiving antiplatelet therapy, and
only one fifth of the patients stopped the antithrombotic therapy within one year after PFO closure.
Antiplatelet therapy discontinuation was not associated with any increase in ischemic events. The
authors concluded that, in patients without any other risk factors, shorter-term (≤1 year) antiplatelet
treatment after PFO closure is a safer option [116].
6.4. Left Atrial Appendage Occlusion (LAAO)
Imaging studies have shown that 90% of thrombotic formations detected in patients with
non-valvular atrial fibrillation are located in the left atrial appendage [117,118]. For this reason,
percutaneous LAA occlusion (LAAO) has become an alternative to anticoagulation for patients that
are ineligible or contraindicated to the medical treatment [119].
The first case of LAA surgical occlusion was reported in 1949 [120], while the first device for
percutaneous exclusion was the PLAATO [121]. This was followed by introduction of the Watchman
device (Boston Scientific) in 2002 and the Amplatzer cardiac plug in 2008, which are currently the
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most used devices in clinical practice. Watchman remains the only device studied in properly sized
randomized trials, such as PROTECT AF [122] and the PREVAIL [123].
The device-oriented need for antithrombotic therapy after percutaneous LAAO has been tackled
differently in various randomized studies and is meant to reduce the risk of device thrombosis,
which is associated with an increased risk of stroke (Figure 4). Device thrombosis was observed
in 4.2% of patients in the PROTECT AF trial with a stroke rate attributable to this event of 0.6%.
Device thrombosis in other recent registries ranged from 1.3% to 7.2% [124]. While most of the data
currently available are obtained from the Watchman device, there is currently a similar approach
to antithrombotic therapy irrespective of the type and size of device implanted. Complete device
endothelization has been observed after 90 days in animal models, but this time may be protracted
in humans, and interindividual variability may be significant, adding uncertainty regarding the
optimal type and duration of the antithrombotic therapy after LAAO. In the PROTECT AF trial, which
included patients with AF without concomitant high bleeding risk, VKA with a target INR of 2–3 was
implemented for 45 days after LAAO and was followed by DAPT for six months and then lifelong
aspirin monotherapy. The same approach was used in the PREVAIL trial [123]. A different approach
has been used in registries including high bleeding risk patients. The ASAP study included patients
with an absolute contraindication to oral anticoagulation, and in this setting the protocol mandated
six months of DAPT followed by lifelong aspirin [122]. Much more variability have been observed in
recent real-world registries, which reflect the extreme heterogeneity of this patient population often
requiring a personalized approach. In the EWOLUTION registry for example, antithrombotic regimens
after LAAO were as follows: warfarin in 16%, DOAC in 11%, DAPT in 60%, SAPT in 7%, and no
therapy in 6% [125]. In a survey by European Heart Rhythm association, showed that DAPT for six
weeks to six months followed by aspirin monotherapy was the most common regimen, while 41% of
centers would prescribe no therapy after LAAO and less than 10% would follow the antithrombotic
regimen advocated by the PROTECT AF protocol [126].
While a randomized comparison on the efficacy of different antithrombotic strategies is lacking, a
recent propensity matched analysis of 1527 patients from various trials and registries implementing
the WATCHMAN device compared OAC vs. antiplatelet therapy after LAAO. The OAC arm included
patients treated with OAC for 45 days after device implantation followed by six months of single or
dual antiplatelet therapy. The antiplatelet therapy arm included patients managed with antiplatelet
therapy alone, either dual or single, for various durations. While the rate of hard endpoints, including
bleeding and thromboembolic events, was similar between the two treatment groups, a significant
excess of device thrombosis was observed in the group among managed with antiplatelet therapy
alone (OAC 1.4% vs. APT 3.1%; p = 0.018). While this comparison was not randomized and there
was a high heterogeneity of treatment types and duration among the two study arms (e.g., APT
included both DAPT and SAPT for various duration), this study stressed the importance of specific
antithrombotic treatment after LAAO. In a retrospective series of 487 patients undergoing WATCHMAN
or ACP/Amulet implantation, 208 received SAPT therapy only or no antithrombotic therapy after
LAAO. In this series device thrombosis was as high as 7.2%, and in multivariable analysis DAPT or
OAC therapy were protective for device thrombosis compared to SAPT or no therapy, raising concerns
on the safety of such treatment strategy after LAAO [124].
While awaiting future randomized clinical trials which are urgently needed to shed light
on the optimal antithrombotic treatment strategy after LAAO, the European Heart Rhythm
Association/European Association of Percutaneous Cardiovascular Interventions (EHRA/EAPCI)
expert consensus statement recommends treatment with OAC for at least six weeks followed by DAPT
for six months and a single antiplatelet drug thereafter in patients without contraindications for OAC.
Instead, patients ineligible to OAC should be managed with DAPT for 1–6 month followed by aspirin
monotherapy indefinitely [125]. In addition, evidence coming from real-world registries, supported the
safety of treatment with DOAC post-LAAC, and updates in international LAAC device labeling now
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admits three-month DAPT or direct OAC therapy post-LAAC, if the standard regimen with 45 days of
warfarin followed by DAPT up to six months is not an option.
Importantly, since the risk of device thrombosis varies based on both patients’ characteristics and
device placement, personalization of the treatment type and duration taking into consideration these
variables together with the baseline bleeding risk should always be a priority. The most recognized
predictors of stroke and device thrombosis are left ventricular ejection fraction <40%, female sex,
smoking, higher CHA2DS2-VASc score, spontaneous echocardiographic contrast, pre-existing LAA
thrombus, and LAA peak emptying velocity [127–129]. Other mechanical factors such as deep
implantation of the device forming a neoappendage or failure of disc apposition and significant
residual device leak (>5 mm) are other factors of additional thromboembolic risk.
7. Conclusions
Antithrombotic agents are among the most prescribed treatments in cardiology, and their
implementation for secondary prevention of spontaneous vascular or device-related thrombotic
complications after percutaneous cardiovascular interventions has been extensively explored. While
dual antiplatelet therapy after PCI and stenting has been studied in the last two decades, the search for
the optimal antithrombotic therapy after structural interventions is still in its infancy. Intensification
or prolongation of the antithrombotic strategy is generally associated with a superior efficacy for
ischemic events prevention but also to an excess of bleeding, which should be avoided. Patient-centered
data informing decision-making and treatment personalization represent the main objective of future
research, in order to optimize the balance between ischemic and bleeding complications.
Author Contributions: A.C.: Conceived the review, drafted and critically revised the text. P.M.: Conceived the
review, drafted and critically revised the text. G.L.: Conceived the review, G.M.-G.: Conceived the review, drafted
and critically revised the text Critically revised the text. V.G.-R.: Critically revised the text. A.P.: Critically revised
the text. F.D.: Conceived the review, drafted and critically revised the text G.G.: Conceived the review, drafted
and critically revised the text. F.C.: Conceived the review, drafted and critically revised the text. S.C.: Critically
revised the text. F.S.: Critically revised the text. S.G.: critically revised the text.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
ACS Acute coronary syndrome
AF Atrial fibrillation
ASA Aspirin
BARC Bleeding Academic Research Consortium
BMS Bare metal stent
CABG Coronary artery bypass graft surgery
CAD Coronary artery disease
CI Confidence interval
DAPT Dual antiplatelet therapy
DAT Dual antithrombotic therapy
DES Drug eluting stent
DOAC Direct Oral anticoagulant
HR Hazard ratio
ISTH International Society on Thrombosis and Haemostasis
LAA Left atrial appendage
LAAO Left atrial appendage occlusion
MACCE Major Adverse Cardiovascular and Cerebrovascular Events
MI Myocardial infraction
NSTEMI Non ST-segment Elevated Myocardial Infarction
OAC Oral anticoagulant
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P2Y12i Receptor P2Y12 inhibitor
PAD Peripheral arterial disease
PCI Percutaneous coronary intervention
PFO Patent foramen ovale
PTCA Percutaneous transluminal coronary angioplasty
PV Prosthetic Valve
RCT Randomized controlled trial
SAPT Single antiplatelet therapy
TAT Triple antithrombotic therapy
TAVI Transcatheter aortic valve implantation
TVMR Transcatheter mitral valve repair
VKA Vitamin k antagonist
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Abstract: Since its introduction, the transradial access for percutaneous cardiovascular procedures has
been associated with several advantages as compared to transfemoral approach, and has become the
default for coronary angiography and intervention. In the last 30 years, a robust amount of evidence on
the transradial approach has been mounted, promoting its diffusion worldwide. This article provides a
comprehensive review of radial artery access for percutaneous cardiovascular interventions, including
the evidence from clinical trials of transradial vs. transfemoral approach, technical considerations,
access-site complications and limitations, alternative forearm accesses (e.g., ulnar and distal radial
artery), and ultimately the use of the radial approach for structural interventions.
Keywords: radial; ulnar; distal radial; snuffbox; percutaneous coronary intervention;
aortic valvuloplasty
1. Introduction
The radial artery has progressively become during the last decade the standard access site for
percutaneous coronary diagnostic and interventional procedures. The first report of transradial access
(TRA) for cardiovascular diagnostics dates to 1947, when Radner performed an aortography via radial
artery employing a cut-down technique [1]. Afterwards, in 1989, Campeau published the first case
series of 100 transradial coronary angiographies performed through the radial access, emphasizing
the safety and the fast mobilization of patients with this approach [2]. Hereafter, in 1993, Kiemeneij
described three cases of transradial coronary stenting [3]. On the basis of this pioneering work, TRA
gradually diffused supported by a growing body of evidence. As compared to the transfemoral
approach (TFA), the radial artery has a more superficial location that allows an easier localization
and compression resulting in a lower rate of hemorrhagic complications. Furthermore, the absence
of damageable structures reduces the risk of complications due to the puncture itself, while the
vascular reserve provided by ulnar artery limits distal ischemic injury of the hand. In addition,
the radial access improves patient comfort and accelerates mobilization. On the contrary, radial
interventions may result tricky in case of tortuous anatomies of the subclavian axis and results in a
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more difficult coronary cannulation and catheter manipulation. This results in a significant learning
curve for operators that trained with femoral approach as a standard access site. While radial access
provides undoubted advantages in most of coronary interventional cases, femoral access remains the
preferred route for complex high-risk coronary interventions or when bulky devices are necessary
(e.g., mechanical circulatory support, structural procedures etc.). The purpose of this review is to
provide a comprehensive overview of the evidence, technical considerations, and future perspectives
of the radial artery and other forearm arterial approaches for cardiovascular interventions.
2. Evidence Supporting Transradial Artery Access
A solid body of evidence have mounted in the last 10 years regarding the advantages provided
by the radial approach for coronary interventions (Table 1). The Mortality benefit Of Reduced
Transfusion after percutaneous coronary intervention via the Arm or Leg (MORTAL) registry [4],
a large retrospective study including 30,900 patients treated with percutaneous coronary intervention
(PCI), showed for the first time a reduced need for blood transfusion and 1-year mortality with TRA as
compared to TFA. These preliminary findings were confirmed by other observational studies. The lack
of randomized evidence confronting radial vs. femoral approach was filled by the RadIal Vs. femorAL
access for coronary intervention (RIVAL) trial [5], the first randomized comparison between TRA
and TFA for PCI in patients with acute coronary syndromes. The RIVAL trial enrolled 7021 patients,
which were randomly assigned to TRA (N = 3507) or TFA (N = 3514) at the time of vascular access.
The primary endpoint, a composite of death, myocardial infarction, stroke, or non-coronary artery
bypass graft (CABG)-related major bleeding at 30 days, was similar in both groups (3.7% in TRA
vs. 4.0% in TFA; HR 0.92, 95% CI 0.72–1.17; P = 0.50). No difference for ischemic endpoints was
observed between the two treatment arms, neither a difference in terms of the primary safety endpoint
of non-CABG major bleeding. Post-hoc analysis including an alternative definition of bleeding showed
a significant reduction of major bleeding with TRA. Major vascular complications were more common
in the TFA group (1.4% vs. 3.7%; P < 0.0001), whereas the need for access-site crossover (i.e., transition
between the randomly assigned access to an alternative access) was more common in the TRA group
(7.6% vs. 2.0%; P < 0.0001). The subgroups analysis of the primary endpoint revealed a significant
interaction favoring TRA over TFA in highest tertile volume radial centers (HR: 0.49, 95% CI: 0.28–0.87;
P = 0.015) and in patients presenting with ST-segment elevated myocardial infarction (STEMI) (HR:
0,60, 95% CI: 0.38–0.94; P = 0.026). In particular, in patients with STEMI approached via TRA a lower
rate of the composite of death, MI and stroke (P int = 0.011), and death for all causes (P int = 0.001) was
also observed, in line with the hypothesis that a more intensive antithrombotic regimen implemented
in STEMI patients could unveil the benefit of the radial access.
The overall neutral findings of the RIVAL trial contrasted with the previous evidence from
observational studies. A possible explanation for this inconsistency could be found in a deeper
evaluation of this study. A subsequent analysis of the RIVAL trial showed that all the access-site major
bleeding reported in the radial arm were due to intra-aortic balloon pump use and radial-to-femoral
crossover, which were assigned to the radial cohort in keeping with the intention-to-treat analysis.
After relocating these events in the femoral group in the as-treated analysis, a significant relationship
between femoral approach and access-site major bleeding was found also for the study safety endpoint
(0 vs. 18 events) [5]. Finally, the RIVAL trial may have been underpowered to observe differences in
non–CABG-related major bleeding, hence reducing its ability to find superiority for the radial approach
on the primary endpoint [5].
In line with the STEMI subgroup analysis of the RIVAL trial, the Radial versus Femoral Randomized
Investigation in ST-Elevation Acute Coronary Syndrome (RIFLE-STEACS) trial, tested the superiority
of TRA vs. TFA in patients presenting with STEMI [6]. This study enrolled 1001 patients undergoing
primary or rescue PCI. The primary endpoint of the study was a composite of death, myocardial
infarction, target lesion revascularization, stroke or non–CABG-related major bleeding defined by
Bleeding Academic Research Consortium (BARC) at 30-days. TRA was ultimately associated with
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a significant reduction of the primary endpoint (13.6% in TRA vs. 21% in TFA; P = 0.003), reduced
non–CABG-related major bleeding (7.8% in TRA vs. 12.2% in TFA; P = 0.026) and overall mortality
(5.2% in TRA vs. 9.2% in TFA; P = 0.02). These impressive results should be closely analyzed
to understand major differences with the RIVAL study. All operators in the RIFLE-STEACS were
experienced and highly skilled performing more than 200 PCI per year with the radial approach.
Furthermore, the mortality and the bleeding event-rate observed in the RIFLE-STEACS population
was higher compared to previous studies, likely owing to the inclusion of a higher risk population
with extensive use of GPIIb/IIIa inhibitors. Moreover, a subsequent analysis using the more stringent
Thrombosis in Myocardial Infarction (TIMI) bleeding definition revealed no difference in access-site
bleeding among the two treatment arms [6].













Radial 3507 27 73 1.3 3.2 1.4 0.7
Femoral 3514 29 71 1.5 3.2 3.7 0.9
RIFLE-STEACS, 2012
Radial 500 100 - 5.2 7.2 2.6 1.8
Femoral 501 100 9.2 11.4 6.8 2.8
STEMI-RADIAL, 2014
Radial 348 100 - 2.3 3.4 0.6 1.4
Femoral 359 100 3.1 4.2 5.3 7.2
MATRIX, 2015
Radial 4197 48 52 1.6 8.8 0.4 1.5
Femoral 207 48 52 2.2 10.2 1 2.3
SAFARI-STEMI, 2019
Radial 1136 100 - 1.5 4 - 1.1
Femoral 1156 100 1.3 3.4 1.3
STEMI: ST-Elevation myocardial infraction. NSTE-ACS: non-ST-Elevation acute coronary syndrome. MACE: major
adverse cardiovascular events.
Subsequently, the STEMI-RADIAL trial, a multicenter randomized study, compared TRA and
TFA in patients undergoing primary PCI performed by high-volume operators experienced in both
access sites. The study enrolled 707 patients with STEMI who were randomized to TRA (N = 348) or
TFA (N = 359) before the primary PCI [7]. The primary endpoint, a composite of major bleeding and
vascular access-site complications at 30 days, was significantly lower in the radial cohort (1.4% vs. 7.2%;
P < 0.0001). Likewise, the net adverse clinical events (NACE) rate, a composite of death, myocardial
infarction, stroke, major bleeding and vascular complications was lower in the radial cohort (4.6% vs.
11%; P = 0.0028). The mortality at 30 days was similar in both group (2.3% in the TRA group vs. 3.1%
in TFA group; P = 0.64).
A paramount contribution in the field was given by the Minimizing Adverse Hemorrhagic
Events by TRansradial Access Site and Systemic Implementation of angioX (MATRIX) program [8,9].
This large multicenter study was designed to assess if TRA or bivalirudin, compared with TFA or
unfractionated heparin, decrease the 30-day incidence of ischemic or and/or bleeding events in patients
with acute coronary syndrome undergoing early invasive management. The MATRIX access [10],
the first trial from this program, was a multicenter superiority trial comparing TRA versus TFA.
The study population was composed of 8404 patients with acute coronary syndrome, with or without
ST-segment elevation myocardial infarction, undergoing coronary angiography and PCI which were
randomized to TRA (N = 4197) or TFA (N = 4207). The two co-primary endpoints were Major Adverse
Cardiovascular Events (MACE) at 30 days and NACE at 30 days using the BARC major bleeding
definition. Results showed a similar MACE rate in both groups (8.8% in TRA group vs. 10.3% in TFA
group; RR: 0.85, 95% CI: 0.74–0.99; P = 0.0307, non-significant α of 0.025) whereas NACE rate was
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lower in patients of TRA group (9.8% vs. 11.7%, RR: 0.83, 95% CI: 0.73–0.96; P = 0.092). The benefit in
radial access was mainly due to a significant reduction of non-CABG-related major bleeding (1.6% in
TRA group vs. 2.3%, RR: 0.67, 95% CI: 0.49–0.92; P = 0.013) and all-cause mortality (1.6% in TRA group
vs. 2.2% in TFA group, RR: 0.72, 95% CI: 0.53–0.99; P = 0.045). Results remained consistent also at a
longer-term follow-up of one year [11].
A meta-analysis of the these four multicenter randomized trials (RIVAL, RIFLE-STEACS,
STEMI-RADIAL, and MATRIX access) including a total of 17,133 patients (8552 in TRA group
and 8581 in TFA group) demonstrated that TRA reduced mortality (RR: 0.73, 95% CI: 0.59–0.90;
P = 0.003), major adverse cardiovascular events (RR: 0.86, 95% CI: 0.75–0.98; P= 0.025) and major
bleeding (RR: 0.57, 95% CI: 0.37–0.88, P = 0.011) with no effect on myocardial infarction or stroke. Yet,
a minimal procedural time delay (standardized mean difference of 0.11 min; 95% CI: 0.04–0.18 min;
P = 0.002) and a higher rate of access-site crossover (6.3% vs. 1.7% P = 0.001) was associated with
TRA [12]. These results remained consistent in a second subanalysis including also observational
studies [13].
Recently, the SAFARI-STEMI trial, presented at the American College of Cardiology in 2019 [14]
compared TRA and TFA in 4884 patients undergoing primary PCI for STEMI. At interim analysis,
due to lower than expected rate of the primary outcome, the study was terminated for futility. Finally,
just 2292 patients were enrolled a randomized to TRA (N = 1136) or TFA (N = 1156). Results showed
no difference in 30-day all-cause mortality (1.8% in TRA group vs. 1.6% in TFA group; P = 0.83),
reinfarction (1.8% in TRA group vs. 1.6% in TFA group; P = 0.83), stroke (1.0% in TRA group vs. 0.4%
in TFA group; P = 0.12) and a composite endpoint including death, reinfarction and stroke (4.0% in
TRA group vs. 3.4% in TFA group; P = 0.45). Unexpectedly, the bleeding rate was comparable between
the two groups independently from bleeding definition used (1.1% in TRA group vs. 1.3% in TFA
group; P = 0.74).
3. Technical Factors and Access-Site Complications
The radial artery originates, together with the ulnar artery, from the brachial artery bifurcation at
the proximal border of the antecubital fossa (Figure 1).
Figure 1. Arterial anatomy of the wrist/hand and potential vascular accesses.
The radial artery can be divided in three segments: the proximal segment laying in the forearm,
the middle segment running in the back of the wrist, and the distal segment transitioning from the
wrist to the dorsal side in the hand through the anatomical snuffbox. An intricate anastomotic network
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formed by the deep palmar arch, deriving mainly from the radial artery, and the superficial palmar arch
deriving mainly by the ulnar artery provides the hand a dual blood supply. As observed in post-mortem
studies [15] this anastomotic circle can present highly variable patterns. Sometimes, a superficial
palmar branch can stem from the radial artery in the forearm and it can converge in the distal ulnar
artery segment, completing the superficial palmar arch; in the same way, a deep palmar branch can
stem from distal ulnar artery and it can converge in the distal radial artery completing the deep palmar
arch. Theoretically, the patency of palmar connection between radial and ulnar artery is essential to
prevent hand ischemic complications if the radial or the ulnar artery occludes. Several non-invasive
tests have been proposed to evaluate the palmar arch circulation: the Allen test, the modified Allen
test, and the Barbeau test. In the modified Allen test, the patient first has to lift the hand and clench the
fist, then the operator compresses both radial and ulnar artery to block the flow and finally the patients
opens the fingers, the operator removes ulnar artery compression and counts the time necessary to
recolor the hand. The test is normal if blushing appears within 5 s, it is intermediate if blushing appears
between 6 and 10 s, it is abnormal if blushing takes more than 10 s to appear. Similarly, the Barbeau
test is performed in a similar manner as the modified Allen test but implements the evaluation of
the plethysmographic waveform and pulse oximetry evaluation of the hand [16]. Recently, the laser
Doppler scan, a novel promising non-invasive diagnostic technique, has been described [17]. It uses a
low-power laser beam and generates color maps of blood perfusion. This test allows quick and easy
diagnosis of radial artery occlusion after catheterization in an operator-independent manner [18].
Nevertheless, the effectiveness of these non-invasive tests is debatable and did not appear essential
to prevent hand ischemia.
The Predictive Value of Allen’s Test Result in Elective Patients Undergoing Coronary
Catheterization Through Radial Approach (RADAR) study [19] evaluated prospectively the safety and
feasibility of TRA approach in relation to the Allen test. The study enrolled 203 patients undergoing
elective or urgent coronary catheterization which were divided based on Allen test results in three
groups: normal (N = 83), intermediate (N = 60) and abnormal (N = 60). Every patient was subjected
to serial assessments of thumb capillary lactate (the primary endpoint), thumb plethysmography,
ulnar frame count, handgrip strength tests, and discomfort ratings. No statistically significant
difference emerged among the 3 study groups for lactate (mean: 1.85 ± 0.93 mmol/L in normal group,
1.85 ± 0.66 mmol/L in intermediate group, and 1.97 ± 0.71 mmol/L in abnormal group; P = 0.59),
handgrip strength test results, and discomfort ratings after the procedure or at other time points during
the study. In patients with abnormal or intermediate results, plethysmography revealed ulnopalmar
collateralization improvements while the ulnar frame count was reduced, indicating augmented ulnar
flow after TRA.
The ACRA anatomy study (Assessment of Disability After Coronary Procedures Using Radial
Access) [20] evaluated the clinical relevance of the palmar arch incompleteness and the correlation to
commonly used patency tests. This study enrolled 234 patients undergoing TRA cardiac catheterization.
Patients were valued angiographically to define the hand vascular anatomy and with modified Allen
test and Barbeau test before TRA. Furthermore, a functional evaluation of the hand was assessed
at baseline and 2-year follow-up by the QuickDASH, a shortened version of the 30-item DASH
(Disabilities of the Arm, Shoulder and Hand) questionnaire. Results showed that incompleteness of the
superficial palmar arch was present in 46% of patients, meanwhile the deep palmar arch was complete
in all patients. Modified Allen test and Barbeau test results were associated with incompleteness
of the superficial palmar arch (P = 0.001 and P = 0.001). The modified Allen test sensitivity and
sensibility for superficial palmar arch incompleteness were 33% and 86% respectively with a cut-off
of >10 s and 59% and 60% respectively with a cut-off of >5 s. The Barbeau test sensitivity and
specificity were 7% and 98% respectively for type D and a 21% and 93% respectively for types C
and D combined. The upper-extremity dysfunction had no correlation with superficial palmar arch
incompleteness (P = 0.77). These results suggested that while the incompleteness of the superficial
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palm arch is common, a complete deep palmar arch guarantees the blood supply to distal districts,
and the preprocedural patency tests do no add benefit to prevent ischemic complications of the hand.
The ACRA-perfusion [21], a prespecified sub-study of the ACRA anatomy study, focused on how
transradial approach may impair digital perfusion. Sequential laser Doppler perfusion imaging was
used to evaluate digital perfusion in 100 patients undergoing elective transradial cardiac catheterization
in comparison with contralateral hand. The primary outcome was thumb perfusion at baseline,
during radial access, at TR band application and at discharge. The vascular anatomy was assessed
with angiography and the upper-extremity function was measured by QuickDASH questionnaire at
baseline and follow-up. Results showed a reduced tissue perfusion during radial access and during TR
band application both in the homolateral thumb (−32% and −32%, respectively) than in contralateral
thumb (−34% and −21%, respectively). No perfusion difference emerged during TRA between the
homolateral and the contralateral thumb (arbitrary flux units: 217; IQR, 112–364 vs. 209; IQR, 99–369;
P = 0.59). There was no association between reduced thumb perfusion and superficial palmar arch
incompleteness (complete superficial palmar arch 56% vs. incomplete superficial palmar arch 71%;
P = 0.13). Digital perfusion at discharge remained below baseline levels but showed an improving
trend (homolateral −11% and contralateral −14%). Reduced digital perfusion during TRA was not
associated with hand dysfunction at 18 months.
The radial approach procedure begins with the administration of local anesthetic to limit the
patient’s discomfort, usually a modest dose (1–2 mL) is used to not distort the normal anatomy.
The radial artery cannulation is commonly obtained close to the styloid process with two different
techniques: the Seldinger and the modified Seldinger technique [22]. The Seldinger technique employs
a catheter-over-needle system which is used first to pass the anterior wall and subsequently, when
blood fills the needle, the posterior wall; the needle is then removed and the catheter is slowly draw
back until a pulsatile blood flow is obtained; finally a 0.021-inch guidewire is advanced, the catheter is
removed, and the introducer over the wire is placed. The modified Seldinger technique employs a
micro-puncture needle entering arterial lumen, as soon the blood flows through the needle a 0.018 inch
or 0.021 inch guidewire is advanced into the vessel, the needle is removed, and an introducer over
the wire is placed. A randomized evaluation of these two techniques was performed in 412 patients
undergoing TRA catheterization [23]. 210 patients were approached with the Seldinger technique and
212 with the modified Seldinger technique. Results showed a statistically significant advantage for the
Seldinger technique regarding time to gain radial artery access (mean time in seconds 78.3 ± 37.7 vs.
134.2± 87.5; P< 0.001) and total procedure time (mean time in minutes 17.1± 6.4 vs. 19.3± 7.1; P < 0.01),
while no difference emerged in post-procedural hematoma (0.5% vs. 1.5%, P > 0.2), and radial artery
occlusion at 24 h (8% vs. 7.9%; P > 0.5) or at 30 days (4.3% vs. 3.9%; P > 0.5). A meta-analysis comparing
all available studies on the use of 5-Fr versus 6-Fr system in coronary procedures through the TRA
showed a significant lower contrast medium administration (MD = −22.20 (−36.43 to −7.9), P < 0.01)
and bleedings (OR = 0.58 (0.38–0.90), P = 0.02) of 5-Fr system, without compromising procedural
success (OR = 0.95 (0.53–1.69), P = 0.86) or procedure length (OR = 0.55 (−2.58 to 3.69), P = 0.73),
compared to the 6-Fr system [24].
Introducer sheaths of different sizes are available on the market and many operators usually
prefer longer sheaths (23 cm) as compared to short sheaths (13 cm) due to a supposed spasm reduction
and easier catheter manipulation. A randomized controlled trial investigated the impact of length
and hydrophilic coating of the introducer sheath on radial artery spasm, radial artery occlusion, and
local vascular complications in patients undergoing elective transradial coronary procedures [25].
This study enrolled 790 patients, which were randomly assigned to long (23-cm) or short (13-cm) and
hydrophilic-coated or uncoated introducer sheaths. Results showed a reduction of radial artery spasm
(19.0% vs. 39.9%, OR: 2.87; 95% CI: 2.07 to 3.97; P = 0.001) and patient reported discomfort (15.1% vs.
28.5%, OR: 2.27; 95% CI: 1.59 to 3.23; P = 0.001) in patients receiving a hydrophilic-coated sheath while
no difference emerged between long and short sheaths.
224
J. Clin. Med. 2019, 8, 1727
The R-RADAR study [26] (The Rotterdam Radial Access Research Ultrasound-Based Radial Artery
Evaluation for Diagnostic and Therapeutic Coronary Procedures) investigated structural changes
of the radial artery wall after catheterization to define predictors of radial pulsation loss, occlusion,
local pain, or functional impairment of the upper extremity. This prospective, single-center study
enrolled 90 patients undergoing TRA coronary angiography or intervention, which were scanned with
a high-resolution 40-MHz ultrasound (US) before cannulation, at 3 h and 30 days after procedure.
All patients presented acute injuries, predominantly dissection and intramural hematoma, but these
were not associated with loss of radial pulsation, occlusion, local pain, or functional impairment at
30 days. An intimal thickening and total wall thickness increase was observed at 3 h after puncture and
persisted at 30 days, while a modest luminal inner caliber reduction was observed at the puncture site.
Radial occlusion and pulsation loss rate at 30 days were 3.9% and 9.2% respectively. Smaller radial
artery lumen at baseline was associated with an increased the risk of radial pulsation loss at 30 days
(OR 1.23; P = 0.049). The number of radial puncture attempts was associated with 30-day pulsation
loss (OR, 2.64; P = 0.027), artery occlusion (OR, 3.49; P = 0.022), and symptoms (OR 2.24; P = 0.05).
The utility of US for guiding TRA was evaluated in the RAUST study (Radial Artery access with
Ultrasound Trial) [27]. This prospective multicenter trial enrolled 698 patients undergoing transradial
cardiac catheterization that were randomized to needle insertion with palpation (N = 351) or real-time
US guidance (N = 347). The primary endpoints were the first-pass success rate, the total number of
attempts needed for access, and the time to access. US guidance was related to a number attempts
reduction mean: 1.65 ± 1.2 vs. 3.05 ± 3.4; P < 0.0001; median: 1 (IQR: 1 to 2) vs. 2 (1 to 3); P < 0.0001
and to a first-pass success rate improvement (64.8% vs. 3.9%; P < 0.0001) with a consensual time to
access reduction (mean: 88 ± 78 s vs. 108 ± 112 s; P = 0.006; median: 64 (IQR: 45 to 94) vs. 74 (IQR: 49 to
120); P = 0.01). Crossover from palpation to US guidance was necessary in 10 patients with subsequent
successful sheath insertion rate of 80%. US guidance also reduced the difficult access rate procedures
(2.4% vs. 18.6% for ≥5 attempts; P < 0.001; 3.7% vs. 6.8% for ≥5 min; P = 0.07).
The right-sided controls position in the catheterization laboratory predisposes to a right radial
approach (RRA) that both operator and the patients generally prefer [28]. Despite this, the left arterial
access (LRA) offers a direct entrance to the left subclavian artery with a better support for guides
or catheters and ease left internal mammary artery cannulation. Furthermore, the LRA has been
associated with a reduced procedural duration and a higher rate of procedural success mainly due to
the low prevalence of left subclavian artery tortuosity. Controversial data emerged comparing right
and LRA about radiation exposure duration.
The Transradial approach left vs. right and procedural times during percutaneous coronary
procedures (TALENT) [29] study evaluated the safety and efficacy of LRA compared with RRA
for coronary procedures focusing on fluoroscopy time for coronary angiography and PCI (primary
endpoints). Patients age and operator experience were also analyzed. This dual-center study enrolled
1540 patients which were randomized to RRA (N = 770) or LRA (N = 770); 1467 patients underwent
coronary angiography (diagnostic group: 732 with LRA approach and 735 with RRA) and 688 patients
underwent percutaneous coronary procedures (PCI group: 344 each group). Fluoroscopy time (median:
149 s, IQR 95–270 s), as well as Dose Area Product (DAP) (median: 10.7 Gy cm2, IQR 6–20.5 Gy cm2),
were significantly lower with LRA in the diagnostic group when compared with RRA (median: 168 s,
IQR 110–277 s; P = 0.0025 and 12.1 Gy cm2, IQR 7–23.8 Gy cm2; P = 0.004, respectively). No significant
differences emerged in the PCI group in fluoroscopy time (median: 614 s, IQR 367–1087 s for LRA vs.
695 s for RRA, IQR 415–1235 s; P = 0.087) and DAP (median: 53.7 Gy cm2, IQR 29–101 Gy cm2 for LRA
vs. 63.1 Gy cm2 for RRA, IQR 31–119 Gy cm2; P = 0.17). Subgroup analyses revealed that the differences
between left and RRA were linked to patients age (≥70 years old) and to operator experience.
The REVEREE (Randomized Evaluation of Vascular Entry Site and Radiation Exposure) trial [30]
evaluated radiation exposure during cardiac catheterization comparing TFA with LRA and RRA.
This study enrolled 1493 patients undergoing cardiac catheterization that were randomized in a 1:1:1
fashion. The primary endpoint was air kerma, the secondary endpoints included DAP, fluoroscopy
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time, operator dose per procedure, number of cineangiograms, and number of catheters. Results
showed no significant differences among the three group concerning the primary endpoint (medians:
TFA: 421 mGy, IQR 337–574 mGy; LRA: 454 mGy IQR: 331–643 mGy; RRA 483 mGy, IQR: 382–592
mGy; P = 0.146), and DAP (medians: TFA: 25.5 Gy cm2 IQR: 19.6–34.5 Gy cm2; LRA: 26.6 Gy cm2 IQR:
19.5–37.5 Gy cm2; RRA 27.7 Gy cm2, IQR: 21.9–34.4 Gy cm2; P = 0.40), or fluoroscopy time (medians:
TFA 1.3 min IQR: 1.0–1.7 min; LRA: 1.3 min, IQR: 1.0–1.7 min, and RRA: 1.32 min, IQR: 1.0–1.7 min;
P = 0.19). Conversely operator exposure was significantly higher in the LRA group (3 mrem, IQR:
2– 5 mrem) compared with TFA (2 mrem, IQR: 2–4 mrem; P = 0.001) and TRA (3 mrem, QR: 2 to
5 mrem; P = 0.0001).
The RAD-MATRIX [31], a sub-study of the MATRIX [10] investigated if TRA access procedures
compared to TFA increases the radiation exposure risk of operator or patient. A total of 18 expert
operators, performing 777 procedures in 767 patients were recruited and randomized to TRA or TFA.
Each operator was equipped with lithium fluoride thermoluminescent dosimeter to measure radiation
exposure on the thorax (primary endpoint), on the wrist and on the head (secondary endpoints).
Results showed an equivalent dose at the thorax significantly higher with TRA (77 μSv, IQR: 39.9 μSv
to 112 μSv) than TFA access (41 μSv, IQR: 23.4 mSv to 58.5 μSv; P = 0.019) which was still significant
after normalization of operator radiation dose by fluoroscopy time or DAP. Otherwise, there was no
difference in radiation dose at wrist or head among the two cohort. Similar thorax operator dose was
observed for RRA (84 μSv) and LRA (52 μSv; P = 0.15). Operator effective dose was significantly
higher with RRA than LRA (2.6 vs. 1.6 μSv; P = 0.016). A subsequent analysis [32] was performed to
appraise the determinants of operator radiation overexposure with RRA. Operator radiation exposure
was investigated in relation to the right arm position and the upper leaded glass size. Results showed
a greater-than-10-fold difference in radiation at thorax level among the 14 operators who agreed to
participate (from 21.5 to 267 μSv and from 0.35 to 3.5 μSv/Gy*cm2 after DAP normalization). Thorax
dose was higher among operators who positioned the instrumented right arm far from the body (110.4
μSv, interquartile range 71.5–146.5 μSv), when compared to those that placed the instrumented right
arm adjacent to the right leg (46.1 μSv, 31.3–56.8 μSv; P = 0.02) and the difference persisted after
normalization by DAP (P = 0.028). In the same way, smaller full glass shield was associated with a
higher radiation exposure when compared to a larger composite shield (147.5 and 60 μSv, respectively,
P = 0.016).
Apart from the evident impact on vascular complications and access-site bleeding,
the implementation of the radial access showed several additional clinical benefits [33,34]. In the
AKI-MATRIX [35] study, the radial vs. femoral access impact on post-procedural acute kidney injury
was explored. Renal function evaluation regarded 8210 patients, 4109 in the TRA cohort and 4101 in
the TFA cohort. The primary endpoint was acute kidney injury defined as an absolute (>0.5 mg/dl) or a
relative (>25%) increase in serum creatinine. Results showed an overall lower acute kidney injury rate
with TRA compared to TFA (15.4% vs. 17.4%, OR 0.87; 95% CI: 0.77 to 0.98; P = 0.0181). In particular,
a >25% relative serum creatinine increase regarded the 15.4% of the TRA cohort patients and the 17.3%
of the TFA cohort patients (OR: 0.87; 95% CI: 0.77 to 0.98; P = 0.0195), while a >0.5 mg/dl absolute serum
creatinine increase occurred in the 4.3% of patients in the TRA cohort and in the 5.4% of patients in the
TFA cohort (OR: 0.77; 95% CI: 0.63 to 0.95; P = 0.0131). By applying the Kidney Disease Improving
Global Outcomes criteria, acute kidney disease rate was 3-fold less prevalent with TRA access (OR:
0.85; 95% CI: 0.70 to 1.03; P = 0.090), with stage 3 acute kidney injury in the 0.68% of patients in the
TRA cohort and in the 1.12% of patients in the TFA cohort (P = 0.0367). Post-intervention dialysis
was needed in the 0.15% of patients in the TRA cohort and in the 0.34% of patients in the TFA cohort
(P = 0.0814).
A subsequent analysis evaluated how radial and femoral access relate to bleeding, acute kidney
injury and all-cause mortality to clarify the correlation between these different types of events [36].
A multistate and competing risk models highlighted large relative risk reductions in mortality for
TRA compared with TFA access for the transition from acute kidney injury to death (HR 0.55, 95% CI
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0.31–0.97) and for the pathway from PCI to acute kidney injury to death (HR 0.49, 95% CI 0.26–0.92).
On the contrary, there was little evidence for a difference between TRA and TFA groups for the transition
from bleeding to death (HR 1.05, 95% CI 0.42–2.64) and the pathway from PCI to bleeding to death
(HR 0.84, 95% CI 0.28–2.49). These results suggest that radial approach benefit on mortality is mainly
driven by acute kidney injury prevention while bleeding role in this association was minor [33,36].
4. The Distal Radial Approach
The distal radial artery (Figure 2) approach was first introduced by anesthesiologists for
perioperative patient monitoring [37] at the anatomical snuffbox or at the dorsum of the hand.
This access is obtained where the vessel runs superficially, at the intersection of the thumb and first
finger over the bony structures of the snuffbox or at the dorsum of the hand, distal to the tendon
of the extensor pollicis longus muscle. The technique described by Kiemeneij [38] and Davies and
Gilchrist [39] starts with a subcutaneous injection of 1–5 cc of local anesthetic, then the artery is
punctured with a 21-gauge open needle, directed to point of highest pulsation, from lateral to medial
with a 30–45◦ angle. When the blood flows through the needle a flexible, soft, J-shaped 0.21 metallic wire
is inserted and the needle is removed. A small skin incision before introducer placement is sometimes
necessary because the skin is thicker and harder than at the forearm [40]. A through-and-through
technique should be avoided, especially if the artery is approached at the snuffbox, for the high risk of
puncturing the periosteum of the scaphoid or trapezium bones, which can be painful [38]. Hemostasis
is obtained compressing the artery against the base of the 1st or 2nd metacarpal bone and an elastic
bandage might be necessary [39]. Theorized advantages of distal radial approach are a decreased risk
of radial artery occlusion at the forearm, lower bleeding risk, lower vascular access-site complication
rate [41] and an improved operator and patient comfort, especially when approaching left radial
artery [40]. Ongoing randomized controlled trials are evaluating the feasibility and safety of distal
radial approach compared to radial approach in various settings, including patients with STEMI [42].
 
Figure 2. Echocolordoppler image of the distal radial artery.
5. Radial Artery Approach Limitations
Radial artery occlusion (RAO) after radial artery interventions remains an important issue after
TRA. Despite this did not show a significant impact of hand ischemia, RAO may prevent future use
of the radial artery for interventional purposes, for using the radial artery as an arterial conduit for
CABG or in the need for fistula for dialysis.
For this reason, several studies evaluated strategies to reduce the risk of RAO and optimize
radial puncture.
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The PROPHET (Prevention of radial artery occlusion-patent hemostasis evaluation trial) study [43]
enrolled 436 consecutive patients undergoing cardiac catheterization which were randomized to
conventional compression or compression maintaining radial artery patency using plethysmography.
Results showed that implementation of patent hemostasis is highly effective in reducing RAO (59%
decrease at 24 h and 75% decrease at 30 days; P < 0.05).
The PROPHET-II study [44] investigated whether ipsilateral ulnar compression increases radial
artery flow and could impact the incidence of RAO. This trial enrolled 3000 patients undergoing
diagnostic cardiac catheterization, which were randomized to standard patent hemostasis or
prophylactic ipsilateral ulnar compression in addition to patent hemostasis. Plethysmography
was used to evaluate radial artery patency resulting in a lower RAO occurrence at 30 day in patients
with patent hemostasis and prophylactic ulnar compression (0.9% vs. 3.0%; P = 0.0001).
The effect of duration of hemostatic compression on RAO was evaluated in a retrospective
study [45] that involved 400 consecutive patients undergoing transradial PCI. Half of patients received
hemostatic compression for 6 h after the procedure, and the other group for 2 h. Shorter duration of
hemostatic compression was associated with a lower incidence of early RAO (5.5% vs.12%; P = 0.025)
and chronic RAO (3.5% vs. 8.5%; P = 0.035) without differences in bleeding complications although
maintaining radial patency during hemostatic compression, eliminates the adverse effect of duration
of compression.
Use of anticoagulants, administered directly into the radial artery or intravenously, during the
procedure has been demonstrated to reduce the incidence of RAO [46,47], particularly a dose-dependent
effect of unfractionated heparin [48,49].
The artery spasm may determine friction between the artery wall and devices used during TRA
and this endothelial stress can contribute to RAO development. For this reason, the use of vasodilators
has been proposed. Nitroglycerin administrated into radial artery before sheath removal was associated
with RAO incidence reduction [50], as well as and the use of verapamil or verapamil in combination
with nitroglycerin is effective in preventing radial artery spasm [51].
On top of the added risk of long-term RAO, the radial artery has some intrinsic anatomical
limitations that impedes its use in specific types of intervention. The smaller caliber of the artery,
which is 2.5–3.5 times smaller than the common femoral artery, restrict its use in case of larger
devices. For this reason, the femoral artery remain the default access in procedures where bulky
device are needed such as transcatheter aortic valve implantation (TAVI) [52], mechanical circulatory
support including intra-aortic balloon pump (IABP), Impella (Abiomed, Danvers, Massachusetts),
or veno-arterial extracorporeal membrane oxygenation (ECMO) [53]. Furthermore, femoral approach
is still the preferred access site for some complex procedures, particularly angioplasty of coronary
chronic total occlusion [54,55].
6. The Ulnar Artery Approach
The ulnar artery represents an alternative access for percutaneous procedures, and it is increasingly
being used when radial access is not available (Table 2) [56–62]. The ulnar artery stems at the inferior
margin of the antecubital fossa as a large branch of the brachial artery. It passes in the forearm on
the ulnar bone side deep to the flexor muscles and it reaches the hand through the Guyon canal.
As compared to the radial artery, the ulnar artery has a lower incidence of anatomical variations,
loops, and tortuosity; furthermore, the ulnar artery has a modest concentration of adrenergic receptors
that limit the arterial spasm [60]. Conversely the deeper position of the vessel and the absence of a
bony structure to compress against expose to a higher rate of access-site complication and impose a
heavier compression [58]. The access technique for the ulnar artery is similar to the radial, and both
the Seldinger technique and the modified Seldinger technique can be used. The ulnar nerve passes
lateral to the ulnar artery, so it is recommended to start the puncture on the medial side of the ulnar
artery to avoid pain and spasm.
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The PCVI-CUBA [63], a single-center randomized study, compared efficacy and safety of the
transulnar access (TUA) and the TRA in patients undergoing coronary angiography and PCI. This study
enrolled 431 patients who were randomized to TUA (N = 216) or TRA (N = 215). Results showed no
difference among the two groups for successful vascular access (93.1% in the TUA group vs. 95.5%
in the TRA group; P = 0.84), procedural success (95.2% in the TUA group vs. 96.2% in the TRA
group; P = 0.82), arterial occlusion (5.7% in the TUA group vs. 4.7% in the TRA group, P = 0.76) and
major bleeding (5.5% in the TUA group vs. 8.1 in the TRA group, P = 0.47). Procedural time (mean
14 ± 8.2 min vs. 12.7 ± 6.7 min P = 0.06), fluoroscopy time (mean 5.6 ± 5.1 min vs. 5.2 ± 4.2 min,
P = 0.35) and X-ray DAP (mean 7559 ± 4865 mGy/cm2 vs. 7195 ± 4850 mGy/cm2 P = 0.43) were similar
between the two group. Freedom from MACE at 30 days was comparable between the two groups
(97.8% for ulnar group and 95.8% for radial group, P = 0.41).
Another single-center, randomized study [64] evaluated the safety and efficacy of the TUA versus
the TRA for coronary angiography and PCI. This study randomized 240 patients undergoing coronary
angiography, followed or not by intervention. Results showed a comparable artery stenosis rate
between the two groups at 1 day (11.0% in TUA group vs. 12.3% in the TRA group; P = 0.758) and at
30 days (5.1% in the ulnar group vs. 6.6% in the radial group; P = 0.627). Arterial occlusion rate was
similar in the two cohort at 1 day (5.1% in the TUA group vs. 1.7% in the TRA group, P = 0.627) and at
30 days (6.6% in the TUA group vs. 4.9% in the TRA group; P = 0.164). Minor bleeding was similar
between the two groups (5.9% in the TUA group vs. 5.7% in the TRA group; P = 0.949).
In contrast to these single-center studies, the AURA of ARTEMIS trial [62] failed to demonstrate
the non-inferiority of a default TUA compared to TRA. This prospective randomized multicenter study
enrolled 902 patients undergoing diagnostic coronary angiography and PCI who were randomized
to TRA (N = 440) or TUA (N = 462). The primary endpoint was a composite of crossover to another
arterial access, MACE, and major vascular complications of the arm at 60 days. The trial was early
stopped because the first interim analysis showed the inferiority of the TUA for primary outcome
(42.2% vs. 18.0%; P < 0.0001). After adjustment for operator clustering, the difference in the primary
endpoint became inconclusive (24.30%; 99.99% CI, −7.98% to 56.58%; P = 0.03 at α = 0.0001). Moreover,
the crossover rate, which driven most of the difference for the primary endpoint, was higher in the
TUA group, with a difference of 26.34% (95% CI, 21.53%–31.27%; P < 0.001).
A subsequent single-center randomized study [59] including 535 consecutive patients evaluated
safety and feasibility of TUA for coronary catheterization. The primary endpoints were the success of
artery cannulation and the access-site-related complications at day 30 (hematoma, artery stenosis, artery
occlusion, arteriovenous fistula, pseudoaneurysm, and nerve injury). Results showed a comparable
successful puncture rate between the two cohort (91.5% in the TUA group vs. 95.1% in TRA group;
P > 0.05). Hematoma occurrence was similar in between the two groups (7.7% in the TUA group vs.
4.2% in the TRA group; P = 0.100). Ulnar nerve injury occurred in one patient in the TUA group.
Asymptomatic arterial occlusion rate was similar in the two group (1.1% in the TUA group vs. 3.0% in
TRA group; P = 0.137). Freedom from MACE rate was also similar between the two group (90.6% in
the TUA vs. 91.3% in the TRA group; P = 0.985).
A randomized single-center, trial [65] compared the clinical outcomes of 445 patients undergoing
coronary artery intervention with TUA (N = 220) and TRA (N = 225). At 1-year follow-up, the primary
outcome, arterial occlusion of a forearm artery, was lower in the TUA group (2.7% vs. 9.3%; P = 0.007).
The occlusion rate of approached vessel was lower in TUA group (OR 3.85, P 0.006). A higher of
incidence of hematomas (13.2% vs. 5.8%, P = 0.01) and symptoms of discomfort (15.5% vs. 5.8%,
P= 0.002) emerged in the TUA group.
Finally, the AJmer ULnar ARtery Working Group Study (AJULAR) study [56], a single-center,
randomized study, tested the non-inferiority on TUA as compared to TRA when performed by an
experienced operator (at least 150 TRA/year and 50 TUA performed). This study enrolled 2532 patients
undergoing cardiac catheterization who were randomized to TUA (N = 1270) or TRA (N = 1262).
The primary endpoint was a composite of MACE during hospital stay, crossover to another arterial
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access, major vascular events during hospital stay (large hematoma with hemoglobin drop of ≥3 g%)
or vessel occlusion rate. Secondary endpoints were each component of the primary endpoint, failed
attempts (≥3 attempts prior to successful cannulation), procedural and fluoroscopy times, contrast
volume used, and vasospasm. Results showed a similar occurrence of primary endpoint (14.6% in TUA
group vs. 14.4% in TRA group; RR: 1.01; 95% CI: 0.83–1.2; P= 0.92 at α= 0.05). The secondary endpoints
were all comparable among the two groups, except large hematoma, for which non-inferiority could
not be proved. Twelve patients in the TUA group suffered transient paresthesia.
A meta-analysis [66] of six randomized controlled of TUA vs. TRA has been presented, including
5299 patients undergoing percutaneous coronary procedure. Results showed a comparable incidence of
MACE between the two access sites (RR 0.90; 95% CI 0.66–1.23) but an excess of vascular complications
in the TUA group (RR 3.58; CI 2.67–4.79, P < 0.00001). No difference for arterial access time, fluoroscopy
time, and contrast load was observed.
7. Radial Access for Non-Coronary Cardiovascular Interventions
The exponential growth of the technique expanded TRA use also to endovascular peripheral
artery disease interventions and some selected structural heart disease interventions [66–68] TRA has
been reported as primary access-site for alcohol septal ablation [69] paravalvular leak closure [70],
ventricular septal defect closure [71], or balloon aortic valvuloplasty (BAV) [72]. Also, more extensively,
TRA has been used as secondary access for transcatheter aortic valve replacement (TAVR), patent
ductus arteriosus closure, and endovascular repair of abdominal or thoracic aneurysm [68].
In the domain of structural heart interventions, BAV can be a useful tool in patients with severe
aortic stenosis who require urgent non-cardiac surgery or safely bridge to either to Surgical Aortic
Valve Replecement (SAVR) or TAVR [72]. In addition, population’s mean age in western countries
is increasing and it is increasingly important to avoid futile TAVR procedures. Still, there is no clear
evidence on which patients should be preliminarily excluded from aortic valve intervention because of
excessive risk or clinical futility. In this setting BAV as bridge to TAVR, might serve as a stratification
method in uncertain TAVR recipients.
Yet, considering the higher rate of comorbidities in this frail population, the rate of vascular
complications and the relative attributable mortality remain high [73].
For this reason, using alternative vascular approaches, which may reduce the risk of such
complications is attractive. Mini-invasive radial BAV reduces the rate of vascular complications with
feasibility and efficacy comparable with standard femoral approach [74].
Implementation of large-bore access sites from the femoral artery and increasing sheath-artery
diameter ratio invariably increases the rate of vascular complications [75]. Moreover, during
transfemoral TAVR, CT studies of the ilio-femoral arteries confirmed the need for a <1:1 lumen
to sheath ratio to avoid risk of vascular damage and serious adverse events [72].
Yet, owing to specific histologic characteristics of the radial artery wall, the 1:1 safety rule could be
less important in this scenario. The radial artery wall is thicker than that of other arteries [76] and the
prevalent muscular tunica has unique elastic features resulting more compliant than the other arterial
vessels, in which progressive elastic fiber degeneration often increases stiffness in older patients [77].
These features, together with the more superficial position and the easier compression, could
explain the lower incidence of vascular complications during radial BAV.
The first step to perform radial BAV is obtaining two radial accesses with standard technique, or
ulnar access in case radial access would be unavailable. In case only one radial access is possible a
mono-lateral approach could be performed, even if two different arterial accesses provide opportunity
to switch quickly to the contralateral access, check the hemodynamic efficacy of rapid pacing and the
possibility to inject contrast.
After obtaining vascular accesses, the aortic valve should be crossed with conventional 0.035”
guidewire. Then a pigtail catheter is advanced in the left ventricle and basal peak-to-peak and mean
gradients are measured. In this phase, vascular tortuosity of the epi-aortic branches could hinge on
231
J. Clin. Med. 2019, 8, 1727
catheter control. In this case, switching from one radial access to the contralateral could be useful.
After placing a stiff 0.035” guidewire in the left ventricle carefully avoiding mitral chordae along the
path, the 6 French sheath should be exchanged with an 8 or 9 French femoral sheath (depending on the
compatibility of the aortic balloon’s manufacturer used). A very short sheath is preferable (5.5 cm)








Figure 3. Vascular access for radial balloon aortic valvuloplasty. (a) Brite Tip 5.5 cm pediatric 8 French
sheath (CORDIS, Ireland). (b) regular 11 cm 8F sheath, 5 cm out of the distal radial artery. (c) Vascular
access for radial balloon aortic valvuloplasty: “Push and pull” maneuver for balloon retrieval.
When the sheath is in place, advancement of the aortic valvuloplasty balloon is usually very easy.
When the balloon is across the aortic valve the two electric alligator-connectors should be connected
to the distal end of the stiff guidewire placed inside the left ventricle and to a needle placed on the
patient’s skin and connected to a temporary pacemaker [78]. Alternatively, a transvenous temporary
pacemaker stimulating in the right ventricle could be placed through the standard routes. One rapid
160–200 bpm burst should be attempted before the balloon is advanced through the valve to test
pacing efficacy. Once the balloon is advanced through the aortic valve and rapid pacing is started the
balloon is inflated making sure to maintain position inside the valve. When several inflations have
been performed (usually 2–3), the balloon should be exchanged with a pigtail catheter to measure the
final pressure gradient.
The balloon could be then retrieved: this is usually easy until it reaches the radial artery. Ideally,
two operators should coordinate a “push and pull” maneuverer to minimize the friction of the balloon
on the arterial wall in this phase (Figure 3c) and perform a gentle retrieval through the sheath. At this
stage of the procedure the patient may complain of acute but transient pain in the forearm region.
It is advisable to perform a careful hemostasis of the radial artery to minimize the risk of occlusion.
Good results have been described with patent hemostasis.
According to the experience gained with the radial BAV pilot study and the subsequent ongoing
multicenter SOFTLY2 Register, mini-invasive radial BAV is feasible in most patients, regardless of the
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body weight. Nevertheless, there are some contraindications to the procedure that, even if uncommon,
they should to be highlighted: first, the presence of a very small artery with a high take-off of the
artery above the elbow or a diffusely diseased radial artery, which is often discovered after several
failed attempt to advance diagnostic catheters over the elbow. In addition, severe loops or accessory
radial artery anatomy, could increase the risk of arterial rupture. Finally, the evidence of Monkeberg’s
disease of the forearm arteries (extended calcifications) should discourage any procedure’s attempt.
8. Conclusions
TRA is now established as the standard of care access for percutaneous coronary diagnostic and
intervention. While TRA already demonstrated a sizable benefit in terms of hard endpoints compared
to TFA, a continuously growing body of evidence is focused on surpassing current TRA limitations and
expanding alternative vascular accesses, as TUA or distal radial artery for cardiovascular interventions.
The recent implementation of TRA as primary or secondary access site for peripheral and structural
interventions might provide some of the advantages already observed in the coronary domain also
in these new techniques. Nevertheless, owing to the intrinsic anatomical limitations of the TRA
preventing large-bore device use, mastering best practices for femoral access remain a priority for
future generations of interventional cardiologists.
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Abstract: The idea of right heart catheterization (RHC) grew in the milieu of modern thinking about
the cardiovascular system, influenced by the experiments of William Harvey, which were inspired by
the treatises of Greek philosophers like Aristotle and Gallen, who made significant contributions to the
subject. RHC was first discovered in the eighteenth century by William Hale and was subsequently
systematically improved by outstanding experiments in the field of physiology, led by Cournand and
Dickinson Richards, which finally resulted in the implementation of pulmonary artery catheters (PAC)
into clinical practice by Jeremy Swan and William Ganz in the early 1970s. Despite its premature
euphoric reception, some further analysis seemed not to share the early enthusiasm as far as the safety
and effectiveness issues were concerned. Nonetheless, RHC kept its significant role in the diagnosis,
prognostic evaluation, and decision-making of pulmonary hypertension and heart failure patients.
Its role in the treatment of end-stage heart failure seems not to be fully understood, although it is
promising. PAC-guided optimization of the treatment of patients with ventricular assist devices and
its beneficial introduction into clinical practice remains a challenge for the near future.
Keywords: right heart catheterization; pulmonary hypertension; heart failure; diagnosis; prognostic
evaluation; clinical implications
1. Introduction
1.1. Aim of the Review
To elucidate the state of the art of right heart catheterization, focusing on the background of the
initial experiments and its physiological meaning, which leads to its implementation in clinical practice.
To indicate potential directions for future research.
1.2. From Greek Philosophy into Modern Understanding
Right heart catheterization (RHC) has emerged as an invasive procedure with a potent role
among the current armory of clinical diagnostic tools, including computed tomography (CT), magnetic
resonance imaging (MRI), and genetical immunoassays sampling [1,2]. The birth of this technique is
strictly associated with the genial English physiologist and physician William Harvey (1578–1657),
who actually proposed a theoretical model of the functioning of an animal circulatory system, which
he unveiled in the work entitled Exercitatio Anatomica de Motu Cordis et Sanguinis in Animalibus
and published in 1628 in Frankfurt [3].
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The work, containing 17 chapters within 72 pages, irretrievably changed the modern understanding
of the blood circulation. It is important to keep in mind that Galen was the first person to make
extraordinary contributions to the concepts of physiology and medicine that turned out to be widely
accepted paradigms. He believed that the circulatory system consisted of two separated parts:
venous, originating from the liver, and arterial, originating from the heart. The idea of two separate,
unidirectional systems of distribution rather than a unified system of circulation remained unchallenged
for many centuries. Harvey, although heavily influenced by his potent predecessor, unwillingly found
himself in the position of a revolutionary antagonizer. Harvey’s way of thinking and analyzing
different phenomena was heavily influenced by another ancient Greek philosopher, Aristotle [4,5].
The Aristotelian way of thinking would be to engage not only rigorous mathematical calculations but
also analogies to the natural phenomena covered by physics, biology, and other empirical sciences.
“De motu cordis” was released in Europe during the Thirty Years’ War, described as one of
the most destructive and violent periods in human history. This era was characterized by different
political, religious, and cultural movements (the Reformation, Counter-reformation, and forming of
the Anglican Church). During these times of overwhelming crime, plagues, and the rising wave of
inquisition, the signs of independent thinking, especially when based on evidence and experiments,
were unwanted and considered dangerous [6,7].
1.3. Pioneers of Right Heart Catheterization
As time passed, further attempts to experimentally evaluate the circulatory system were made.
In 1711, Stephen Hale reported the measurement of cardiac output (CO) with the use of brass
pipes introduced into equine veins and arteries [8–11]. The technical aspects of these examinations
were further improved by Claude Bernard, who challenged the pulmonary combustion model
of circulation, claiming that the blood temperature varies significantly between the systemic and
pulmonary circulatory system [12]. Since his previous attempts to encounter surgical techniques in the
temperature measurement appeared to be inaccurate, Bernard developed the technique of exposing
the jugular vein and carotid artery of a horse in order to perform the measurements above. Bernard
proved the technical feasibility of those examinations, which were continued by another two French
physiologists, Baptiste Chauveau and Étienne Marey [13–15]. The collaboration of these has been
linked to the virtual beginning of intracardiac pressure recordings.
The innovative dual-lumen catheter device was designed to simultaneously assess the intracardiac
pressures of the left ventricle and the aorta, as well as the atrium and the right ventricle.
These experiments discovered the so far unreported phenomena of ventricular pressure curves,
isometric phase of ventricular contraction, interventricular synchrony, and the chronology of valve
closing. It is worth noting that Marey was also renowned as a pioneer of electrocardiography,
with significant contributions in the field made by the discovery of the refractory period in 1875 and
the first recording of electrocardiogram with the use of capillary electrometer in 1876 [16].
Remarkably, it was nearly three decades before Willem Einthoven reported his invention,
which was about to revolutionize the modern diagnosis and treatment of cardiovascular disorders.
In his late years, Marey, being somehow possessed by the idea of a general visualization of the
motion of different species present in the environment, turned his professional activity towards
chronophotography, which he documented in books entitled Le mouvement and Le vol des oiseaux [17].
1.4. Nobel Prize for the Famous Three
German scientists Fritz Bleichroeder, Ernst Unger, and W. Loeb continued the pathway of right
heart catheterization in animals, and performed self-experiments in that field; however, these were
scarcely documented [18]. A breakthrough came when a recently graduated doctor Werner Forssmann
performed the first in-vivo catheterization of his own heart, which took place in Eberswalde in
1929 [19–24]. This experiment was an act of bravery which took the human cardiac catheterization
from theory into practice in a short period of time. Forssmann’s attitude towards the National Socialist
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German Workers’ Party (NSDAP) arose from the phase of an early euphoria into the late deception
and was basically indifferent from the typical attitude of his fellow countrymen [25].
The denazification process, to which he had been submitted in the late 1940s, did not alter his
recognition in the area of right catheterization, for which he was awarded the Nobel Prize in 1956,
along with Doctors André Cournand and Dickinson Richards. Remarkably, Doctors Cournand and
Richards, during their work at the Department of Physiology of the Bellevue Hospital in New York,
made an extraordinary contribution to the refinement of the antecedents techniques; they were the first
to report a reliable measurement of CO using the Fick principle [26].
1.5. Jeremy Swan and William Ganz—Catheterization in Clinical Practice
Moreover, they understood the phenomenon of oxygen debt in the setting of “clinical shock”,
which they managed to treat successfully with the implementation of a human serum albumin [27].
These observations set the stage for future scientific research in the field of different kinds of shock, their
risk stratification and management [28,29]. Interestingly, Cournand positively verified the usefulness
of a ballistocardiogram and its correlation with the results of invasive measurement of CO performed
using the Fick principle [30]. Having proven that the catheter might be uneventfully left in the right
heart cavities for a prolonged period, exceeding twenty-four hours, some further improvements were
made, which eventually evolved into the discovery of the pulmonary capillary/artery wedge pressure
(PCWP/PAWP).
Its monitoring, first demonstrated by Hellems and co-workers, was a fairly safe technique
of estimating left atrial pressure in the absence of mitral regurgitation [31]. Remarkably, another
innovation was associated with the introduction of a balloon at the end of the tip, whose presence
facilitated migration with the blood flow [32,33]. Another improvement was associated with the
utilization of the thermodilution method to precisely assess CO. Needless to say, it added important
information that, along with the modifications above, appears safe and reliable [34,35]. To see the
milestones of RHC, please refer to Figure 1.
1.6. Technique of the Measurement and Basic Definitions
The preferred access point is the internal jugular vein. Its patency and anatomical
conditions are reassured during an ultrasound examination, which is believed to reduce access
site complications [36–39]. The currently used Seldinger technique is based on the principle of a
guiding wire that enters into the vessel lumen. After an anatomical evaluation of a correct position,
a special, dedicated sheath with a valve is inserted into the lumen, enabling easy access into the internal
jugular vein and the subsequent structures [40–43]. A Swan-Ganz (S-G) catheter, basically not different
from the prototype used by its inventors in 1970, is inserted via the internal jugular vein into the
right atrium, ventricle, and pulmonary arteries. In some cases, RHC might be technically demanding,
particularly in individuals with severely dilated right ventricle (RV) due to pulmonary hypertension,
severe tricuspid regurgitation (TR), or other obstacles located in the right heart, like pacemaker leads
or artificial valves. In these cases, the use of fluoroscopic guidance or even the angioplasty wire in
order to acquire an adequate PAWP may be beneficial. An unreliable PAWP value may be verified by a
direct left ventricular end-diastolic pressure (LVEDP) measurement via the arterial access [44]. Several
potential pitfalls may occur during RHC. It should be underlined that PAWP is vulnerable to errors in
parameter of key importance in the diagnosis of pulmonary hypertension (PH). It might be either over-
or, more often, under-wedged, which may lead to a misdiagnosis and, consequently, inappropriate
treatment [45]. Since the PAWP is heavily dependent on respiration, it is a subject of debate whether it
should be measured at the end-expiration or averaged during spontaneous breathing [44,45]. It applies
mainly to the patients with respiratory disorders, in whom there is an intrathoracic pressure swing
influencing the intracardiac conditions [45].
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Figure 1. The milestones of right heart catheterization (RHC).
2. Physiological Aspects of Right Heart Catheterization
The European Society of Cardiology (ESC) and the European Respiratory Society (ERS) recommend
performing the zeroing of the transducer at the mid-thoracic line (with the reference point defined
by the crossing of the frontal plane at the mid-thoracic level, the transverse plane at the level of the
fourth anterior intercostal space, and the midsagittal plane in a supine patient halfway between the
anterior sternum and the bed surface [1,46]). It is important to emphasize the role of an adequate
calibration of the pressure transducer; however, the theoretical and experimental background of right
ventricle elasticity, along with the associations concerning volumes in different clinical states and
different species, falls beyond the scope of the current review [47–56]. For research purposes, it is
recommended to perform a single-beat estimation of the right ventricular end-systolic pressure–volume
relationship [57–59]. To see the typical pressure curves and values assessed during RHC within the
physiological states please refer to Figure 2.
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Figure 2. Typical pressure curves and values assessed during RHC within the physiological states. (a)
right atrium, (b) right ventricle, (c) pulmonary artery, (d) tip of the catheter in a small artery.
After zeroing, the measurements of the right atrium, right ventricle, pulmonary artery, and
capillary wedge pressure are performed. The currently accepted and recommended measurement of
cardiac output is the thermodilution method, in which a constant amount of saline (usually 10 cL) is
injected into the bloodstream—the difference in the temperature is analyzed by the thermistor and
recorded. It is important to collect at least three to five results of CO in order to acquire reliable values,
especially given that it affects the decision-making process in the real-life clinical setting (eligibility
for heart transplantation, mechanical circulatory support–mono/bi–ventricular assist device). It is
noteworthy that inaccurately measured, reduced CO will result in raised pulmonary vascular resistance
(PVR), according to the equation (PAPm (PAPm—pulmonary artery pressure mean)—PAWP/CO=PVR).
In clinical practice, the assessment of the CO by the use of thermodilution is preferred to the evaluation
by the Fick method. The latter, in which the cardiac output is calculated as the quotient of oxygen
uptake (O2) and the difference of the arterial and mixed venous oxygen content, is advised in the case
of tricuspid regurgitation. The main limitation of the Fick method is caused by the fact that the bedside
measurement of oxygen uptake is technically demanding. To see the basic definitions and range of
normal values please refer to Table 1.
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Table 1. Basic definitions and the range of normal values.
Parameter Abbreviation Normal Value Definitions/Comments
Heart rate HR 60–100 bpm number of beats per minute
Stroke volume SV 60–100 mL/beat the amount of blood pumped by each ventricle of the heartduring contraction
Cardiac output CO 4.0–8.0 L/min volume of blood being pumped within the minute
Body surface area BSA 1.6–1.9 m2 the measured or calculated surface area of a human body
Cardiac index CI 2.5–4.0 L/min/m2 CO/BSA
Central Venous Pressure CVP 2–6 mmHg superior vena cava pressure—might be used to estimatepreload and right atrial pressure
Right atrial pressure RAP 2–6 mmHg usually RAP~CVP
Pulmonary artery pressure
(systolic/diastolic/mean) (s/d/m) PAPs/d/m 15–30/8–15/9–18 mmHg assessed by a Swan-Ganz catheter placed in either RPA or LPA
Pulmonary artery wedge pressure PAWP 6–12 mmHg the inflated balloon of the catheter tip passively transmits thepressure of LA
Transpulmonary gradient TPG ≤12 mm Hg PAPm—PAWPm
Pulmonary vascular resistance PVR <3.125 WU PAPm—PAWPm/CO
Diastolic pulmonary gradient DPG <7 mmHg PAPd—PAWPm
Systemic vascular resistance SVR 10–15 WU SBPm—RAPm/CO
Table legend: SBPm–systemic blood pressure mean, WU–Wood Units.
3. Clinical Practice Implications
3.1. Safety of Right Heart Catheterization—The Evaluation of Clinical Outcomes
Since there existed a vital need to monitor the severely ill patients’ pulmonary artery, catheterization
has been widely introduced into clinical practice, including pediatrics, cardiac surgery, invasive
treatments in different kinds of clinical settings, including a wide variety of shock states originating
from the circulatory and/or septic background [60–68]. The use of this technology, mainly without
appropriate guidance or experience, resulted in few complications, reported thereafter in the form of
case reports [69–75].
These complications had different natures—from relatively mild dissections in the puncture site
to serious ones with systemic clinical implications, like tricuspid valve chord rupture or pulmonary
hemorrhages. Apparently, the learning curve and equipment imperfections could have been blamed
to some extent; however, re-evaluation of this clinical modality of invasive cardiovascular system
assessment, according to the evidence-based medicine, rapidly generated interest in the community of
intensive care practitioners and physicians [76–82].
The Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments
(SUPPORT) lead by Connors and co-investigators was the first prospective cohort study designed
to address the issue of pulmonary artery catheter (PAC) effectiveness and costs [76]. PAC (formerly
called the Swan-Ganz catheter) did not have any favorable effect, moreover it significantly raised
the cost of treatment. This work has been succeeded by others, like Wheeler et al., who evaluated
one thousand patients with acute lung injuries and stated that PAC did not have a positive influence
on the course of the management process in comparison to the central venous catheter and should,
therefore, not be used in this clinical condition [77]. Harvey and co-workers did not report any
benefit from the PAC-guided treatment in severely ill patients enrolled within the “PAC-man” trial
in the United Kingdom [78]. Ramsey et al. [82] retrospectively analyzed the outcomes of PAC use
in non-emergent coronary artery bypass graft surgery and stated that not only did PAC not have
any beneficial effect in reducing complications, but it was also associated with a two-fold increase
in mortality, extended the length of hospital stay, and significantly raised the costs [82]. It referred
predominantly to the low volume centers in which the PAC-derived data were apparently inadequately
interpreted. These studies gradually changed the clinical practice in the USA, resulting in a decrease in
PAC use in response, which was reported by Wiener and Ikuta [83,84].
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3.2. The Position of Right Heart Catheterization in the Diagnostic and Management Algorithm of Heart Failure
RHC is currently often used to monitor patients and guide the therapy to optimize filling pressures
and volume overloads. Some centers use it excessively in almost all patients, highlighting the point
that this technique is basically less prone to subjective inter-observer variability. The Evaluation
Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE)
(85) investigators assessed the results of using RHC in 433 patients enrolled randomly in either
an interventional or conservative arm. Remarkably, RHC was used intentionally to optimize
pharmacological treatment, not only for those that did not prove any benefit; additionally, it was
associated with a higher risk of adverse events, predominantly PAC infection [85]. Sionis [86] and
co-workers analyzed the data of cardiogenic shock (CS) patients included in the CardShock registry.
Eighty-two of them (37.4%) diagnosed with PAC received goal-oriented therapy consisting of mechanical
ventilation, renal replacement therapy, and mechanical assist devices more often as compared to the
routinely assessed group of patients (p < 0.01). Nevertheless, PAC use was not associated with any
survival benefit within a 30-day observation period, even after propensity score-matching analysis.
Doshi et al. [87] compared the trends in the utilization of PAC between 2005 and 2014 in a total of over
six million of patients with heart failure (HF) with reduced or preserved ejection fraction (HFrEF/HFpEF
respectively). They found that the PAC utilization per 1000 hospitalizations significantly declined
from 2005 to 2010 in both HFrEF and HFpEF. On the contrary, from 2010 to 2014, the use of PAC per
1000 hospitalizations increased in both HFrEF and HFpEF. The temporary decline in risk-adjusted
mortality during the study period for HFrEF and HFpEF is mostly associated with the improvements
in HF therapies. Hernandez [88] and co-authors retrospectively analyzed the trends in PAC utilization
between 2004 and 2014 in a total of 9,431,944 patients admitted with the primary diagnosis of HF
(n = 8,516,528), or who developed CS (n = 915,416) during the index hospitalization. They observed
a decline in the use of PAC in patients with HF, from 8 PAC used per 1000 admissions in 2004 to 6
PAC used per 1000 admissions in 2007. Additionally, there has been a constant rise in PAC use to
12 PAC per 1000 admissions in 2014 (p < 0.001). Interestingly, there has been a gradual decline in
the use of PAC in patients with CS, from 123 PAC used per 1000 admissions in 2004 to 78 PAC per
1000 admissions in 2014 (p < 0.001). Moreover, patients with PAC had increased hospital costs, length
of stay, and mechanical circulatory support use. In patients with HF, PAC use was associated with a
higher mortality. In those with CS, PAC was associated with a lower mortality and lower in-hospital
cardiac arrest; the paradox was also present after propensity score-matching.
Nevertheless, it should be addressed that PAC-guided therapy improved filling pressures and
reduced the rates of atrium/brain natriuretic peptides (ANP/BNP) and patients’ quality of life expressed
by trade-off protocol. Moreover, its use did not have any impact on overall mortality and, last but not
least, its implementation was not assessed in a triage of patients with cardiogenic shock or eligible for
ventricular assist device (VAD)/orthotopic heart transplantation (OHT). On the other hand, Tehrani
et al. proposed a different, team-based therapy for CS on the base of RHC data. This approach
enabled a significant reduction in mortality from 47% in 2016 to 76.6% in 2018 (p < 0.01) [89]. Ma et al.
re-evaluated publicly accessible data on the previously mentioned ESCAPE trial to discriminate the
potential prognostic role of the invasively derived parameters [90]. Their post-hoc analysis revealed that
a group of patients characterized by a single hemodynamic target, defined as PCWP + RAP ≥ 30 mmHg
(congestion index), was associated with poor prognosis and increased relative risk (RR) of death (RR
5.76), death-or-transplantation (DT) (RR 4.92), and death-or-rehospitalization (DR) (RR 1.80) at six
months follow-up. Moreover, this group had 45.3% mortality, 54.7% DT, and 84.9% DR at six months,
contrasting with the cohort of PCWP + RAP < 30 mmHg, which had 8.7% mortality, 13.0% DT, and
58.7% DR at six months. These observations suggest that the PAC-guided treatment of filling pressures
and volume overload in the specific groups of most demanding patients with end-stage heart failure
or after VADs implantations needs to be assessed in randomized controlled trials [91–95], especially
given that the progress in the management of HF through the last decade, including pharmacology and
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technical possibilities, has been promising [96]. To see the recapitulative table with the major studies
and findings, please refer to Table 2, depicted below.
3.3. Position of the RHC in the Diagnostic Algorithm of Pulmonary Hypertension
RHC is currently considered a gold standard in the assessment of PH, which by definition
is associated with the elevation of PAPm above 25 mmHg at rest [1,2,97]. Clinical investigation,
electrocardiogram, chest radiograph, and echocardiography are the first-line examinations in this
entity; however, RHC is obligatory not only to establish the definite diagnosis but also to differentiate
between the subtypes of PH and prognosticate response to treatment and survival rate. Guidelines,
along with the World Health Organization, classify PH into five groups of etiologic entities characterized
by different hemodynamic profiles.
Pre-capillary PH is characterized by PAPm ≥ 25 mmHg, and PAWP ≤ 15 mmHg may occur
in clinical groups 1, 3–5, where groups 2 and 5 in special conditions consist of different forms of
post-capillary PH, which is characterized by PAPm ≥ 25 mmHg and PAWP > 15 mmHg. It can be
further divided into isolated postcapillary PH with DPG (diastolic pressure gradient) < 7 mmHg and/or
PVR ≤ 3 Wood Units (WU), or a combined form of either pre–and post-capillary component with DPG
≥ 7 mmHg and/or PVR > 3 WU. It needs to be underlined that the role of DPG in the diagnosis of PH
has decreased recently, since it is challenging to prove its influence on a patient’s prognosis [98,99].
The physiological characteristics of pulmonary hypertension presented from the clinical point of view
are depicted in Figure 3.
 
Figure 3. The clinical characteristics of pulmonary hypertension on the base of current guidelines.
PH—pulmonary hypertension, PAPm—pulmonary artery pressure mean, PAWP—pulmonary artery
wedge pressure, DPG—diastolic pressure gradient, PVR—pulmonary vascular resistance.
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The performance of vasorecactivity testing is recommended in the arterial form of PH, where it
contributes significantly to the choice of the treatment regimen [100]. The encouraged vasoreactive
agent is nitric oxide (NO), with a dose of 10–20 ppm, and the test is interpreted as reactive, whether the
reduction in mean PAP is 10 mmHg or higher. However, the absolute value should be 40 mmHg or
less [1,99]. Patients presenting significant reductions in pulmonary pressures in vasorreactivity testing
during RHC may benefit from calcium channel blockers therapy, although the absolute number of
these cases is quite restricted [101,102].
Some experienced heart centers use the vasoreactivity testing in heart failure scenario associated
with type 2 PH as a part of the integral stratification prior to OHT. Paradoxically, increased PVR above
2.5 WU was associated with unfavorable prognosis only if it was associated with a decrease in systolic
blood pressure below 85 mmHg during vasoreactive testing with sodium nitroprusside [103,104].
These data, although not standardized, sustain the theoretical assumptions that reversibility testing
has the prognostic competence to discriminate the patients prone to developing acute right ventricle
failure after OHT.
4. Conclusions
RHC, although present in experimental physiology and medicine since the beginning of the
seventeenth century, still has safety concerns. These, however, are predominantly related to its
depersonalized, randomly assigned utilization, regardless of its risk-to-benefit ratio to the patients.
RHC is indispensable in PH diagnosis settlement, treatment monitoring, and decision-making.
Moreover, it is imperative prior to OHT to stratify the risk of early post-operative RV failure, which
might be useful in the end-stage heart failure group of patients (including VADs) in the optimization
of pharmacotherapy.
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Abstract: Given the tremendous progress in interventional cardiology over the last decade, a growing
number of older patients, who have more comorbidities and more complex coronary artery disease,
are being considered for technically challenging and high-risk percutaneous coronary interventions
(PCI). The success of performing such complex PCI is increasingly dependent on the availability and
improvement of mechanical circulatory support (MCS) devices, which aim to provide hemodynamic
support and left ventricular (LV) unloading to enable safe and successful coronary revascularization.
MCS as an adjunct to high-risk PCI may, therefore, be an important component for improvement
in clinical outcomes. MCS devices in this setting can be used for two main clinical conditions:
patients who present with cardiogenic shock complicating acute myocardial infarction (AMI) and
those undergoing technically complex and high-risk PCI without having overt cardiogenic shock.
The current article reviews the advancement in the use of various devices in both AMI complicated by
cardiogenic shock and complex high-risk PCI, highlights the available hemodynamic and clinical data
associated with the use of MCS devices, and presents suggestive management strategies focusing
on appropriate patient selection and optimal timing and support to potentially increase the clinical
benefit from utilizing these devices during PCI in this high-risk group of patients.
Keywords: mechanical circulatory support; percutaneous coronary intervention; cardiogenic shock;
acute myocardial infarction; outcome; patient selection
1. Introduction
Recent advances in percutaneous coronary intervention (PCI) technologies, including mechanical
circulatory support (MCS) devices, have facilitated treatment of high-risk patients with complex
coronary artery disease (CAD) and low left ventricular (LV) systolic function as well as patients
with acute myocardial infarction (AMI) complicated by cardiogenic shock. These high-risk patients
would otherwise be poor candidates for coronary artery bypass grafting (CABG) due to high surgical
morbidity and mortality risks, and the ability to provide adequate hemodynamic support using MCS
devices would potentially enable safer PCI and improve outcomes as compared to unprotected PCI
strategy, surgical revascularization, or medical therapy alone [1]. However, despite the preemptive
improvement in hemodynamics with the use of MCS devices [2], randomized trials using intraaortic
balloon pump (IABP) or Impella 2.5 devices have not demonstrated significant reduction in mortality
during high-risk and complex PCI as compared to unprotected PCI [3,4]. A clinical benefit from the
use of MCS in the setting of cardiogenic shock complicating AMI has also not yet been conclusively
demonstrated [5,6]. Besides possible methodological flaws in these trials, other important factors might
J. Clin. Med. 2019, 8, 1209; doi:10.3390/jcm8081209 www.mdpi.com/journal/jcm255
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have contributed to the lack of benefit seen in these studies and should be taken into consideration, such
as inadequate hemodynamic support, inappropriate patient selection, and deferred or inappropriate
timing of device insertion during the course of cardiogenic shock and also in relation to PCI.
In light of the development of new generation MCS devices with greater hemodynamic support
and lower device-associated complications combined with careful planning and optimal timing of
device utilization, a growing body of data is suggestive of improvement in procedural success and
clinical outcomes [7,8], and thus opens the door for future research in this field to examine the benefit
of optimal MCS use in the setting of high risk PCI among a highly selective group of patients. Herein,
we provide the most updated data available on MCS in two different situations involving high risk
patients undergoing PCI: (1) high risk patients without cardiogenic shock undergoing complex PCI,
and (2) patients with AMI complicated by cardiogenic shock.
2. High-Risk Percutaneous Coronary Interventions
Over the last few decades, there has been a tremendous progression in coronary interventional
techniques that enables performance of PCI in complex coronary lesions (heavily calcified and type C)
that would previously not have been amenable to intervention. This includes improved guide catheters
and wires, mother-child guide catheters, low-profile balloons, coronary atherectomy devices, dedicated
chronic total occlusion devices and algorithms, and superior stent designs that enhance deliverability
to achieve complete multivessel revascularization including those involving chronic totally occluded
coronary vessels. However, each aspect of PCI, beginning from guide catheter engagement and ending
with balloon inflation and stent deployment, is associated with potential risk of vascular damage
and impairment of myocardial perfusion. For instance, patients at advanced age, with increased
comorbidities, and underlying left ventricular dysfunction, may pose a clinical challenge, as complex
PCI among these patients may incur a substantial risk that overweighs any benefit achieved from
revascularization [4]. On the other hand, utilization of PCI even in older adults with AMI and
cardiogenic shock has been shown to be associated with substantial reduction in mortality in a recent
contemporary analysis involving older adults ≥75 years of age [9]. Although clinical judgment is
important, one should not, therefore, exclude patients from PCI solely based on advanced age in the
absence of clear contraindications.
Among high-risk patients with active ischemia, the need and the type of revascularization should
be discussed by Heart Team in an individual base. The recommendation with respect to the type of
revascularization (PCI versus CABG) should be generally guided by important criteria including the
predicted surgical mortality (based on the Society of Thoracic Surgeons (STS) score), the anatomical
complexity of CAD (based on the SYNTAX (Synergy between Percutaneous Coronary Intervention with
Taxus and Cardiac Surgery) score), and the anticipated completeness of revascularization. The risks of
periprocedural complications should be weighed up against the anticipated improvement in quality of
life and long-term freedom from death, MI, and repeat vascularization for electing whether conservative
therapy, PCI, or CABG is the recommended strategy. According to the current ESC guidelines [10],
when suitable coronary anatomy for both procedures and low predicted surgical mortality exist,
patients with three-vessel disease and diabetes in particular achieve greater benefit from CABG than
PCI regardless of the SYNTAX score, while in patients without diabetes CABG is favored over PCI only
when SYNTAX score is intermediate or high (>22). In the presence of significant left main CAD, CABG
is preferred for patients with SYNTAX score >22 irrespective of the diabetic state. However, in the
presence of complex CAD anatomy (i.e., unprotected left main CAD or three-vessel disease) and high
surgical mortality (i.e., previous cardiac surgery, severe comorbidities, and frailty) precluding CABG,
high-risk PCI with MCS protection may be suggested as an alternative strategy for achieving complete
revascularization safely in this high-risk group of patients. Although high-risk PCI has not been
well defined, it can be generally categorized into three major groups based on patient characteristics,
lesion characteristics, and clinical presentation [2,11] (Table 1). Patient characteristics include increased
age, comorbidities (such as diabetes mellitus, chronic kidney disease, and chronic obstructive lung
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disease), reduced left ventricular systolic function, and prior myocardial infarction [12–14]. Lesion
characteristics include anatomical and procedural variables that determine the complexity of PCI from
the technical perspectives and the potential risk of complications. These include PCI of unprotected
left main stenosis, bifurcation disease, heavily calcified lesions, saphenous vein grafts, and chronic
total occlusions [15,16]. Finally, the clinical characteristics, among which acute coronary syndrome
presentation and heart failure symptoms are important elements to take into consideration when
assessing PCI risk [17]. An example of a high-risk PCI that can be facilitated by MCS is in an elderly
patient with comorbidities who presents acutely with reduced LV systolic function and has a heavily
calcified left main bifurcation or three-vessel coronary artery disease.
Table 1. High-Risk Percutaneous Coronary Intervention Characteristics.
Patient Characteristics
Increased age
Comorbidities (diabetes mellitus, chronic lung disease, prior myocardial infarction, peripheral arterial disease,
frailty)
Severe LV systolic dysfunction (EF < 20–30%)
Severe renal function impairment (eGFR < 30 mL/min/1.73 m2).
Lesion Characteristics
Severe three-vessel coronary artery disease
Unprotected left main stenosis
Bifurcation disease or ostial stenosis
High SYNTAX score or type C lesions
Chronic total occlusions
Saphenous vein graft disease
Heavily calcified lesions requiring coronary atherectomy
Clinical Presentation
Acute coronary syndrome
Heart failure symptoms (dyspnea, orthopnea, PND, exercise intolerance, peripheral edema)
Arrhythmias (atrial fibrillation with RVR, ventricular tachycardia)
Elevated LV end-diastolic pressure
Severe mitral regurgitation (or other valvular disease)
Abbreviations: EF, ejection fraction; eGFR, estimated glomerular filtration rate; LV, left ventricular; PND, paroxysmal
nocturnal dyspnea; RVR, rapid ventricular response; SYNTAX, Synergy between Percutaneous Coronary Intervention
with Taxus and Cardiac Surgery.
As high-risk PCI is associated with increased risk of myocardial ischemia and hemodynamic
compromise that may lead to circulatory collapse, the purpose of MCS is to diminish myocardial oxygen
consumption and provide adequate cardiac output and myocardial perfusion during the procedure.
Use of appropriate MCS devices allows adequate time to safely perform complex PCI with optimal
results in these high-risk patients who would not otherwise tolerate complete revascularization [18].
It is critical, therefore, that MCS device insertion in this setting is performed prior to PCI as this
enables confident proceeding with revascularization without the risk of circulatory collapse that
may subsequently require emergent bailout MCS implementation. Although several patient- and
lesion-specific variables are well-recognized predictors of adverse outcomes after PCI, a risk score
to assess the need for MCS during PCI has not yet been developed and warrants further research.
Despite the lack of a risk calculator, most interventional cardiologists would now consider the use
of MCS devices in patients with severely reduced LV systolic function and complex coronary artery
disease involving a large territory (such as sole-remaining vessel, unprotected left main, or three-vessel
disease) [11].
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3. Cardiogenic Shock Complicating Acute Myocardial Infarction
Cardiogenic shock is defined as the combination of sustained systemic tissue hypoperfusion
and decreased cardiac output despite adequate circulatory volume and LV filling pressure. Specific
clinical and hemodynamic criteria that define cardiogenic shock include systolic blood pressure of
<90 mmHg for >30 min, cardiac index <2.2 L/min/m2 with hemodynamic support or <1.8 L/min/m2
without support, pulmonary capillary wedge pressure (PCWP) >15 mmHg, and evidence of end-organ
damage (such as urinary output <30 mL/h, high lactate levels, or cool extremities) [19,20]. Cardiogenic
shock can develop because of various pathologies that affect the heart with AMI involved in the
majority of cases. It occurs in 6–10% of patients with AMI and remains a leading cause of death with
in-hospital mortality exceeding 50% despite the implementation of guideline-directed medical therapy
and early myocardial reperfusion by primary PCI [21,22]. Consequently, patients with cardiogenic
shock complicating MI represent a high-risk group of patients with compromised cardiac function
and hemodynamics who are more susceptible to circulatory collapse during PCI [23]. Indeed, even
though a substantial improvement in PCI techniques and pharmacology has occurred over time,
this has not translated to further improvement in outcomes beyond what is achieved with prompt
revascularization in the setting of cardiogenic shock [5,6]. Therefore, utilization of percutaneous MCS
devices to augment cardiac output and decrease LV filling pressures by LV unloading may act as a
successful adjunct to PCI as a bridge to myocardial recovery in these critically ill patients [24].
4. Hemodynamic Effects of Percutaneous Mechanical Circulatory Support Devices
The hemodynamic condition in steady state as well as in various cardiac abnormalities is illustrated
by the pressure-volume loop, which provides fundamental information to the understanding of the
underlying hemodynamic imbalance and the anticipated effect with the use of each type of the available
MCS devices (Figure 1) [11,18]. Pressure-volume loops not only provides a platform for explaining
ventricular mechanics, such as contractile and relaxation properties, stroke volume, and cardiac work,
but provides a platform for understanding the determinants of myocardial oxygen consumption
represented mainly by LV work [11,18,25,26]. Each one of these hemodynamic variables can be
compromised based on the clinical presentation. In AMI, for example, patients may mainly present
with decreased myocardial contractility and stroke volume in addition to increased myocardial oxygen
demand and diminished coronary blood flow (Figure 1B). In cardiogenic shock, LV contractility and
stroke volume are severely reduced, while LV end-diastolic volume (LVEDV) and pressure (LVEDP) as
well as myocardial oxygen demand are considerably increased (Figure 1C). In the setting of mechanical
support, the change in the volume-pressure loops is dependent on the type of the MCS device and
the amount of support [18,27,28]. IABP provides modest hemodynamic support demonstrated by
modest reduction in both LV systolic and diastolic pressures with afterload reduction and increase
in stroke volume (Figure 1D). Percutaneous LV assist devices (including Impella and TandemHeart)
result in remarkable reduction in LV systolic and diastolic pressures, LV volumes, and stroke volume
resulting in significant decrease in LV work. Unlike the other forms of support, continuous pumping
of blood directly from the LV by Impella is not dependent on blood ejection through the aortic
valve and LV unloading can, therefore, be augmented by increasing the flow rate, thus resulting in
further reduction in LV filling pressures and in myocardial oxygen demand (Figure 1E). Venoarterial
extracorporeal membrane oxygenation (VA-ECMO) has the capacity to assume responsibility for the
entire cardiac output providing biventricular support in combination with full gas exchange. Strictly
on a hemodynamic basis and without an LV venting strategy, use of VA-ECMO results in increased LV
systolic and diastolic pressures and reduced stroke volume, with a final flow-dependent increase in
afterload and LVEDP (Figure 1F). Therefore, LV venting assisted by Impella or IABP may be ultimately
required to mitigate LV loading and decrease left-sided filling pressures and myocardial oxygen
demand, especially when the aortic valve remains persistently closed during ECMO support indicating
a maximal LV loading condition.
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Figure 1. (A) Normal pressure-volume (PV) loop. Effective arterial elastance (Ea) is the slope of the line
extending from the left ventricular (LV) end-diastolic pressure-volume point through the end-systolic
pressure-volume point of the loop. Ea is determined by the total peripheral resistance and heart rate and
gives an estimate of the LV afterload. End-systolic elastance (Ees) is the slope of the line extending from
the volume-axis intercept V0 through the end-systolic pressure-volume point of the loop and represents
the ventricular contractility. The width of the PV loop represents stroke volume (SV), which can be
extracted by calculating the difference between the end-diastolic and end-systolic volumes. (B) PV loop
in the setting of acute myocardial infarction (AMI) showing decreased contractility (Ees) and SV in
addition to increased LV end-diastolic pressure (LVEDP). (C) PV loop of patients with cardiogenic shock
showing severe reduction in contractility (Ees) and SV in addition to markedly increased LVEDP and
LV end-diastolic volume (LVEDV). (D) Illustration of PV loop change after intraaortic balloon (IABP)
counterpulsation showing mildly reduced LVEDP and LV end systolic pressure (LVESP) resulting in
modest afterload (Ea) reduction and increase in SV. (E) PV loop with percutaneous LV assist device
support (Impella or TandemHeart) showing marked reduction in LVEDP, LVESP, and SV, with a net
effect of substantial afterload, preload, and LV workload reduction. (F) LV loop with veno-arterial
extracorporeal membrane oxygenation (VA-ECMO) without LV venting increases LVEDP and LVESP,
while reduces stroke volume and an ultimate increase in afterload (Ea) and LV loading.
5. Available Percutaneous Mechanical Circulatory Support Devices
Several percutaneous MCS devices are currently available to assist interventional cardiologists
during high-risk PCIs both for patients undergoing a complex PCI and for those requiring PCI in
the setting of cardiogenic sock complicating AMI. Types of available percutaneous MCS devices
and comparisons of their characteristics and hemodynamic impact are presented in Table 2 [29,30].
Generally, the goal of MCS devices is to improve cardiac power (defined as the product of mean
arterial blood pressure and cardiac output), which has been demonstrated to be a strong predictor
of outcomes in patients with cardiogenic shock [31,32]. Therefore, each device has its unique impact
on cardiovascular hemodynamics, but an ideal MCS device should ultimately provide circulatory
support to achieve adequate systemic tissue perfusion, by increasing mean arterial pressure, while
concurrently decreasing myocardial oxygen demand, by reducing both LV volume (preload) and
pressure (afterload).
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5.1. Intraaortic Balloon Bump
Since its introduction in the 1960s, IABP remains the most widely used device for temporary
support in hemodynamically unstable patients due to its greater availability and ease of insertion as
compared to other temporary devices [33]. It is typically inserted via femoral arterial access, though
axillary or subclavian approaches are also feasible and have the advantage of enabling ambulation
among stabilized patients. IABP support is driven by electrocardiogram (ECG)-guided balloon inflation
with helium (due to its low viscosity that facilitates easy transfer in and out of the balloon in addition
to its rapid absorption in blood in case of balloon rupture) at the onset of diastole and deflation at
the onset of LV systole. This diastolic pressure augmentation results in increased coronary perfusion,
decreased afterload, decreased cardiac work, and decreased myocardial oxygen demand. Despite
these favorable effects, the increase in cardiac output is usually minimal and it may not, therefore,
provide adequate support to improve end-organ perfusion in patients with severe cardiogenic shock.
Moreover, optimal support is dependent on the underlying heart work and also on other factors, such
as a stable electrical rhythm, optimal balloon position and sizing, and the timing of balloon inflation in
diastole and deflation in systole [34].
The complications associated with IABP use are mainly vascular, including limb ischemia,
vascular injury, and stroke [35]. Although it rarely occurs, trauma to the aorta or ostia of the visceral
arteries can result in life-threatening complications, including acute renal failure, bowel ischemia,
and atheroembolic events. Other complications include bleeding, infection, and thrombocytopenia.
Anticoagulation therapy (usually with heparin) is generally recommended for patients supported
with an IABP to prevent ischemic complications though no definitive evidence exists to support this
approach and some centers do not use anticoagulation with 1:1 pumping, particularly in patients at high
bleeding risk. IABP is contraindicated in patients with severe peripheral arterial or aortic disease and
in those with moderate or severe aortic valve regurgitation. With the emergence of newer short term
support strategies that provide greater hemodynamic support and ventricular unloading, the role of
IABP support in the setting of cardiogenic shock or high risk PCI will continue to decline as experience
grows with more promising short-term MCS therapies. According to the current European Society of
Cardiology (ESC) guidelines, IABP is not indicated for patients with cardiogenic shock complicating
AMI (Class III) [10], and a recent study has found that IABP is considered one of the medical reversals
in clinical practice as this widespread therapeutic strategy bolstered by retrospective studies and
previous guidelines was strongly challenged by subsequent large prospective and randomized studies
showing no clinical benefit of its utilization in this clinical setting [36].
5.2. Impella Devices
The Impella pumps are continuous nonpulsatile microaxial flow devices that are deployed into
the LV across the aortic valve and unload the LV by pumping blood from the LV cavity to the ascending
aorta. The Impella 2.5 and CP pumps (Abiomed Inc, Danvers, MA, USA) can be placed percutaneously
and provide maximal flow rates of 2.5 and 3.0–4.0 L/min, respectively, while the Impella 5.0 and
Impella LD (Abiomed Inc, Danvers, MA, USA) devices are larger LV assist axial-flow pumps that
require surgical cutdown and provide up to 5.0 L/min of cardiac output [14,37,38]. Similarly, the
right-sided Impella RP is designed for right ventricular (RV) hemodynamic support by propelling
blood from the inferior vena cava and right atrium (RA) to the pulmonary arteries and can also
be deployed percutaneously. The percutaneous Impella devices for LV support are inserted most
commonly through the femoral artery and then advanced in a retrograde fashion to the LV with a
flexible pigtail loop that stabilizes the pump in the LV chamber and protects from LV perforation.
Impella insertion requires large-bore arterial cannulation (13-F for Impella 2.5 and 14-F for Impella CP)
and therefore, it is essential to ensure adequate femoral and iliac arterial diameters to enable device
delivery via a femoral approach. Alternatively, though less commonly used, axillary or subclavian
arterial accesses can be used to deliver these pumps percutaneously. For high-risk PCI, the device is
usually removed at the end of the procedure. However, in patients with persistent cardiogenic shock
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despite revascularization, Impella should be retained for further hemodynamic support, a condition
that may pose some challenges and thus requires careful assessment and management in the cardiac
care unit. Optimal device functioning is crucial and largely depends on appropriate positioning in the
LV cavity, as device migration can lead to low flow, ventricular arrhythmias, and hemolysis [39]. In
such cases, bedside transthoracic echocardiography-guided device repositioning is usually successful
without the need for fluoroscopy [11].
Unlike IABP, Impella (as other percutaneous ventricular assist devices) functions independently
of the remaining LV function and does not require synchronization with the cardiac cycle. Therefore,
Impella devices are more helpful than IABP in patients with severely depressed LV function who present
with significant arrhythmias. Impella results in effective LV unloading thus resulting in decreased
LV filling pressures (LVEDP) and myocardial oxygen consumption, while improving cardiac output,
mean arterial pressure, and coronary perfusion [40]. All the hemodynamic parameters, including
cardiac output, are more markedly improved with Impella use compared with an IABP. Additionally,
the more powerful Impella CP and 5.0 devices provide greater hemodynamic support than Impella
2.5 and thereby are more beneficial in patients with profound cardiogenic shock requiring greater
hemodynamic support [30].
Despite the improvement in hemodynamic parameters, device-related complications are not rare
and can be clinically meaningful, thereby contradicting the potential hemodynamic benefits that can
be achieved with the use of Impella devices in some cases. As with any mechanical support device,
common complications associated with Impella include vascular trauma, limb ischemia, and bleeding
requiring blood transfusion. Moreover, hemolysis is frequently encountered during Impella support
due to mechanical erythrocyte shearing, but usually improves after repositioning the device. Based on
the Impella EUROSHOCK Registry [39], utilization of Impella 2.5 in the setting of acute cardiogenic
shock was found to be associated bleeding at the vascular access site requiring blood transfusion in
24% of cases and hemolysis requiring blood transfusion in 7.5% of cases after a mean Impella support
duration of approximately 48 h. Impella may also worsen right-to-left shunting and hypoxemia
among patients with a preexisting ventricular or atrial septal defect. As device technology continues to
improve and the Impella-associated complications continue to decrease, the use of Impella devices
has been steadily increasing over the last several years [41]. This is also owing to its relative ease of
deployment and more efficient hemodynamic support compared with other MCS devices.
Impella should not be used in patients with a mechanical aortic valve or LV thrombus as well
as in those with severe peripheral arterial disease or who cannot tolerate systemic anticoagulation
therapy. Although severe aortic stenosis and regurgitation are considered relative contraindication, the
use of Impella in this setting has been shown to be feasible and may be considered in selected high-risk
patients with severe aortic stenosis and cardiogenic shock or those with severe LV dysfunction and
CAD who require high-risk PCI and/or balloon aortic valvuloplasty as well as in selected patients who
develop hemodynamic collapse during transcatheter aortic valve replacement (TAVR) [42].
5.3. TandemHeart
The TandemHeart (CardiacAssist) system is an extracorporeal, centrifugal, continuous flow pump,
which is available on the market for left, right, and biventricular failure. For LV support, TandemHeart
device is percutaneously inserted to pump blood extracorporeally from the left atrium through a
transseptal cannula back into the femoral/iliac artery through an arterial cannula using a centrifugal
pump that provides 3 to 5 L/min of continuous flow at 3000 to 7500 rpm, respectively [11,37]. The
transseptal inflow cannula is a 21-F and contains a large end-hole and 14 side holes that enable effective
blood aspiration from the left atrium while the arterial outflow cannula ranges in size between 15-F and
19-F according to the flow rate via the iliofemoral arterial system [43]. The pump is also FDA-approved
and available in market for an oxygenator to be added to the circuit thereby allowing for blood
oxygenation with simultaneous LV unloading. As with Impella support, anticoagulation (typically
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with unfractionated heparin) is required with a recommended activated clotting time (ACT) goal of
about 250–300 s prior to device activation.
By propelling blood from the left atrium directly to the arterial system, TandemHeart results in a
significantly reduced LV preload, filling pressures, and myocardial oxygen demand, while cardiac
output and mean arterial pressures are improved. However, because LV output through the aortic
valve competes with the retrograde flow from the device, LV afterload increases as the device support
is augmented, which may ultimately result in aortic valve closure requiring LV venting [44,45].
Similar to other percutaneous MCS devices, TandemHeart use may infrequently cause limb
ischemia and vascular injury [37]. Additionally, as transseptal puncture is needed to insert a large
caliber venous cannula, expertise with this technique is crucial for TandemHeart application in
clinical practice, which may limit its widespread use, particularly among inexperienced interventional
cardiologists not regularly performing transseptal punctures in their practice. Although rare, unique
complications related to the transseptal puncture required for MCS with TandemHeart may occur
and include cardiac tamponade, hemolysis, and thrombus or air embolism. Finally, device migration
with dislodgement of the left atrial cannula to the RA during patient transport or leg movement
may cause significant right-to-left shunt, resulting in severe hypoxemia and hemodynamic collapse.
Severe peripheral arterial disease, left atrial thrombus, and profound coagulopathy are considered
contraindications for TandemHeart use. Moreover, limited experience exists regarding the use of this
device among patients with moderate to severe aortic regurgitation or those with ventricular septal
defect [46].
5.4. Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO)
Based on the Extracorporeal Life Support Organization (ELSO) registry data, the number of
ECMO devices and the number of centers utilizing ECMO are markedly increasing [47,48]. VA-ECMO
provides both circulatory and oxygenation support, and therefore it is ideally used in patients
with biventricular failure who develop cardiogenic shock and impaired oxygenation requiring
cardiopulmonary resuscitation at the time PCI is initiated [49]. This is unlike venovenous ECMO
(VV-ECMO), which is reserved for patients with respiratory failure but without significant cardiac
dysfunction. When percutaneously inserted, VA-ECMO bypasses both the right and left side of the
heart by draining deoxygenated blood from a central vein or RA with an 18-F to 21-F venous cannula
and pumping oxygenated blood, after passing via an extracorporeal membrane oxygenator, into the
iliofemoral arterial circulation (14-F to 19-F arterial cannula). The VA-ECMO system provides cardiac
flow between 3 and 7 L/min depending on cannula sizes and can potentially be maintained for several
days to weeks among patients with persistent cardiogenic shock as a bridge to recovery, permanent
LV assist device implantation, or heart transplantation. Due to the substantial hemodynamic support
provided by VA-ECMO, the hemodynamic and metabolic derangement resulted from cardiogenic
shock is generally corrected within hours of device activation. Unfractionated heparin is typically
used during ECMO support but other anticoagulants, such as bivalirudin, particularly in patients with
heparin-induced thrombocytopenia who are unable to receive heparin, have been increasingly used as
alternatives. The extent of anticoagulation during ECMO support is largely dependent on the type of
membrane oxygenator and ranges from 180–250 s [50].
VA-ECMO support results in a remarkable increase in cardiac output and mean arterial pressure.
However, its use is limited by retrograde blood flow leading to LV afterload mismatch, inadequate
LV decompression, and high myocardial oxygen demand. The concurrent use of IABP or Impella
can add further support by direct unloading of the LV and reducing ventricular wall stress [51,52].
Recently, a novel electrocardiogram (ECG)-synchronized, pulsatile VA-ECMO system, labeled i-cor
(Xenios AG), has been introduced. The i-cor system consists of an ECG-triggered diagonal pump,
which has a feature of diastolic augmentation and a capacity of providing a support up to 8 L/min.
The main difference of the i-cor pump is the ability to generate a physiological pulse and to manage
rotational timing to synchronize the pulse with the cardiac cycle of the native heart in order to provide
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adequate and physiologic circulatory support. By decreasing extracorporeal blood flow during systole
and increasing flow during diastole, i-cor assist device flow decreases afterload and LV end-diastolic
pressure and improves LV function and coronary flow compared with standard continuous VA-ECMO
flow [53–55]. The first-in-man study, involving 15 patients with cardiogenic shock (71% due to AMI),
showed that the i-cor pump was safe and applicable in clinical practice and implicated a hemodynamic
benefit [56]. A multicenter study designed to test the safety and feasibility of this innovative pulsatile
cardiac-synchronous MCS system in a larger population (the “SynCor” trial) is still ongoing.
One of the recent advancements in the percutaneous extracorporeal life support (ECLS) technology
is the development of the Lifebridge B2T “bridge to therapy” system (Zoll Medical GmbH, Köln,
Germany), which is a miniaturized and portable heart-lung support system similar in design to standard
ECMO systems with an ability to provide cardiovascular stabilization and sufficient end-organ perfusion
immediately after circulatory arrest. The Lifebridge system enables rapid application within 5 min
due to its automated set-up and portable design in addition to less cumbersome transportation of
the patient than standard ECMO equipment due to its smaller size and suitcase configuration. Other
technical features include a battery life of 2 h, an overall weight of 18 kg (39.6 lb.), and a maximal
blood flow of 6 L/min. Real-world clinical data of the German Lifebridge Registry involving 444
patients from 60 tertiary cardiovascular centers has been recently published [57] showing that this
transportable automated ECLS system was safely applicable for hemodynamic stabilization with
acceptable complications. However, mortality rates remained extremely high in these critically ill
patients with immediate survival rates of 36% and 16% at 30-days after device implementation,
especially in those with high lactate levels on admission.
Adverse events related to VA-ECMO include bleeding (with excessive anticoagulation),
thromboembolic events in the circuit or systemically (if anticoagulation is inadequate), cannula-induced
vascular injuries, infection, stroke (ischemic or hemorrhagic), hemolysis, and limb ischemia [58].
To reduce the risk of limb ischemia, a second antegrade arterial sheath can be inserted into the
superficial femoral artery and when fed by the main arterial cannula can provide secured antegrade
perfusion to the limb. Contraindications to peripheral VA-ECMO include patients with severe chronic
organ dysfunction (renal failure, cirrhosis, or emphysema), prolonged cardiopulmonary resuscitation
without adequate tissue perfusion, severe peripheral arterial disease, and patients unable to receive
anticoagulation [11].
5.5. Other Percutaneous Mechanical Support Devices
Percutaneous LV MCS pumps under investigation include the pulsatile iVAC 2L (PulseCath
BV, Arnhem, The Netherlands), which has been recently evaluated prospectively in a pilot study
of 14 patients undergoing high-risk PCI demonstrating 100% angiographic success [59]. The Aortix
(Procyrion, Houston, TX, USA) and Reitan (Cardiobridge, Hechingen, Germany) devices are other
investigational devices that are deployed in the descending aorta similar to the IABP.
Apart from LV support, RV failure refractory to medical therapy is increasingly becoming a clinical
challenge, thereby prompting the development of devices to specifically provide RV support. Large
inferior AMI may cause predominant RV failure with cardiogenic shock with or without severe LV
dysfunction. When cardiogenic shock is persistent despite maximal medical therapy, the options for
MCS in this setting include VA-ECMO, surgical implantation of RVAD or total artificial heart (TAH),
and heart transplantation [60]. The recent development of Impella RP launched an evolving field of
percutaneous mechanical therapies for refractory RV failure. Impella RP is an intracardiac microaxial
pump designed predominantly for management of primary RV failure, particularly in the setting of
AMI, and can be inserted through the femoral vein to eject blood from the inferior vena cava directly
to the pulmonary artery. The safety and reliability of the RP Impella has been established in the
prospective RECOVER RIGHT study for severe isolated RV dysfunction [61]. Like LV Impella devices,
complications that may occur with RP Impella support include bleeding, thrombosis, hemolysis,
or infection.
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6. Clinical Benefit of Percutaneous MCS Devices for PCI
The most recent clinical practice guidelines regarding the use of percutaneous MCS for PCI and
management of ACS recommend consideration of the use of these devices in the setting of high-risk
PCI and AMI complicated by cardiogenic shock [11]. However, despite accumulating evidence
of hemodynamic improvement using various MCS devices, a convincing clinical benefit based on
randomized controlled trials has not yet been demonstrated among this population. Because this is an
extremely high-risk group of patients, improving clinical outcomes can be challenging and further
research is still necessary to examine the optimal device features, the timing of support, and the
appropriate patient for achieving maximal clinical benefit from these devices during PCI. The salient
findings of contemporary studies examining the effect of MCS devices on outcomes in cardiogenic
shock complicating AMI and high-risk PCI are summarized in Tables 3 and 4, respectively.
6.1. Intraaortic Balloon Bump
In the setting of PCI with cardiogenic shock complicating AMI, a previous retrospective study has
suggested a potential benefit with early IABP support placed prior to PCI showing decreased rates of
in-hospital mortality and cardiac adverse events compared with IABP placed only following PCI [62].
In a meta-analysis by Sjauw et al. [63], no mortality benefit or improvement in LV ejection fraction
were found with utilizing IABP among patients undergoing PCI for ST-elevation myocardial infarction
(STEMI), while higher stroke and bleeding rates were observed in the IABP group. Furthermore, among
patients with cardiogenic shock undergoing PCI, there was a 6% increase in 30-day mortality [63]. Not
only were randomized studies analyzed but cohort studies were also included in this meta-analysis;
therefore, it could be subject to selection bias as sicker patients with more profound cardiogenic shock
were more likely to be supported with IABP. In the SHOCK trial [64], IABP was not been shown to
reduce mortality or major adverse events in patients with cardiogenic shock or high-risk PCI except in
patients with STEMI. Subsequently, the IABP-SHOCK II trial [5], a prospective randomized controlled
trial designed to study the effect of IABP involving 600 patients with AMI and cardiogenic shock
undergoing early revascularization, showed no improvement in survival with IABP at 30 days [5] and
subsequently at 1 year [65] and 6 years [66] post AMI. Moreover, there were no significant differences
in any of the secondary clinical and laboratory (including lactate and creatinine) endpoints, and there
were no significant differences in subgroup analyses. Based on the current guidelines, IABP is largely
recommended in patients with mechanical complications post AMI or during transport of unstable
patients from PCI centers without to centers with on-site cardiac surgery [12,67].
Among patients undergoing PCI without evident cardiogenic shock, IABP use was tested in the
CRISP-AMI (Counterpulsation to Reduce Infarct Size Pre-PCI Acute Myocardial Infarction) trial [68];
a 30-center randomized controlled trial involving 337 patients with anterior STEMI, which found
that routine IABP placement immediately prior to PCI had no significant effect on the infarct size as
assessed by magnetic resonance imaging 3 to 5 days post PCI or on survival rates after 6 months of
follow-up. Similarly, in a nonrandomized study using the National Cardiovascular Data Registry
database, IABP utilization in high-risk PCI was not associated with lower mortality, and wide regional
variations in the use of IABP was noted among the different centers [69]. Finally, the BCIS-1 trial [3], a
prospective randomized controlled trial involving 301 patients randomized to routine IABP versus
provisional IABP support for high-risk PCI, found no significant differences in mortality between
the two groups. However, a long-term follow-up of more than four years showed a 34% relative
reduction in all-cause mortality risk with routine IABP in patients with severe ischemic cardiomyopathy
undergoing high-risk PCI, which might be attributed to lower incidence of procedural hypotension
with preplanned IABP insertion [70].
Given these conflicting results and the controversy surrounding its benefit, the use of IABP in the
setting of STEMI complicated with cardiogenic shock is decreasing and its routine use has been recently
downgraded to class III (harm) by the ESC [10] and to class IIa (should be considered) by the American
Heart Association (AHA)/American College of Cardiology (ACC) [71] guidelines. Furthermore, due to
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the introduction of new devices, such as Impella, and the continuous advancement in MCS technology,
which provides superior hemodynamic support and potentially more favorable outcomes, the future
role of IABP in management of cardiogenic shock and ventricular unloading may continue to decline.
6.2. Impella Devices
There are currently limited available data to establish a significant clinical benefit of Impella use
in patients with cardiogenic shock undergoing PCI. Impella devices provide greater hemodynamic
support with a more pronounced cardiac output augmentation and LV unloading than IABP. In 2008, the
ISAR-SHOCK (Impella LP 2.5 versus IABP in Cardiogenic SHOCK) trial [72] was the first randomized
clinical study to assess the safety and efficacy of Impella 2.5 in the setting of AMI complicated by
cardiogenic shock as compared to IABP. Twenty-five patients were randomized to the Impella 2.5 LP
device or IABP, and the primary endpoint was a change in cardiac index after 30 min of support. All
patients received PCI of the infarct-related artery and remained in shock. Patients supported with
an Impella had greater increase in cardiac index and mean arterial blood pressure after 30 min of
support. However, there was no difference in mortality or in the rates of bleeding or limb ischemia
between the two groups [72]. Subsequently, the safety and efficacy of Impella 2.5 LP was examined
in the EUROSHOCK multicenter registry [39] involving 120 patients with severe cardiogenic shock
refractory to conventional therapy, among which cardiopulmonary resuscitation was performed in
more than 40%, showing high overall in-hospital mortality rates reaching 64% without survival benefit
in the group treated with an Impella. Similarly, the IMPRESS in Severe SHOCK (IMPella versus
IABP Reduces mortality in STEMI patients treated with primary PCI in Severe cardiogenic SHOCK)
trial [6] enrolled 48 mechanically ventilated patients with severe cardiogenic shock after AMI who were
randomized 1:1 to Impella CP or IABP and followed for all-cause mortality at 30 days and 6 months
post AMI. Importantly, 44 (92%) patients had cardiac arrest prior to randomization with interquartile
time till return of spontaneous circulation ranging from 15 to 52 min and a considerable proportion
of patients (46%) died due to anoxic brain damage. The overall mortality in the study was 50% and
there were no significant differences between the two arms (50% versus 46% at 30 days and 50%
versus 50% at 6 months in the IABP and Impella CP groups, respectively), thus reflecting a very high
risk cohort presenting with late-stage cardiogenic shock [6,73]. The only study reporting a mortality
benefit of Impella in the setting of cardiogenic shock complicating AMI was by Karatolios et al. [74],
who conducted a retrospective, single-center study including 90 patients suffering from AMI and
cardiogenic shock treated with Impella (n = 27) or medical treatment alone (n = 63). Patients in the
Impella group were sicker, evidenced by higher lactate levels, longer low cardiac output duration, and
lower LV ejection fraction than those treated medically. When 20 patients of each group were matched,
patients supported with Impella had decreased rates of in-hospital (35% versus 80%; p = 0.01) and
6-month (40% versus 80%; p = 0.02) mortality [74]. More recently, using IABP-SHOCK II trial inclusion
and exclusion criteria, a retrospective analysis of 237 patients with AMI and cardiogenic shock treated
with Impella 2.5 (~30% of patients) or Impella CP (~70% of patients) were propensity matched to
the same number of patients from the IABP-SHOCK II trial [75]. There was no significant difference
in 30-day all-cause mortality. Moreover, severe or life-threatening bleedings as well as peripheral
vascular complications occurred more often in the Impella group. Limiting the analysis to IABP-treated
patients as the control group showed comparable results with no evidence of favorable outcomes with
Impella use [75]. Finally, a meta-analysis including 588 patients from the main aforementioned studies,
the use of MCS with Impella in the setting of AMI and cardiogenic shock was not associated with
improved short-time survival but there were higher rates of complications when compared with IABP
and medical treatment [76]. It is important to recognize, however, that the vast majority of patients
included in these studies were in profound cardiogenic shock and after cardiac arrest. As the use of
Impella in patients with less severe shock or pre-shock conditions was not the focus of these studies,
its effect on outcomes cannot, therefore, be addressed based on the current data and further studies are
still warranted in these settings.
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The effectiveness and safety of Impella support for planned high-risk coronary interventions
have been investigated in small studies showing encouraging results. In the AMC MAC1 study [77],
19 consecutive high-risk and poor surgical candidates with moderate-to-severe LV dysfunction (ejection
fraction < 40%) underwent PCI of an unprotected left main or the last remaining vessel with Impella
2.5 support showing 100% procedural success and no important device-related adverse events, thereby
demonstrating safety and feasibility of utilizing Impella devices for high-risk PCI. This has also been
confirmed in the PROTECT I trial [78], a prospective and multicenter study, which showed that Impella
2.5 system is safe, easy to implant, and provides excellent hemodynamic support for a mean duration of
1.7 h (range: 0.4–2.5 h) during high-risk PCI. The real-world use of the Impella 2.5 in complex high-risk
PCI showed an angiographic revascularization success of 99% in the overall cohort and in 90% of
patients with multivessel revascularization. Survival rates were 91% and 81% at 6 months and 12
months, respectively, despite including inoperable patients with a high prevalence of LV dysfunction,
New York Heart Association (NYHA) class III and IV heart failure, and chronic renal dysfunction [14].
The largest prospective randomized clinical study to examine the effect of hemodynamic support
with Impella in patients undergoing high-risk PCI was the PROTECT II trial [4]. In this multi-center
study, 452 patients with complex three-vessel disease or unprotected left main CAD and severely
depressed LV function were assigned to IABP or Impella 2.5 during non-emergent high-risk PCI. The
composite primary endpoint of 30-day incidence of 11 major adverse events was similar between the
Impella and IABP groups (35.1% for Impella 2.5 versus 40.1% for IABP, p = 0.227 in the intention-to-treat
population, and 34.3% versus 42.2%, p = 0.092 in the per-protocol population). Impella did provide
greater hemodynamic support and at 90-day follow-up there was a trend towards a decreased incidence
of adverse events with Impella in the intention-to-treat population (40.6% versus 49.3%, p = 0.066)
and significantly decreased events in the per-protocol population (40.0% versus 51.0%, p = 0.023) [4].
A subsequent analysis of the outcomes using a prognostic ally important definition of AMI based
on new Q-waves or >8× increase in creatinine kinase-MB, demonstrated that that Impella resulted
in improved event-free survival after 90 days of follow-up, supporting a late benefit that could be
attributed to more stable procedural hemodynamics that facilitate the performance of more complete
revascularization and complex PCI procedures, such as rotational atherectomy and bifurcation coronary
disease intervention, more safely [79]. A more recent consecutive real-world cohort of high-risk PCI
patients, new generation MCS devices (including Impella CP, Heartmate PHP, and PulseCath iVAC2L)
have demonstrated a significant reduction in the composite endpoint of serious peri-procedural adverse
events, including cardiac arrest and 30-day mortality despite worse LV function and higher Synergy
between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX)-I score
observed in patients protected with MCS [8]. Interestingly, patients under age of 75, with a SYNTAX-I
score > 32, and with an LV ejection fraction < 30% derived most potential benefit from MCS utilization
during PCI. These promising findings indicate that the more powerful LV support obtained using
new generation MCS devices may be necessary for improving clinical outcomes, which has not been
evidently seen using the IABP or Impella 2.5 devices.
6.3. TandemHeart
Small studies have shown a significant improvement in hemodynamics with TandemHeart use,
but were underpowered to show improvement in survival. In an observational study by Kar et al. [43],
TandemHeart placement in patients with severe cardiogenic shock refractory to conventional inotropic
or IABP therapy was associated with improvement in cardiac index (increased from 0.5 to 3 L/min/m2),
PCWP (decreased from 31 to 17 mmHg), and mixed venous oxygen saturation (increased from 49 to
69%), as well as improvement in kidney function (urine output increased from 70 to 1200 mL/day and
creatinine decreased from 1.5 to 1.2 mg/dL) and lactic acid level (decreased from 11 to 1.5 mg/dL).
However, overall mortality (40.2% at 30 days and 45.3% at 6 months) and bleeding complications
remained high [43]. In a small randomized study involving patients in cardiogenic shock after AMI, with
intended PCI to the infarcted artery, who were assigned to either IABP (n= 20) or TandemHeart (n = 21),
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hemodynamic and metabolic parameters was more effectively reversed by TandemHeart than by IABP
treatment. However, adverse events, such as severe bleeding and limb ischemia, were encountered
more frequently after TandemHeart support, and 30-day mortality was similar [80]. Similarly, a small
randomized trial of patients presenting within 24 h of the development of cardiogenic shock and
assigned to IABP or TandemHeart showed superior hemodynamic parameters with TandemHeart,
even in patients failing IABP, but no significant differences in in-hospital mortality or severe adverse
events when compared with IABP alone [81].
Data on the use of TandemHeart in high-risk PCI is limited to observational studies. A study
from the Mayo Clinic summarized data on 54 consecutive patients undergoing high-risk PCI using
a TandemHeart device for support, demonstrating feasibility and safety of this device to allow
performance of high-risk and complex intervention [82]. All patients were deemed high risk for
surgery and underwent complex PCI, with a Society of Thoracic Surgery (STS) mortality risk score of
13%, a median SYNTAX score of 33, and the majority of patients underwent left main and multivessel
PCI. Procedural success was achieved in 97% of cases, with hemodynamic improvement during the
procedure, and 6-month survival was 87%. However, major vascular complications occurred in 13% of
cases [82]. Additional small series of patients undergoing TandemHeart-assisted high-risk PCI have
shown comparable results. A meta-analysis of usefulness of percutaneous MCS devices, including
eight cohort studies with 205 patients supported by TandemHeart and 12 studies with 1346 patients
supported with Impella 2.5 during high-risk PCI, found 30-day mortality rates of 8% and major
bleeding rates of 3.6% with TandemHeart compared with 3.5% and 7.1% with Impella 2.5, respectively.
Overall periprocedural outcomes were comparable between the two groups [83].
6.4. Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO)
While ECMO provides excellent cardiopulmonary support with a relative ease of implementation,
its use in the setting of AMI and shock is limited by the need for specialized perfusion expertise
and nursing as well as the possibility for increased LV stroke work and myocardial oxygen demand,
which can precipitate further myocardial ischemia. Additionally, there is need for large bore cannulas
and aggressive antithrombotic therapy which increase the risk of bleeding. A recent single-center
study [84] reported a 67% survival to discharge rate among 18 consecutive patients who received
femoral VA-ECMO in the cardiac catheterization lab for severe shock due to ACS. The average length of
ECMO support was 3.2 days and 17 (94%) patients required at least one blood transfusion with higher
bleeding rates observed among those treated with glycoprotein IIb/IIIa inhibitors [84]. In another
small retrospective study [85], a total of 15 patients undergoing VA-ECMO placement for AMI with
refractory cardiogenic shock were analyzed. One-third of patients presented with out-of-hospital
resuscitation and 60% had IABP placed for LV venting. The survival rate after 30 days was 47%
and vascular complications occurred in 53% of patients. There is a growing utilization of VA-ECMO
in patients suffering from cardiac arrest requiring prolonged cardiopulmonary resuscitation (CPR)
showing acceptable survival rate and outcome [86]. A meta-analysis including 1866 patients treated
with VA-ECMO for cardiogenic shock or cardiac arrest showed an approximate overall survival
of 30% and significant associated morbidity with the performance of this intervention [58]. These
data suggest that use of VA-ECMO should be individualized based on risk-benefit analysis derived
from vascular anatomy and comorbidities to maximize clinical benefit. Finally, LV unloading during
VA-ECMO treatment for cardiogenic shock appears beneficial either with predominant use of IABP [51]
or Impella [87] demonstrating significant improvement in survival with the two unloading tools.
7. Recommendations for MCS Use During PCI
A suggested algorithmic approach to MCS use during PCI for cardiogenic shock complicating
AMI and high-risk PCI without cardiogenic shock is depicted in Figure 2. Interventional cardiologists
are challenged with a growing number of patients in need of coronary revascularization but who are
hemodynamically unstable or deemed poor surgical candidates and too high risk for PCI. The use of
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percutaneous MCS devices has been proven to be feasible and safe in clinical conditions previously
considered for conservative therapy only. However, data on survival benefit as a result of utilizing
these percutaneous devices is still lacking. It is not therefore surprising that there has been a modest
adoption of these devices in the current practice, reflecting the equivocal results from the current
evidence base in addition to the uncertainty as to which patients MCS will add a real benefit. Optimal
timing of device insertion is also an important variable. In light of the currently available data, it is
reasonable that utilization of MCS devices in clinical practice should be advocated in an individualized
manner based on a detailed review of the risks and benefits rather than as a standard of care for
every complex procedure. The recommendations on the use of a specific MCS device are based on
the anticipated hemodynamic effects and risks as well as clinical outcome data. Based on the recent
SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement published in 2015 [11], percutaneous MCS
may be considered in carefully selected patients with severe cardiogenic shock complicating AMI
unresponsive to pharmacologic support as a bridge to recovery following PCI or definitive therapy.
The evidence is stronger in the setting of mechanical complications post MI, such as ischemic mitral
regurgitation when hemodynamic derangement is usually acute and more substantial and the benefit
from these devices is more pronounced. There is an increasing indication for temporary MCS use
during and after primary PCI for patients presenting with large AMI causing severe LV dysfunction,
and RV mechanical support with Impella RP can be considered for RV infarction complicated by
cardiogenic shock. Early insertion of MCS devices is essential to attenuate the sequelae that may result
from persistent cardiac ischemia and systemic hypoperfusion. The type of MCS device is dependent
on multiple factors including the amount of hemodynamic support needed and the ultimate goal of
support as well as technical characteristics that should be taken into consideration, such as the ease or
deployment, and availability of these devices. IABP is more often used due to the ease of insertion and
availability although the benefit of its utility is questionable in patients with AMI and cardiogenic
shock. Impella 2.5 or CP provide more powerful hemodynamic support and can be inserted as rapidly
as an IABP in experienced centers and are thus considered more favorable devices in appropriate
patients. Finally, TandemHeart, VA-ECMO, or Impella 5 (which requires surgical cutdown for delivery)
should be reserved for patients who continue to deteriorate despite such support. In patients who
present with biventricular or cardiopulmonary failure, VA-ECMO is recommended as the first choice.
For isolated RV failure with cardiogenic shock, Impella RP is an available percutaneous MCS option
that may be considered in such cases [28].
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Figure 2. Suggested algorithmic approach for MCS in patients with cardiogenic shock complicating
AMI and high-risk PCI. MCS, mechanical circulatory support; AMI, acute myocardial infarction;
PCI, percutaneous coronary intervention. IABP, intraaortic balloon bump; VA-ECMO, venoarterial
extracorporeal membrane oxygenation. * High-risk PCI is defined as presented in Table 1 and mainly
include comorbidities, severe LV dysfunction (EF< 35%), and complex coronary artery disease involving
a large territory, such as unprotected left main, sole-remaining vessel, or three-vessel disease. ‡ Severe
cardiogenic shock is defined as markedly abnormal hemodynamic parameters (systolic blood pressure
< 90 mmHg, heart rate > 120 beats per minute, cardiac index < 1.5 L/min/m2, pulmonary capillary
wedge pressure/left ventricular end-diastolic pressure > 30 mmHg), metabolic (lactate > 4 mg/dL), and
clinical (confusion, cool extremities, on ≥2 vasopressors/inotropes) parameters.
For prophylactic percutaneous MCS use in the setting of high-risk PCI, great emphasis should be
on identifying the patient’s anatomic, hemodynamic, and procedural features that indicate adjunctive
MCS support may be necessary and also determine the optimal device to utilize [2]. The current
recommendation is to consider using MCS devices in patients with severe LV dysfunction (EF < 35%) or
recent presentation with decompensated heart failure in the setting of complex coronary artery disease
involving a large territory, such as unprotected left main, sole-remaining vessel, or three-vessel disease.
Generally, patients with anticipated noncomplex PCI may be considered for IABP as the first-line
MCS option with Impella as back up support, whereas those with anticipated technically challenging
or prolonged procedure (rotational atherectomy or bifunctional stenting) may be considered for
Impella, TandemHeart, or VA-ECMO depending on vascular anatomy, RV function, expertise, and
availability [2,88]. The more severe the clinical and anatomic circumstances, the greater the potential
benefit of MCS use [11]. MCS support should be initiated before the start of the PCI and in most cases
can be removed immediately after the intervention. In cases with hemodynamic derangement after
PCI, prolonged MCS support should be considered until hemodynamic improvement. Continuous
hemodynamic monitoring with pulmonary arterial catheter in encouraged as early as possible to tailor
therapy and help with determining the amount and duration of MCS support needed. Finally, the use
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of MCS devices in the emergent setting has been suggested to be cost-effective compared with surgical
ECMO or ventricular assist device support [89], as well as in the elective setting when compared with
IABP [90].
8. Future Directions
The majority of studies involving the new MCS devices for cardiogenic shock and high risk PCI
have demonstrated superior hemodynamic improvement as compared to IABP but these studies were
largely underpowered to find mortality benefit and therefore should be regarded as feasibility trials and
a basis for larger clinical trials in the future. The DanGer Shock study [91] is an ongoing prospective
randomized multicenter study with planned enrollment of 360 patients with AMI complicated by
cardiogenic shock randomized 1:1 immediately after shock diagnosis to either Impella CP prior to PCI
or current guideline-driven therapy. Patients with coma after out of hospital cardiac arrest are excluded.
The primary endpoint is all-cause mortality at 180 days. The DanGer trial will be the first adequately
powered randomized controlled trial to examine whether MCS with Impella CP improves survival
among patients with cardiogenic shock complicating AMI and will therefore provide fundamental
knowledge on the use of transvalvular LV unloading in this setting [91].
Despite the lack of current evidence, we believe that advanced MCS devices may improve clinical
outcomes, including survival, in a selected group of patients and in specific circumstances. Future
studies should largely focus on three major considerations when examining the clinical benefit of MCS.
First, the optimal MCS device design and amount of support needed to achieve hemodynamic as
well as metabolic improvement is unclear. For instance, in the IMPRESS in Severe Shock trial, one
third of the patients died due to refractory cardiogenic shock and lactate levels remained high in
many patients while being on Impella CP support, suggesting that the actual level of support was not
sufficient [6,73]. Second, appropriate patient selection is a key factor that should be emphasized in
future studies. Because utilization is currently determined based on subjective criteria, many patients
may survive without MCS while others with irreversible anoxic brain injury from prolonged shock
may not survive even with adequate hemodynamic support. Additionally, patients with shock and
multiorgan dysfunction are at significantly higher risk of bleeding due to increased inflammation
and coagulopathy which may progress to disseminated intravascular coagulation. Therefore, studies
focusing on identifying patients are higher risk of device-associated complications among whom the
harm of these complications may outweigh the benefit is clinically meaningful for mitigating device
complications. For example, lactate has been shown to be an important biomarker for risk stratification
in the setting of cardiogenic shock. Among patients undergoing extracorporeal cardiopulmonary
resuscitation due to cardiac arrest, lactate clearance was the sole predictor of neurological outcome
as assessed by the Glasgow Outcome Scale (GOS) [92] and in patients with refractory cardiogenic
shock requiring VA-ECMO support, lactate levels and lactate clearance during ECMO therapy were
predictive markers for 30-day mortality [93]. In patients with cardiac arrest, lactate levels prior to
ECMO initiation was significantly associated with increased risk of all-cause mortality at 90 days.
Interestingly, lactate was found to be more predictive of outcome than duration of cardiopulmonary
resuscitation or absence of return of spontaneous circulation [94]. These findings suggest that early
metabolic assessment by measuring plasma lactate levels may be an important prognostic marker for
risk stratification when considering MCS in patients with cardiogenic shock. One study has shown
that high body mass index (BMI) was an additional predictor of 30-day mortality in patients with AMI
and cardiogenic shock supported by VA-ECMO [95]. However, the influence of BMI on outcomes
among patients supported by other MCS devices is unclear.
Third, the timing of MCS device insertion in relation to primary PCI among patients with AMI
and cardiogenic shock can be critical to achieve survival benefit and future studies should focus on
determining the optimal timing of MCS, which remains elusive. Recent studies have shown in an
animal model that mechanical support with LV unloading reduces infarct size and favorably mediates
key biological pathways associated with inflammation and maladaptive cardiac remodeling when
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mechanical support is initiated prior to coronary reperfusion compared with early reperfusion without
support [96–99]. In a prospective safety and feasibility first-in-human study known as the Door to
Unloading With Impella CP System in Acute Myocardial Infarction to Reduce Infarct Size (DTU), LV
unloading with the Impella CP with a 30-min delay prior to reperfusion in patient with STEMI is
feasible with similar rates of adverse cardiovascular events and 30-day mean infarct size and without
prohibitive safety signals [100]. These data suggest that LV unloading prior to PCI initiation in the
setting of myocardial ischemia may be pivotal to achieve significant benefit from MCS devices but
clinical evidence from randomized control trials is still awaiting. In support of this hypothesis, in the
setting of AMI and cardiogenic shock, data from the catheter-based ventricular assist device registry
have shown that early MCS implantation (either the Impella 2.5 or Impella CP) before PCI, prior to
escalating doses of inotropes or vasopressors and within 75 min from shock onset, was independently
associated with improved survival compared with later MCS support [24]. Similarly, data from a
quality improvement registry including over 15,000 patients with AMI complicated by cardiogenic
shock and supported with Impella have shown wide variation in outcomes across centers with higher
survival rates seen when Impella was used as first support strategy, when invasive hemodynamic
monitoring was used, and at higher institutional Impella implantation volume [101]. A meta-analysis
of 3 available studies on the use of early Impella in patients with AMI and cardiogenic shock found
that early initiation of Impella decreased in-hospital or 30-day mortality by 48% compared with late
initiation of Impella [102].
Based on these promising retrospective data, and after the FDA’s approval of Impella for
cardiogenic shock complicating AMI, investigators have organized the construct of a multicenter
national shock protocol now referred to as the “National Cardiogenic Shock Initiative” (NCSI)
emphasizing invasive hemodynamic monitoring and rapid initiation of percutaneous MCS support.
The analysis of the first 171 patients enrolled in NCSI was recently published [7] and included patients
presenting with AMI and cardiogenic shock using the same inclusion and exclusion criteria from
the “SHOCK” trial (with an additional exclusion criteria of IABP use prior to MCS). The majority of
patients were supported with Impella CP (92%) prior to PCI (74%) with an average door to support
of 85 min in STEMI cases. Moreover, right heart catheterization with hemodynamic monitoring was
performed in 92% of cases. The use of a protocol-based approach showed improved survival compared
with previously reported studies [7]. Despite the limitations of being an observational single arm study,
these findings highlight the importance of early MCS prior to PCI for achieving the most benefit from
MCS. Future studies are still warranted to confirm these promising findings. Finally, it is necessary
to derive efficient risk scores for identifying patients at high risk of developing cardiogenic shock
following AMI as this may aid in risk stratification and potential prophylactic utilization of MCS
during PCI to mitigate subsequent hemodynamic derangement in this high-risk population [103].
Another field of future research is the percutaneous LV unloading strategy using Impella in
combination with VA-ECMO (ECMELLA) to improve outcomes in patients with refractory cardiogenic
shock [87,104]. In an all-comers retrospective study, percutaneous LV unloading with Impella on
top of VA-ECMO showed improved outcomes, including higher 30-day survival, as compared to
predicted outcomes by established risk scores [87]. In addition to the ECMELLA approach, previous
studies have also suggested that a combination of VA-ECMO plus IABP is safe and associated with
improved in-hospital survival in cardiogenic shock patients [105]. However, given the retrospective
nature of these studies, prospective and randomized studies are still warranted to further investigate
this therapeutic strategy.
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9. Conclusions
The use of MCS devices is expanding and several MCS devices are currently available and can
provide varying magnitude of hemodynamic support during high-risk and complex PCIs. Small
randomized controlled trials have provided conflicting results regarding survival benefit using these
devices despite substantial hemodynamic and metabolic benefit. However, given the high morbidity
and mortality burden among patients undergoing high-risk and complex PCI, detailed hemodynamic
assessment and careful patient selection is mandatory to achieve incremental benefit over early
revascularization and pharmacologic therapy with utilizing these devices. Furthermore, the optimal
timing and magnitude of hemodynamic support during PCI as well as prevention of device-related
complications are all important considerations in future research in this field. Until adequate data
supporting MCS use in a broader patient population is available, MCS devices during PCI should
be individualized based on multiple factors with a recommended use in patients with the greatest
potential benefit and a relatively low risk of device-related complications.
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Abstract: In many, but not all studies, people living with HIV (PLWH) have an increased risk of
coronary artery disease (CAD) events compared to the general population. This has generated
considerable interest in the early, non-invasive detection of asymptomatic (subclinical) atherosclerosis
in PLWH. Ultrasound studies assessing carotid artery intima-media thickness (CIMT) have tended to
show a somewhat greater thickness in HIV+ compared to HIV−, likely due to an increased prevalence
of cardiovascular (CV) risk factors in PLWH. Coronary artery calcification (CAC) determination by
non-contrast computed tomography (CT) seems promising to predict CV events but is limited to the
detection of calcified plaque. Coronary CT angiography (CCTA) detects calcified and non-calcified
plaque and predicts CAD better than either CAC or CIMT. A normal CCTA predicts survival free
of CV events over a very long time-span. Research imaging techniques, including black-blood
magnetic resonance imaging of the vessel wall and 18F-fluorodeoxyglucose positron emission
tomography for the assessment of arterial inflammation have provided insights into the prevalence
of HIV-vasculopathy and associated risk factors, but their clinical applicability remains limited.
Therefore, CCTA currently appears as the most promising cardiac imaging modality in PLWH for
the evaluation of suspected CAD, particularly in patients <50 years, in whom most atherosclerotic
coronary lesions are non-calcified.
Keywords: subclinical coronary artery disease; accelerated atherosclerosis; HIV infection; carotid
intima-media thickness; coronary calcium scoring; coronary CT angiography; magnetic resonance
angiography; fluorodeoxyglucose positron emission tomography
1. Introduction
Cardiovascular disease (CVD) has become one of the leading causes of death in people living
with HIV (PLWH) worldwide [1–4]. Reducing the burden of CVD, particularly coronary artery disease
(CAD), is therefore emerging as a major public health goal in medical care for PLWH [5,6].
Data is inconsistent with respect to whether PLWH have an increased incidence of CAD events
compared to the general population [2,7] or not [8–10]. Early reports have observed a 2- to almost 4-fold
increased rate in CAD events as compared to HIV-negative patients [11,12], but traditional risk factors,
particularly smoking, and socioeconomic factors were not always adjusted for in those studies [13].
Danish data suggest a 1.5- to 2-fold increase in CAD events in PLWH vs. controls [14]; a 2-fold CAD
event increase in PLWH was also the conclusion of a recent systematic review and meta-analysis [2].
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Other studies have reported smaller increases [15–17] in cardiovascular (CV) events in PLWH.
In a large cohort study from California that evaluated the myocardial infarction (MI) risk from 1996
to 2011, a declining relative risk for MI was observed in PLWH vs. HIV-negative persons over time.
Between 2010 and 2011, no increased risk of MI was seen in PLWH [17]. In a cohort of US veterans,
a 50% increased risk in acute MI was recorded, after adjusting for Framingham risk score, comorbidities
and substance use [16]. In another large North American analysis, HIV infection was associated with
only a 21% increased incidence of CV events in comparison with a well-matched HIV-negative control
group, and the risk increase was not statistically significant in the age group ≥60 years of age [15].
Moreover, in recent studies from Switzerland and Denmark, no increased risk of CAD events and, in
Switzerland, no increased subclinical atherosclerosis prevalence was described, perhaps due to the
prevalence of modern antiretroviral therapy (ART) regimens, reliably suppressive ART, decreased
smoking prevalence, and access to regular medical follow-up [8,9,18]. Also, the data do not generally
suggest that CV events occur earlier in PLWH, contradicting the widely held notion of “accelerated
atherosclerosis” or even “accelerated aging”. Some reports that CV events occur at a younger age
seem to be related to the younger median age of many HIV+ populations compared to the general
population [19].
The pathogenesis of CV events in HIV-positive individuals likely represents a complex interaction
of different factors that contribute to the development of atherosclerosis [18,20–23]. Studies in
multiple countries have consistently recorded an increased prevalence of smoking and drug use in
PLWH [11,13]. A link between inflammation related to HIV infection and CAD in PLWH is well
documented. Several serum biomarkers that are associated with CV risk or overall mortality may be
elevated in PLWH compared to HIV-negative persons, including biomarkers of systemic inflammation
(high sensitivity C-reactive protein, interleukin-6, soluble tumor necrosis factor-α receptor 1) [24–27],
coagulation (D-dimer, fibrinogen) [24–27], monocyte activation (lipopolysaccharide, soluble CD14,
CD163, CC-chemokine ligand 2) [24,28–31], and endothelial dysfunction (intercellular adhesion
molecule 1) [24]. Although the exact mechanisms underlying the development of atherosclerosis in
PLWH have not been conclusively determined, smooth muscle cell proliferation may play an important
role [32]. Moreover, endothelial dysfunction due to adhesion molecules may lead to adhesion of
circulating leukocytes, transmigration of monocytes/macrophages to the intima and subsequently to
vascular inflammation [20,32,33]. In combination with procoagulatory mechanisms in the setting of
increased concentrations of D-dimer and coagulation factors, and in the presence of other metabolic
disorders (e.g., dyslipidemia), the progression of atherosclerosis might be enhanced in PLWH [20,32].
It is well accepted that viral suppression, in the setting of adequate ART, is associated with lower
levels of inflammatory biomarkers and decreased CV risk [34,35]. Advanced immunosuppression has
contributed to CV risk in PLWH in some [15,36,37] but not in other studies [38,39].
Also, certain ART agents have been associated with increased CV risk. This notion is most reliably
based on findings from the large, multinational, observational D:A:D study [20,23,39]. Dyslipidemia
was among the first described deleterious metabolic effects of ART, most notably in the setting of
certain protease inhibitors, i.e., lopinavir, indinavir and darunavir [23,40,41]. Within the drug class
of nucleoside reverse transcriptase inhibitors, abacavir and didanosine were found to increase CV
risk [42].
The potentially increased CV event rate in PLWH has generated considerable interest in early
detection of asymptomatic (subclinical) atherosclerosis, in order to improve CAD event prediction
and to allow appropriate CVD prevention by early intervention [21]. Most published literature on
noninvasive cardiac imaging for the detection of subclinical atherosclerosis in PLWH has focused
on carotid artery intima-media thickness (CIMT), coronary artery calcification (CAC), coronary CT
angiography (CCTA) [18,43,44] and, more recently, magnetic resonance imaging of the vessel wall
(MRI) and 18F- fluorodeoxyglucose positron emission tomography (FDG-PET).
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2. Carotid Artery Intima-Media Thickness (CIMT)
CIMT is an ultrasound technique to measure the thickness of the two layers of the carotid artery
wall, the intima and the media [45]. CIMT is well recorded to predict future CV events in the general
population [46–49]. According to the results of a 2009 meta-analysis that analyzed six cross-sectional,
seven case-control and 13 cohort studies (5456 HIV positive and 3600 HIV negative patients) PLWH
tend to show a greater thickness in CIMT (0.04 mm thicker; 95% confidence interval: 0.02–0.06 mm,
p < 0.001) when compared to HIV-negative controls [50]. However, the findings are not concordant
with some studies showing increased CIMT was increased in PLWH compared to HIV-negative
controls [12,51–71] while other studies did not show a difference or showed only weakly increased
CIMT in PLWH [12,45,50–59,61–68]. Those discordant findings may be attributable to differences in
study design, participant characteristics, duration of follow-up, and different approaches of ultrasound
measurement [45,50].
The largest differences in CIMT between HIV-positive and HIV-negative participants were noted in
studies with the greatest demographic differences between the analyzed groups [45,50]. Moreover, small
studies were more likely than larger studies to identify an increase in CIMT in PLWH vs. controls [45,50].
In addition, a large report of repeated CIMT measurements over a median of 7 years did not find
accelerated CIMT progression in PLWH (747 women, 530 men) compared to HIV-negative controls
(264 women, 284 men), but focal plaque prevalence was increased, after adjusting for traditional CV
risk factors [70]. These findings are in accordance with another report that observed no different
progression in CIMT over 144 weeks in 133 extensively matched HIV+ and HIV− participants [59].
CIMT has a number of limitations for the prediction of CV events, including a limited correlation
with angiographically defined atherosclerosis [72,73], limited improvement in CV event prediction by
the addition of CIMT to the Framingham risk score [46], and different results when CIMT findings at
the common carotid artery level are compared with results obtained at the carotid bifurcation and/or
the internal carotid artery level [45,61,65]. Finally, CIMT measurement is dependent on investigator
experience, with the reproducibility of results generally being higher in research settings than in
practitioner-based settings [74].
3. Coronary Artery Calcium (CAC) Scoring
CAC scoring using non-contrast enhanced CT is a well-established and easily applicable tool for
detection and quantification of coronary calcifications [75–80] (Figure 1). Applying different scoring
systems, most frequently the Agatston score, based on the landmark work of Arthur Agatston in the
late 1980s [81], CAC scoring has emerged as a robust non-invasive atherosclerosis imaging modality
characterized by high inter- and intra-observer reliability [74,80,82].
In the general population, there is a strong correlation between CAC score and future CV
endpoints [74,80,83–86]. Persons with no detectable coronary calcium have a very low risk for CV
events over the following years [87,88] and a ten-year survival of 99.4% [89]. Longitudinal CAC studies
have suggested that annual CAC score change of ≥15% may constitute CVD progression [90]. CV event
prediction by CAC and CIMT were similar in one report [91], but CAC was a more reliable CV event
predictor than CIMT in several other reports [86,92–94]. CV event prediction may be improved when
CAC is added to Framingham risk score [88,89].
Current evidence remains equivocal as to whether the presence of HIV is associated with
an increased prevalence of coronary calcifications [18,71,95,96]. An increased vascular age was
identified in Italian PLWH compared with age-specific CAC percentiles based on the MESA study
done in a general US population [95]. However, these findings were not confirmed in a recent study
assessing a large Swiss cohort [18]; other studies have also found similar CAC scores in HIV-positive
and HIV-negative persons [18,50,96]. High pre-treatment HIV viremia levels were associated with
a CAC score >0 [18]. In the US MACS study, CAC scores were elevated in those with metabolic
syndrome but were not altered by HIV serostatus [57,96].
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Figure 1. Coronary artery calcium scoring in an asymptomatic 43-year old HIV-positive male patient.
Maximum intensity projection depicts extensive calcifications in the left anterior descending artery
(purple), in the left circumflex artery (blue), and in the right coronary artery (yellow). The total Agatston
score was 1031, classifying this patient as at high risk for future CV events and prompting lifestyle
interventions and the initiation of a statin.
A major limitation of CAC is the inability to detect non-calcified plaque. This is of importance
because a non-calcified or only partially calcified plaque is more likely to take on morphological
features typical of high-risk plaque which is prone to adverse future CV events (e.g., plaque rupture
or erosion potentially leading to MI) [97,98]. In addition, coronary artery plaque is predominantly
non-calcified in patients <50 years of age [80,99,100]. This point may be particularly relevant to PLWH:
as, in Western countries, even though HIV-positive populations are aging, their median age is still
relatively low, e.g., 48 years in the Swiss HIV cohort study (www.shcs.ch and [101]). Their Framingham
risk scores and CAD event rates have also been relatively low, and the median age at the time of the
first CAD event in SHCS participants was 50 years [38].
4. Coronary CT Angiography (CCTA)
CCTA is a non-invasive imaging technique involving contrast-enhanced multi-slice CT for the
accurate morphological assessment of the coronary arteries [102] (Figure 2).
Importantly, and in contrast to CIMT and CAC, CCTA can be used to detect calcified and
non-calcified plaques, and due to its high spatial resolution also allows for the accurate assessment of
plaque composition [74,103] (Figure 3).
CCTA has seen a tremendous development over the last two decades, both in terms of hardware
advancements and improvements in image acquisition protocols. Among the latter, the introduction of
prospectively electrocardiogram-triggered acquisition has contributed most substantially to lowering
radiation dose exposure from 15–20 millisieverts (mSv) [104–106] down to 2–3 mSv [104,107–110].
The addition of sophisticated reconstruction algorithms and widespread use of latest-generation
wide-coverage CT devices may now enable routine scanning in the sub-millisievert range [111].
Sensitivity of CCTA in the detection of relevant coronary stenosis is similar to standard invasive
coronary angiography [112–114]. However, both modalities inherently lack the ability to predict
hemodynamic relevance if a stenosis is found. This is of the utmost importance because the optimal
treatment, i.e., the benefit of optimal medical therapy versus revascularization, depends heavily on
the presence and extent of myocardial ischemia [115]. While, theoretically, measurement of pressure
drops along a vessel and the derivation of the so-called fractional flow reserve constitutes an invasive
technique to overcome this limitation, the application of hybrid imaging, that is, the combination and
fusion of two non-invasive imaging modalities, has evolved into a robust and elegant technique for the
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assessment of both coronary anatomy and potential hemodynamical effects of any given lesion, hence
providing the non-invasive grounds for optimized patient management decisions (Figure 4).
 
Figure 2. Coronary computed tomography angiography of a 48-year old HIV+ female patient with
typical angina. The patient had a positive family history for cardiovascular events and was an active
smoker, putting her at intermediate risk for having coronary artery disease. Volume rendering (A)
of the image datasets depicts normal coronary anatomy, while the curved multiplanar reformats of
the left anterior descending (B), the left circumflex (C), and the right coronary (D) arteries reveal only
minimal and non-obstructive coronary atherosclerosis in the proximal left anterior descending (white
arrow). Coronary artery disease was, therefore, excluded as a cause for her symptoms. BMI 24.2 kg/m2.
Radiation dose exposure 0.57 mSv. Contrast volume 40 mL.
 
Figure 3. Non-invasive evaluation of an asymptomatic 65-year old HIV+male patient. The patient
had a history of treated arterial hypertension, was an active smoker and suffered from peripheral
artery disease with the latter prompting further cardiovascular work-up despite a normal
stress-electrocardiogram. Multiplanar curved reconstruction of the coronary computed tomography
angiography dataset (A) reveals multiple calcified but non-obstructive lesions and 70–90% stenosis
(white filled arrow) in the mid-right coronary artery. This obstructive lesion (B, cross sectional view)
exhibits several morphological high-risk features typical for an event-prone lesion, such as positive
remodeling and a low-attenuation core (*) with calcifications only at the edge of the lesion (white empty
arrow), constituting the so-called napkin-ring sign.
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Figure 4. Evaluation of a 49-year old HIV+ male patient with typical angina. The patient had no
cardiovascular risk factors and he was referred for exclusion of coronary artery disease with a calculated
pre-test probability of 69%. Total cholesterol was 3.6 mmol/L (<5.0), HDL-cholesterol 1.45 mmol/L
(>1.0), and LDL-cholesterol 1.8 mmol/L (<3.0). Maximum intensity projection and multiplanar curved
reconstruction of the coronary computed tomography angiography (CCTA) datasets (A) depict a 70–90%
stenosis (white filled arrow) in the proximal left anterior descending artery as shown in the cross-section
(inlet). As per clinical routine and in accordance with current guidelines, lesions are primarily graded
visually with regard to maximal percent diameter stenosis in our institution. In this particular patient,
the qualitative evaluation was complemented by quantitative measurements (using version 2 of CardIQ
Xpress/GE Healthcare), because the lesion in the LAD was non-calcified, allowing for more accurate
lumen delineation due to the lack of blooming artifacts. The quantitative analysis resulted in a diameter
stenosis of 75%. Myocardial perfusion single-photon-computed-emission-tomography (SPECT, (B))
confirmed hemodynamical relevance of the lesion, revealing a large perfusion defect during stress (top
rows) with reversibility during rest (bottom rows), constituting ischemia in the anteroseptal wall of
the left ventricular myocardium. Hybrid CCTA/SPECT imaging (C) clearly demonstrates a large area
of ischemia in the myocardium subtended by the left anterior descending artery. Finally, obstructive
coronary artery disease (white empty arrow) was confirmed during invasive coronary angiography
(D), and the lesion was treated with a drug-eluting stent.
Compared to intravascular ultrasound, CCTA can precisely detect coronary plaque with a positive
and negative predictive value >98% [18,107,116,117]. It is well recorded, however, that CCTA tends to
overestimate the degree of coronary stenosis [118,119]. In the general population, among individuals
without known CVD, the large scale CONFIRM study documented that the degree of non-obstructive
and obstructive coronary artery stenosis and the number of vessels affected in CCTA are closely
correlated with CV events and mortality rates over 3 years of follow-up [107]. CCTA improves
prediction of future CV events compared to Framingham risk score [120], CAC [107,108,121] or
CIMT [108,118].
In early studies, results regarding the presence of subclinical atherosclerosis in CCTA in
HIV-positive relative to HIV-negative persons were not uniform. Some investigators recorded
an increased [44,100,122–124] prevalence, while others noted a similar [18,43,125] or even lower
prevalence in PLWH, compared to HIV-negative controls [18,103]. In a 2015 meta-analysis summarizing
initial CCTA studies (1229 HIV-positive and 1029 HIV negative participants), a 3-fold higher prevalence
of non-calcified coronary artery plaque on CCTA was recorded in asymptomatic HIV+ compared to
HIV-negative subjects [100]. The analyzed studies typically included a small number of participants,
that, in addition, were not always matched on CV risk factors [124].
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Today, there are three published CCTA studies that enrolled large numbers of HIV+ and
HIV-negative participants, with the following key findings: In men who had sex with men that were
enrolled in the US-American multicenter AIDS cohort study (MACS), Post et al. [44] recorded a higher
prevalence of any coronary plaque and non-calcified plaque in 618 HIV+ compared to 383 HIV-negative
men in the baseline CCTA. In a follow-up report, with a median interval of 4.5 years between CCTAs,
increased progression of coronary plaques was observed in HIV-positive compared to the HIV-negative
MACS participants, but only in men with detectable HIV viremia and, thus, presumably, higher degrees
of ongoing systemic inflammation, compared to persons with optimal virological control [44,126].
Lai et al. described the presence of subclinical atherosclerosis in CCTA of 953 HIV+ and 476
HIV-negative African American study participants from Baltimore/USA of whom more than 50% were
frequent cocaine users [43]. In this study, there was a trend towards HIV infection being independently
associated with non-calcified plaque, however, this association was largely explained by chronic
cocaine use.
In addition to these two studies from the US [43,44,126], we recently assessed subclinical
atherosclerosis in a cross-sectional study of 428 HIV-positive participants of the Swiss HIV Cohort Study
(SHCS) and 276 HIV-negative control individuals with similar Framingham risk scores. HIV-positive
participants had similar degrees of non-calcified/mixed plaque and high risk [97] plaque, and, indeed,
had less calcified coronary plaque, and lower coronary atherosclerosis involvement and severity scores
compared to their negative controls with similar Framingham risk score [18]. These Swiss CCTA
results, together with Swiss data showing similar CV incidence rates in HIV+ and HIV-persons [8],
attenuate concerns about accelerated atherosclerosis in HIV, and have prompted experts to ask the
question whether the prevalent notion of increased CV risk in PLWH amounts to “much ado about
nothing” [127].
The different CCTA results in these three large studies [18,43,44] might be related to a number
of features. First, CAD rates are lower in southern/central Europe compared to the US [128,129].
Second, we speculate that the low subclinical atherosclerosis prevalence in Swiss PLWH might further
be attributable to high rates of successful treatment in the setting of modern ART regimens, regular
follow-up, and declining smoking rates in recent years [9,130].
As regards the duration of ART, the Swiss study did not find any association with any type of
plaque. This was in line with findings from Lai et al. in the group of non-cocaine users and contrary to
MACS [18,43,44]. Concerning the use of antiretroviral agents and subclinical atherosclerosis, the MACS
investigators observed no clear association between different ART drugs and any form of coronary
artery plaque on CCTA [131]. In contrast, the Swiss study identified an association with exposure to
abacavir and an increased prevalence of non-calcified/mixed plaque [132]. This observation seems
important, as it may afford a mechanism by which abacavir increases CV risk, i.e., the promotion of
atherosclerosis, in addition to putative deleterious effects of abacavir on platelet reactivity [133,134].
Consistent with the MACS findings, the Swiss patients with a low nadir CD4+ cell count had more
non-calcified plaque [18,44] and more coronary stenosis greater than 50% [44]. These findings suggest
that advanced immunosuppression may contribute to subclinical atherosclerosis in PLWH [100].
In summary, coronary plaque in young persons typically is non-calcified [80,99,100]. CCTA (but
not CAC) can detect non-calcified plaque [74] and predicts CVD better than CAC [107] or CIMT [118].
Therefore, and because the median age of most populations of PLWH remains below 50 years today,
CCTA is emerging as the preferred research-setting imaging tool to detect subclinical atherosclerosis.
There remains a need for additional studies to examine the exact role that CCTA may play in clinical
HIV practice.
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5. Magnetic Resonance Rmaging (MRI)
Based on CIMT being strongly predictive of CV events [135], multiple studies have reported the
use of MRI rather than ultrasound in assessing CVD in PLWH [103,136–139]. Such studies mainly used
black-blood MRI (BBMRI), an advanced imaging technique relying on nulling of the MR signal from the
vascular lumen while retaining signal from the vascular wall, allowing better visualization of the wall
thickness [140,141]. Multiple variations of the BBMRI technique have already been used in extracranial
(e.g., aorta, carotid and coronary arteries) as well as intracranial vessel wall imaging [140–146].
In age-related atherosclerosis, BBMRI is generally used to assess the vulnerability characteristics
of eccentric, lipid-rich plaques (e.g., lipid core, fibrous cap, hemorrhage). In HIV vasculopathy on
the other hand, where intimal smooth muscle hypertrophy occurs in a symmetrical circumferential
manner [32,33], BBMRI is more commonly used to assess diffuse wall thickening. This is why the
majority of vessel wall imaging studies in HIV have concentrated on measuring the vessel wall
thickness (VWT) akin to the measurement of CIMT using ultrasound [103,138,147,148]. In a group
of treated HIV+ subjects with low measurable CVD risk, HIV-status was significantly associated
with increased wall/outer-wall ratio (W/OW), an index of vascular thickening, after adjusting for
age [139]. In another study, increased carotid artery wall thickness was noted in HIV+ subjects on
chronic ART compared to controls with similar CVD risk, [137]. Interestingly, while in one study [139],
no correlation of CVD with the type of ART was identified, another study [137] found that a longer
duration of protease inhibitor therapy was associated with greater wall thickness. Using MRI to assess
coronary rather than carotid arteries, subclinical CAD has been documented in ART-treated subjects,
with HIV infection being independently associated with increased proximal right coronary artery wall
thickness [103].
The connection between HIV-associated inflammation and atherosclerosis burden in HIV infection
was also evaluated in a group of HIV+ subjects (treated and untreated) in comparison to a group
of demographically similar controls. As expected, HIV-1 viral burden was found to be associated
with higher serum levels of the chemokines monocyte chemoattractant protein-1/CC-chemokinligand
2 (MCP-1/CCL2). At the same time, HIV infection correlated with atherosclerosis burden, mainly
detectable as increased vessel wall area and thickness in the thoracic aorta [148].
BBMRI has also been important in delineating that traditional CVD risk factors, which seem
to disproportionately burden PLWH, need to be controlled. In one study evaluating asymptomatic,
young-to-middle-aged African-Americans with and without HIV infection and cocaine use, only total
cholesterol (and not HIV status) was significantly associated with the presence of a lipid core in carotid
plaques [136]. In another more recent study, carotid VWT was increased in treated PLWH relative to
controls with the 10-year ASCVD (atherosclerotic cardiovascular disease) risk score being the only
variable significantly associated with VWT whereas HIV status was not. The authors concluded that
traditional CVD risk factors in PLWH are adequately captured in the ASCVD risk score which was
closely associated with subclinical carotid disease [138].
Over the last few years, there have been significant advances made in MR imaging of the vessel
wall, with the ability nowadays of assessing atherosclerotic involvement of the intracranial arteries.
To our knowledge, such high-resolution techniques have not yet been applied in the evaluation of
PLWH [146,149–153]. At this point, BBMRI of the vessel wall remains a research application rather
than a clinically used technique in assessing CVD in PLWH (Figure 5). Whether this would eventually
change in the future, as PLWH get older, remains unclear.
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Figure 5. Black-blood MR imaging of the carotid arteries. Fat saturated T2-weighted black-blood MR
images at the level of the common carotid arteries in a 56-year-old HIV+man (A) and a 47-year-old HIV−
man (B). Similar imaging technique at the level of the internal carotid arteries (ICAs) in a 56-year-old
HIV+ woman (C) shows narrowing of the vascular lumen bilaterally by a plaque (small arrows),
more significant on the right side. (D) shows similar imaging at the level of ICAs in a 47-year-old HIV
negative man with no evidence of atherosclerosis.
6. 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG PET)
The most common application of FDG PET imaging in the clinic is the baseline assessment and
follow-up of neoplastic diseases. Applications in imaging infectious and inflammatory diseases using
FDG PET, however, have been increasing in the last decade.
One such use is the assessment of vasculitis seen as increased glucose metabolism of the vessel
wall, reflecting inflammatory changes [154] (Figure 6).
 
Figure 6. FDG-PET imaging of the major vessels. (A) Coronal FDG PET images, (B) coronal CT scan
images and (C) fused PET CT scans show subtle FDG uptake in the vascular wall of the ascending
aorta (arrows).
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A similar approach has been used by multiple groups to assess HIV-vasculopathy using FDG
PET [155–162]. A common presumption is that PLWH will demonstrate increased vessel wall FDG
uptake reflecting premature aging and atherosclerotic changes. In fact, in one paper assessing only
HIV+ patients, a relationship was found between arterial inflammation on FDG PET and features of
high-risk coronary atherosclerotic disease including number of low attenuation plaques and plaque
vulnerability characteristics [160].
The results from studies utilizing FDG PET to assess HIV-vasculopathy, however, have been
rather inconsistent. In one paper [162], arterial inflammation in the aorta (measured as aortic target
to background ratio (TBR)) was higher in the HIV+ group compared to the non-HIV control group
matched for CVD, even after adjusting for traditional CV risk factors [162]. More recently, HIV was
found to be associated with 0.16 higher aortic TBR compared to controls, independent of traditional
risk factors [155]. On the other hand, in one paper assessing virologically controlled HIV+ persons
with no known CVD, there was no evidence of increased arterial inflammation on FDG PET compared
to healthy volunteers [159]. In a more recent paper looking at a larger group of patients, there was
only a marginally higher TBR in PLWH, with significant overlap of TBR values with HIV-negative
controls [156]. The discrepancy in the results of those studies could be related to variations in study
populations, treatment status of patients and the presence or absence of co-morbid CVD. Another
element of variability could also be related to the imaging technique and analysis methods.
Another use for FDG PET is in longitudinally assessing PLWH for changes in arterial inflammation
over time. To our knowledge, only one such longitudinal study has been reported, with twelve ART
naïve subjects imaged at baseline and again six months after ART initiation. Interestingly, there were
no significant changes in TBR between baseline and follow-up scans [157]. This could be due to short
interval imaging after ART initiation. Another paper assessing PLWH treated with statins versus
placebo found no significant change in arterial inflammation as measured by FDG PET despite the fact
that statin therapy reduced non-calcified plaque volume and high-risk coronary plaque features on
CCTA [158].
At this point, using FDG PET in PLWH is more likely to be useful in evaluating co-morbidities,
specific organ involvement or assessment of central nervous system involvement [163–167]. The role
of FDG PET in assessing CVD in individual subjects on the other hand remains uncertain.
7. Outlook
Consistent with Swiss data [8], a nationwide cohort study in Denmark found that after the
exclusion of participants with risk factors including illicit drug use or hepatitis B or C co-infections,
the mortality rate was similar in HIV-positive and HIV-negative persons [168]. In general, persons
with well-controlled HIV infection and a healthy lifestyle appear to have similar survival rates today
as do HIV-negative persons, with potentially increased death rates mainly ascribed to traditional
risk factors [168,169]. Thus, for efficient primary CAD prevention in PLWH, our aim should be
the optimization of traditional risk factor management, early initiation of ART therapy, and regular
patient follow-up.
Few studies have simultaneously applied more than one cardiac imaging modality (CIMT and
CAC [170], CCTA and MRI [103]) in the same patients, but did not correlate CIMT results with CAC or
MRI with CCTA results. Hsue and colleagues found that with or without detectable CAC, PLWH had
higher CIMT than HIV-negative controls [171]. Interestingly, among those without detectable CAC,
a third of PLWH but no controls had increased CIMT.
CCTA is emerging as an accurate and reliable non-invasive imaging modality for detection of
subclinical atherosclerosis in PLWH, especially in persons <50 years who typically have non-calcified
or partially calcified plaque. However, in asymptomatic PLWH today, cardiac imaging is not yet
indicated to assess coronary atherosclerosis. The exception might be asymptomatic persons with
diabetes [172]. Studies that compared coronary imaging to optimization of medical treatment in
asymptomatic patients have not yet shown any clinical benefit, but a number of relevant studies are
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ongoing. Particularly in patients with atypical symptoms suggestive of myocardial ischemia, or in
patients with suspected acute coronary syndrome but without ST-segment elevations on EKG, CCTA is
now increasingly well established as a valuable diagnostic tool to rule out CAD in the emergency
room [173–175], because of its non-invasiveness compared to coronary angiography and its extremely
high negative predictive value [176].
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Abstract: Aim. To evaluate by meta-analysis of interventional studies the effect of statin therapy
on arterial wall inflammation. Background. Arterial exposure to low-density lipoprotein (LDL)
cholesterol levels is responsible for initiation and progression of atherosclerosis and arterial wall
inflammation. 18F-fluorodeoxyglucose Positron Emission Tomography-Computed Tomography
(18F-FDG PET/CT) has been used to detect arterial wall inflammation and monitor the vascular
anti-inflammatory effects of lipid-lowering therapy. Despite a number of statin-based interventional
studies exploring 18F-FDG uptake, these trials have produced inconsistent results. Methods. Trials
with at least one statin treatment arm were searched in PubMed-Medline, SCOPUS, ISI Web of
Knowledge, and Google Scholar databases. Target-to-background ratio (TBR), an indicator of
blood-corrected 18F-FDG uptake, was used as the target variable of the statin anti-inflammatory
activity. Evaluation of studies biases, a random-effects model with generic inverse variance weighting,
and sensitivity analysis were performed for qualitative and quantitative data assessment and
synthesis. Subgroup and meta-regression analyses were also performed. Results. Meta-analysis of
seven eligible studies, comprising 10 treatment arms with 287 subjects showed a significant reduction
of TBR following statin treatment (Weighted Mean Difference (WMD): −0.104, p = 0.002), which
was consistent both in high-intensity (WMD: −0.132, p = 0.019) and low-to-moderate intensity statin
trials (WMD: −0.069, p = 0.037). Statin dose/duration, plasma cholesterol and C-reactive protein
level changes, and baseline TBR did not affect the TBR treatment response to statins. Conclusions.
Statins were effective in reducing arterial wall inflammation, as assessed by 18F-FDG PET/CT
imaging. Larger clinical trials should clarify whether either cholesterol-lowering or other pleiotropic
mechanisms were responsible for this effect.
J. Clin. Med. 2019, 8, 118; doi:10.3390/jcm8010118 www.mdpi.com/journal/jcm311
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1. Introduction
Atherosclerosis, the leading cause of cardiovascular (CV)-related deaths worldwide [1], is a disease
process that is initiated, maintained and destabilized by an abnormal engagement of several cellular
and molecular pathways of the inflammation cascade [2]. Exposure to elevated plasma low-density
lipoprotein (LDL) cholesterol levels, either in the presence of or in the absence of additional CV risk
factors, initiates and drives progressive lipid and inflammatory cell infiltration in the arterial wall [1,2],
which may result in atherosclerotic plaque complications (e.g., erosion, rupture, etc.), ischemic-related
organ injury and death [3,4].
Due to the recognized role of LDL cholesterol (LDL-C) in initiating and promoting atherosclerosis,
followed by arterial wall inflammation [1,2], the anti-inflammatory effect of statins, as the most widely
prescribed class of cholesterol-lowering drugs, has been largely explored [5–8]. Among a plethora of
documented pleiotropic actions [9–14], there is accumulating evidence showing that statin therapy
reduces inflammation in vitro, in experimental and clinical studies, though it is still debated whether
it may depend on either cholesterol-lowering or pleiotropism [15]. Regardless of the mechanisms
underlying the anti-inflammatory effects of statins, several circulating biomarkers of inflammation
and acute phase reactants are down-regulated by statin treatment [7,15]. Despite low-grade systemic
inflammation being frequently associated with atherosclerosis [16,17], the relationship with serum is
sometimes contradictory [18–20], possibly suggesting that plasma biomarkers might not accurately
reflect the degree of arterial wall inflammation. Hence, diagnostic tools that are more directly reflective
of arterial inflammation have been sought.
One such method is 18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
combined with computed tomography (CT), which has been used in both preclinical and clinical studies
for the evaluation of inflammation in the arterial wall [18–22]. Over the last few years, significant
technical progresses have been achieved in order to extend the CV applications of 18F-FDG PET/CT,
which include improved image acquisition, measurements, and reconstruction protocols [23]. This has
allowed a number of clinical trials to provide promising results of 18F-FDG PET/CT in detecting
atherosclerotic plaque inflammation [18–20], discriminating stable from unstable plaques [24,25],
predicting CV prognosis [26–29], and monitoring response to CV-related therapies [21,30,31].
In addition, 18F-FDG PET has been used to assess the impact of statin treatment on arterial wall
inflammation in a few interventional studies [32–38]. In these studies [32–38], arterial 18F-FDG uptake
was expressed as the Target-to-Background Ratio (TBR), that is a measure of the blood-normalized
standardized uptake value (SUV). Since the reliability of TBR may be hampered by the low spatial
resolution of PET, CT has been combined to improve 18F-FDG detection [21]. In these studies [32–38],
the impact of different statins, at different doses, on inflammation of different arterial segments and
in different clinical settings has been investigated. However, most of the studies have involved small
numbers of patients, different clinical settings, varying statins with varying doses and treatment duration,
different arterial segments, image acquisition/analysis, etc. Not surprisingly, the results of statin therapy
on arterial wall inflammation using 18F-FDG PET/CT have been varied and inconclusive [32–38].
In order to overcome some of the inconsistencies, we carried out a systematic review and
meta-analysis of previously reported trials with statins and 18F-FDG uptake, expressed as TBR.
2. Methods
2.1. Search Strategy
This study was designed according to the guidelines of the preferred reporting items for systematic
reviews and meta-analysis (PRISMA) statement. PubMed-Medline, Scopus, ISI Web of Knowledge
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and Google Scholar databases were searched using the following search terms in titles and abstracts:
(18F-fluorodeoxyglucose OR “18 F-fluorodeoxyglucose” OR FDG OR “18 F-FDG” OR “FDG-18 F”
OR “18F-FDG” OR “FDG-18F” OR fluorodeoxyglucose OR “18 F FDG” OR “18F FDG” OR 18FDG
OR “18 FDG”) AND (atorvastatin OR simvastatin OR rosuvastatin OR lovastatin OR fluvastatin OR
pravastatin OR pitavastatin). The wild-card term “*” was used to increase the sensitivity of the search
strategy. The search was limited to articles published in English language. The literature was searched
from inception to 19 January 2018.
2.2. Study Selection
Original studies were included if they met the following inclusion criteria: (i) being an
interventional study with a statin treatment arm, (ii) investigating the impact of statin treatment
on arterial wall inflammation based on the 18F-FDG PET/CT method, and (iii) presentation of arterial
wall FDG uptake as TBR values (as a vein-normalized index) at baseline and after statin therapy or
presenting the net change values. Exclusion criteria were: (i) non-clinical studies, (ii) non-interventional
studies, e.g., observational studies with case-control, cross-sectional, or cohort designs, and (iii) lack of
sufficient information on baseline or follow-up TBR values or presenting arterial wall FDG uptake as
non-normalized indices.
2.3. Data Extraction
Eligible studies were reviewed and the following data were abstracted: (1) first author’s name, (2)
year of publication, (3) country where the study was performed, (4) study design, (5) number of treated
subjects, (6) type of statin used, (7) statin dose, (8) duration of treatment, (9) age, gender and body mass
index (BMI) of study participants, (10) baseline and follow-up TBR values, and (11) concentrations of
plasma lipids, lipoproteins, and C-reactive protein (CRP).
2.4. Quality Assessment
The quality of involved studies in this meta-analysis was evaluated using the Cochrane criteria as
previously described [39].
2.5. Quantitative Data Synthesis
Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) V2 software (Biostat,
NJ, USA). A random-effects model (using DerSimonian-Laird method) and the generic inverse variance
weighting method were used to compensate for the heterogeneity of studies in terms of study design,
treatment protocol and the populations being studied [40]. Standard deviations (SDs) of the mean
difference were calculated as follows: SD = square root (SDpost-treatment)2 − (2R × SDpre-treatment
× SDpost-treatment), assuming a correlation coefficient (R) = 0.5. Where standard error of the mean (SEM)
was only reported, SD was estimated using the following formula: SD = SEM × sqrt (n), where n is the
number of subjects. Heterogeneity was assessed quantitatively using Cochrane Q and I2 statistic. Effect
sizes were expressed as weighted mean difference (WMD) and 95% confidence interval (CI). If the
outcome measures were reported in median and range (or 95% confidence interval [25]), mean and SD
values were estimated using the method described by Wan et al. [41]. In order to evaluate the influence
of each study on the overall effect size, a sensitivity analysis was conducted using the leave-one-out
method (i.e., removing one study each time and repeating the analysis) [42,43]. Subgroup analyses
were performed to evaluate the impact of treatment intensity on the estimated effect size and also to
assess the effect size based on the TBR of most-diseased segment (MDS) of the index vessel.
2.6. Meta-Regression
As potential confounders of treatment response, duration of treatment, statin dose, mean
changes in plasma levels of LDL-C and CRP, and baseline TBR were entered into a random-effects
meta-regression model to explore their association with the estimated effect size on arterial
wall inflammation.
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2.7. Publication Bias
Evaluation of the funnel plot, Begg’s rank correlation, and Egger’s weighted regression tests
were employed to assess the presence of publication bias in the meta-analysis. When there was an
evidence of funnel plot asymmetry, potentially missing studies were imputed using the “trim and fill”
method [44]. The number of potentially missing studies required to make the p-value non-significant
was estimated using the “fail-safe N” method as another index of publication bias.
3. Results
Overall, 77 articles were found following the multi-database search. After screening of titles and
abstracts, 16 articles were assessed in full text. Of these, nine were excluded because of a duplicate
report (n = 3), not reporting TBR values (n = 5), and non-interventional study (n = 1). This left seven
eligible articles for meta-analysis (Figure 1).
 
Figure 1. Flow chart of studies. Procedure of studies identification and inclusion into the meta-analysis.
3.1. Study Characteristics
Data were pooled from seven clinical trials comprising 10 treatment arms with 287 individuals.
Of the selected studies, all reported whole vessel TBR of the index vessel. Aside from whole vessel
TBR, three trials also reported TBR of the MDS of the index vessel. The included studies [32–38]
used different types and doses of statins, and they were published between 2010 [33] and 2016 [36].
The range of treatment duration was from three months [32,35,36,38] to one year [34]. Study designs
of included trials were open-label [32,33,36–38] and parallel group [34,35]. Selected studies enrolled
subjects with atherosclerosis [32,38], hyperlipidemia [37], stable angina pectoris [33], HIV-infection [34],
arterial inflammation [35], and ankylosing spondylitis [36]. The clinical and biochemical characteristics
of the included clinical trials are presented in Table 1.
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3.2. F18-FDG PET/CT Procedure
FDG-PET and contrast-enhanced CT imaging of the arteries was performed in different vessels.
In this regard, Emami et al. [32] assessed the arterial FDG in the right carotid, left carotid, and aorta.
Ishii et al. [33] evaluated the ascending aorta and the right and left femoral arteries. Lo et al. [34]
measured FDG-PET of the aorta. Two studies [35,37] performed FDG-PET/CT imaging of the thoracic
aorta and carotid arteries. Van der Valk et al. [36] assessed arterial wall inflammation in carotid arteries.
Finally, Wu et al. [38] determined FDG uptake in several arterial segments, including the ascending
aorta, arch, thoracic descending aorta, abdominal aorta, and bilaterial iliofemoral arteries.
3.3. Risk of Bias Assessment
With respect to the random sequence generation and allocation concealment, two trials exhibited
high risk of bias [36,38]. Additionally, several studies had risk of bias for blinding of participants,
personnel, and outcome assessors [32,33,36–38]. Nonetheless, all selected studies showed low risk of
bias for incomplete outcome data and selective outcome reporting. Details of the risk of bias assessment
are shown in Table 2.


















Emami et al. (2015)
[32] U U H L L U
Ishii et al. (2010)
[33] U L H L L U
Lo et al. (2015) [34] L L L L L L
Tawakol et al. (2013)
[35] U U U L L U
van der Valk et al.
(2016) [36] H H H L L U
Watanabe et al.
(2015) [37] U U H L L U
Wu et al. (2012) [38] H H H L L U
L, low risk of bias; H, high risk of bias; U, unclear risk of bias.
3.4. Quantitative Data Synthesis
Meta-analysis of data from seven studies comprising 10 treatment arms suggested a significant
reduction of arterial wall FDG uptake based on TBR index following treatment with statins (WMD:
−0.104, 95% CI: −0.171, −0.038, p = 0.002; I2: 89.32%) (Figure 2A). The effect size was robust in the
leave-one-out sensitivity analysis (Figure 2B) and not mainly driven by any single study. Four studies
comprising five treatment arms reported arterial MDS TBR, which showed a significant reduction by
statin therapy (WMD: −0.186, 95% CI: −0.272, −0.100, p < 0.001; I2: 61.71%) (Figure 3A). Subgroup
analysis showed a significant reduction of arterial wall TBR with both high-intensity (WMD: −0.132,
95% CI: −0.242, −0.021, p = 0.019; I2: 93.44%) and low-to-moderate-intensity (WMD: −0.069, 95% CI:
−0.134, −0.004, p = 0.037; I2: 64.93%) statin therapy (Figure 3B); however, there was no significant
difference between the two subgroups (p = 0.340).
3.5. Meta-Regression
Random-effects meta-regression was performed to assess the impact of potential confounders on
the effects of statin therapy on arterial wall inflammation. The results did not suggest a significant
association between the impact of statins on TBR and treatment duration (slope: 0.005; 95% CI: −0.002,
0.01; p = 0.138), atorvastatin dose (slope: −0.001; 95% CI: −0.004, 0.002; p = 0.512), LDL-C change
(slope: 0.004; 95% CI: −0.0002, 0.01; p = 0.062), CRP change (slope: 0.05; 95% CI: −0.01, 0.11; p = 0.087),
and baseline TBR (slope: 0.023; 95% CI: −0.136, 0.181; p = 0.779) (Figure 4).
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A 
B 
Figure 2. Impact of statin treatment on arterial wall fluorodeoxyglucose (FDG) uptake. Forest plot
displaying weighted mean difference and 95% confidence intervals for the impact of statin therapy on
arterial wall FDG uptake based on whole vessel target-to-background ratio (TBR) index (A). (B) shows
the results of leave-one-out sensitivity analysis.
A 
B 
Figure 3. Impact of statin treatment on FDG uptake of the most diseased arterial segment. Forest plot
displaying weighted mean difference and 95% confidence intervals for the impact of statin therapy on
arterial wall FDG uptake based on the most diseased segment of vessel TBR (A). (B) shows the results
of meta-analysis stratified according to the intensity (high versus low-to-moderate) of statin therapy.
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Figure 4. Associations of potential confounders with changes in arterial wall TBR. Meta-regression
bubble plots of the association between mean changes in arterial wall TBR index with treatment
duration (a), atorvastatin dose (b) and mean changes in plasma LDL-cholesterol (c), C-reactive protein
(d), and baseline TBR (e). The size of each circle is inversely proportional to the variance of change.
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3.6. Publication Bias
Visual inspection of Begg’s funnel plots showed a slight asymmetry in the meta-analyses of statins’
effects on arterial wall inflammation. This asymmetry was corrected by imputing one potentially
missing study using “trim and fill” method, yielding a corrected effect size of −0.12 (95% CI: −0.18,
−0.05) (Figure 5). Begg’s rank correlation (tau = −0.11, z = 0.45, p = 0.655) and Egger’s regression test
(t = 0.02, df = 8, p = 0.988) did not suggest the presence of publication bias. The results of “fail-safe
N” test suggested that 230 missing studies would be required to make the observed significant result
non-significant. Given that for this meta-analysis we were able to identify seven eligible studies (with
10 treatment arms), it is far too unlikely that 230 studies were missed, thereby implying the lack of any
significant publication bias.
Figure 5. Publication biases. Funnel plot detailing publication bias in the studies reporting statin
therapy on arterial wall FDG uptake based on whole vessel TBR index. Open and closed circles
represent reported studies and potentially missing studies imputed using “trim and fill” method.
4. Discussion
In this meta-analysis, statin treatment resulted in a significant reduction of arterial wall
inflammation, based on TBR measurement by 18F-FDG PET/CT imaging. Although the included
clinical trials recruited only a limited number of patients for larger subgroup analyses and estimate
of confounders, we did not find any significant influence of statin doses, duration of treatment, and
cholesterol-lowering efficacy on TBR changes.
The pro-inflammatory role of increased LDL cholesterol levels has been documented by in vitro,
experimental and clinical studies [1,2,45–47]. Additionally, statin-related cholesterol-lowering has been
accompanied by the down-regulation of multiple pro-inflammatory pathways in atherogenesis [48].
Intriguingly, early anti-inflammatory effects of statins have often been described even before the
reduction of plasma cholesterol levels occurs, thus suggesting that the anti-inflammatory effects of
statins might be, at least in part, independent of their cholesterol-lowering action [15]. Irrespective
of the mechanisms explaining the recognized ability of statin therapy to suppress inflammation,
statin-related reduction of plasma CRP levels has been prospectively associated with atherosclerotic
plaque regression [49] and reduction of several clinical meaningful CV end-points [50], though this
has not been always confirmed [51].
Measurement of some plasma biomarkers may be useful to detect atherosclerosis-related systemic
inflammation [52–55]; however, the same biomarkers may not accurately reflect the degree of the
inflammatory burden within the arterial wall and, more specifically, in the atherosclerotic plaques.
In this regard, the association between inflammation at the plasma and arterial wall levels was
not always confirmed across the different studies [18–20]. Based on this background, several
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techniques have been proposed with the aim of detecting inflammation within the arterial wall
and atherosclerotic plaques [23]. 18F-FDG PET/CT has been used for this purpose both in preclinical
and clinical studies, with the progressive attempt to improve and standardize image acquisition
and reconstruction protocols, as well as measurement of 18F-FDG uptake [18–31]. Overall, these
studies have consistently demonstrated that 18F-FDG is taken up mostly by macrophages within
the atherosclerotic plaques, albeit other cells (i.e., endothelial cells, vascular smooth muscle cells,
neutrophils, lymphocytes) may participate in tracer uptake [21,22]. TBR, as a measure of SUV,
demonstrated to be a reproducible index for quantification of 18F-FDG uptake in the inflamed arterial
wall [21]. However, although TBR represents a useful tool for detecting arterial inflammation, it must
be underlined that arterial 18F-FDG uptake is not necessarily atherosclerosis-related, but may be
associated with other less frequent disease processes (e.g., giant cell arteritis, Takayasu arteritis,
arterial grafts and aortic aneurysm infections, periaortitis, chemotherapy- or radiation-induced arterial
inflammation, etc.) in the absence of atherosclerosis [56]. Regardless of this limitation, TBR was
able to discriminate stable from unstable plaques (i.e., culprit lesions), as well as patients with stable
angina from those with unstable angina [24,25]. In a retrospective study of 309 older subjects without
history of cancer and coronary heart disease at baseline, ascending aorta TBR has been associated
with coronary heart disease events [27]. Also, a few studies have revealed that arterial 18F-FDG
uptake was prospectively associated with an unfavorable CV prognosis [26,28,29]. Hence, 18F-FDG
PET/CT has been increasingly considered as a promising diagnostic and prognostic tool in the
atherosclerosis-mediated CV disease field.
An additional use of 18F-FDG PET/CT is the monitoring of vascular wall inflammation during
treatment of CV risk factors [21,30–38]. Few interventional studies in humans have reported the
impact of statin treatment on arterial TBR values extracted from 18F-FDG PET/CT analysis [32–38].
In particular, seven studies (including 10 treatment arms) fulfilled the inclusion/exclusion criteria
of this meta-analysis. Arterial TBR improved in 6 out of 10 arms [32,33,35–38], with the remaining
four [33–35,37] showing unaltered TBR after statin treatment. Specifically, TBR of the thoracic aorta and
carotid atherosclerotic plaques did not improve in one arm, including hyperlipidemic patients taking
low-dose (10 mg/daily) pravastatin therapy [37]; in this study, not including a placebo-controlled
arm, a modest 27% reduction of plasma LDL cholesterol level was observed along with a 2.29-fold
increase in plasma CRP level. Two additional studies not including a placebo-controlled arm did not
observe a significant arterial TBR change after low-dose atorvastatin treatment [33,35]. Specifically,
only 5 mg/daily of atorvastatin has been used by Ishii et al [33]. Also, in the 10 mg/daily atorvastatin
arm of the study by Tawakol et al. [35], 65% of patients received a statin before randomization to
atorvastatin, thus limiting the ability of the low-dose atorvastatin 10 mg/daily to improve a baseline
statin-influenced TBR value. This limitation was overcome, however, by atorvastatin 80 mg/daily
in the second arm of the study by Tawakol et al. [35]. Finally, 40 mg/daily of atorvastatin was
administered for one year in the study by Lo et al [34], but this was not sufficient to improve aortic
TBR in HIV-infected patients receiving antiretroviral therapy, despite a significant 31% LDL cholesterol
reduction and a three-fold decrease of plasma CRP level. However, as stated in Reference [34], technical
issues compromised the possibility of reaching adequate statistical power to detect changes in the
arterial wall inflammation. Regardless of the possible reasons explaining the failure of statin therapy
in 4 out of 10 arms, it must be pointed out that: (1) overall, statin therapy significantly reduced arterial
wall TBR, (2) neither duration/dose of statin treatment nor statin-related changes in plasma LDL
cholesterol and CRP levels had a significant influence on the association between statin treatment and
TBR improvement, and (3) unmeasured confounding variables or combinations of confounders might
have interfered with the latter association, which was not tested in this meta-analysis.
There were some limitations for this meta-analysis. The overall sample size was relatively small,
and populations differed in health status at baseline, statin preparations, doses, and duration of therapy,
which limited the ability to draw direct conclusions, as well as the statistical power for additional
subgroup and meta-regression analyses. However, it is worth noting that the present meta-analysis
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could provide a total population size that is considerably higher than the numbers recruited in each
individual study, thus providing a more reliable conclusion. We also reported the presence of biases
with respect to random sequence generation, allocation concealment, and blinding procedures in some
studies, which may have reduced the quality of the results. Finally, heterogeneity of clinical settings
and arterial segments examined by 18F-FDG PET/CT, in the absence of a larger sample size, have
precluded the possibility to explore the impact of statin treatment in specific populations and arterial
regions. Despite these potential limitations, statistical compensation for heterogeneity was performed,
and the overall result of this meta-analysis was robust in sensitivity analysis.
In conclusion, our meta-analysis showed the significant anti-inflammatory effect of statin
treatment at the arterial wall level; however, unresolved issues remain regarding the presumptive
factors that either mediate or confound such an effect. Larger clinical trials are warranted to resolve
this uncertainty and to verify whether the local anti-inflammatory effects of satins, as detected by
arterial 18F-FDG PET/CT, might translate into favorable clinical outcomes. Moreover, given that most
of the studies included in this analysis had a relatively short duration of follow-up, it remains to be
established if the anti-inflammatory effects of statins, as assessed by 18F-FDG PET/CT, are enhanced
over time and following prolonged exposure of arteries to low concentrations of LDL. It also remains
to be investigated if the findings of 18F-FDG PET/CT are correlated with alterations of biomarkers of
vascular inflammation, as well as circulating levels of pro-inflammatory cytokines in statin-treated
subjects. Finally, biomimetic nanoparticles have recently emerged as potential tools for targeting and
imaging of inflammation, e.g., through mimicking the interactions between cell adhesion molecules
and selectins in the inflamed vascular site [57,58]. The use of these nanoparticles, with modalities like
radioisotope imaging, magnetic resonance imaging, and ultrasound, could allow efficient monitoring
of the anti-inflammatory action of statins and other lipid-lowering therapies on the arterial wall and
could be confirmatory to 18F-FDG PET/CT findings as detailed in this study.
Funding: No funding was received for this study.
Acknowledgments: The authors thank Evan A. Stein for his valuable help in improving the manuscript.
Conflicts of Interest: This meta-analysis was written independently; no company or institution supported
it financially. Gerald F. Watts has received honoraria for advisory boards and lectures from Amgen, Sanofi,
Regeneron, Kowa and MSD. Maciej Banach: speakers bureau: Abbott/Mylan, Abbott Vascular, Actavis, Akcea,
Amgen, Biofarm, KRKA, MSD, Sanofi-Aventis, Servier and Valeant; consultant to Abbott Vascular, Akcea, Amgen,
Daichii Sankyo, Esperion, Lilly, MSD, Resverlogix, Sanofi-Aventis; Grants from Sanofi and Valeant.
References
1. Roth, G.A.; Johnson, C.; Abajobir, A.; Abd-Allah, F.; Abera, S.F.; Abyu, G.; Ahmed, M.; Aksut, B.; Alam, T.;
Alam, K.; et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to
2015. J. Am. Coll. Cardiol. 2017, 70, 1–25. [CrossRef]
2. Hansson, G.K. Inflammation and Atherosclerosis: The End of a Controversy. Circulation 2017, 136, 1875–1877.
[CrossRef]
3. Catapano, A.L.; Graham, I.; De Backer, G.; Wiklund, O.; Chapman, M.J.; Drexel, H.; Hoes, A.W.; Jennings, C.S.;
Landmesser, U.; Pedersen, T.R.; et al. ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the
Management of Dyslipidaemias. Eur. Heart J. 2016, 37, 2999–3058. [CrossRef] [PubMed]
4. Ference, B.A.; Ginsberg, H.N.; Graham, I.; Ray, K.K.; Packard, C.J.; Bruckert, E.; Hegele, R.A.; Krauss, R.M.;
Raal, F.J.; Schunkert, H.; et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1.
Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European
Atherosclerosis Society Consensus Panel. Eur Heart J. 2017, 38, 2459–2472. [CrossRef] [PubMed]
5. Deshmukh, H.; Chasman, D.; Trompet, S.; Li, X.; Sun, F.; Hitman, G.; Colhoun, H. Meta-analysis of
genome-wide association studies to assess C-reactive protein response to statin therapy. Lancet 2016, 387,
S37. [CrossRef]
6. Ridker, P.M.; Danielson, E.; Fonseca, F.A.; Genest, J.; Gotto, A.M., Jr.; Kastelein, J.J.; Koenig, W.; Libby, P.;
Lorenzatti, A.J.; MacFadyen, J.G.; et al. Rosuvastatin to prevent vascular events in men and women with
elevated C-reactive protein. N. Engl. J. Med. 2008, 359, 2195–2207. [CrossRef] [PubMed]
321
J. Clin. Med. 2019, 8, 118
7. Zhang, L.; Zhang, S.; Jiang, H.; Sun, A.; Wang, Y.; Zou, Y.; Ge, J.; Chen, H. Effects of statin therapy on
inflammatory markers in chronic heart failure: A meta-analysis of randomized controlled trials. Arch. Med.
Res. 2010, 41, 464–471. [CrossRef]
8. Bielecka-Dabrowa, A.; Mikhailidis, D.P.; Rizzo, M.; von Haehling, S.; Rysz, J.; Banach, M. The influence
of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality
in patients with dilated cardiomyopathy—5-year follow-up. Lipids Health Dis. 2013, 12, 47. [CrossRef]
[PubMed]
9. Mohajeri, M.; Banach, M.; Atkin, S.L.; Butler, A.E.; Ruscica, M.; Watts, G.F.; Sahebkar, A. MicroRNAs: Novel
Molecular Targets and Response Modulators of Statin Therapy. Trends Pharmacol. Sci. 2018, 39, 967–981.
[CrossRef]
10. Bahrami, A.; Parsamanesh, N.; Atkin, S.L.; Banach, M.; Sahebkar, A. Effect of statins on toll-like receptors:
A new insight to pleiotropic effects. Pharmacol. Res. 2018, 135, 230–238. [CrossRef]
11. Sahebkar, A.; Kotani, K.; Serban, C.; Ursoniu, S.; Mikhailidis, D.P.; Jones, S.R.; Ray, K.K.; Blaha, M.J.; Rysz, J.;
Toth, P.P.; et al. Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized
controlled trials. Atherosclerosis 2015, 241, 433–442. [CrossRef] [PubMed]
12. Parizadeh, S.M.R.; Azarpazhooh, M.R.; Moohebati, M.; Nematy, M.; Ghayour-Mobarhan, M.; Tavallaie, S.;
Rahsepar, A.A.; Amini, M.; Sahebkar, A.; Mohammadi, M.; et al. Simvastatin therapy reduces
prooxidant-antioxidant balance: Results of a placebo-controlled cross-over trial. Lipids 2011, 46, 333–340.
[CrossRef] [PubMed]
13. Serban, C.; Sahebkar, A.; Ursoniu, S.; Mikhailidis, D.P.; Rizzo, M.; Lip, G.Y.H.; Kees Hovingh, G.;
Kastelein, J.J.P.; Kalinowski, L.; Rysz, J.; et al. A systematic review and meta-analysis of the effect of
statins on plasma asymmetric dimethylarginine concentrations. Sci. Rep. 2015, 5, 9902. [CrossRef]
14. Sahebkar, A.; Serban, C.; Mikhailidis, D.P.; Undas, A.; Lip, G.Y.H.; Muntner, P.; Bittner, V.; Ray, K.K.;
Watts, G.F.; Hovingh, G.K.; et al. Association between statin use and plasma d-dimer levels: A systematic
review and meta-analysis of randomised controlled trials. Thromb. Haemost. 2015, 114, 546–557. [CrossRef]
[PubMed]
15. Diamantis, E.; Kyriakos, G.; Quiles-Sanchez, L.V.; Farmaki, P.; Troupis, T. The Anti-Inflammatory Effects
of Statins on Coronary Artery Disease: An Updated Review of the Literature. Curr. Cardiol. Rev. 2017, 13,
209–216. [CrossRef] [PubMed]
16. Buffon, A.; Biasucci, L.M.; Liuzzo, G.; D’Onofrio, G.; Crea, F.; Maseri, A. Widespread coronary inflammation
in unstable angina. N. Engl. J. Med. 2002, 347, 5–12. [CrossRef] [PubMed]
17. Libby, P.; Ridker, P.M.; Hansson, G.K. Progress and challenges in translating the biology of atherosclerosis.
Nature 2011, 473, 317–325. [CrossRef] [PubMed]
18. Duivenvoorden, R.; Mani, V.; Woodward, M.; Kallend, D.; Suchankova, G.; Fuster, V.; Rudd, J.H.; Tawakol, A.;
Farkouh, M.E.; Fayad, Z.A. Relationship of serum inflammatory biomarkers with plaque inflammation
assessed by FDG PET/CT: The dal-PLAQUE study. JACC Cardiovasc. Imaging 2013, 6, 1087–1094. [CrossRef]
[PubMed]
19. Rudd, J.H.; Bansilal, S.; Machac, J.; Woodward, M.; Fuster, V. Relationships among regional
arterial inflammation, calcification, risk factors, and biomarkers: A prospective fluorodeoxyglucose
positron-emission tomography/computed tomography imaging study. Circ. Cardiovasc. Imaging 2009,
2, 107–115. [CrossRef] [PubMed]
20. Yang, S.J.; Kim, S.; Choi, H.Y.; Kim, T.N.; Yoo, H.J.; Seo, J.A.; Kim, S.G.; Kim, N.H.; Baik, S.H.; Choi, D.S.; et al.
High-sensitivity C-reactive protein in the low- and intermediate-Framingham risk score groups: Analysis
with 18F-fluorodeoxyglucose positron emission tomography. Int. J. Cardiol. 2013, 163, 277–281. [CrossRef]
[PubMed]
21. Rosenbaum, D.; Millon, A.; Fayad, Z.A. Molecular imaging in atherosclerosis: FDG PET. Curr. Atheroscler.
Rep. 2012, 14, 429–437. [CrossRef] [PubMed]
22. Tarkin, J.M.; Joshi, F.R.; Rajani, N.K.; Rudd, J.H. PET imaging of atherosclerosis. Future Cardiol. 2015, 11,
115–131. [CrossRef] [PubMed]
23. Huet, P.; Burg, S.; Le Guludec, D.; Hyafil, F.; Buvat, I. Variability and uncertainty of 18F-FDG PET imaging
protocols for assessing inflammation in atherosclerosis: Suggestions for improvement. J. Nucl. Med. 2015, 56,
552–559. [CrossRef]
322
J. Clin. Med. 2019, 8, 118
24. Dilsizian, V.; Jadvar, H. Science to Practice: Does FDG Differentiate Morphologically Unstable from Stable
Atherosclerotic Plaque? Radiolog 2017, 283, 1–3. [CrossRef]
25. Rogers, I.S.; Nasir, K.; Figueroa, A.L.; Cury, R.C.; Hoffmann, U.; Vermylen, D.A.; Brady, T.J.; Tawakol, A.
Feasibility of FDG imaging of the coronary arteries: Comparison between acute coronary syndrome and
stable angina. JACC Cardiovasc. Imaging 2010, 3, 388–397. [CrossRef] [PubMed]
26. Figueroa, A.L.; Abdelbaky, A.; Truong, Q.A.; Corsini, E.; MacNabb, M.H.; Lavender, Z.R.; Lawler, M.A.;
Grinspoon, S.K.; Brady, T.J.; Nasir, K.; et al. Measurement of arterial activity on routine FDG PET/CT images
improves prediction of risk of future CV events. JACC Cardiovasc. Imaging 2013, 6, 1250–1259. [CrossRef]
[PubMed]
27. Iwatsuka, R.; Matsue, Y.; Yonetsu, T.; O’uchi, T.; Matsumura, A.; Hashimoto, Y.; Hirao, K. Arterial
inflammation measured by 18F-FDG-PET-CT to predict coronary events in older subjects. Atherosclerosis
2018, 268, 49–54. [CrossRef]
28. Marnane, M.; Merwick, A.; Sheehan, O.C.; Hannon, N.; Foran, P.; Grant, T.; Dolan, E.; Moroney, J.; Murphy, S.;
O’rourke, K.; et al. Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography
predicts early stroke recurrence. Ann. Neurol. 2012, 71, 709–718. [CrossRef]
29. Rominger, A.; Saam, T.; Wolpers, S.; Cyran, C.C.; Schmidt, M.; Foerster, S.; Nikolaou, K.; Reiser, M.F.;
Bartenstein, P.; Hacker, M. 18F-FDG PET/CT identifies patients at risk for future vascular events in an
otherwise asymptomatic cohort with neoplastic disease. J. Nucl. Med. 2009, 50, 1611–1620. [CrossRef]
[PubMed]
30. Van Wijk, D.F.; Sjouke, B.; Figueroa, A.; Emami, H.; van der Valk, F.M.; MacNabb, M.H.; Hemphill, L.C.;
Schulte, D.M.; Koopman, M.G.; Lobatto, M.E.; et al. Nonpharmacological lipoprotein apheresis reduces
arterial inflammation in familial hypercholesterolemia. J. Am. Coll. Cardiol. 2014, 64, 1418–1426. [CrossRef]
31. Xu, J.; Nie, M.; Li, J.; Xu, Z.; Zhang, M.; Yan, Y.; Feng, T.; Zhao, X.; Zhao, Q. Effect of pioglitazone on
inflammation and calcification in atherosclerotic rabbits: An 18F-FDG-PET/CT in vivo imaging study. Herz
2017, 43, 733–740. [CrossRef]
32. Emami, H.; Vucic, E.; Subramanian, S.; Abdelbaky, A.; Fayad, Z.A.; Du, S.; Roth, E.; Ballantyne, C.M.;
Mohler, E.R.; Farkouh, M.E.; et al. The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38
MAPK) inhibitor on arterial inflammation: A multicenter FDG-PET trial. Atherosclerosis 2015, 240, 490–496.
[CrossRef] [PubMed]
33. Ishii, H.; Nishio, M.; Takahashi, H.; Aoyama, T.; Tanaka, M.; Toriyama, T.; Tamaki, T.; Yoshikawa, D.;
Hayashi, M.; Amano, T.; et al. Comparison of atorvastatin 5 and 20 mg/d for reducing F-18
fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed
tomography: A randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled
for percutaneous coronary intervention. Clin. Ther. 2010, 32, 2337–2347. [CrossRef] [PubMed]
34. Lo, J.; Lu, M.T.; Ihenachor, E.J.; Wei, J.; Looby, S.E.; Fitch, K.V.; Oh, J.; Zimmerman, C.O.; Hwang, J.; Abbara, S.;
et al. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in
HIV-infected patients with subclinical atherosclerosis: A randomised, double-blind, placebo-controlled trial.
Lancet HIV 2015, 2, e52–e63. [CrossRef]
35. Tawakol, A.; Fayad, Z.A.; Mogg, R.; Alon, A.; Klimas, M.T.; Dansky, H.; Subramanian, S.S.; Abdelbaky, A.;
Rudd, J.H.; Farkouh, M.E.; et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic
inflammation: Results of a multicenter fluorodeoxyglucose-positron emission tomography/computed
tomography feasibility study. J. Am. Coll. Cardiol. 2013, 62, 909–917. [CrossRef] [PubMed]
36. Van der Valk, F.M.; Moens, S.J.; Verweij, S.L.; Strang, A.C.; Nederveen, A.J.; Verberne, H.J.;
Nurmohamed, M.T.; Baeten, D.L.; Stroes, E.S. Increased arterial wall inflammation in patients with
ankylosing spondylitis is reduced by statin therapy. Ann. Rheum. Dis. 2016, 75, 1848–1851. [CrossRef]
37. Watanabe, T.; Kawasaki, M.; Tanaka, R.; Ono, K.; Kako, N.; Saeki, M.; Onishi, N.; Nagaya, M.; Sato, N.;
Miwa, H.; et al. Anti-inflammatory and morphologic effects of pitavastatin on carotid arteries and
thoracic aorta evaluated by integrated backscatter trans-esophageal ultrasound and PET/CT: A prospective
randomized comparative study with pravastatin (EPICENTRE study). Cardiovasc. Ultrasound 2015, 13.
[CrossRef]
38. Wu, Y.W.; Kao, H.L.; Huang, C.L.; Chen, M.F.; Lin, L.Y.; Wang, Y.C.; Lin, Y.H.; Lin, H.J.; Tzen, K.Y.; Yen, R.F.;
et al. The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose
tissue and circulating biomarkers. Eur. J. Nucl. Med. Mol. Imaging 2012, 39, 399–407. [CrossRef]
323
J. Clin. Med. 2019, 8, 118
39. Green, S.; Higgins, J. (Eds.) Cochrane Handbook for Systematic Reviews of Interventions; Version 5.0.2;
The Cochrane Collaboration: London, UK, 2009.
40. Sutton, A.J.; Abrams, K.R.; Jones, D.R.; Jones, D.R.; Sheldon, T.A.; Song, F. Methods for Meta-Analysis in
Medical Research; J. Wiley: Hoboken, NJ, USA, 2000.
41. Wan, X.; Wang, W.; Liu, J.; Tong, T. Estimating the sample mean and standard deviation from the sample
size, median, range and/or interquartile range. BMC Med. Res. Methodol. 2014, 14, 135. [CrossRef]
42. Sahebkar, A.; Simental-Mendía, L.E.; Watts, G.F.; Serban, M.C.; Banach, M. Comparison of the effects of
fibrates versus statins on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of
head-to-head randomized controlled trials. BMC Med. 2017, 15, 22. [CrossRef]
43. Sahebkar, A. Does PPARγ2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk?
Evidence from a meta-analysis. DNA Cell Biol. 2013, 32, 188–198. [CrossRef] [PubMed]
44. Duval, S.; Tweedie, R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for
publication bias in meta-analysis. Biometrics 2000, 56, 455–463. [CrossRef] [PubMed]
45. Paciullo, F.; Fallarino, F.; Bianconi, V.; Mannarino, M.R.; Sahebkar, A.; Pirro, M. PCSK9 at the crossroad
of cholesterol metabolism and immune function during infections. J. Cell. Physiol. 2017, 232, 2330–2338.
[CrossRef] [PubMed]
46. Pirro, M.; Bianconi, V.; Paciullo, F.; Mannarino, M.R.; Bagaglia, F.; Sahebkar, A. Lipoprotein(a) and
inflammation: A dangerous duet leading to endothelial loss of integrity. Pharm. Res. 2017, 119, 178–187.
[CrossRef] [PubMed]
47. Pirro, M.; Schillaci, G.; Savarese, G.; Gemelli, F.; Mannarino, M.R.; Siepi, D.; Bagaglia, F.; Mannarino, E.
Attenuation of inflammation with short-term dietary intervention is associated with a reduction of arterial
stiffness in subjects with hypercholesterolaemia. Eur. J. Cardiovasc. Prev. Rehabil. 2004, 11, 497–502. [CrossRef]
[PubMed]
48. Montecucco, F.; Mach, F. Update on statin-mediated anti-inflammatory activities in atherosclerosis.
Semin. Immunopathol. 2009, 31, 127–142. [CrossRef]
49. Nissen, S.E.; Tuzcu, E.M.; Schoenhagen, P.; Crowe, T.; Sasiela, W.J.; Tsai, J.; Orazem, J.; Magorien, R.D.;
O’shaughnessy, C.; Ganz, P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
N. Engl. J. Med. 2005, 352, 29–38. [CrossRef] [PubMed]
50. Ridker, P.M.; Cannon, C.P.; Morrow, D.; Rifai, N.; Rose, L.M.; McCabe, C.H.; Pfeffer, M.A.; Braunwald, E.
C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 2005, 352, 20–28. [CrossRef]
51. Yousuf, O.; Mohanty, B.D.; Martin, S.S.; Joshi, P.H.; Blaha, M.J.; Nasir, K.; Blumenthal, R.S.; Budoff, M.J.
High-sensitivity C-reactive protein and cardiovascular disease: A resolute belief or an elusive link? J. Am.
Coll. Cardiol. 2013, 62, 397–408. [CrossRef]
52. Krintus, M.; Kozinski, M.; Kubica, J.; Sypniewska, G. Critical appraisal of inflammatory markers in
cardiovascular risk stratification. Crit. Rev. Clin. Lab. Sci. 2014, 51, 263–279. [CrossRef]
53. Mannarino, E.; Pirro, M. Endothelial injury and repair: A novel theory for atherosclerosis. Angiology 2008,
59, 69S–72S. [CrossRef] [PubMed]
54. St-Pierre, A.C.; Bergeron, J.; Pirro, M.; Cantin, B.; Dagenais, G.R.; Després, J.P.; Lamarche, B. Effect of plasma
C-reactive protein levels in modulating the risk of coronary heart disease associated with small, dense,
low-density lipoproteins in men (The Quebec Cardiovascular Study). Am. J. Cardiol. 2003, 91, 555–558. [CrossRef]
55. Wang, J.; Tan, G.J.; Han, L.N.; Bai, Y.Y.; He, M.; Liu, H.B. Novel biomarkers for cardiovascular risk prediction.
J. Geriatr. Cardiol. 2017, 14, 135–150. [PubMed]
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Abstract: Periprocedural imaging assessment for percutaneous Left Atrial Appendage (LAA)
transcatheter occlusion can be obtained by utilizing different imaging modalities including
fluoroscopy, magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound
imaging. Given the complex and variable morphology of the left atrial appendage, it is crucial
to obtain the most accurate LAA dimensions to prevent intra-procedural device changes, recapture
maneuvers, and prolonged procedure time. We therefore sought to examine the accuracy of the most
commonly utilized imaging modalities in LAA occlusion. Institutional Review Board (IRB) approval
was waived as we only reviewed published data. By utilizing PUBMED which is an integrated
online website to list the published literature based on its relevance, we retrieved thirty-two articles
on the accuracy of most commonly used imaging modalities for pre-procedural assessment of the
left atrial appendage morphology, namely, two-dimensional transesophageal echocardiography,
three-dimensional transesophageal echocardiography, computed tomography, and three-dimensional
printing. There is strong evidence that real-time three-dimensional transesophageal echocardiography
is more accurate than two-dimensional transesophageal echocardiography. Three-dimensional
computed tomography has recently emerged as an imaging modality and it showed exceptional
accuracy when merged with three-dimensional printing technology. However, real time
three-dimensional transesophageal echocardiography may be considered the preferred imaging
modality as it can provide accurate measurements without requiring radiation exposure or contrast
administration. We will present the most common imaging modality used for LAA assessment
and will provide an algorithmic approach including preprocedural, periprocedural, intraprocedural,
and postprocedural.
Keywords: left atrial appendage; WATCHMAN occlusive device; 2D transesophageal
echocardiography; 3D transesophageal echocardiography; computerized tomography
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1. Introduction
Atrial Fibrillation (AF) is a major burden on public health, it is estimated to be the cause of ≥15%
of all strokes in the United States, and >100,000–125,000 embolic strokes per year, of which >20%
are fatal [1]. AF risk factors, pathogenesis, prevention, and treatment are beyond the scope of this
review. We will focus on the classification when patients may or may not have valvular heart disease.
The distinction still an area of debate. Valvular AF is the terminology used in those patients who have
heart valve disorder or a prosthetic heart valve. Nonvalvular AF is generally referred in those patients
who have other etiology causing the AF. The rapid and chaotic heartbeats restrict the left atrium from
pumping the blood properly, which may cause it to pool and form a clot. More than 90% of thrombi
in AF is formed in the left atrial appendage (LAA) [2]. The standard treatment for AF is heart rate or
rhythm control and stroke prevention. Prophylactic anticoagulation is the gold standard to prevent
embolic strokes in AF patients with CHADS-VASC score greater than or equal to two. For many years
there has been no alternative treatment available to prevent strokes in AF patients who have high risk
of bleeding and only 50–60% are therapeutically anticoagulated which make the effective long-term
anticoagulation very challenging [3].
In 2001 a successful percutaneous implantation of a device to occlude the LAA cavity was done in
a patient with non-valvular AF to prevent embolism [4]. Interventional closure of the LAA employing
the Watchman device (Boston Scientific) was shown to be non-inferior to Oral anticoagulation (OAC) in
randomized trials and has since been approved in the United States and Europe [5]. The LAA exhibits
complex anatomy that commonly varies morphologically among different individuals. Post-mortem
analysis of 100 left atrial appendages has demonstrated significant variability in appendage shape,
dimensions, and the number of lobes presents [6]. Therefore, accurate visualization of the LAA
and appreciation of its morphological considerations is an essential step in occlusion procedures.
Specifically, accurately measuring the dimensions of the LAA ostium, landing zone, and maximum
length of the main anchoring lobe is necessary for selecting an adequately sized occlusion device
successful device placement [4]. Choosing a device that is too small increases the risk of device
instability and peri-device leakage, whereas selecting a device that is too large increases the risk of
LAA perforation and cardiac tamponade [7,8]. Additionally, improper device selection can result in
intra-procedural device changes and recapture maneuvers and increasing length of the procedure [9].
We present a review on the most commonly used imaging modality for pre-procedural planning
and assessment of the LAA morphology, which include 2D Transesophageal echocardiography
(2D TEE), 3D Transesophageal echocardiography (3D TEE), Computed tomography (CT), and 3D
Printing (3DP).
1.1. 3D TEE Modality Is Superior to 2D TEE
2D TEE has been the most commonly used imaging modality for pre-procedural planning.
However, three-dimensional multiplanar transesophageal electrocardiography is a more accurate
alternative to 2D TEE in the assessment of the LAA morphology. Advantages of 3D TEE vs. 2D TEE
are illustrated in (Table 1), and comparative studies using 3D TEE are illustrated in (Table 2).
Zhou et al. found 3D TEE to be more accurate than 2D TEE for measuring the LAA Landing zone,
LAA depth, and LAA ostial dimensions, LAA morphology after the occlusion device deployment,
and visualizing any residual shunts around the entire device in one more view. In the Zhou et al.
study, a residual shunt of less than 1mm was identified in three cases by 3D TEE and only once by 2D
TEE [7]. Salzman et al. determined that area-derived diameter (ADD) and perimeter-derived diameter
(PDD) measurements obtained via 3D TEE correlated well with the occlusion device size chosen in the
procedure. Furthermore, the 3D landing zone measurements demonstrated a higher reproducibility
relative to 2D TEE [8].
Yosefi et al. found that RT3DTEE provides more accurate measurements of the maximal LAA
orifice than 2D TEE. 2D TEE significantly undersized the diameter of the LAA orifice relative to
RT3DTEE, when compared to CT [10]. Nucifora et al. found that RT3DTEE is in more significant
326
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agreement with the dimensions obtained from CT as demonstrated by smaller bias and narrower limits
of agreement with CT. Therefore, these authors believe that RT3DTEE may be the preferred imaging
modality to assess LAA dimensions as it can provide accurate measurements of the LAA without
requiring radiation exposure or contrast administration [11].
The real-time 3DTEE method is a feasible, fast way to assess the LAA number of lobes, the area of
the orifice, maximal LAA diameter, minimum LAA diameter, and LAA depth with similar accuracy
to RT3DTEE and CT according to a study published by Yosefy et al. Real-time 3DTEE consists of
converting a 3DTEE image into three 2D planes (X,Y,Z), at which time a 360 degree rotational in the
sagittal plane creates a single “stop shop” image that displays all aspects of the LAA morphology
including number of lobes, orifice area, and maximal and minimal diameter [12]. Nakajima et al.
determined that 3D TEE could accurately visualize LAA morphological variations. They studied
55 patients in normal sinus rhythm and 52 patients with atrial fibrillation. 3D TEE provides adequate
3D full volume images of all patients in NSR, whereas sufficient images were obtained in 94.6% of
patients with AF using zoom mode. Excellent correlation was found between full volume mode and
zoom mode [13].
Table 1. Advantages of 3D TEE vs. 2D TEE.
Author Advantages of 3D TEE vs. 2D TEE Study
Zhou et al.
-More accurate measuring of Landing zone and depth
-More significant association between the closure device
-Displaying cross-sectional images from any angle using Flexi Slice mode
-Useful in displaying the LAA morphology after the occlusion device deployed
-Visualizing any residual shunts around the entire device in one more view
[7]
Salzman et al. -Producing (ADD) and (PDD) measurements of the LAA ostium-3D landing zone measurements demonstrated a higher reproducibility [8]
Yosefi et al. -3DTEE is a feasible, fast way to assess LAA morphology with similar accuracyto RT3DTEE and CT [10]
Nucifora et al.
-RT3DTEE more significant agreement with the dimensions obtained from CT
-RT3DTEE Provide accurate measurements without radiation exposure
or contrast
[11]
Yosefi et al. -RT3DTEE provides more accurate measurements of the maximal LAA orifice [12]
Nakajima et al. -Accurately visualize LAA morphological variations-Excellent correlation was found between full volume mode and zoom mode [13]
327









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































J. Clin. Med. 2018, 7, 441
1.2. CT Is More Accurate Than TEE
CT has been considered the gold standard for visualizing the LAA for its ability to acquire
3D volumetric data of the LAA at various points in the cardiac cycle [4]. However, it has only
recently emerged as an imaging modality for sizing the LAA before occlusion and for post-procedural
evaluation of residual peri-device shunts. Although TEE remains the most commonly used imaging
modality for sizing the LAA, CT may be the most accurate imaging modality. Yosefy et al. compared
2D TEE to CT and found 2D TEE to be non-inferior to CT for determining LAA area and volume.
Additionally, Yosefy et al. found that of 30 patients who underwent routine TEE examination and
CT in the workup of PE, RT3DTEE was found to yield measurements not significantly different than
CT for the number of LAA lobes, LAA depth, LAA internal area, and LAA maximal and minimal
diameter. They concluded that 3DTEE might be more practical for sizing the LAA due to its accuracy,
lack of radiation, and bedside capabilities [10]. In contrast, other studies have demonstrated that
measurements obtained via TEE and CT are not interchangeable and may result in clinically significant
consequences. One such study by Sievert et al. showed that LAA sizing by 2D TEE alone might result
in the selection of a closure device that is undersized by 20–40% [2]. Advantages of CT are illustrated
in (Table 3), and comparative studies using CT are illustrated in (Table 4).
MSCT is a more accurate tool in selecting proper LAA closure device size than the conventionally
used TEE according to the study by Chow et al. [14] 2D-TEE measurements of orifice size are not
interchangeable with those obtained via CT according to a study by Rawjani et al. The researchers
concluded that due to the irregular and eccentric nature of the LAA orifice, obtaining mean orifice
diameter measurements may be more accurate than planar maximal diameters for sizing circular
occluder devices [15].
In the study by Wang et al. patients who underwent advanced CT imaging at this site required
1.245 devices per implantation attempt with 100% success rate, compared to patients in the first half of
the PROTECT AF study who averaged 1.8 devices used per implantation attempt with an 82% success
rate. Accurate sizing of the LAA landing zone is critical in successful implantation of the WATCHMAN,
and this study suggests high-resolution volumetric imaging with CT should be preferred over TEE [9].
Budge et al. determined that measurements obtained via CTsb, CTp, and TEE are not interchangeable.
CTsb was found to yield larger mean orifice diameters than both TEE and CTp, which produced similar
mean orifice diameters. It was speculated that this was due to foreshortening associated with 2D
modalities. Furthermore, when compared to TEE, both CT modalities yielded larger ostial measurements
for small LAA orifices and smaller ostial measurements for larger LAA orifices within this cohort [16].
Table 3. Advantages of CT when assessing the left atrial appendage.
Author Advantages of CT Study
Chow et al.
-Allows more accurate assessment of the LAA ostium and landing zone.




-device sizing by CT-derived mean diameter was in most agreement
with the actual device implanted
-Better in detection and avoidance of sizing error by 2D TOE
[15]
Wang et al.
-WATCHMAN device selection was 100% accurate when selected by CT
imaging
-Provides a comprehensive assessment for LAA which is accurate
[9]
Budge et al. -Provides accurate sizing of LAA occlusion devices [16]
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1.3. The Use of 3D Printing Can Facilitate LAA Occlusion
As more LAA occlusion procedures have been conducted, physicians have recognized the unique
and diverse morphology of the LAA [17]. This anatomical intricacy may be deceptively portrayed
in standardized diagnostic modalities such as 2D and 3D transesophageal echocardiography (TEE),
which are the conventional pre-procedural image technique. 3D CT characterization may provide
exceptional accuracy when merged with 3D printing technology. By creating a model customized to
each patient’s anatomy, a physical Watchman device (Boston Scientific, Marlborough, MA, USA) can
be implanted ex vivo so that spatial navigation and geographic accuracy of the left atrium may be
established before the cardiac catheterization procedure commences. The following findings show
this modality technology applied and successively replicated. They also suggest 3D CT as the best
imaging technique when establishing device size. Hell et al. [18] and Li et al. [19] supported the use of
3D printing while, Goiten et al. did not support it [20] (Table 5).
Hell et al. and Li et al. in prospective studies both found that 3D printing of LAA was a feasible
mechanism of predicting correct Watchman devices. In the study conducted by Hell et al. Mean LAA
ostium diameter based on TEE was 22 ± 4 mm and based on CT 25 ± 3 mm (p = 0.014) [18]. Similarly,
Li et al. performed successful Watchman implantation in 21 patients based on 3D model printing (3DP).
In this study, although all patients in both groups underwent successful device implantation, significant
differences did occur. After the occlusion, TOE showed that three patients in the control group had mild
residual shunting (two patients with a 2 mm residual shunt, one patient with a 4 mm residual shunt).
No residual shunt was observed in the 3DP group. The procedure times, contrast agent volumes,
and costs were 96.4 ± 12.5 vs. 101.2 ± 13.6 min, 22.6 ± 3.0 vs. 26.9 ± 6.2 mL, and 12,676.1 vs. 12,088.6
USD for the 3DP and control groups, respectively. Compared with the control group, the radiographic
exposure was significantly reduced in the 3DP group (561.4 ± 25.3 vs. 651.6 ± 32.1 mGy, p = 0.05) [19].
Goiten et al. found that LAA printed 3D models were accurate for prediction of LAA device
size for the Amulet device but not for the Watchman device. Two procedures were aborted due to
mismatch between LAA and any Watchman device dimensions in which all three interventional
cardiology physicians that were involved in the study predicted the failures using the printed 3D
model. Although 3D prints were found to be more accurate for Amulet compared to Watchman, strong
agreement among physicians was demonstrated for both devices (average intra-class correlation of
0.915 for Amulet and 0.816 for Watchman) [20].
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2. Algorithmic Approach for the WATCHMAN Procedural
Here, we will provide an algorithmic approach including preprocedural, periprocedural,
intraprocedural, and postprocedural. (Figures 1 and 2) [21].
Figure 1. A stepwise approach for pre-, peri-, and post-procedure for the successful implantation of
WATCHMAN device.
 
Figure 2. The WATCHMAN implant intra-procedural steps.
3. Pre-Procedural Assessment of the LAA
Here, we will provide the pre-procedural assessment of the LAA on 2D TEE, 3D TEE, and MDCT
(Figure 3).
334
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Figure 3. Pre-procedural assessment of the LAA using different imaging modalities.
4. Conclusions
Rotational three-dimensional transesophageal echocardiography is a more accurate alternative to
two-dimensional transesophageal echocardiography in the assessment of the left atrial appendage
morphology and has been the most commonly used imaging modality for sizing the left atrial
appendage. Three-dimensional computed tomography has recently emerged as an imaging modality
and it has showed exceptional accuracy when merged with three-dimensional printing technology.
However, real-time three-dimensional transesophageal echocardiography may be considered the
preferred imaging modality to assess left atrial appendage dimensions as it can provide accurate
measurements without requiring radiation exposure or contrast administration (Table 6).
Table 6. Preprocedural imaging impact on predicting the correct size of the WATCHMAN device.
Imaging Modality Impact on Implantation Success
2D TEE Less accurate
3D TEE Accurate without requiring radiation exposure or contrast administration
3D CT Exceptional accuracy when merged with three-dimensional printing technology
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